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Abstract 
Background and purpose: Systemic delivery of hydrophobic therapeutics represents substantial 
formulation challenges impeding optimal benefits due to side effects and sub-therapeutic drug 
levels at the target site consequently leading to progression of multi-drug resistance. This thesis 
describes three distinct novel nanotechnology-based strategies with desirable aerosolization 
characteristics for delivery via the airways, aimed at enhancing the therapeutic efficacy of 
hydrophobic drugs for pulmonary and neurological disorders. 
Methods: The first approach involved the development of dry powder microparticles for 
pulmonary delivery of antifungal amphotericin B nanocomplexes, prepared by co-grinding the 
drug with ascorbic acid. Nanocomplexes developed were characterized for molecular interactions 
by FT-IR, size, zeta potential, morphology, in vitro aerodynamic behavior and antifungal activity. 
The second strategy entailed design of liposomes co-encapsulating rifampicin and ibuprofen 
using Design of Experiment, targeted to the mannose and/or scavenger receptors on the alveolar 
macrophages where TB infection resides. Spray dried microparticles were characterized for in 
vitro aerodynamic behavior and macrophage uptake using the flow cytometer in RAW 264.7 cells. 
The third approach involved the development of Kolliphor® HS 15 micelles incorporating 
neuroprotective agents CNB001 or curcumin and Kolliphor® TPGS micelles encapsulating 
curcumin for the treatment of neurodegeneration and neuroblastoma respectively. Nasal delivery 
of these micellar systems was intended for brain targeting. Micelles were characterized for size, 
charge, aerosol droplet size distribution, drug release, morphology and in vitro cellular studies on 
SH-SY5Y cells. 
Results: Successful development of nanocarrier-based systems with a high encapsulation 
efficiency greater than 80% for all the systems was achieved, with particle size desirable for the 
end-use. Spray dried microparticles of amphotericin B nanocomplexes with L-leucine showed a 
high fine particle fraction of around 58% signifying likely deposition in the peripheral airways, 
to the areas of fungal infection. There was no loss of antifungal activity against Candida spp on 
complexation of amphotericin B. Microparticles of liposomes encapsulating antitubercular drugs 
showed good aerosolization, and up to 65% fine particle fraction on addition of L-leucine could 
be achieved. An enhanced in vitro cellular uptake was evident for negative-charged liposomes 
targeted to the scavenger receptors and the mannosylated liposomes targeted to the mannose 
receptors on the macrophage cell line RAW 264.7. Finally, Kolliphor® micelles encapsulating 
CNB001 or curcumin showed desired aerosol droplet size for delivery to the posterior nasal 
olfactory epithelium with median size of 42.75-54.86 µm when aerosolized by the Nasal™ 
Mucosal Atomization Device. The formulations intended for neuroprotection showed improved 
cellular viability, reduction in reactive oxygen species and nuclear morphology in the in vitro 
Parkinson’s model. 
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Conclusion: The nanotechnology-based formulations combined with administration to or 
through the airways using commercially available delivery devices, represent a highly attractive 
formulation strategy for delivery of hydrophobic agents to the target site at a therapeutic level to 
combat issues of multi-drug resistance.
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Research Impact Statement 
The majority of failures in the development of new drug candidates from the bench-to-bedside 
have been attributed to poor water solubility, leading to low bioavailability and suboptimal drug 
concentrations at the target site. Advances in combinational chemistry have led to an increase in 
the development of hydrophobic drug candidates, accounting for 90% of the discovery pipeline. 
The study of nanotechnology or nanocarrier-based drug delivery to combat problems such as drug 
solubility and toxicity is increasing, with an estimated market size of $136 billion by 2021. Use 
of nanotechnology to combat diseases like cancer and fungal infections is not new to the market, 
with the development of several nanocarrier-based treatments currently undertaken.  
Following systemic administration of medicaments aimed at treating airways-related diseases, 
tissue concentration of the drugs is often suboptimal, potentially leading to development of multi-
drug resistance, in the case of infections. Hence, for diseases associated with the airways, 
inhalation would be an attractive approach to overcome challenges posed by systemic delivery of 
medicaments. The global market for inhalation therapies has been expanding rapidly and is 
forecast to reach $42 billion by the end of 2025. Inhalation therapies already provide essential 
and often life-saving remedy, with a quick onset of action, for a range of respiratory diseases, 
including asthma and chronic obstructive pulmonary disorder. Moreover, due to attractive 
properties associated with the airways, such as high vascularity and low enzymatic action, this 
route has been exploited for systemic delivery of medicaments for conditions such as migraine, 
pain control and sexual dysfunction. Furthermore, nasal inhalation is being extensively 
investigated for direct brain targeting, with the first two candidates namely oxytocin and 
monoterpene perillyl alcohol in clinical trials for the treatment of autism and malignant gliomas 
respectively. 
The efficacy of inhalations relies greatly on the capacity of the device and formulation to deliver 
the correct dose of medicament to varied patient populations, with minimal dependence on 
patients’ parameters namely inspiratory flow rate and disease conditions. Unforeseen changes in 
the performance of inhalation systems might pose serious implications to treatment, hence, 
making it necessary to understand various aerosol parameters and potential deposition behaviour 
that dictates aerosol performance. Research group led by Emeritus Professor Graham Buckton, 
Professor Kevin Taylor and Dr Satyanarayana Somavarapu at the UCL School of Pharmacy have 
greatly focussed for over a decade to research the performance variations of numerous inhalation 
systems and their potential outcomes on treatment, mostly in the form of nebulization and dry 
powder inhalation.  
Specifically, the impact of research presented in this thesis has established three distinct and 
coherent strategies, demonstrating the feasibility for non-systemic delivery of hydrophobic drugs, 
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representing potential solutions to major delivery challenges for the pharmaceutical industry. 
Thus, this research demonstrates: 
1. Co-grinding of amphotericin B and ascorbic acid-2-glucoside, followed by spray drying, 
allows pulmonary delivery of hydrophobic antifungal drug amphotericin B, at 
therapeutically relevant concentrations to combat lung fungal infections, 
2. Co-encapsulation of hydrophobic drugs rifampicin and ibuprofen in mannosylated and 
anionic liposomes represent a promising formulation strategy for targeting and hence 
treatment of intracellularly-located TB bacilli, in the form of spray-dried microparticles, 
3. Potential for treatment of Parkinson’s disease and neuroblastoma by generating optimum 
aerosols of Kolliphor® micelles incorporating hydrophobic drugs CNB001 or curcumin, 
intended for brain targeting via the nasal airways. 
Hence, combining the benefits of nanotechnology and inhalation would be an attractive approach, 
to engineer systems that may be therapeutically effective and help improve the quality of life of 
diseased patients.  
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Preface 
The aim of the thesis is to examine various nanocarriers encapsulating hydrophobic drugs 
engineered with favorable aerosol characteristics to be delivered via the airways. For this, the 
thesis comprises of 6 major chapters namely: 
Chapter 1: Introduction 
This chapter covers the literature on pulmonary and nasal delivery systems, with reference to 
varied types of lung infections and neurological disorders. It summarizes the limitations of current 
treatment options considering the biological barriers for effective drug delivery. It lastly 
highlights the consolidation of aerosol delivery and nanotechnology to combat these barriers and 
improve the therapeutic efficacy of treatment. 
Chapter 2: General experimental methods 
This chapter covers the basic experimental methodology that are common to the different chapters 
Chapter 3: Preparation and characterization of spray-dried inhalable microparticles of co-
ground and solubilized amphotericin B nanocomplexes 
This chapter presents the results for nanocomplexes prepared by co-grinding amphotericin B with 
ascorbic acid-2-glucoside. These were characterized for size, charge, stability to ensure the 
complexes were stable and did not dissociate on storage, and the drug remained solubilized. The 
nanocomplexes intended for dry powder inhalation were spray dried and characterized for drug 
content, surface morphology, crystallinity, molecular interactions between amphotericin B and 
AA2g, in vitro pulmonary aerosol characteristics and in vitro antifungal assessment on Candida 
spp namely Candida albicans and Candida tropicalis. 
Chapter 4: Preparation and characterization of spray-dried inhalable microparticles of co-
encapsulated rifampicin and ibuprofen in mannosylated targeted liposomes 
This chapter focuses on designing liposomal formulations targeted to the alveolar macrophages 
since Mycobacterium bacilli behaves as an intracellular pathogen, and hence its eradication is 
challenging, increasing tuberculosis prevalence and multi-drug resistance. Negatively-charged 
liposomes proposed to target to the scavenger receptors on the macrophages co-encapsulating 
rifampicin and ibuprofen were prepared by thin-film hydration technique, using Design of 
Experiment, by varying the amount of lipids DPPC: DSPG: cholesterol and drugs rifampicin: 
ibuprofen, to achieve maximal drug encapsulation along with desired size and charge. Moreover, 
negatively-charged targeted liposomes embedding mannosamine or p-amino phenyl 
mannopyranoside were formulated.  
Mannosylated chitosan (targeting polymer) was synthesized and characterized by FT-IR and 1H 
NMR. Negatively-charged non-targeted liposomes were coated electrostatically with 
mannosylated chitosan to confer a final positive charge to the liposomes with mannose on the 
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liposomal surface. Final formulations co-encapsulating rifampicin and ibuprofen i.e. negatively-
charged DPPC: DSPG: Chol liposomes, neutral charged DPPC: Chol liposomes, positively-
charged chitosan-coated DPPC: DSPG: Chol liposomes, positively-charged mannosylated 
chitosan-coated DPPC: DSPG: Chol liposomes and negatively-charged DPPC: DSPG: Chol 
mannosylated liposomes were spray dried with lyoprotectant trehalose and dispersibility enhancer 
L-leucine and characterized for surface morphology, in vitro pulmonary aerosol characteristics 
and in vitro cellular uptake studies using fluorescence qualitatively assessed on the microscope 
and quantitatively on the flow cytometer.  
Chapter 5: Preparation and characterization of Kolliphor® micelles for nose-to-brain 
delivery of neuroprotective agents and cancer chemotherapeutics 
Kolliphor® HS 15 (Solutol® HS 15) micelles incorporating hydrophobic neuroprotective 
molecules CNB001 or curcumin and Kolliphor® TPGS micelles incorporating anticancer drug 
curcumin were prepared by thin-film hydration technique, intended for nose-to-brain delivery. 
Kolliphor® HS 15 micelles were stabilized by addition of different molar ratios of cholesterol and 
characterized for size, morphology, aerosol droplet size distribution and in vitro drug release. 
Moreover, the biological efficacy i.e. neuroprotection, reactive oxygen species formation and 
nuclear morphology to assess the neuroprotection efficacy of the micellar formulations was 
studied on the in vitro cellular-based SH-SY5Y Parkinson’s disease model. Kolliphor® TPGS 
micelles incorporating curcumin were prepared to mitochondrially target cancer cells with 
dequalinium. These micelles were characterized for size, charge, morphology, aerosol droplet size 
distribution and in vitro drug release. The in vitro anticancer efficacy of these formulations was 
studied on the neuroblastoma SH-SY5Y and lung adenocarcinoma A549 cell lines. 
Chapter 6: General discussion and future work 
Chapter 6 entails principal conclusions of the research and general discussion summarizing the 
major findings, relating the outcome of this thesis to present literature. Subsequently, suggestions 
for the future development of these systems were considered.
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1.1     Background 
Inhalation is one of the oldest forms of medicament delivery dating back to the ancient Egyptian 
civilization, where inhalation of vapors of black henbane was used to aid breathless patients to 
breathe [1]. Currently, this complex route is used primarily for the local treatment of respiratory 
diseases, such as cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD), 
bronchiectasis, asthma, pneumonia, aspergillosis and tuberculosis (TB). Small molecules such as 
glucocorticoids e.g. budesonide (Pulmicort Flexhaler®, Pulmicort Turbuhaler®), fluticasone 
(Flovent®, Flixotide®), beclometasone (Pulvinal Beclometasone®, Qvar®); β2-adrenoceptor 
agonists e.g. salbutamol (albuterol; Proventil®, Asthalin®, Salbulin®), terbutaline (Bricanyl®), 
salmeterol (Serevent®, Neovent®); anti-muscarinic bronchodilators e.g. ipratropium (Atrovent®), 
tiotropium (Spiriva HandiHaler®) and antimicrobials e.g. tobramycin (TOBI Podhaler®, TOBI 
TIS™, aztreonam (Caystone®), colistin (Colomycin®, Promixine®, Colobreathe®), pentamidine 
(Nebupent®), levofloxacin (Aeroquin™) have been, and are being successfully administered to 
the lungs for treatment of respiratory diseases.  
Nasal inhalation is also attractive with the development and commercialization of nasal products 
for treatment of local diseases of the upper respiratory tract, such as allergic and non-allergic 
vasomotor rhinitis e.g. Azelastine (Allergodil®, Astelin®), fluticasone (Flonase®), budesonide 
(Rhinocort®); nasal congestion e.g. xylometazoline (Sudafed®, Afrin®) and nasal infections. Over 
the last few decades, nasal inhalation has also been exploited for systemic delivery of small drug 
molecules which require a rapid onset of action like migraine e.g. zolmitriptan (Zomig®), 
sumatriptan (Imigran®, Imitrex®, Onzetra® Xsail®); nicotine spray for smoking cessation 
(Nicorette®, Nicotrol®) and treatment of menopausal symptoms (Aerodiol®) [2]. Moreover, due 
to attractive properties such as high vascularity of nasal mucosa and low enzymatic action of nasal 
fluids the nose represents a lower physiological barrier to delivery of proteins and peptides, 
compared to the oral route. Hence, peptides requiring low systemic levels to be therapeutically 
effective e.g. desmopressin (Desmospray®), oxytocin (Syntocinon®) and calcitonin (Miacalcin®, 
Fortical®) are marketed as nasal sprays [2]. 
This introduction outlines the relevant literature vital for the reader to grasp important aspects for 
understanding the experimental work that follows in Chapter 3-5. It summarizes pulmonary drug 
delivery taking into account the pre-requisites, aerosol characteristics and delivery devices 
necessary for efficient aerosolization to the target site in the lungs, and briefly outlines lung 
infections and barriers to effective delivery of antimicrobials. Furthermore, it summarizes nasal 
airway drug delivery for brain targeting (nose-to-brain drug delivery) considering the pre-
requisites, aerosol characteristics and delivery devices necessary for effective targeting to the 
central nervous system (CNS), and outlines neurogenerative diseases and brain cancer along with 
the barriers to treatment of neurological disorders. Finally, it describes the various nanocarrier 
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systems in literature and the advantages of nanotechnology for delivery to the airways (for the 
diseases of interest), concluding with the scope and content of the thesis. 
1.2     Pulmonary drug delivery 
For local rather than systemic delivery, on inhalation, the drug directly reaches the desired site of 
action, leading to the possibility of dose reduction as compared to oral and parenteral routes, 
reducing medicament costs and ensuring a higher concentration of the drug is retained at the target 
site [2, 3]. This reduces the possible side effects due to decreased systemic exposure and helps in 
achievement of a faster onset of action [3]. Numerous studies have demonstrated that 
antimicrobials, such as amikacin, tobramycin, rifampicin and amphotericin B used for treatment 
of lower respiratory tract infections caused by organisms like Pseudomonas aeruginosa, Candida 
albicans and Mycobacterium tuberculosis have serious adverse effects, including ototoxicity and 
nephrotoxicity, when administered orally or intravenously (IV), which are ameliorated by direct 
pulmonary delivery [4–8]. Due to the relatively low metabolic activity in the lung, pulmonary 
delivery is attractive for delivery of drugs which are sensitive to gastric pH, enzymes and 
metabolizing enzymes, particularly those associated with metabolism within the liver [9]. It is 
also useful for drugs belonging to Class IV of the Biopharmaceutics Classification System, such 
as amphotericin B, which has low water solubility and low membrane permeability, resulting in 
limited oral absorption and hence is administered routinely by the IV route [10–12].  
Effective pulmonary drug delivery requires sophisticated aerosol formulation approaches and 
complex delivery devices. The drug formulation needs to be engineered with respect to size, 
shape, particle size distribution and density to achieve maximum therapeutic benefit from the 
treatment. Moreover, pulmonary delivery is a challenge due to the complex anatomy and 
physiology of the airways, restricting access and promoting clearance of inhaled materials [3].  
1.2.1 Pre-requisites for pulmonary drug delivery: factors affecting local drug deposition 
The therapeutic effect of an inhaled medicament depends largely on its deposition pattern and 
distribution in the lungs; hence, understanding the concepts and mechanisms of these processes 
is of fundamental importance to inhalation therapy. Deposition is a process by which particles 
come into contact with and adhere to the surface [3].  
From a formulation viewpoint, the deposition profile is largely dependent on the aerosol particle 
characteristics, namely; aerodynamic size, particle size distribution, shape, density, electric 
charge, hygroscopicity and stability. Other non-formulation factors include lung morphology, 
clearance mechanisms (mucociliary and alveolar macrophages), type and severity of lung disease, 
airflow obstruction and patient factors, such as inhalation pattern, flow rate, breath-holding time 
and correct use of devices [14-15]. 
Aerosol particle deposition in the airways is governed by three principal mechanisms (Figure 1.1) 
namely: inertial impaction, gravitational sedimentation and Brownian diffusion [5]. Figure 1.1B 
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indicates that regional deposition in the airways is dependent on the particle diameter; pulmonary 
deposition is dominant for particles between 1-5 µm. 
 
 
Figure 1.1: (A) Major mechanisms of particle deposition in the respiratory tract [6], (B) Regional pulmonary 
deposition of inhaled particles dependent on the particle diameter (µm) [7] 
Inertial impaction 
Large particles with high momentum (i.e. the product of mass and velocity) do not follow the 
lung structure with the flowing air stream. These particles are deflected by the airway branching 
due to inertia and hence convective fluid motion leading to deposition on the airway wall [3,5,8].  
This occurs mainly at bifurcations of large conducting zones of the airways, nose, mouth, 
pharynx, larynx and bronchial region. This is a velocity-dependent mechanism and is the main 
method for deposition of particles greater than 5 µm [9]. 
 
Gravitational sedimentation 
This results from the gravitational force acting on particles with sufficient mass. Deposition due 
to gravity increases with increasing particle size, density and with longer residence time, acting 
when the particle velocity is low resulting in loss of balance between the gravitational force and 
the drag force of air leading to subsequent deposition on the lower airway surface. Gravitation 
sedimentation is an important mechanism of deposition for particles in the range 1-3 µm in small 
conducting airways, like bronchioles and alveoli where the air flow rate is low [3,5,8]. 
 
Diffusion  
This mechanism of deposition predominates for particles <1 µm and is governed by random 
Brownian motion. Particles are displaced by random motions of air molecules and deposit on 
contact with the cells by sequential bombardments. Deposition by diffusion is inversely 
proportional to particle size and occurs in the alveoli and smaller respiratory bronchioles, where 
bulk airflow rate is low or absent [3,5].  
(A) (B)  
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1.2.2 Aerosol characteristics 
Aerodynamic diameter (dae) is the most important physical property of an aerosol that governs 
the proportion of the dose deposited in the different parts of the airways and can be defined as the 
diameter of a unit density sphere that has a similar terminal settling velocity to the particle under 
consideration [10]. It can be mathematically described as equation 1.1 below:  !"# = 	!&	 ((#/(*+) 
where dg is the particle geometric diameter, ρe and ρs are the effective particle density and unit 
particle (1 g/cm3) density respectively and λ is the dynamic shape factor of the particle, i.e. the 
ratio of particle drag force to that of a sphere of equivalent volume, being 1 for a perfect sphere. 
Aerodynamic diameter explains the movement of aerosol particles in an air flow not only with 
respect to their geometric diameter but also taking into consideration their shape and density [10]. 
 
Particle shape plays an important role in the aerodynamics of dry powders. Studies have shown 
that the elongation ratio and shape factor of a particle dictate its trajectory in the respiratory tract. 
Rod-shaped particles of lactose and cromoglycic acid showed an increase in fine particle fraction 
compared to approximately spherical particles, due to their shape being analogous to that of 
asbestos fibers which have a higher susceptibility for pulmonary deposition by spatial hindering 
effect [11–14]. The study of the relationship between shape and surface properties is important as 
it can affect the aerodynamics of dry powders. With higher elongation ratios, the contact area 
between the particles is greater, leading to an increased cohesiveness between the particles which 
may ultimately affect the aerodynamic performance of the particles.  
 
Formulation characteristics 
Surface roughness of a particle impacts the aerosolization efficiency of a dry powder inhalation 
as it determines the interaction forces between the drug particles, and between the drug and carrier 
particles (if present) in a formulation. An appropriate balance between the interaction forces 
(during mixing/filling) and separation forces (during inhalation) of these particles is essential to 
ensure efficient delivery of the medicament to the peripheral lung when delivered as dry powder 
inhalations [13,15,16]. Studies have demonstrated that an increase in surface roughness of lactose 
carrier particles and sieved sorbitol particles proportionately improves the drug carrying capacity 
of the carrier; however, the drug particles are held tightly to the carrier particles and hence the 
emitted dose from the inhaler device decreases [13,15,16]. 
Other than size, shape and surface roughness, deposition is also governed by various other 
formulation parameters, such as hygroscopicity, polymorphic form, inter-particulate forces and 
surface charge. 
Equation 1.1 
Chapter 1| Introduction  
   
6	
	
1.2.3 Pulmonary drug delivery devices 
Aerosols are an effective way to deliver medications to the pulmonary site. These are two-phased, 
stable dispersions or suspensions of solid particles or liquid droplets in a gaseous phase usually 
air, and can be generated by a passive breath-driven or an active single or multiple dose inhaler 
[17]. Therapeutic inhalation aerosols can be delivered using three broad types of devices, namely: 
nebulizers, pressurized metered-dose inhalers (pMDIs) and dry powder inhalers (DPIs), although 
other delivery means like non-pressurized metered dose inhalers have been described. The 
advantages and disadvantages of the different inhaler devices are outlined in Table 1.1. 
Table 1.1: Advantages and disadvantages of different inhaler devices [18] 
Inhaler type 
Nebulizer 
(jet, ultrasonic, vibrating 
mesh) 
Pressurized metered- 
dose inhaler (pMDI) 
Dry powder inhaler 
(DPI) 
Advantages 
§ Does not require 
inhalation actuation 
synchronization 
§ No propellant 
§ High doses can be 
delivered 
§ Optimal for paediatric, 
gaeriatric and diseased 
patients who cannot use 
other devices 
§ Present generation of 
vibrating mesh 
nebulizers can be battery 
operated and hence 
portable (e.g: Aerogen 
Vibronic™) 
 
§ Portable and 
compact 
§ No preparation 
required 
§ No contamination 
risks 
§ Multi-dose (approx. 
200 doses) 
§ High reproducibility 
between doses 
§ Sealed environment 
prevents drug 
degradation 
§ Cost-effective 
§ Portable and 
compact 
§ Does not require 
inhalation actuation 
synchronization 
§ No propellant 
§ Ease of use 
§ Breath actuated 
§ No need for 
spacers 
Disadvantages 
§ Expensive, wasteful 
§ Contamination risk 
§ Time consuming 
§ Different models and 
operating conditions 
lead to high-
performance variability 
§ Drug formulation 
preparation may be 
necessary 
§ Nebulizer performance 
may decline over time 
§ Nebulization of 
nanocarrier-based 
systems can lead to 
instabilities of 
formulation like drug 
leak and aggregation or 
agglomeration of the 
nanocarriers  
§ Requires inhalation-
actuation 
synchronization 
§ High oropharyngeal 
deposition observed 
§ Maximum dosage 
that can be 
administered is 
approximately 5 mg 
§ Young children 
require a valve-
holding chamber 
(spacer) 
§ Propellant- based 
§ Fine particle dose 
dependent on 
inspiratory flow 
rate, tidal volume 
and breathes/cycle 
§ Fine particle dose 
dependent on the 
dry powder particle 
properties 
§ Moisture/electrosta
tic attraction may 
lead to powder 
aggregation, 
changing 
aerodynamic 
properties and/or 
causing capsule 
softening 
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1.2.3.1 Nebulizers 
These were the first devices to be used for pulmonary drug delivery and are still in practise 
particularly by the paediatric and gaeriatric populations for delivering drugs such as salbutamol 
for paediatric asthma, sodium cromoglicate for inflammation, corticosteroids and bronchodilators 
for severe COPD and tobramycin for infections associated with CF and COPD. Nebulizers need 
minimum patient skills or inhalation/actuation co-ordination [19]. They deliver the drug as 
droplets generated from solutions or suspensions, and have an advantage of delivering large doses 
during tidal breathing. Nebulizers can be classified as: 
Pneumatic or jet nebulizers 
These operate on the Bernoulli principle by which high velocity compressed air passes through a 
narrow orifice creating an area of low pressure at the outlet, causing the drug solution to be drawn 
up from the reservoir, forming a liquid film which breaks down into liquid droplets due to surface 
tension. Large droplets are retained in the device and a fine mist is emitted for inhalation via a 
mouthpiece or a facemask [4,20].  
Ultrasonic nebulizers 
These contain a piezoelectric crystal which vibrates at a frequency of 1-3MHz producing waves 
which are transmitted to the surface of the drug solution leading to the formation of standing 
waves, forming a fountain of fine mist. Small droplets having a size inversely proportional to the 
value of crystal vibrational frequency are produced in the mist [4,20,21].  
Vibrating-mesh nebulizers 
These contain a piezo-element which vibrates a perforated membrane in resonant bending mode. 
The cross-section of the perforations is larger at the reservoir side and narrower at the droplet 
emergence side. The size of aerosol droplets produced can be modulated by changing the number 
and sizes of perforations [22]. 
Electrohydrodynamic atomizers (EHDA) 
Also referred to as electro-spraying, these produce particles suitable for deep lung delivery by a 
low-shear technique. Application of electrical forces in a controlled manner can be useful in 
production of monodispersed droplets of size in the nanometric to micrometric range, depending 
on the frequency applied during particle production [23]. 
1.2.3.2 Pressurized metered-dose inhalers: pMDIs 
These multi-dose devices consist of an aluminum canister equipped with a metering valve, which 
contains drug dissolved or suspended in liquid propellant(s) along with other excipients, such as 
surfactants, e.g. Span 85, oleic acid and soya lecithin and co-solvents, usually ethanol. Actuation 
of the valve leads to emission of the aerosol as a metered dose of drug dissolved or dispersed in 
the propellant, usually a hydrofluoroalkane [4,20,21,24].  
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1.2.3.3 Dry powder inhalers: DPIs 
Subsequent to the development of pMDIs, dry powder inhalers (DPIs) were designed, and these 
received added interest in recent years since ozone-depleting chlorofluorocarbon (CFC)-based 
pMDIs were phased out for environmental reasons. DPIs have no propellant and in some respects 
are more user-friendly devices [25].  
DPIs exist in many designs which need for their operation a degree of manual dexterity, although 
simpler DPIs are being researched [26]. DPIs dispense a metered quantity of powder in an air 
stream drawn through an inlet system by the patient’s inspiration, directing air through the loose 
powder aggregates and forming a drug aerosol cloud. Hence, these are passive breath-actuated 
devices [21,27]. They are robust, portable and convenient in terms of formulation, processing, 
and stability as they are a one-phase solid system. They do not require to be sterile and avoid the 
formulation issues of nebulizers and pMDIs, particularly for suspension formulations, such as 
sedimentation, flocculation and foaming which may impact aerosol performance [28].  
DPIs are receiving increasing interest due to drawbacks of the use of propellants and the 
requirement of inhalation-actuation synchronization when using pMDIs. The characteristics of an 
ideal DPI can be divided based on: 
Patient acceptance [29–31] 
• Simple operation 
• Portable and easy to carry 
• Multiple dosage reservoir 
• Cost effective and/or reusable 
• Dose counter, dose-ready indicator and an audiovisual indicator of doses remaining 
• Patient feedback mechanism to indicate successful dosage administration  
 
Device reliability and reproducibility with respect to dosing [29–33] 
• Consistent and homogeneous dose delivery of medicament throughout the life of inhaler, 
at least comparable to a pMDI 
• Accurate and uniform dose delivery of medicament over a wide range of inspiratory flow 
rates with minimal variation with respect to age, gender and disease state 
• Optimum and reproducible control of respirable fractions with high fraction of particles 
in respirable range for deep lung delivery 
• Low oropharyngeal deposition with high bronchial deposition 
 
Efficient device [29–33] 
• Good protection from environmental moisture to prevent change in powder aerosol 
characteristics 
• In-process quality control  
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• Minimal adhesion between the drug and inhalation device 
• Device suitable for a wide range of drugs and doses 
• Environmentally accepted device 
No DPI can fulfill all the requirements of an ideal inhaler; however, continuous research is being 
conducted to improve their performance to achieve optimal fine particle dosage of medicament, 
with improved patient acceptability. Patient education is of utmost importance with regards to use 
and storage of their DPI preparations.  
Some presently marketed DPIs, nebulizers and metered-dose inhalers (MDIs, pressurized or non-
pressurized) used for pulmonary delivery of medicaments are as shown in Table 1.2. 
Table 1.2: Some marketed pulmonary delivery devices [4] 
Cyclohaler 
DPI 
Turbuhaler 
DPI 
HandiHaler 
DPI 
Diskus 
DPI 
Easyhaler 
DPI 
 
 
 
  
 
 
eFLOW 
nebulizer 
I-neb 
nebulizer 
Compare Elite 
nebulizer 
Respimat 
Non-pressurized 
MDI 
Vannair 
pMDI 
    
 
1.2.4 Types of lung infections 
Lung infections can be defined as infectious diseases of the upper or lower respiratory tract, 
wherein, upper respiratory tract infections include common cold, tonsillitis and acute 
rhinosinusitis, whereas, lower respiratory tract infections include acute bronchitis, bronchiolitis, 
pneumonia and tracheitis, and these pose a major health issue in many countries [34,35]. 
Bacterial, fungal and viral infections occur frequently and play a crucial role in the progression 
of chronic pulmonary diseases due to acute exacerbations leading to substantial long-term 
consequences, morbidity and mortality [35–37]. 
1.2.4.1 Bacterial infections 
Bacterial pathogens can be classified based on their infection lifestyle in the host and hence can 
be either intracellularly or extracellularly located. 
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Extracellular pathogens 
Most infections in CF, COPD and chronic bronchitis (CB) are caused by bacterial pathogens, such 
as Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa. These organisms live 
extracellularly and hence are easier to eradicate than intracellular infections. Intracellular 
pathogens are present in special compartments, for instance, alveolar macrophages and epithelial 
cells, where delivery of antibiotics encounters greater barriers. Nevertheless, extracellular 
bacterial pathogens overcome antibiotic susceptibility by other means such as genetic 
modification and production of a sessile, slimy covering called a ‘biofilm’. [38]. These are 
explained briefly in the following sections on the barriers to effective pulmonary antimicrobial 
therapy (section 1.2.5). 
Pseudomonal infections are clinically significant and can lead to life-threatening diseases and 
multiple organ failure [39]. Pseudomonas aeruginosa is the most prevalent of this class of 
pathogens and has been long associated with a variety of clinical pulmonary problems. It is an 
opportunistic nosocomial pathogen and is a major infective organism leading to high mortality 
and morbidity in hospitalized patients [39,40]. It leads to sepsis in hospitalized patients and is also 
associated with mortality in cases of pulmonary hospital-associated pneumonia (HAP), namely 
ventilator-associated pneumonia (VAP) and bronchoscope-associated pneumonia [40]. This 
pathogen causes exacerbations of pulmonary conditions including CF and COPD, primary 
bacteremia in AIDS patients and pulmonary community-acquired pneumonia (CAP) [40]. 
Pseudomonas aeruginosa is also highly involved with the pathogenesis of CF [41,42].  
 
Intracellular pathogens 
Eradication of intracellular infections faces challenges due to the difficulty of access to the 
protective environment within cells being the major reason for multi-drug resistance to current 
antimicrobials. Some organisms, such as Mycobacteria spp, Salmonella spp and Neisseria spp 
are primarily located in phagocytic intracellular compartments, including macrophages, 
polymorphonuclear leukocytes and neutrophils, which recognize pathogen-associated molecular 
patterns (PAMPs) present on the surface of pathogens which are unique to the pathogen type. 
These proteins expressed on the pathogens are essential for their pathogenicity [43–47].  
 
Mycobacterial infections: Tuberculosis, a ubiquitous and highly contagious chronic bacterial 
infection caused by the bacillus Mycobacterium tuberculosis has re-emerged dramatically since 
the mid-1980s, particularly since the escalation of HIV infection, which renders the host 20-30 
times more susceptible to infection by mycobacterium [48]. According to the WHO Global 
Tuberculosis Report 2016, TB affected about 10.4 million people in 2015, of which 1.4 million 
died from TB [49,50]. Additionally, strains of mycobacterium which are resistant to the first-line 
drugs, like isoniazid and rifampicin. have a high prevalence (3.6%) amongst newly emergent TB 
cases worldwide [51]. Although TB can be both pulmonary and extra-pulmonary, the pulmonary 
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tract is a major portal of entry for mycobacterium, the initial site of immune response and 
resurgence of the disease. Mycobacterium tuberculosis has been shown to bind to and internalize 
into the alveolar macrophages, where it enhances its survival by suppression of macrophage 
immune responses ultimately leading to the pathogenesis of TB [45,47,52]. Furthermore, it 
spreads to cause extra-pulmonary TB also known as ‘miliary TB’ which becomes difficult to 
control. Treatment of such intracellular pathogens requires delivery of antibiotics to these 
protective compartments where the bacilli reside, making eradication and treatment particularly 
challenging.  
1.2.4.2 Fungal infections 
In the past few decades due to concurrent increases in organ transplantations, aggressive 
antineoplastic therapies, and immunocompromised patients; the prevalence and severity of 
pulmonary fungal infections have increased [53].  These infections have a lethality rate of 30-
80% in immunocompromised and organ-transplant patients [54,55]. The airways being the major 
portal of entry of fungal spores, causing such infections, suggests direct pulmonary administration 
of antifungal agents to the lungs using inhaled drug delivery, could be an attractive way to treat 
invasive pulmonary fungal infections [53,56].  
Common fungal pathogens which infect the pulmonary tract are those that cause [57]: 
Invasive pulmonary aspergillosis- Aspergillus spp  
Pulmonary candidiasis- Candida albicans 
Pulmonary mucormycosis- Rhizopus, Mucor and Rhizomucor spp 
Pulmonary cryptococcosis- C. gattii and C. neoformans 
Pulmonary blastomycosis- B. dermatitidis 
Pulmonary histoplasmosis- H. capsulatum 
Pulmonary coccidioidomycosis- Coccidioides immitis and C. posadasii [57] 
Pneumocystis pneumonia has emerged as a serious healthcare problem due to the increased 
incidence of HIV which causes weakening of the patients’ immune systems leading to infection 
with opportunistic fungus Pneumocystis jirovecii. This infection invades the alveolar lumen in 
the lungs of susceptible hosts, blocking oxygenation, leading to death [58]. Current pulmonary 
fungal infections and their treatment strategies are considered in great detail in chapter 3. 
Antimicrobial aerosols currently marketed and in clinical/preclinical trials are outlined in Table 
1.3 and Table 1.4 respectively.  
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Table 1.3: Marketed antimicrobial aerosols [59–65] 
CF- cystic fibrosis, COPD-chronic obstructive pulmonary disease, CB-chronic bronchitis, VAP-ventilator-
associated pneumonia, CAP-community-acquired pneumonia 
Formulation name Drug and indication Device and dose Treatment outcome(s) 
TOBI® 
Tobramycin inhalation 
solution USP (TIS™) 
 
Novartis 
Tobramycin 
Aminoglycoside 
antibiotic 
 
CF, COPD, CB, VAP, 
CAP 
Nebulization 
PARI-LC® Plus 
300 mg 
nebulized twice 
daily 
Improved lung function, 
prevention of pulmonary 
exacerbations 
BRAMITOB® 
 
Chiesi Farmaceutici 
Tobramycin 
Aminoglycoside 
antibiotic 
 
CF, CAP 
Nebulization 
PARI-LC® Plus 
300 mg 
nebulized twice 
daily 
Improved lung function, 
prevention of pulmonary 
exacerbations 
 
TOBI®  
Tobramycin 
PulmoSphere™ 
inhalation powder 
USP (TIP) 
 
Novartis 
Tobramycin 
Aminoglycoside 
antibiotic 
 
CF, COPD, CB, VAP 
Podhaler 
112 mg (28 
mg/capsule)  
4 capsules 
twice daily 
Improved lung function, 
well tolerated and safe, 
prevention of 
exacerbations 
CAYSTONE® 
Aztreonam inhalation 
solution (AZLI) 
 
Gilead Sciences 
Aztreonam lysine 
Monobactam 
antibiotic 
 
CF 
Nebulization 
PARI eFLOW® 
Altera® handset 
75 mg thrice 
daily 
Safe and efficacious in 
prevention of lung 
exacerbations, no 
antibiotic resistance 
evident, superior lung 
function improvement to 
TIS™ 
COLOMYCIN® 
 
Forest Laboratories 
Colistimethate sodium 
Polymyxin antibiotic 
 
CF 
Nebulization 
PARI eFLOW®  
80-160 mg 
twice daily 
Eradication of 
P.aeruginosa 
PROMIXINE® 
(TADIM®) 
 
Profile Pharma 
Colistimethate sodium 
Polymyxin antibiotic 
 
CF 
Nebulization  
I-neb® AAD®  
80-160 mg 
twice daily 
Eradication of 
P.aeruginosa 
COLOBREATHE® 
 
Forest Laboratories 
Colistimethate sodium 
Polymyxin antibiotic 
 
CF 
Turbospin 
inhaler device- 
125 mg twice 
daily 
Safe, well tolerated, 
efficacy like TIS™ 
NEBUPENT® 
 
APP Pharmaceutical 
 
Pentamidine 
isethionate 
 
Antifungal 
Pneumocystis carinii 
pneumonia 
Respirgard® II 
nebulizer 
System 
300 mg/4 
weeks 
Safer compared to 
parenteral delivery 
 
AEROQUIN™ 
Levofloxacin 
inhalation solution 
 
Aptalis Pharma/ Forest 
laboratories 
Levofloxacin 
Fluoroquinolone 
antibiotic 
 
CF, COPD 
Nebulization 
PARI eFLOW®  
In study 3 dose 
levels-120 mg 
or 240 mg once 
daily or 240 mg 
twice a day 
Decrease in P.aeruginosa 
density, reduced need for 
other anti P.aeruginosa 
antibiotic, broad spectrum 
activity 
Similar efficacy to 
TOBI® from Phase III 
clinical trial 
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Table 1.4: Clinically studied antimicrobial aerosols [59–65] 
Formulation name Drug and indication Device and dose Treatment outcome(s) 
ARIKAYCE™ 
Liposomal amikacin 
for inhalation 
 
Insmed Inc. 
 
(Phase III clinical 
trials) 
Amikacin 
Aminoglycoside 
antibiotic 
 
CF, 
Non-tuberculous 
mycobacterial 
infections 
PARI eFLOW® 
nebulization 
560 mg once daily 
Sustained release 
of Amikacin, well 
tolerable, 
reduction in P. 
aeruginosa 
density 
ABELCETÂ® 
(Aerosolized 
Abelcet®) 
Amphotericin B lipid 
complex for 
nebulization 
 
(Phase II clinical 
trials) 
Amphotericin B 
Antifungal 
 
Invasive fungal 
infections in paediatric 
patients with acute 
leukemia 
50 mg nebulized once 
daily for four days 
Reduction in 
parenteral side 
effects of IV 
Abelcet® like 
nausea, vomiting, 
disseminated 
fusariosis and 
withdrawal 
CIPROINHALE 
Ciprofloxacin 
PulmoSphere™ 
inhalation powder 
(CPIP) 
 
Bayer HeathCare 
 
(Phase III clinical 
trials) 
Ciprofloxacin 
Fluoroquinolone 
antibiotic 
 
CF, COPD 
Powder inhalation 
In study at 2 dose 
levels- 32.5 mg or 
48.75 mg twice daily 
High 
concentration in 
the lungs, 
decrease in P. 
aeruginosa 
density 
CF- cystic fibrosis, COPD-chronic obstructive pulmonary disease 
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1.2.5 Barriers to effective pulmonary antimicrobial therapy 
1.2.5.1 Intracellular pathogens 
Intracellular bacterial infections are a major cause of morbidity and mortality. Intracellular 
bacteria have the ability to adapt and develop to form stronger and less susceptible variants to 
current antibiotic treatments, as verified by a high incidence of multi-drug resistance to these. 
This represents a considerable public health and economic burden as these variants are difficult 
to eradicate and more expensive to treat. This highlights the importance of developing new and 
improved methods of bacterial eradication from intracellular compartments. However, 
development of new chemotherapy approaches to combat the rapidly growing resistant strains of 
bacteria is too slow, threatening our ability to treat infectious diseases in the near future [66]. 
1.2.5.2 Biofilms 
Microbiological research focuses predominantly on planktonic state cells, i.e. bacterial cells 
floating in culture, to study antimicrobial activity. However, in more than 80% of microbial 
infections, bacteria grow as a protected structured community of sessile cells encased in a self-
produced hydrated polysaccharide slimy matrix i.e. a biofilm [67–69]. Initially, a layer is formed 
on a surface, i.e. the foundation of the biofilm made up of organic/inorganic substances deposited 
and adhered to a substrate.  
Planktonic bacteria from the bulk liquid are then adsorbed and start forming microcolonies by 
physical processes such as steric interactions, electrostatic interactions and Van der Waals forces, 
or by bacterial appendages such as flagella, pili and fimbriae. These then develop irreversible 
attachments by secretion of polysaccharide intercellular adhesion proteins and divalent cations 
that consolidate the surface- bacteria bond. These structures contain channels in which nutrients 
for the bacterial cells are circulated, and hence there is a rapid population growth of daughter 
sessile bacterial cells which adapt to the biofilm environment by changes in the expression of 
genes and in the surface properties of bacterial cells. The final stage of biofilm development is 
completed by quorum sensing (QS) cell signaling mechanisms, wherein stimulation of genetic 
expression takes places leading to the production of alginate which forms a part of the 
extracellular matrix of the biofilm, along with many other signal molecules that help in 
coordination of the biofilm bacteria. These signals govern processes such as bacterial dispersion 
which is essential to prevent overgrowth of the rapidly dividing bacteria, and their escape and 
colonization of new niches when nutrients become limited and waste products accumulate [70]. 
Biofilms being the refuge of mycobacterial spp have been reported to decrease the susceptibility 
of the organism up to 50 times to the common antitubercular drugs, rifampicin and isoniazid 
[71,72]. Moreover, Candida spp growing in biofilms become relatively resistant to azoles, 
whereas, amphotericin B formulations are completely ineffective against Pneumocystis carinii 
biofilms [73]. Numerous mechanisms are involved in the avoidance of antibiotic challenges by 
biofilm-associated bacteria. One mechanism is the failure, retardation or reduction in penetration 
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and diffusion of antibiotics into the full depth of the biofilm due to the presence of a physical 
polymeric barrier [67,68]. A further mechanism is a change in the microenvironment of the 
biofilm. Studies have shown that there are anaerobic niches in the deeper regions of the biofilms 
which render some antibiotics, such as those of the aminoglycoside class inactive [67,68]. 
Moreover, accumulation of waste products may cause a change in the pH of the biofilm niche 
which can directly cause inactivation or antagonism of certain antibiotics, limiting their activity 
[67,68].  Additionally, alteration in the osmotic environment leads to an osmotic stress response, 
ultimately resulting in a reduction in the permeability of bacteria to antibiotics by altering the 
proportion of porins in the bacterial cell wall [67,68]. A further proposed mechanism to explain 
reduced biofilm susceptibility is the development of slow-growing or non-growing dormant 
bacterial cells which become less susceptible to antibiotics, e.g. penicillin antibiotics which target 
cell-wall synthesis of bacteria [67,68].  
1.2.5.3 Antimicrobial resistance 
Multiple resistance to numerous antibiotics represents a considerable therapeutic challenge. The 
global report on antibiotic resistance by the WHO in 2014 revealed a serious threat worldwide 
and the need for urgent interventions to combat an imminent future crisis [74]. Multi-drug 
resistant tuberculosis (MDR-TB) has emerged swiftly, representing a global health concern, 
threatening TB control and treatment worldwide [75]. WHO reported a doubling in the people 
diagnosed with MDR-TB between 2011 and 2012, with 0.58 million new incidences of MDR-TB 
in 2015 [49,50]. Instances of extensively drug resistant (XRD-TB) and totally drug resistant 
(TDR-TB) cases have risen persistently in the past decade, posing a major challenge to the limited, 
time-consuming treatment options currently available to treat TB. 
Bacterial resistance to antibiotics can be innate or acquired by genetic and phenotypic 
modifications. A speculative hypothesis explaining reduced antibiotic susceptibility is the 
development of resistance due to genetic chromosomal mutations of bacteria. These can result in: 
(1) reduced permeability or uptake of the antibiotic; e.g. resistance to chloramphenicol antibiotics 
due to decreased permeability into Gram-negative bacteria, resistance to penicillin and 
tetracycline is evident in Neisseria gonorrhea due to the reduced permeability of the antibiotics 
[76];  
(2) increased efflux of the antibiotic from the bacterial cell; e.g. in the presence of tetracycline, 
the TetK gene responsible for efflux, transcription, and translation is activated leading to an 
increase in the number of efflux pumps and consequently resistance to tetracycline antibiotics 
[77].  Moreover, up-regulation of the norA gene in Staphylococcus aureus leads to an increase in 
activity of efflux pumps leading to fluoroquinolone antibiotic resistance [77];  
(3) enzymatic inactivation of antibiotics; e.g. β-lactamases catalyzing ring-opening of β-lactam 
antibiotics, aminoglycoside antibiotics are inactivated by addition of acetyl, adenyl and 
phosphoryl groups onto the antibiotic by aminoglycoside inactivating enzymes [78];  
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(4) alterations of the drug target site; e.g. alterations in the target site of DNA gyrase subunit A 
and B are responsible for resistance to fluoroquinolone antibiotics [79]. Moreover, resistance 
against rifampicin arises from mutation in the β subunit of the RNA polymerase site required by 
the drug to show activity and streptomycin resistance has been evident due to target site mutation 
on the rrs gene encoding 16s rRNA [80]; 
(5) loss of enzymes necessary for activation of the antibiotic; e.g. inactivation of the katG gene 
leads to reduced catalase activity and hence the ineffective conversion of isoniazid into its active 
hydrazine derivative. Moreover, inactivation of pyrazinamidase by a mutation in the pncA gene 
required for conversion of pyrazinamide to its active form pyrazinoic acid results in loss of 
antimycobacterial activity of the antibiotic [81,82].  
Further, phenotypic modifications involve sessile bacteria in biofilms that grow as spore-like 
biologically programmed bacterial subpopulations which are unique and highly protected 
dormant phenotypes, which are resistant to antibiotics in the dormant state. Another type of 
phenotypic modification involves the presence of salicylates, such as aspirin which make bacteria, 
including Pseudomonas spp, Mycobacterium tuberculosis and E.coli, less susceptible to common 
antibiotics due to an increased antibiotic efflux and reduced permeability, by a reduction in the 
level of porin expression [83].    
1.2.5.4 Sputum 
Mucus in the healthy lung is 10-30 µm thick in the trachea and 2-5 µm thick in the bronchial 
regions [84]. This thickness allows easy diffusion of gas, nutrients, ions and proteins, and the 
entrapment of particulate matter which is then efficiently removed by the mucociliary clearance 
process. Chronic lung diseases, such as COPD, CB, asthma, TB and CF are associated with 
impaired mucociliary clearance and necrotic death of epithelial and inflammatory cells in the 
patients’ lungs. This leads to bronchiectasis and deposition of thick, stationary, tenacious mucus 
plaques where heavy colonization of bacteria is evident, due to the availability of a nutrient-rich 
environment that is optimal for bacterial growth [85–87]. This viscoelastic and adhesive mucus 
acts as a physical and electrostatic barrier which hinders diffusion of antibiotics. Necrotic cells 
contribute to the excess release of a network of copolymerized polyanionic contents including 
DNA, mucin glycoproteins and F-actin which physically bind to polycationic antibiotics, such as 
tobramycin leading to their deactivation  [85,87,88]. Antibiotics delivered locally for treating 
bacterial infections associated with these diseases needs to penetrate the sputum and distribute 
evenly. Drugs such as ion-channel modulators or gene therapeutics which need to reach the 
epithelial layer must first traverse the thick mucus layer to achieve their desired activity [89,90].  
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1.3     Nose-to-brain delivery: Brain targeting 
Intranasally-delivered therapeutics can reach the CNS by three pathways, predominantly the 
olfactory neural pathway and olfactory epithelial pathway (as seen in Figure 1.2) [91]. The third 
pathway of delivery is via systemic absorption; however, this requires transport of systemically 
delivered drug molecule through the BBB to reach the CNS.  
 
 
The CNS meets the outside world only at the point of the nose. The olfactory filaments or axons 
of the 12th cranial nerve ‘olfactory nerve’ penetrate the nasal mucosa on the roof, i.e. the posterior 
segment of the nose as seen in Figure 1.3A. Millions of neurons at this point have found usefulness 
in rapid delivery of medication directly to the CNS in therapeutic concentrations by intracellular, 
paracellular or transcellular transport as seen in Figure 1.3B. This pathway is referred to as nose-
to-brain transport and has been exploited for non-invasive delivery of medicaments in numerous 
publications, with the first two candidates, namely, oxytocin in Phase II clinical trials for the 
treatment of autism OPN-300 (OptiNose US Inc.) and monoterpene perillyl alcohol in Phase I/II 
clinical trials for the treatment of malignant gliomas [92] (http://www.optinose.com). 
 
Figure 1.3: (A) Olfactory nerves innervating the nasal mucosa, the site for nose-to-brain delivery; (B) Passage 
of drug molecules from the nasal olfactory mucosa via the olfactory neurons into the brain. Transport of drug 
molecules inside the nerve axon can follow a paracellular, intracellular or transcellular pathway [93] 
(A) (B) 
Figure 1.2: Pathways of nose-to-brain delivery 
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1.3.1 Pre-requisites for nasal inhalation: factors affecting nose-to-brain delivery 
Drugs in solution 
Although many different types of drugs and nanocarrier systems have shown nose-to-brain 
delivery efficacy, numerous studies on the direct nose-to-brain transport efficiency related to the 
physiochemical properties of drugs like molecular weight, logP and logD have been carried out 
previously, however they have been unsuccessful in identifying a correlation [94–96]. Lee et al. 
investigated the brain transport of 17 drugs with different physicochemical properties on 
intranasal administration in rats [94]. On multiple linear regression analysis, no statistically 
significant correlation for these was determined [94]. This was supported by Kozlovskaya et al. 
who studied 73 publications in the literature from 1970-2014 on direct nose-to-brain targeting of 
drugs in solution versus particles or gel based drug delivery systems [95].  
However, contrasting findings were presented by Toshiyasu et al. who reported the dependence 
of lipophilicity, pH partition coefficient (ionized versus unionized form) and molecular weight of 
the drugs on the bioavailability in the brain on intranasal administration [97–99]. They reported 
that increasing the lipophilicity of drugs increased the direct transport of sulphonamides [99]. 
Toshiyasu et al. also reported that an increase in unionization of the drug sulfisomidine caused an 
increase in drug transport to the CNS by passive diffusion [98]. Furthermore, an increase in the 
molecular weight of fluorescent dextran increased CNS transport and suggested that drugs up to 
20 kDa can successfully transport directly to the cerebrospinal fluid on intranasal delivery, with 
an inverse correlation between transport and molecular weight [97]. However, on the basis of 
these contradictory studies, conclusions on the relationship between the physiochemical 
properties and transport of drugs to the CNS on intranasal delivery cannot be drawn accurately. 
Receptor-mediated endocytosis of peptides and proteins, and chemically modified drug molecules 
to enhance carrier-mediated transport through nasal olfactory epithelia has shown promise in the 
development of CNS therapeutics [93]. The bioavailability of drugs in the brain are dictated by 
their affinity to efflux transporters at the apical membrane of olfactory epithelium [100]. 
However, human studies to determine nose-to-brain transport of drug molecules is greatly limited 
by ethical and practical issues decelerating the development in this field.  
 
Drugs in nanocarriers 
To overcome the issues with the passage of drug molecules across the nose to the CNS, re-
engineering drug molecules by encapsulating them within nanocarriers have been extensively 
researched over the past few years. Passage of nanoparticles larger than 20 nm through olfactory 
epithelial cells has been known to involve the transcellular route [101]. Moreover, by engineering 
nanoparticles by means surface modification with lectin or coating with chitosan, increased 
mucoadhesion and hence increased bioavailability of the drugs in the CNS can be achieved. The 
currently investigated nanocarrier-based systems for nose-to-brain delivery of therapeutics have 
been outlined with more detail in section 1.4. 
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1.3.2 Approaches to tackle challenges posed by nose-to-brain delivery 
This route poses numerous delivery challenges. Approximately 150 µL-1000 µL of liquid can be 
administered through the nasal tract without considerable harm to the nasal physiology, and hence 
nose-to-brain delivery can only be used for delivery of potent molecules [101]. Furthermore, 
formulations of non-potent drugs can be delivered as a powder to overcome the volume limitation 
of liquid aerosols [101]. Less than 1% of drug administered intranasally is transported to the brain. 
This is mainly due to rapid nasal clearance (12-20 min) of administered medication [101].  
Hence, techniques to increase the residence of medication in the nose by means of mucoadhesion 
using chitosan or targeted nanoparticle engineering e.g. lectin-conjugated delivery systems with 
a higher affinity to the olfactory mucosa have shown promise in previous studies to improve drug 
bioavailability in the brain on intranasal administration (Table 1.6) [102–105]. Another approach 
to improve delivery to the brain on intranasal administration of medication is by proper choice of 
nasal delivery device. The novel breath-powered Bi-Directional™ nasal delivery device 
developed by OptiNose Inc. has been shown to significantly improve the amount of medication 
delivered to the brain via the nose [93,106–108]. Other delivery devices developed over the last 
few years namely the LMA® mucosal atomization device (MAD) and Kurve Inc.’s ViaNase™ 
have also shown promise to improve CNS bioavailability on intranasal administration, and are 
considered in detail in section 1.3.4. Focused ultrasound after intranasal delivery (FUS+IN) of 
microbubbles has been shown to significantly improve CNS delivery in an in vivo mice model as 
compared to the group where focused ultrasound did not follow intranasal microbubble delivery 
[109,110]. The study of fluorescence intensity of microbubble in the brain on FUS+IN and 
FUS+IV was not significantly different. Hence, intranasal delivery to the brain could be used as 
a non-invasive alternative to the invasive IV administration of drugs for neurological disorders 
[109]. Intranasally administered monoterpene perillyl alcohol, a Ras-protein inhibitor for the 
treatment of malignant gliomas has been undertaken in clinical trials in Brazil [111]. Phase I/II 
study on patients with recurrent malignant glioma confirmed the antitumour activity by regression 
of tumour size, due to tumouristatic effect and signal transduction inhibition effect of perillyl 
alcohol on intranasal administration, which was well tolerated [111]. 
1.3.3 Nasal drug delivery devices 
Devices for nasal delivery depends on the dosage form of the medicament, proposed indication 
and patient population; wherein liquid dosage forms mostly aqueous-based systems dominate the 
market at present. Effective delivery of medicament to the nasal airways and beyond, and hence 
the use of a suitable nasal drug delivery device is highly dependent on the target site of action i.e. 
local nasal delivery (nasal decongestants and allergic rhinitis), delivery to the mucosal rich 
vascular bed of highly permeable capillaries in the respiratory region (migraine, acute pains, 
seizures, opioid reversal) or the olfactory mucosa and nerves for brain targeting (autism-Phase II 
trials, malignant gliomas- Phase I/II trials). 
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Instillation of liquid formulation drops with a pipette/dropper 
This is the oldest form of formulation delivery to the nasal tract. Drops are instilled using a glass 
dropper in a head-down body position and/or extension of the neck to achieve a gravity-driven 
nasal deposition [2,112]. These can be single-unit pipettes/droppers or multi-unit pipettes. These 
have however largely been replaced by metered-dose spray pumps [2,112]. The major drawback 
of this conventional delivery approach is poor compliance especially in patients with 
rhinosinusitis who experience increased headache with head-down body positions [2,112].  
Delivery of liquid formulation with rhinyle catheter or squirt tube/pipette 
This involves squirting liquid formulation to the desired area under visual control by a physician 
by inserting the tip of a fine catheter/micropipette into the nose [2,112]. However, utmost care to 
prevent contact with sensitive mucosal membranes is necessary and hence self-administration 
using the squirt tube is not appropriate. Moreover, delivery could also be achieved by breath 
powered actuation technique using a rhinyle catheter which involves placing one end of the tube 
in the nostril and the other end in the mouth, wherein, the liquid is dispensed as a liquid drop or 
jet by blowing into the tube [2,112]. This is currently being used to deliver desmopressin for the 
treatment of diabetes insipidus and primary nocturnal enuresis [2,112]. However, use of the 
rhinyle catheter suffers from drawbacks of the variability of dose and cumbersomeness.  
Delivery of liquid formulation filled in a squeezed bottle 
Mainly used for delivery of OTC nasal decongestants is by squeezing a partially air-filled plastic 
bottle with a jet outlet which atomizes a certain volume of liquid [2,112]. This device, however, 
has a high risk of contamination due to sucking back of microorganisms and nasal fluids after 
formulation instillation, and difficulty in dose control as patient-to-patient pressure variation 
exists [2,112]. Hence, this device is not recommended to be used for instillation of 
vasoconstrictors in children. 
Delivery of liquid formulation using metered-dose spray pumps 
Metered-dose sprays at present dominate the market for the delivery of aqueous liquid solutions, 
suspensions and emulsions, mainly for topical decongestants, antihistamines and corticosteroids. 
Simple metered-dose spray pumps disperse medicaments as a spray or mist by a hand operated 
actuation mechanism involving replacement of emitted liquid with air. For this reason, multi-dose 
spray pumps require the use of preservatives [2,112].  More sophisticated pump sprays involving 
compensation of the emitted liquid by compressed gas, use of a collapsible bag, movable piston 
or aseptic air filter to filter the replacing air have been developed to allow the absence of 
preservatives [2,112]. However, these systems are more complex and expensive, and hence the 
traditional metered-dose pump sprays with preservatives are still widely used [2,112]. These 
devices offer high reproducibility of emitted medicament dose and plume geometry depending 
on the liquid formulation viscosity and surface tension, pump valve and actuator orifice [2,112].  
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Delivery of liquid formulation using single-dose devices 
These are very valuable as preservative-free medicaments can be delivered if sterile 
manufacturing has been undertaken. Single-dose devices pose a reduced risk of formulation 
instability and hence is attractive for delivery of vaccines where aggregation in multi-dose units 
could cause a reduction in dose-titre [2,112]. The device consists of a vial to hold the unit dose, a 
piston and a swirl chamber, where the product is sprayed on hand actuation using a pressure point 
mechanism. Currently, marketed influenza vaccine FluMist, zolmitriptan Zomig® nasal spray and 
sumatriptan Imitrex® nasal spray for migraine are delivered using such single dose nasal devices 
[2,112]. 
Delivery of liquid formulation using Nasal pMDIs 
Since the ban on use of CFC propellants due to ozone depletion, nasal and pulmonary pMDIs 
have been withdrawn from the market. Lately, however, hydrofluoroalkane-based pMDIs have 
been developed, like for the delivery of beclometasone dipropionate for local allergic rhinitis 
[2,112]. 
1.3.4 Nose-to-brain drug delivery devices 
Although the nostril in the anterior position is only a few cm away from the olfactory epithelium, 
the complex labyrinth of passages ending into the slit-like olfactory cleft behind the narrow nasal 
valve, greatly limits the passage of medicament instilled within the nostril to the posterior region 
of the nose [93]. Hence traditional techniques are inadequate to deliver medicaments for nose-to-
brain delivery. Specialized devices for nose-to-brain delivery of medicaments have evolved from 
the traditional nasal drug delivery devices. 
Delivery of blue food dye with traditional nasal delivery devices e.g. pipette/dropper, spray and 
squirt tube was studied by Scheibe et al. [113]. Delivery using a pipette/dropper showed 
deposition following forces of gravity and mucociliary clearance, largely in the anterior nasal 
floor and nasopharynx [113]. Delivery using the nasal spray (Sprayer) evenly distributed the food 
dye in the nose, however, distribution was intercepted by the middle turbinate and hence did not 
effectively reach the olfactory cleft [113]. Other studies by means of gamma camera scanning, 
radiographic CT scanning, endoscopic evaluation and fluorescence dye studies on delivery using 
nasal sprays in healthy human volunteers have confirmed that these devices largely deposit 
medication to the anterior part of the nose [113–117]. Moreover, inability to reach the olfactory 
region using a squeeze bottle was demonstrated in a study to deposit fluorescein, evaluated by 
endoscopy, wherein, major deposition was seen on the septum and the inferior turbinate [118]. 
Using a squirt tube to deliver the drug directly into the posterior nose after decongestion by a 
trained physician showed olfactory epithelium deposition in most of the patients. These studies 
demonstrated the importance of the nasal delivery device characteristics on the area of deposition 
[113]. This has been confirmed by computational fluid dynamics in an MRI-based nasal airway 
model that has revealed that olfactory epithelium deposition is most likely when delivering 
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medicaments by deep nasal intubation [119]. However, use of a squirt tube/deep intubation is not 
a feasible technique for routine delivery of medicament at home. Hence, as delivery using 
traditional nasal devices is sub-optimal, alternative delivery devices to target the nasal olfactory 
epithelium and hence the CNS is necessary. 
 
Powered nebulizers and atomizers 
Nasal nebulizing devices use ultrasonic power, mechanical power or compressed gases (air, 
oxygen or nitrogen) to produce fine aerosols of liquids or suspensions. The speed of the droplets 
emitted from the aerosol and the aerosol droplet size (around 6 µm) has been shown to be 
advantageous in nebulizing an increased dose of medicament to the paranasal sinuses as compared 
to conventional spray nebulizers [93,112,120]. 
The vibrENT™ pulsating membrane nebulizer (PARI Pharma GmbH) and Aeroneb Solo® 
nebulizer (Aerogen, Ireland) have been routinely used in nasal delivery for treatment of chronic 
rhinosinusitis, the target site being the upper posterior parts of the nose. These are similar to the 
standard pulmonary nebulizers fitted with a nostril adapter to deliver medicament to nasal sinuses. 
Hence, these delivery systems can be exploited for studies where nose-to-brain targeting is 
intended [93,112].  
Nasal atomizers are handheld battery-driven devices or highly pressurized compressed gas based 
systems. The Controlled Particle Dispersion® ViaNase™ atomizer (Kurve Technology Inc., USA) 
has been used in pre-clinical studies to administer insulin intranasally to patients with early 
Alzheimer’s disease. The ViaNase™ is capable of generating aerosols with a narrow droplet size 
distributions from 3-50 µm, which can be further customized to achieve varied droplet trajectories 
and aerosol flow velocity; hence this device is capable of aerosolization of liquids and suspensions 
with varied surface tension and viscosities [93,112]. Insulin delivered using the ViaNase™ has 
been shown to improve memory, verbal information, attention and increased plasma beta-amyloid 
peptide 40 [121,122]. However, it was proposed that nasal inhalation of insulin using this device 
may cause significant lung deposition which could cause airway irritation and reduction in 
pulmonary function, as seen previously with the administration of Exubera® i.e. inhaled insulin 
[121,122]. Hence, longer trials of intranasal insulin therapy are necessary. Gamma camera 
imaging has confirmed that the ViaNase™ atomizer can target the upper roof of the nose and 
sinuses and hence is attractive for nose-to-brain delivery. MRI studies (Figure 1.4) have 
confirmed the use of ViaNase™ to saturate the nasal cavity, with distribution of 99mtechnetium 
reaching the olfactory regions and sinuses was evident [121,122]. 
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Figure 1.4: Intranasal delivery using Kurve Inc.’s ViaNase™ to target the olfactory region  
(left:http://www.medgadget.com/2007/06/vianase_devices_and_vortical_flow_technology_will_make_your_nos
e_go_round.html, right: http://www.kurvetech.com/TechnologyGamma.asp) 
The use of a nitrogen-driven atomizer i.e. the Precision Olfactory Delivery™ device (POD™, 
Impel NeuroPharma) was intended to deliver medicament to the brain via the nose due to the 
narrow plume produced by the device that is directed towards the posterior nasal valve. The first 
human study evidence of nose-to-brain delivery was announced by Impel NeuroPharma Inc., 
wherein a significant increase in deposition of radiolabelled tripeptide i.e. 68.3% versus 31.7% 
(for conventional nasal pump) in the olfactory regions was evident by SPECT (Single-photon 
emission computed tomography) imaging in seven healthy volunteers (Figure 1.5), which might 
be attractive for brain targeting [93,123,124]. However, the reports this far are in the form of press 
release and poster presented at the American Association of Pharmaceutical Scientists conference, 
and peer-reviewed detail of trials are yet to be published. 
Figure 1.5: 2D SPECT image showing deposition of radiolabelled tripeptide using Impel Inc.'s Precision 
Olfactory Delivery (POD) device (A) versus traditional nasal pump (B). Cribriform plate that is where the nasal 
cavity meets the CNS is denoted by a white bar. (C) 3D SPECT image showing deposition in the olfactory bulb 
and cerebellum/brainstem (marked by arrows) indicating direct nose-to-brain delivery [123,124] 
Breath-powered™ Bi-Directional™ technology 
To overcome the medicament access problem due to complex anatomy and physiology of the 
airways, exploitation of natural functional aspects of the airways was undertaken to develop a 
novel breath-powered Bi-Directional™ nasal delivery device (OptiNose, USA, Figure 1.6) 
[93,112]. This device delivers medicament precisely to the upper deeper parts of the nose, by 
isolating the nasal tract from the rest of the respiratory system due to exhaling from the mouth 
into the mouthpiece of the device during nasal inhalation as seen in Figure 1.6A [93,112]. This 
leads to a higher oropharyngeal pressure by elevation of the soft palate and hence medicament is 
delivered to the upper nasal tract [93,112]. This technology has been adapted to deliver both 
C  
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powder and liquid formulations, and a special nose-to-brain delivery device has also been 
developed by slight modification [93]. The device consists of a flexible mouthpiece that is breath 
powered and an optimized conical shaped sealing nosepiece that when inserted forms a 
mechanical seal with the flexible soft tissue at the nostril opening and expands the narrow slit of 
the nasal triangular valve [93,112]. The nose-to-brain variant of the device contains an elongated 
nosepiece tip to enable better insertion into the nostril opening [93]. This technology involves 
exhalation of warm and humidified air into the mouthpiece when the device is in position. This 
air carries the medicament posteriorly along the nasal septum and then exits through the opposite 
nostril after passing around the nasal septum (Bi-directional™ technology) [93,112]. The liquid 
variant of this device requires manual triggering during actuation by pressing on a bottle to open 
the valve to dispense the medicament. 
  
 
 
 
 
 
 
 
 
using (B) traditional spray and (C) Breath-powered nose-to-brain variant device; (D) Deposition profile using 
the nose-to-brain variant device in seven healthy human volunteers [92,93,112]. 
Unpublished data from OptiNose Inc. has reported that the nose-to-brain variant (Figure 1.6D) 
can successfully achieve higher deposition compared to the Breath-Powered™ Bi-Directional™ 
liquid device, which are superior to the traditional spray devices, with around 30% being 
deposited in the upper one-third of the nose at the olfactory mucosa and 60% in the upper two-
thirds, where olfactory nerve filaments are found (Figure 1.6D) [93]. Numerous human evidence 
and clinical studies indicating the superiority of the breath-powered devices over conventional 
nasal devices for delivery to the upper and middle posterior regions of the nose have been 
previously published [92,107,125–127]. Delivery of oxytocin using the Breath-Powered™ Bi-
Directional™ nose-to-brain variant device is currently in Phase II clinical trials for the treatment 
of autism spectrum disorders. Previous reports from the double-blind crossover trial studies in 
healthy human volunteers validated the use of the breath-powered device for targeting to the brain 
and significantly improving social cognition as compared to IV oxytocin [92]. 
 
Mucosal Atomization Device (MAD) 
The Intranasal Mucosal Atomization Device™ (Nasal™ MAD, Figure 1.7) consists of a spray tip 
nosepiece that can be screwed onto a syringe with a leur lock. It is an easy to use device suitable 
Figure 1.6: Breath-Powered™ Bi-Directional™ nose-to-brain device variant. (A) Lateral view of the nasal 
passages explaining the working principle of the breath-powered device; Gamma camera images superimposed 
on sagittal MRI section for intranasal delivery  
A B C D 
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for self-administration and for administration to patients where IV access is difficult, allowing 
delivery of consistent amounts of medicament to the nasal mucosal surfaces.  
 
 
Figure 1.7: Atomized MAD Nasal™ delivering medicament to the upper posterior nasal tract towards the 
olfactory mucosa (http://www.lmaco.com/products/lma-mad-nasal) 
It has a simple design consisting of a syringe for accurate dosing, which locks by means of a stylet 
into a soft conical plug that forms a seal with the nostril to prevent fluid expulsion during 
atomization as seen in Figure 1.7 [121]. The soft conical plug houses an atomization spray that 
delivers the formulation as a fine mist of aerosol droplets, in the size range of 30-100 µm on 
application of high pressure to the syringe plunger [121]. For efficient delivery to the posterior 
nasal tract, a median particle size of 30-120 µm is considered appropriate [128]. Hence, this 
device was used to study the aerosol droplet size of the Kolliphor® micelles formulated for nose-
to-brain delivery of neuroprotective molecules and cancer chemotherapeutics (Chapter 5). 
Numerous studies have highlighted that use of intranasal fentanyl opioid for paediatric acute long-
bone fractures, paediatric severe painful sickle cell crises, paediatric and adult analgesia, 
paediatric orthopaedic trauma using the MAD Nasal™ is superior to IV/IM fentanyl/morphine, 
with a significant decrease in time to achieve analgesia and a reduction in pain scales/scores, 
hence, better pain relief especially in emergency departments [129–133]. Moreover, intranasal 
delivery of the antiseizure drug midazolam delivered using the MAD Nasal™ as compared to 
rectal/IV diazepam resulted in better seizure control in a shorter time with fewer respiratory 
complications and fewer hospital admissions in prehospital setups, along with better social 
acceptance, administration feasibility, and ease of use by caregivers [134–136]. This was 
concluded to be largely due to two mechanisms, one being increased absorption through the 
highly vascularized absorptive surface of the nasal mucosa and the drug being absorbed into the 
cerebrospinal fluid via the olfactory epithelium of the nasal mucosa [136]. Intranasal 
administration of naloxone using MAD Nasal™ during opioid overdose has been shown to 
prevent death due to an ease of administration using the intranasal device as compared to the other 
routes of administration namely IV/IM [137].  
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1.3.5 Central Nervous System disorders 
CNS disorders encompassing neurodegenerative diseases and neuroblastoma have increasingly 
prevailed over the past few years, being one of the toughest economic and medical conditions to 
treat at present, causing considerable strain to the society and an emotional burden on patients 
and caregivers [138,139].  
1.3.5.1 Neurodegenerative diseases 
Neurodegeneration is the degeneration of the neurons in the brain and is progressive and 
incurable. Neurodegeneration is characterized by loss of neuronal cells, progressive cognitive 
decline, alterations in the motor behavior and sensory processes of patients leading to gait 
disturbances, postural instability and dementia [138–140]. This occurs mostly due to increased 
oxidative stress, mitochondrial dysfunction, and deposition of senile plaques of b-amyloid peptide 
and Lewy bodies  [138–140]. The aging population suffers from neurodegenerative disorders like 
Alzheimer’s and Parkinson’s diseases, which are among the top 10 causes of death and disability 
in developed countries at present, as per the WHO [141]. Medication only improves the quality 
of life marginally since these pharmacological treatments do not halt the progression of the 
disease or address the underlying pathology, but only provide temporary symptomatic relief 
[138]. 
 
Alzheimer’s disease (AD) 
AD is the leading cause of dementia in aged people accounting for more than half the cases of 
dementia worldwide. Approximately 5 million people in the USA over the age of 65 have AD 
and this is expected to increase by 2050, wherein one million new cases are expected to develop 
every year i.e. one new case every 33 seconds [142]. The pathology of AD consists of different 
types of lesions: (1) senile plaques consisting primarily of extracellular amyloid protein deposits 
leading to cerebral amyloid angiopathy, (2) intracellular neurofibrillary tangles composed of 
hyperphosphorylated tau protein helical filaments and (3) cortical atrophy which leads to loss of 
cholinergic inputs [138,139,142]. There are neither diagnostic tests nor curative therapeutic 
treatments for AD. Present pharmacological agents serve to replace lost neurotransmitters in the 
CNS, consequently alleviating AD symptoms and slowing down disease progression 
[138,139,142]. The US FDA-approved treatments for improving cognitive manifestations in mild 
to moderate AD are limited to 5 drugs belonging to the class acetylcholinesterase inhibitors, i.e. 
rivastigmine (Exelon), donepezil (Aricept), galantamine (Razadyne, Reminyl), tacrine (Cognex) 
and NMDA receptor antagonist memantine (Namenda) [142]. Beyond the moderate level of AD 
progression, considerable loss of neurons and synapses causes patients to become unresponsive 
to treatment [139]. It is essential that research on discovering disease-modifying therapies 
targeting molecular pathway of neurodegeneration is undertaken as at present at least half of the 
patients are unresponsive to the current treatments [142]. 
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Parkinson’s disease (PD) 
PD, the second most common neurodegenerative disorder, is characterized by loss of midbrain 
dopaminergic neurons in the substantia nigra pars compacta of the brain leading to aggregation 
of a-synuclein protein and ubiquitin i.e. Lewy bodies and Lewy neurites, and is an age-related 
disease [138,139,143,144]. Progressive tremor, rigidity/stiffness of limbs and trunk, bradykinesia 
and dementia are associated with PD due to dopamine deficiency especially evident in later stages 
of the disease. It is believed to advance over many years due to an interplay between 
environmental and genetic familial inheritance by initiation of neurotoxic factors because of 
inflammatory responses caused by immune activation of neuroglia. [138,139,143,144] Treatment 
involves an increase of dopamine in the brain by administration of L-DOPA, i.e. a metabolic 
precursor of dopamine, and a DOPA decarboxylase inhibitor carbidopa to increase the 
bioavailability of dopamine in the brain [139]. However, administered orally these drugs have a 
very limited bioavailability of approximately 1% in the brain and long-term treatment results in 
tolerance to drug and symptom resurgence [139]. There is no proper test for disease diagnosis and 
current pharmacological treatments only help in alleviating clinical symptoms for a short time, 
however, dopaminergic neuronal degeneration in the midbrain ensues [139,145]. Hence, research 
on treatments directed towards interfering with signaling pathways impeding the progression of 
consequent neuronal death is to be undertaken [145]. 
1.3.5.2 Brain Cancer 
Prognosis of malignant gliomas accounting for approximately 80% of malignant primary brain 
tumour has been extremely poor due to therapeutic resistance and tumour reoccurrence [146]. 
Moreover, treatment is particularly challenging due to the limited permeability of most cancer 
drugs, like methotrexate and carboplatin through the blood-brain barrier (BBB) [139,147]. Most 
prominent subclass of malignant gliomas namely anaplastic gliomas (WHO III, median survival 
12-15 months) and glioblastomas (WHO IV, median survival 2-5 years) are essentially incurable, 
hence research of novel treatment strategies are essential [138,146,148]. Other types of brain 
tumours have diverse etiology affecting different parts of the brain parenchyma from the 
intracranial tissues to the meninges; treatment and prognosis of these can be quite varied and 
hence challenging. 
Modern pharmacological treatment modalities only provide symptomatic relief to patients 
marginally improving the quality of life and do not halt or reverse disease progression [138]. 
Moreover, lack of knowledge on the complex mechanisms involving neurological diseases is the 
greatest limitation to the development of efficacious treatment [138]. 
1.3.5.3 Barriers to effective neurological disorder therapy 
Blood-brain barrier (BBB) 
Pharmacologically treatment of CNS disorders like AD, PD, schizophrenia, brain tumour and 
meningitis faces a substantial challenge due to the presence of an interfacial structure i.e. blood-
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brain barrier (BBB) which thwarts the entry of drugs into the brain and acts as a bottleneck to the 
development of neurotherapeutics. The BBB majorly consists of the brain capillary endothelial 
cells (BCECs) (Figure 1.8) which are connected with continuous tight junctions that acts like a 
zip resulting in a high transendothelial electrical resistance (TEER, 1500-2000 Ω cm2) as 
compared to the TEER of other tissues like skin, lungs, bladder and colon (3-33 Ω cm2). This 
physical barrier along with high electrical resistance prevents the paracellular and passive 
diffusion of molecules from the blood into the brain interstitial fluid with almost 100% 
macromolecules and 98% of small molecules unable to reach the CNS depending on their charge 
and lipid solubility [149]. Certain membrane transporters present on the BBB helps uptake, efflux, 
and exchange of necessary nutrients like glucose and amino acids, and waste/toxin removal [150]. 
Passage of chemotherapeutics through the BBB is highly restricted due to their hydrophobic 
nature, hydrogen bonds and size. Hydrophobic molecules like caffeine and ethanol can penetrate 
the CNS easily, however, hydrophilic molecules are severely limited by passage through the BBB 
[93]. To permeate through the BBB drug molecules must have greater lipophilicity, less positive 
charge and hydrogen bond donors, and size less than 400 Da [151]. Drugs with a molecular weight 
lower than 20 kDa, lipid soluble with less than 8 hydrogen bonds and unionized can readily pass 
the BBB to reach the CNS [24, 139] 
 
 
 
 
 
 
 
 
 
 
Blood-brain tumour barrier (BBTB) 
In advanced brain tumours, drug distribution is highly restricted due to the BBTB, which exhibits 
a smaller pore size and overexpresses several drug efflux pumps resulting in a considerably lower 
concentration of chemotherapeutic agent inside the tumour than that seen in peripheral tumours, 
hence making treatment even more challenging [149]. With advanced brain tumours reduction in 
transvascular exchange of drug molecules take place due to reducing vascular surface area with 
increasing tumour size, leading to greater diffusional distance and depth into neoplastic cells 
[152]. Moreover, an increase in hydrostatic pressure in the brain parenchyma due to high tumour 
interstitial pressure and peri-tumoural edema is evident leading to a furthermore reduction in 
permeability of drugs into the neoplastic microvasculature [152]. Conventional cancer 
Figure 1.8: (A) Blood brain barrier surrounding cappilaries indicating 
astrocytes, tight junctions and brain capillary endothelial cells 
(BCECs) [530] 
(B) Cross section electron microscopy showing tight junctions between 
neighbouring BCECs [531] 
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chemotherapeutics like doxorubicin, paclitaxel, methotrexate, cisplatin and carmustin, do not 
cross the BBB and hence recurrence of fatal gliomas are very common [147].  
Significant research has been conducted on ways to enhance drug bioavailability in the brain by 
means of circumventing the formidable barriers BBB and BBTB by invasive and non-invasive 
techniques.  
 
Overcoming the BBB 
Complex strategies have been employed to improve the bioavailability of drugs in the CNS to 
treat neurological disorders. The most common approach in clinical use to deliver the drug to 
brain lesions involves invasive administration directly into the brain by means of intrathecal or 
intra-arterial injections, however, these are impractical and unattractive particularly for 
neurological disorders requiring frequent dosing [151]. An increased systemic dose of cancer 
chemotherapeutic drug is administered to improve brain bioavailability, however, significant 
systemic drug toxicity is associated with this approach [151].  
Another common approach involves transient disruption of the BBB by means of osmosis using 
hypertonic solutions like mannitol, ultrasound, focussed ultrasound, chemical agents like perrilyl 
alcohol or synthetic analog of bradykinin RMP-7 that has known to disrupt tight junctions of the 
BBB (studied in clinical trials), all followed by administration of chemotherapy [151]. The 
invasive procedure of osmotically opening the BBB has been shown to improve the tumour 
bioavailability of cancer chemotherapeutics from 10 to 100-fold, however, an increased risk of 
seizure and post-treatment neurological damage, for example, ubiquitinated neurons and 
deposited plaques in neuronal gap junctions and astrocytes have been associated with this invasive 
technique due to long treatment course [139]. Focused ultrasound a new frontier for opening the 
BBB has been studied at clinical set ups in the USA and its development is underway. This 
technique shows promise in controlling chemotherapeutic delivery to the affected part in the brain 
and is less invasive than other BBB opening techniques [139,153]. However, pre-clinical studies 
have not ruled out the prevalence of post-treatment injury and consequently permanent brain 
damage [139].  
Nose-to-brain delivery is a non-invasive means of circumventing the BBB. This delivery 
approach overcomes the conventional delivery limitations and delivers drug to the CNS at 
therapeutic concentrations and early onset, however, it is a long way to go with only the first two 
candidates namely oxytocin and monoterpene perillyl alcohol in Phase II and Phase I/II clinical 
trials for treatment of autism and malignant gliomas respectively. 
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1.4     Nanotechnology for delivery of drugs to the airways 
1.4.1 Choice of drug delivery systems 
Researchers have made great advances in engineering new nanotechnology-based carrier systems 
for different airways applications. The choice of the delivery system largely depends on factors 
such as: 
 
Site specificity 
For different disease conditions, varied formulations are required to transport the drug to the 
particular site of action and impart desired pharmacological effect. Delivery of water-insoluble 
drugs and highly unstable drug molecules may be achieved by loading them into nanometric 
systems delivered directly to the site intended. Systemic delivery of insulin for the treatment of 
Diabetes Mellitus, dry powder microparticles have been marketed as Exubera® (Pfizer; now 
withdrawn) and Afrezza™ (MannKind) which is a Technosphere™-based inhaled insulin 
product. Both of these need to be deposited in the alveoli and hence require an optimized delivery 
device [154–156].  Moreover, local administration of antitubercular drugs needs a delivery system 
which not only transports the drug to the alveolar macrophages but also has the capacity of being 
endocytosed by these macrophages [154]. On the other hand, endocytosis of β-agonists leads to 
their inactivation and clearance leading to loss of efficacy, hence formulations with minimal 
macrophage uptake properties would be needed for such drugs [154]. Delivery of nanoparticles 
encapsulating antibiotics to the lung for treatment of infections associated with CF, COPD, 
pulmonary TB or pneumonia can present a great challenge due to the thick viscoelastic mucus 
barrier in the lung. To traverse this barrier, nanoparticles must have a small size and should ideally 
be designed with a muco-inert surface so as to prevent their adhesion to mucin fibers which are 
highly prevalent and pose as a severe hurdle to the delivery of antibiotics to the site of infection 
in these disease conditions [157].  
 
Retainment of pharmacological effect 
The formulation and preparation of the delivery system should not affect the pharmacological 
activity of the drug. The release profile of the drug should be optimized to achieve maximum drug 
efficacy and duration of activity [156]. 
 
Fate of delivery system 
This important criterion needs careful consideration for inhaled nanoparticles. Varied delivery 
system engineering parameters, such as shape, size, materials, aggregation state, surface charge, 
chemical properties and formulation, may affect the toxicity profiles [158]. The small size of these 
new delivery systems imparts them with new physical and chemical properties different from 
conventional bulk drug powders [159]. It has been observed that multi-walled carbon-nanotube-
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based delivery systems have the capacity to collect in the subpleural regions of the lung, leading 
to pulmonary fibrosis, multifocal granulomatous inflammation, diffuse histiocytic and 
neutrophilic inflammation and intra-alveolar lipoproteinosis [158,160]. Inhaled nanoparticles can 
not only cause inflammation and other exacerbations but may also interfere with the functioning 
of the pulmonary system. Nanoparticles fabricated of polystyrene, gold or titanium dioxide have 
been reported to alter the function and structure of pulmonary surfactant and hence impede its 
ability to decrease surface tension rapidly during a normal breathing cycle [161]. Hence, use of 
natural surfactants to fabricate these delivery systems would be more attractive as it would 
minimize the risk of interfering with natural airway functions. Clearance of nanoparticles in the 
alveolar region is mediated by alveolar macrophages. These recognize nanoparticles, phagocytize 
them, travel to the mucociliary escalator and are cleared. However, this process is very slow and 
the retention half-life of solid insoluble particles deposited in the alveolar region of humans can 
be up to 700 days. Moreover, larger particles are not easily phagocytized nor are ultrafine 
nanoparticles [162].  
Delivery of drugs to the brain through the nasal olfactory mucosa faces substantial challenges like 
low bioavailability for polar drugs especially proteins and peptides which have a high molecular 
weight necessitating the use of transnasal absorption enhancers. Moreover, properties of the drug 
and the formulations like tonicity (iso, hyper or hypo), pH, temperature and viscosity alter the 
nasal tract mucociliary clearance and hence affect the clearance of the drugs. In general, a 
dominant mucociliary clearance for non-bioadhesive formulations delivered to the nose having a 
shelf-life of 12-20 min has been reported in earlier studies [163,164]. It is important to bear in 
mind the choice of material used to deliver drugs to the brain as it might be a precursor to 
neurological diseases. Inhaled ferrous oxide nanoparticles have been shown to predominantly 
deposit in the olfactory bulb, brainstem, and hippocampus and cause potential neurotoxicity 
[165].  Hence, the fate of the delivery system should be viewed with utmost importance during 
formulation development to ensure that maximum dosage reaches the intended site of action 
without affecting the normal functioning of the airways. 
The various delivery systems which can be used to deliver medicaments to the desired site are: 
1.4.2 Liposomes 
Liposomes are lipid-based carrier systems which have been widely used as drug carriers for 
cosmeceutical and pharmaceutical applications [166,167]. Liposomes are self-assembling 
structures which due to intrinsic interfacial properties imparted by the phospholipids 
spontaneously form spherical vesicles in aqueous media. These vesicles are made up of one or 
more concentric phospholipid bilayers alternating with aqueous compartments [168]. 
Hydrophobic and amphiphilic drugs can be incorporated within the lipid bilayers, whereas, 
hydrophilic drugs can be encapsulated in the aqueous compartments/core. They are safe, non-
toxic, biodegradable, biocompatible delivery systems for encapsulation of a wide range of drugs 
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having varied properties, including molecular size, charge and hydrophobicity. They interact with 
living cells by adsorption, endocytosis, lipid exchange and/or fusion [167,169,170].  
Liposomes can be divided into categories based on their size and lamellarity; namely small 
unilamellar vesicles (SUV), large unilamellar vesicles (LUV) and multilamellar vesicles (MLV), 
or on the basis of their properties, for instance immuno-liposomes, stealth liposomes, 
proteoliposomes, pH-sensitive liposomes and charged liposomes [167,169,171]. Liposomes can 
be prepared using a number of techniques, the most frequently used of which is the thin-film 
method, reverse-phase evaporation, solvent injection, freeze-thaw extrusion and ultrasonication 
[171]. 
 
Liposome delivery to the pulmonary airways  
These are an attractive delivery system to the lungs as they can be made of surfactants which are 
endogenous to the pulmonary tract. The first pulmonary-delivered liposomal product being 
Alveofact® (LyomarkPharma), instilled to the lung for treatment of respiratory distress syndrome. 
Deposition of liposomes, aerosolized with jet nebulizers, into the non-ciliated peripheral regions 
of the lung results in prolonged retention of the liposome-associated drug within the lung  
[172,173]. Cationic liposomes have been successful in the aerosol delivery of gene therapy 
[162,174,175], while liposomes conjugated with cell-penetrating peptides can act as potential 
carriers of macromolecules [162]. Modification of the liposome surface with O-stearyl 
amylopectin has been shown to increase lung tissue affinity [167], while conjugation of liposomes 
with octaargine or antennapedia enhanced cellular uptake in the airway cells [162].  Conjugating 
mannose to liposomes produces superior macrophage uptake to non-conjugated liposomes, with 
potential application in the treatment of diseases such as rheumatoid arthritis, TB and 
leishmaniasis, where the macrophages play a very important role in the disease progression  
[176,177]. 
Stability of the vesicles, vesicle delivery and the size of the aerosol cloud are major considerations 
when atomizing liposomes using nebulizers, and are functions of both formulation properties and 
the nebulizer system employed. The relationship between nebulizer performance and formulation 
development requires in-depth knowledge of formulation properties like lipid concentration, 
bilayer composition, bilayer rigidity; and the working principles of the various nebulizer types 
[172,178–180]. An attractive approach would be to deliver liposomes by DPIs produced by spray 
drying the liposomes and relying on their hydration in situ on delivery in the airways [181,182]. 
This could be advantageous as liposomal rupture and drug loss during aerosolization would not 
affect the drug dosage and hence treatment outcome, which is of major concern during 
nebulization of liposomal formulations. 
The properties of liposomes can be easily manipulated and a variety of drugs can be incorporated 
within them. By encapsulating antimicrobials into liposomes, improved delivery may be 
achieved, for instance by targeting macrophages where infections reside, or due to their small size 
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they can pass through biofilms and reach peripheral sites for complete bacterial eradication 
[169,183]. Rifampicin, an antimycobacterial drug used for TB treatment shows a very high rate 
of hepatotoxicity and nephrotoxicity, along with other side effects, including thrombocytopenia, 
immune haemolytic anaemia and intravascular haemolysis, due to its high metabolism in these 
organs leading to idiosyncratic metabolites which are toxic to these organs on oral delivery [184–
188]. Encapsulation of rifampicin into pulmonary-delivered liposomes improves its toxicity 
profile and reduces hepatotoxicity [189–191].  
 
Liposome delivery to the nasal airways 
For intranasal delivery to the brain cationic liposomal formulations encapsulating fluorescent 
protein showed approximately 10-fold higher retention in the brain and prolonged drug effect, 
assumed to be due to higher residence of liposomes in the nose due to attraction between the 
cationic liposomes and anionic sialic acid in nasal mucus and increased lipophilicity of protein 
formulation, hence leading to higher transport across the olfactory mucosa [192]. Many more 
reports on improved delivery of antioxidants, acetylcholinesterase inhibitors and other 
neuroprotective peptides encapsulated within liposomes for treatment of neurodegeneration have 
shown promise due to improved drug bioavailability in the brain due to effective brain targeting 
[193–197]. 
Various liposomal systems for delivery to the airways of antimicrobials and neuroprotective 
molecules have been described in the literature, a few of which have reached clinical trials, as 
summarized in Table 1.5 and Table 1.6. 
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Table 1.5: Liposomal therapies under investigation for antimicrobial delivery 
Antimicrobial Effective against Treatment outcome(s) 
Amikacin 
Aminoglycoside 
 
DPPC: Chol liposome 
ARIKAYCE™ 
 
Clinical trials phase III 
[198] 
Pseudomonas 
aeruginosa 
 
(Inhalation-
nebulization) 
 
Comparison of Arikayce™ versus 
placebo nebulized to the lungs showed 
beneficial results as liposomal amikacin 
had susceptibility to cross mucus and 
biofilm present in patients suffering 
from CF, hence a sustained and 
significant improvement in lung 
function and reduction of pseudomonas 
density was obtained 
Amikacin 
Aminoglycoside 
 
HSPC: Chol: DSPG 
(2:1:0.1) 
MiKasome® (NeXstar 
Pharmaceuticals, Inc)  
[199–201] 
Mycobacterium 
tuberculosis 
 
(Intratracheal 
administration) 
Increased uptake by the mononuclear 
phagocyte system showed benefits 
especially for multi-drug resistant M. 
avium, wherein, increased killing was 
evident versus free amikacin which 
fails to reach high intracellular levels  
Tobramycin 
Aminoglycoside 
 
Fluidosomes 
(Axentis Pharma) 
 
Clinical Trial II  
[167,202] 
Pseudomonas 
aeruginosa 
Escherichia coli 
Staphylococcus 
aureus 
 
(Intratracheal 
administration) 
Improved management of pulmonary 
infections was seen on intratracheal 
administration of fluid-based liposomes 
encapsulated tobramycin 
Amphotericin B 
Antifungal 
 
AmBisome® (AMBINEB) 
(PETHEMA foundation) 
 
Clinical Trial II 
[203–205] 
Aspergillosis 
 
(Inhalation-
nebulization) 
 
Amphotericin B encapsulated 
liposomes nebulized as prophylaxis to 
768 high-risk patients displayed an 
overall significantly lower incidence of 
invasive pulmonary aspergillosis and 
reduced systemic exposure 
 
Amphotericin B  
Antifungal 
 
Inhalation Powder (ABIP) 
DSPC spray dried powder 
(Nektar Pharmaceuticals)  
[206,207] 
Aspergillosis 
 
(Inhalation-DPI) 
Minimal systemic amphotericin B was 
observed on inhalation of dry powders 
containing high doses of amphotericin 
B up to 25 mg in clinical human studies 
(amphotericin B dose 50% w/w of dry 
powder) 
 
Rifampicin+ isoniazid 
 
DPPC: Chol 
Passively targeted 
[208,209] 
Mycobacterium 
tuberculosis 
 
(Inhalation) 
 
Increased therapeutic drug level found 
in the plasma on inhalation of a single 
dose in guinea pigs 
Drugs found to localize in the alveolar 
macrophages of the lungs  
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Table 1.5: Liposomal therapies under investigation for pulmonary delivery (continued) 
Antimicrobial Effective against Treatment outcome(s) 
Rifampicin+ isoniazid 
 
DPPC: Chol: O-
stearylamylopectin: DCP: 
DSPC-PEG 2K 
 
Actively targeted 
[189,208,210] 
Mycobacterium 
tuberculosis 
 
(Intravenous) 
 
Superior efficacy of the formulations 
against M. tuberculosis with a 
reduction in mycobacterial colony 
forming units in liver, kidney and 
lungs. 
Reduction in nephrotoxicity associated 
with the free drug and normal lung 
morphology observed 
Rifampicin 
 
Egg PC: Chol: O-stearyl 
amylopectin: DCP or 
 
Actively targeted 
[208,211] 
Mycobacterium 
tuberculosis 
 
(Inhalation-
nebulization) 
 
The targeted liposomes showed 
improved lung accumulation 
specifically improved alveolar 
macrophage uptake and accumulation 
showing the feasibility of the inhalation 
for eradication of M. tuberculosis 
No drug specified 
 
HSPC: Chol: DCP: MAN 
 
Actively targeted 
[208,212,213] 
- 
(Intratracheal 
aerosolization 
MicroSprayer™) 
 
Significantly higher internalization and 
selective targeting to alveolar 
macrophages in vivo with the mannose-
linked liposomes compared to non-
targeted liposomes  
Ciprofloxacin-
Fluoroquinolone or 
Azithromycin-Macrolide  
 
DSPG: Chol 
[169,214] 
Mycobacterium 
avium 
 
(In vitro J774 cells) 
43-fold greater potency was seen 
against M.avium compared to free 
ciprofloxacin due to increased negative 
charge imparted by the liposomal 
formulation  
CF- cystic fibrosis, TB- tuberculosis, DSPG- distearoyl phosphatidylglycerol, DCP- dicetylphosphate, HSPC-
hydrogenated soy phosphatidylcholine, Egg PC- egg phosphatidylcholine, EC- dioleoylethyl 
phosphatidylcholine, DOPC-dioleoyl phosphatidylcholine, DSPC- distearoyl phosphatidylcholine, Chol- 
cholesterol, MAN- mannose 
Table 1.6: Liposomal therapies under investigation for nose-to-brain delivery 
Drugs Effective against Treatment outcome(s) 
H102 Peptide 
 
EPC: DSPE-PEG 
2K: Chol 
[196] 
Alzheimer’s 
disease 
IN administered liposomes encapsulating 
peptide showed higher brain absorption as 
compared to IN delivered H102 solution  
Spatial memory impairment was ameliorated in 
AD model rats 
Rivastigmine 
Acetylcholinesterase 
inhibitor 
 
Soy lecithin: Chol 
[195] 
Alzheimer’s 
disease 
Significantly higher concentration of 
rivastigmine (brain Cmax 0.98 µg/mL) was 
observed in the brain along with sustained 
release of drug from liposomes when compared 
to IN (brain Cmax 0.33 µg/mL) or orally (brain 
Cmax 0.17 µg/mL) administered rivastigmine 
Donepezil 
Acetylcholinesterase 
inhibitor 
 
DSPC: Chol: PEG 
[215] 
Alzheimer’s 
disease 
Significantly higher concentration of donepezil 
(brain Cmax 0.22 µg/mL) was observed in the 
brain from intranasally administered liposomes 
when compared to intranasally (brain Cmax 0.15 
µg/mL) or orally (brain Cmax 0.11 µg/mL) 
administered free donepezil  
AD- Alzheimer’s disease, IN- intranasal 
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1.4.3 Polymeric microparticles and nanoparticles 
Microparticles are in the micrometer size range and include microspheres, i.e. uniform spheres 
constructed of polymeric matrices, or microcapsules, i.e. a thin polymer membrane encapsulating 
an oily core [216]. Nanoparticles can also be used for airway delivery; however, due to their small 
size, they may be exhaled and hence not deposit in the airways. To overcome this drawback they 
can be delivered by nebulization after suspending in a suitable liquid, with deposition governed 
by the size characteristics of the nebulized droplets, or incorporated into larger carrier particles 
and delivered as dry powders [217]. Microparticles are used as an alternative to liposomes, being 
more readily stable on storage or in the biological fluids, and they offer the possibility of 
modulation of release rate [218].  
Polymers are used in different fields such as pharmaceutical, biomedicine, tissue engineering and 
cosmeceuticals [219]. Polymeric microspheres prepared from biodegradable or biocompatible, 
natural or synthetic polymers have been studied as systems for airway delivery to control delivery 
of drugs and to protect them from enzymatic degradation. Polymer selection is critical for the 
success of the formulation, with appropriate control of drug release. As for all pulmonary delivery, 
the size of the nanoparticles and microparticles and their adequate dispersion are critical to ensure 
deep lung delivery [216,217]. Moreover, for nasal delivery to the brain, the residence time 
dictated by size and charge of the nanoparticles and microparticles is of critical importance for 
sufficient brain distribution.  
Particulate systems have several key parameters, including morphology, size, size distribution, 
porosity, density, surface charge, surface energy and controlled or sustained release. These 
parameters are functions of many variables to be considered in formulation development, such 
as, polymer lengths, surfactants, use of organic solvent and preparation methods. A wide range 
of natural polymers, for instance, albumin, collagen and chitosan are available, however, users 
must consider a potential lack of purity, the presence of homogeneity and the possibility of disease 
transmission. Nevertheless, these natural polymers can be modified, for instance, the acylation of 
chitosan, to achieve favourable characteristics like release rate. Synthetic polymers, like 
poly(lactide-co-glycolide) (PLGA) copolymers, polyacrylates, poly(lactic) acid (PLA), 
poly(butyl cyanoacrylate) and poly(lactic-co-lysine) graft polymers and poly anhydrides are 
available and offer advantages over natural polymers as they can provide sustained/controlled 
release, and have high purity, homogeneity and other desirable properties [216–218,220]. 
Targeting can also be achieved by using ligands. For instance, lectin may be used with polymeric 
microspheres, as it binds to simple/complex carbohydrates on bacterial cell walls,  and hence has 
been used against Helicobacter pylori infections by conjugation onto gliadin nanoparticles [220]. 
Lectin conjugated nanoparticles have also shown to improve nose-to-brain delivery and hence 
CNS bioavailability by increasing residence of nanoparticles in the nasal cavity (Table 1.8). 
Polymeric nanoparticles can be prepared by various methods, namely, emulsification-solvent 
removal, phase coacervation, interfacial polymerization and spray drying; depending on the 
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desired size and properties of the microsphere to be made, and physicochemical properties of the 
drug [218]. 
Table 1.7: Polymeric nanoparticles/microparticle therapies under investigation for antimicrobial delivery 
Polymer/ antimicrobial Effective against Treatment outcome(s) 
PBCA nanoparticle 
 
Rifampicin 
Antimycobacterial 
[220,221] 
Mycobacterium 
avium 
Staphylococcus 
aureus 
2 to 3-fold superior delivery of rifampicin-
loaded-PBCA to the alveolar macrophages 
leading to 2-fold increase in rifampicin 
efficacy compared to free rifampicin  
PLGA nano embedded 
microparticles 
 
Tobramycin 
Aminoglycoside 
[222] 
Pseudomonas 
aeruginosa 
 
(Inhalation-
DPI) 
PLGA-loaded tobramycin nanoparticles 
embedded in respirable lactose 
microparticles and consisting of helper 
polymers like chitosan showed greater 
mucin interactions and behaved as drug 
reservoirs to achieve sustained drug release 
PLGA nanoparticles 
 
Ciprofloxacin 
Fluoroquinolone 
[198,220,223] 
Staphylococcus 
aureus 
Pseudomonas 
aeruginosa 
 
(Inhalation-
DPI) 
Nano-ciprofloxacin formulations achieved 
sustained release of drug directly at the site 
of pulmonary infection and appropriate 
aerodynamic particle size to achieve deep 
lung access 
PIBSA nanoparticles 
 
Ciprofloxacin 
Fluoroquinolone 
[169] 
Mycobacterium 
avium 
Administration of ciprofloxacin-loaded 
PIBSA showed greater activity due to higher 
uptake in alveolar macrophages compared to 
free ciprofloxacin 
PLGA-Poly(lactide-co-glycolide), PIBSA-Polyisobutyl cyanoacrylate, PBCA-Polybutyl cyanoacrylate,  
 
  
Chapter 1| Introduction  
   
38	
	
Table 1.8: Polymeric nanoparticles/microparticle therapies under investigation for nose-to-brain delivery  
Polymer Effective against Treatment outcome(s) 
Neuroprotective drugs  
Lectin (Wheat 
germ agglutinin) 
conjugated  
PEG-PLA NPs 
[103] 
- Lecithin conjugated NPs showed 2-fold higher 
uptake in the brain owing to binding of lecithin 
to sialic acid and N-acetyl-D-glucosamine found 
in nasal cavity, hence, increasing the residence 
time of the NPs and improving brain uptake 
Odorranalectin 
conjugated  
PEG-PLGA NPs 
 
Urocortin peptide 
[104]  
Parkinson’s 
disease 
Lectin conjugated NPs showed increased uptake 
in DiR fluorescence studies in vivo up to 8 h, 
whereas, unconjugated NPs showed an initially 
similar uptake (to conjugated NPs) for 2 h after 
which fluorescence in the brain reduced. This 
indicated that conjugated NPs could remain 
longer in the nasal mucosa and hence release for 
a longer duration leading to greater brain 
distribution Moreover, neuroprotective effects 
on 6-hydroxy dopamine hemiparkinsonian rats 
was significantly enhanced for conjugated NPs 
encapsulating peptide delivered intranasally  
 
Chitosan NPs 
 
Estradiol/ 
didanosine/ 
thymoquinone 
[224–226] 
Alzheimer’s 
disease (estradiol/ 
thymoquinone) 
 
HIV (didanosine) 
Approximately 2.5-fold increase in estradiol 
delivery, significantly higher levels of 
didanosine and thymoquinone were seen in the 
CSF and brain of rats as compared to IV 
delivery of the NPs. 18-fold higher 
concentration of thymoquinone was seen from 
the NP formulation as compared to simple 
solution and amelioration of cognition was 
evident. Chitosan was considered to 
significantly improve the delivery by increasing 
the residence time due to mucoadhesion 
 
Chitosan NPs 
 
Olanzapine 
[227] 
Schizophrenia 
Bipolar I disorder 
Chitosan NPs encapsulating olanzapine 
delivered intranasally showed higher plasma 
concentration as compared to olanzapine 
solution delivered intranasally and 
approximately 2-fold higher absolute 
bioavailability as compared to IV administered 
olanzapine  
Anticancer drugs 
Chitosan 
microspheres 
 
Methotrexate  
[227] 
Primary central 
nervous system 
lymphoma 
Methotrexate loaded chitosan microspheres 
showed a higher nose-to-brain delivery and 
absolute bioavailability as compared to nasally 
delivered methotrexate solution, whereas, IV 
administered methotrexate solution was not 
detected in the brain sections 
Nano-co-Plex 
magnetic NPs 
 
Carmustin  
[228] 
Glioblastoma Significantly higher uptake and cytotoxicity of 
the Nano-co-Plex encapsulated carmustin in the 
presence of an external magnetic field was seen 
in in vitro studies on human glioblastoma cells 
 
Nano-co-Plex-polyvinyl alcohol/polyethyleneimine/folate (Polyplex) complex coated magnetite, PEG-PLGA-
poly (ethylene glycol)–poly (lactic-co-glycolic acid), NPs- nanoparticles 
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The mechanism of drug release from nanoparticles is governed by either homogenous (bulk) 
erosion or heterogeneous (surface) erosion. Bulk erosion occurs by degradation or erosion of the 
polymeric matrix throughout the entire system, whereas, surface erosion occurs by degradation 
or erosion of the polymeric matrix near the surface of the nanoparticles [229]. If the polymer 
matrix undergoes degradation, it releases the drug by diffusion through the channels created due 
to polymeric chain breakage [229]. Erosion of the polymer matrix leads to spontaneous drug 
release [218,219]. To date, most nanoparticles have been aerosolized using nebulizers. However, 
storage of colloidal preparations results in instabilities, such as polymer hydrolysis, drug loss, 
particle-particle interaction of nanoparticles or microparticles and particle aggregation. Previous 
studies have highlighted the importance of formulation development and nanoparticle size on 
production of aerosols with an optimum droplet size and the incorporation of particles into 
nebulized droplets. In addition to size, the surface properties of individual particles and their 
concentration play an important role in determining formulations release kinetics and the output 
from the nebulizer [230–232]. Dry powder formulations can be achieved by spray drying 
nanoparticle or microparticle dispersions, and this can be an attractive alternative ensuring long-
term stability of the particles. However, redispersion on aerosolization in the airway fluid is an 
important criteria, and retention of the particle size in the airways post-aerosolization can be a 
challenge [232].  
1.4.4 Lipid microparticles and nanoparticles- solid lipid nanoparticles 
Lipid microspheres and nanospheres may be used as an alternative to polymeric microspheres and 
liposomes. Solid-lipid nanoparticles (SLNs) or nanostructured lipid carriers (NLCs) range from 
50-400 nm and have attracted attention in the past 25 years due to the easy fabrication techniques. 
SLNs are viewed as a potential airway delivery system due to the low toxicity of phospholipid 
ingredients compared to polymer-based systems, higher tolerability in lungs, prolonged and 
controlled release properties and rapid in vivo degradation compared to PLGA or PLA particles 
[162,220]. Their composition includes fatty acids, steroids, triglycerides, partial glycerides, waxes 
that are solids/liquids at room temperature as well as surfactants to stabilize the SLNs. They can 
be prepared by simple spray drying, ultra-sonication or high-pressure homogenization and 
delivered as dry powders or dispersions for delivery via a nebulizer [162,220].  
Lipid microparticles and nanoparticles described in the literature are summarized in Table 1.9. 
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Table 1.9: Solid lipid nanoparticles therapies under investigation for antimicrobials, neuroprotective molecules, 
and cancer chemotherapeutics 
Solid lipid Effective against Treatment outcome(s) 
Antimicrobial (For pulmonary diseases) 
Stearic acid, soya, 
phosphatidylcholine and sodium 
taurocholate 
 
Tobramycin- Aminoglycoside 
Ciprofloxacin- Fluoroquinolone 
[220] 
Pseudomonas 
aeruginosa 
Increased drug bioavailability and 
prolonged drug release 
Stearic acid 
 
Rifampicin, isoniazid or 
pyrazinamide- Antimycobacterials 
[220,233] 
Mycobacterium 
tuberculosis 
Increased residence time, increased 
macrophage uptake and lymphatic 
system delivery achieved, decreased 
administration frequency due to 
increased bioavailability 
Neuroprotective molecules (For nose-to-brain delivery) 
Stearic acid, lecithin, poloxamer 
188 
 
Astaxanthin 
Antioxidant 
[234] 
Alzheimer's 
disease 
Parkinson's 
disease 
Intranasal administration of 99mTc 
labeled SLNs encapsulating 
astaxanthin showed approximately 2-
fold higher uptake as compared to IV 
administered formulation as 
confirmed by gamma scintigraphy 
imaging and biodistribution studies in 
vivo. In vitro, neuroprotection studies 
demonstrated protection against 
hydrogen peroxide induced oxidative 
stress  
Anticancer molecules (For nose-to-brain delivery): 
Precirol, Capmul MCM, Tween 80, 
soya lecithin 
 
Curcumin 
[235] 
Astrocytoma-
glioblastoma 
Significantly higher drug 
concentration of curcumin 
encapsulated in NLCs in the brain 
after intranasal administration as 
compared to plain drug suspension 
was reported  
1.4.5 Micelles 
Amphiphilic macromolecules having hydrophobic and hydrophilic regions tend to assemble in 
aqueous environments at a concentration greater than the critical micellar concentration into nano-
sized micelles.  These have widespread application within pharmaceutics, as hydrophobic drugs 
can be solubilized within the hydrophobic core of the micelles, allowing formulation at 
concentrations greater than their intrinsic water solubility. Moreover, these micelles can provide 
protection from degradation of the drug molecules and release kinetics can be manipulated by 
chemical alterations of the micellar surface, e.g. by cross-linking.  
Micellar formulations for airway applications described in the literature are summarized in Table 
1.10. 
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Table 1.10: Micellar therapies under investigation for antimicrobials and cancer chemotherapeutics 
Polymer/lipid Effective against Treatment outcomes(s) 
Antimicrobial (For pulmonary diseases) 
Depolymerized chitosan-stearic 
acid 
Nebulization 
 
Amphotericin B 
Antifungal  
[236] 
Candida 
albicans, 
Aspergillus spp 
Similar efficacy against all the different 
fungi 
Retention of encapsulation of 
amphotericin B after nebulization 
indicating no detrimental effect on the 
physical properties of the micelles on 
aerosolization using a jet nebulizer 
Branched polyethyleneimine-
stearic acid lipopolymer 
DPI 
 
Rifampicin 
Antimycobacterial 
[237] 
Mycobacterium 
smegmatis 
Higher uptake and internalization of 
the cationic micelles encapsulating 
rifampicin into phagosomal 
compartments of the alveolar 
macrophage cells THP-1 due to proton-
sponge effect was observed  
Anticancer molecules (For nose-to-brain delivery) 
MPEG-Polycaprolactam and 
MPEG-Polycaprolactam-Tat 
(cell penetrating peptide) 
targeted 
 
Camptothecin 
[238,239] 
Intracranial 
Glioma Tumour 
Intranasally administered MPEG-PCL-
Tat encapsulated camptothecin showed 
higher mean survival of tumour-
bearing rats compared to intranasally 
administered camptothecin solution 
due to stronger interactions of the 
positive Tat molecule with glioma cells  
 
Micelles can be formed from polymers/lipids that can been synthesized to achieve specific 
functionalities, such as targeting [216]. Polymeric micelles have been shown to be more stable 
than conventional surfactant micelles, having critical micellar concentrations less than 10-6 M 
[216,240–242]. One of the most prominent reasons for resistance to current antibiotics is the 
downregulation of uptake receptors on the surface of microorganisms. It would be an attractive 
approach to encapsulate such antibiotics within self-assembling micelles which would not be 
recognized by the receptor surfaces and hence help in intake of antibiotics into resistant bacteria.  
1.4.6 Large porous carriers 
Large porous carriers referred to as ‘Trojan particles’ by Tsapi et al. are micrometer-sized 
particles for inhaled drug delivery, particularly for pulmonary infections [243]. These can be of 
two types namely: 
1.4.6.1 Large porous particles (LPPs) 
These are characterized by a geometric size greater than 4-5 µm and a mass density less than 0.1 
g/cm3, resulting in the formation of particles which have a low aerodynamic diameter 
[59,243,244]. LPPs are an attractive system for pulmonary delivery as they have superior 
aerodynamic properties as compared to conventional particles of the same physical size. 60% of 
the nominal dose of such particles may reach the deep lung. Moreover, they are not cleared easily 
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by alveolar macrophages, due to their large size. Hence they are attractive for sustained release 
of drug in the lungs [59,245]. The highly porous surfaces and relatively large sizes of such 
particles help to decrease inter-particulate cohesion and consequently disperse more easily in the 
presence of airflow shear forces [59,245].  
Large porous capreomycin particles were manufactured by spray drying with L-leucine from a 
50% aqueous ethanol solution to produce particles having a mass median aerodynamic diameter 
(MMAD) of 5 µm. Insufflation delivery of these particles to guinea pigs resulted in reduced 
bacterial burdens, decreased alveolar clearance and hence a potential to lower the dose and 
decrease toxic side effects [246]. Edwards et al. determined the systemic bioavailability of insulin 
and suppression of blood glucose levels, using large porous PLGA particles encapsulating insulin, 
prepared by solvent evaporation techniques [247]. Inhalation of large porous insulin particles 
(mean physical diameter 6.8 µm, MMAD 2.15 µm) demonstrated higher insulin bioavailability 
and glucose suppression for 96 h than non-porous insulin particles (mean diameter 4.4 µm, 
MMAD 2.15 µm) which showed lower bioavailability and glucose suppression for only 4 h. 
Moreover, inhalation of large porous testosterone particles (mean diameter 20.4 µm and 10.1 µm) 
showed a higher systemic bioavailability when compared to subcutaneous administration of these 
porous particles. These results were attributed to the reduction in phagocytosis by deep lung 
alveolar macrophages, which are inefficient in the removal of particles greater than 3 µm, leading 
to sustained release and greater bioavailability of drug systemically [247].  
 
Figure 1.9: An SEM image of LPPs of tobramycin produced by PulmoSphere™ technology [59] 
An established engineering technique for preparation of LPPs is the Novartis PulmoSphere™ 
technology. These are manufactured by emulsion-based spray drying, wherein the submicron oil 
in water emulsion droplets are generated by high-pressure homogenization of perfluorooctyl 
bromide in water. The principal lipid component of PulmoSpheres is 
distearoylphosphatidylcholine (DSPC). Drugs, such as tobramycin and amphotericin B are 
dissolved in the oil phase of the emulsion [59]. An SEM image of PulmoSphere particles of 
tobramycin (Novartis Pharmaceuticals Canada Inc.) is as shown in Figure 1.9. 
PulmoSphere formulations of antimicrobials, namely tobramycin, amphotericin B, and 
ciprofloxacin have undergone at least Phase II clinical trials. Tobramycin inhalation powder- 
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TIP™ (TOBI® Podhaler®; Novartis Pharmaceuticals) is safe and efficacious in treating P. 
aeruginosa lung infections in CF patients, and has now been licensed and is marketed in several 
European countries, South America and Canada [59], [60]. A questionnaire survey of 39 patients 
and their parents, as well as 54 respiratory therapists, revealed that TIP™ (TOBI® Podhaler®) was 
considered to be more convenient and acceptable than tobramycin inhalation solution (TIS™ 
TOBI®) [59,248].  Ciprofloxacin PulmoSpheres (Bayer HealthCare) have also shown efficacy for 
the treatment of P. aeruginosa in CF patients [249]. This formulation was successful in Phase I 
clinical trials in 2013 to evaluate the potential of ciprofloxacin DPI for mild to moderate COPD. 
It also passed Phase II studies to evaluate safety and efficacy in patients with CF in May 2014 
[64,250,251]. 
1.4.6.2 Large porous nanoparticle aggregates (LPNAPs) 
LPNAPs comprise of micron-sized particles consisting of nanoparticles (1-100 nm) held together 
by Van der Waals forces or present in a matrix having components such as biopolymers, 
surfactants, amino acids, lipids, or proteins (Figure 1.10). LPNAPs have been made from a range 
of materials including silica, polystyrene, DPPC, albumin, hydroxypropyl cellulose and lactose 
in sizes ranging from 25 to 1000 nm. LPNAPs have similar physical and aerodynamic properties 
to LPPs, and once delivered to the lungs they dissociate to form individual nanoparticles [243]. 
LPNAPs can overcome the problems associated with the pulmonary delivery of nanoparticles, 
i.e. exhalation due to their small size, yet provide the advantages of nanoparticles when they are 
liberated in situ following deposition of the larger particles in the lungs.  
Rifampicin encapsulated in PLGA nanoparticles spray dried to form LPNAPs has demonstrated 
sustained release of drug delivered directly as an aerosol wherein a Cmax of rifampicin above the 
MIC was seen in the lungs and alveolar cells for up to 8 h, whereas free unencapsulated rifampicin 
was not detectable in the lung tissue or bronchoalveolar lavage 8 h after dosage [252]. This 
delivery system has a potential therapeutic advantage for treatment of extended resident infections 
which are difficult to eradicate like pulmonary TB.  
 
Figure 1.10: SEM images of LPNAPs, (A) hollow sphere and (B) magnified view of the particle surface [241] 
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1.4.7 Advantages of nanotechnology for airway delivery 
1.4.7.1 Protective vesicles preventing cargo degradation 
Nanocarriers can be an attractive approach for delivery of medicaments as they provide a 
protective environment that shields the cargo preventing degradation. Antibiotic inactivation by 
enzymes or interactions with other components in the biofilm matrix may reduce drug activity or 
cause complete resistance to it which contributes to multi-drug resistance. Human sputum being 
rich in polyanionic components, namely mucin, DNA, F-actin, lipopolysaccharides and 
lipoteichoic acid has been shown to reduce the antimicrobial properties of the cationic antibiotics, 
due to the formation of an electrostatic attraction complex, hampering complete eradication of the 
bacteria [88,253,254]. Encapsulation of these antibiotics in liposomes reduces formation of the 
electrostatic complex 100-fold, giving a 4-fold improved inhibition of P. aeruginosa colonies, 
suggesting a potential application in the eradication of chronic lung infections associated with CF 
[253,255]. 
1.4.7.2 Controlled release 
Antimicrobial therapy is hampered by the short availability of drug at the target site, potentially 
limiting treatment outcomes. Currently, for chronic pulmonary infections, high doses and frequent 
parenteral administration are necessary to achieve the pulmonary sputum concentrations required 
to eradicate the chronic colonies of biofilm and macrophage-associated bacteria [256–258]. 
However, protracted and recurrent administration of high dose antibiotics is associated with 
antibiotic resistance [258–260].  Inhaled antibiotics also face considerable challenges as they are 
rapidly cleared from the lungs by natural clearance mechanisms, namely exhalation for small 
particles, phagocytosis by macrophages and dendritic cells, mucociliary clearance and enzyme 
degradation. This may lead to antibiotic exposure at sub-inhibitory levels, leading to incomplete 
eradication of bacterial colonies embedded in the protective layers of sputum and biofilms, 
leading to higher incidences of antibiotic resistance [87].  
A logical approach to enhance the delivery of antibiotics for treating chronic infections by 
increasing their residence time, is to load them into appropriately sized carriers which could serve 
to deliver the drug to the site of infection.  However, chronic administration of the carrier may 
lead to their accumulation in the airways. Despite the phospholipids used in the preparation of 
liposomes sometimes being endogenous to the lungs; their repeated administration can lead to 
cumulative doses of lipids in the lungs greater than the original surfactant pool, resulting in 
adverse effects, such as phospholipidosis [182,261,262]. Hence, excipients should be minimized, 
with nanocarriers designed to deliver antimicrobials encapsulated in controlled/ sustained/ 
extended release vesicles which release the drug over extended periods, maintaining therapeutic 
levels in the vicinity of the biofilm, improving patient compliance whilst reducing chances for 
development of resistance [87,258]. Although a number of research articles have been published 
on the controlled release of antibiotics given systemically or as post-operative implants, few 
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reports are associated with the controlled release of antibiotics following pulmonary delivery 
[182,263–265]. Sustained release PNAPs comprising of PLGA nanoparticles encapsulating 
rifampicin showed lung tissue Cmax levels above MIC for up to 8 h after aerosolization, whereas 
rifampicin was undetectable in the lung tissue 8 h after aerosolization of the free drug [252].  
Release profiles are of utmost importance for consideration when the medicament is to be 
delivered to the brain via intranasal administration as mucociliary clearance is highly dominant 
which affects the formulation residence time. Due to the limitation of delivery volumes to the 
nasal tract (0.4-1 mL) a combination of mucoadhesive formulations along with sustained/ 
controlled release of medicaments would be optimum to improve the bioavailability in the CNS. 
Nimodipine encapsulated microemulsions which gel in-situ due to temperature differences 
showing a sustained release of nimodipine exhibited a 10-fold higher brain concentration in vivo 
in rats as compared to intranasally administered nimodipine solution [266].  
These studies highlight the susceptibility of chronic bacterial infections and brain bioavailability 
on nasal administration to nanocarrier formulations and the importance of the formulation 
parameters, such as drug properties, choice of polymer, mucoadhesion, particle size and 
distribution, method of preparation of nanoparticles and release profile.  
1.4.7.3 Non-specific/Local delivery 
Pulmonary delivery 
Nanoparticles can be targeted locally by selective extravasation at the site of infection, due to the 
increased porosity of blood vessels induced by increased inflammatory factors [38]. Eradication 
of intracellular organisms presents severe challenges as therapeutic concentrations of 
antimicrobials in intracellular compartments are difficult to achieve due to their limited 
penetration capacity [267,268]. Thus, many antibiotics, such as β-lactam and aminoglycoside 
antibiotics show low concentrations in intracellular compartments due to poor penetration along 
with acidic and enzymatic degradation. However, quinolone and macrolide antibiotics, such as 
clindamycin, levofloxacin and amphotericin B attain higher intracellular concentrations as 
opposed to extracellular concentrations [267–269]. Mycobacterium tuberculosis binds to and 
internalizes in the alveolar macrophages as a survival mechanism, and hence is very difficult to 
eradicate completely. A study of liposome-encapsulated clofazimine against TB showed that 
liposomal formulations were much more effective in being taken up naturally by the 
macrophages, where the infection prevails, improving treatment outcomes and reducing the off-
target toxicity of the antitubercular drug in vitro and in vivo [270,271]. Liposomal clofazimine 
was more effective in the treatment of acute and chronic murine TB, giving a bactericidal effect 
with no re-emergence of Mycobacterium tuberculosis infection in mice [270,271].  
The fusogenic property of liposomes makes them an attractive approach for delivering 
antimicrobials directly to cells, due to their potential to fuse with phospholipid cell membranes. 
The fluidity of the liposomes can be achieved by lowering the phase transition temperature, by 
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incorporation of components of the inactivated Sendai virus envelope, using lipids which have 
the phosphatidylethanolamine moiety, lipids with double bonds and/or asymmetry in acyl chain, 
or by the addition of cholesterol [255,272–276]. Antibiotics enter Gram-negative bacteria by two 
routes: hydrophobic drugs enter by passive transport via the lipopolysaccharide and protein-rich 
outer membrane; whereas hydrophilic drugs enter through the outer membrane water-filled porin 
channels. A reduction in antibiotic susceptibility of resistant strains of bacteria has been reported 
due to the acquisition of genetic factors which lead to changes in the bacterial outer membrane 
porin channels, which strongly impacts the influx of antibiotics and hence bacterial susceptibility 
[275,277–280]. Fluidosomes™-Tobramycin is being developed by Axentis Pharma (Switzerland) 
and has demonstrated good safety and efficacy profiles in pre-clinical and Phase II clinical trials, 
when compared to the present available marketed treatments for management of chronic infection 
caused by Burkholderia cepacia pathogens associated with cystic fibrosis [255]. 
Non-specific approaches to targeting suffer from the drawbacks of non-specific drug delivery and 
uptake, hence selectively targeting to the site of infection may represent an attractive approach to 
increase uptake, to achieve higher doses to eradicate bacteria at the appropriate site, allow a 
reduction in dose and potentially reduce the potential for antimicrobial resistance.  
Nose-to-brain delivery 
Nanoparticles have shown to improve the bioavailability and therapeutic effect of several drugs 
like nimodipine, diazepam and morphine when applied intranasally due to passive/non-specific 
brain targeting [136,266,281]. Technetium-99m-labeled PLGA encapsulated diazepam 
nanoparticles showing sustained release for over 24 h and 61.3% direct nose-to-brain transport as 
compared to 1% for technetium-99m-labeled diazepam solution, whereas, drug targeting 
efficiency i.e. brain uptake via the blood increased 2-fold for the nanoparticles as compared to the 
solution, indicating that diazepam was majorly absorbed into the blood and then delivered to the 
brain when intranasally administered as a solution [282]. Moreover, intranasal morphine 
delivered with maltodextrin nanoparticles showed faster antinociceptive activity as compared to 
its subcutaneous counterpart which produced higher plasma levels of morphine but lower 
analgesia, suggesting direct nose-to-brain passive targeting of nanoparticles when intranasally 
administered [281]. However, there is a lack of literature confirming the route of uptake of 
nanoparticles via the olfactory nerves, as these and several more studies can only demonstrate 
superior drug bioavailability when encapsulated within nanocarriers as opposed to simple 
solutions, but cannot confirm the mechanism of the passage of these nanocarriers [100]. 
For delivery to brain tumours, nanoparticles <100 nm have demonstrated the ability to extravasate 
through the fenestrations and leaky vasculature of tumours and hence locate themselves primarily 
at tumour sites known as the enhanced permeability and retention effect (EPR). Accumulation of 
imaging agents and cancer chemotherapeutics within the porous BBTB has been achieved in the 
past [283,284]. However, circumvention of the BBB remains a major barrier for delivery of cancer 
chemotherapeutics given as an IV to achieve passive targeting to the BBTB. This is because the 
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BBB remains largely intact at the margins of the tumour and is more distorted in the bulk [284]. 
Hence passive nose-to-brain delivery to circumvent the BBB after which passive targeting via the 
EPR effect to the BBTB can be undertaken by encapsulating cancer chemotherapeutics within 
nanocarriers of size <100 nm administered intranasally. 
1.4.7.4 Specific targeting 
Pulmonary delivery 
Biofilm targeting- Understanding the generation of biofilms at the genetic and molecular levels 
has informed the development of drug delivery systems which may help in overcoming this 
physical barrier to effective antimicrobial therapy and help in improved elimination of chronic 
bacterial infections associated with biofilms. An attractive approach in disassembling the EPS 
matrix of bacterial biofilms, and hence enhancing antibiotic therapy has been studied previously 
[285,286]. Ciprofloxacin was loaded into PLGA nanoparticles, with and without a coating of 
DNAse enzyme. This enzyme has been found to be very effective in disrupting the integrity and 
viscoelastic nature of the DNA-rich EPS of biofilms, and greatly improves diffusion through it 
[285,286]. Ciprofloxacin was encapsulated in PLGA coated with DNAse by means of covalent 
linkage using poly-lysine on the surface of PLGA nanoparticles. These particles had improved 
mobility in Pseudomonas aeruginosa biofilms in both static and dynamic conditions, providing a 
platform for the treatment of biofilm-associated bacteria with biofilm disassembling and 
antibacterial agents [286]. 
 
Sputum targeting- Numerous studies have been conducted on the sputum expectorated from CF 
patients to understand the nature of the matrix microstructure, mesh spacing and its components 
to aid in delivering antibiotics and gene vectors through this obstacle majorly challenging the 
treatment of CF.  Suk et al. have shown that densely packed low molecular weight PEG imparted 
‘muco-inertness’ to the surface of polystyrene (PS) nanoparticles of different sizes. Transport of 
these nanoparticles through CF sputum, studied using multiple-particle-tracking analysis, showed 
that the uncoated PS nanoparticles with a charge on the surface due to a terminal amine group had 
a strongly hindered transport, whereas similarly sized nanoparticles with a muco-inert surface 
which showed greater movement in time-lapse studies. This was attributed to possible polyvalent 
adhesion interactions between the hydrophobic mucin fibers and hydrophobic core of PS 
nanoparticles, and electrostatic interactions of the positively-charged nanoparticles with sputum 
components, such as DNA and F-actin, all of which were masked when particles were densely 
coated with hydrophilic, uncharged PEG molecules [286]. This demonstrates the importance of 
nanoparticle properties such as surface charge, hydrophobicity, molecular weight and size, on the 
transport of particles and the encapsulated drug through the sputum [286,287]. 
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Macrophage targeting- As highlighted above, alveolar macrophages play a major role in 
combating infections. However, in chronic infections, bacteria and other organisms take these 
over, locating themselves in the protective environment where they multiply and become difficult 
to eradicate with routine antibiotics. To eradicate these intracellular infections, directly targeting 
to the macrophages could be a highly effective strategy. Much research has been performed to 
study the potential of PLGA microparticles and nanoparticles to target the alveolar macrophages, 
as they may remain membrane bound onto the alveolar macrophages for up to 2 weeks [288–
296]. Makino et al. showed the phagocytic uptake of rifampicin encapsulated in PLGA 
nanoparticles. 19-times higher uptake of rifampicin by the macrophage cells in vitro was found 
for PLGA-encapsulated rifampicin formulation compared to free drug in solution [293]. A similar 
study exploring the reasons for an increased uptake of PLGA nanoparticles into macrophage cells, 
concluded that 90% of PLGA nanoparticles encapsulating rifampicin were taken up and remained 
membrane bound onto the low pH hydrolase-rich regions of the phagolysosomes for 13 days, as 
shown by fluorescence and immune-electron microscopy, from where rifampicin is released over 
time. Further studies have confirmed that this formulation system was more efficient in the 
eradication of mycobacterium bovis infected macrophage RAW 264.7 cells compared to free 
rifampicin at the same concentration. Actively targeting nanoparticles to alveolar macrophages 
has been extensively investigated for the treatment of various infections associated with 
tuberculosis, visceral leishmaniasis and arthritis [297–299].  Gelatin nanoparticles encapsulating 
isoniazid with and without mannose conjugated to the surface of nanoparticles, required for 
selective delivery to macrophages, have been studied. Macrophage-uptake studies showed that 
mannosylated nanoparticles were taken up preferentially into macrophages compared to non-
mannosylated nanoparticles. The antitubercular activity, studied by inducing TB infection in 
BALB/C mice, showed much lower CFU/mL of spleen when the mice were treated with 
mannosylated gelatin nanoparticles encapsulating isoniazid, compared to non-mannosylated 
nanoparticles encapsulating isoniazid and free isoniazid. This suggests the macrophage uptake of 
the drug encapsulated in nanoparticles is an important pre-requisite for the treatment of 
intracellular infections. Similar results have been observed by others, studying conjugation of 
mannose onto SLNs, liposomes and polypropylene imine dendrimers [300–302]. 
 
Nose-to-brain delivery 
Active targeting to brain tumours and hence preferential accumulation within the tumour can be 
achieved by promoting drug release specifically at the tumour site by means of release from 
nanoparticles by microenvironmental change of pH or overexpression of protease and delivery of 
prodrugs active only in the tumour interstitial. Folate receptors are primarily overexpressed in 
cancer cells due to an increased requirement of folic acid for sustaining the rapid rate of growth 
and division of the cells [284]. Folic acid-conjugated nanoparticles have shown promise in the 
delivery of medicaments to many kinds of tumours including lungs, kidneys and brain [303]. 
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Chlorotoxin conjugated chitosan nanoparticles have shown promise in specifically targeting to 
the glioma cells and hence an improved uptake in gliomas in mice [284,304], Mitochondria 
targeting is another strategy for treatment of neurological disorders wherein mitochondria-
specific antioxidants e.g. MitoQ and SS31 have shown to mitigate oxidative stress and synaptic 
dysfunctions associated with AD [305]. Triphenyl phosphonium (TPP)-Ceria nanoparticles were 
targeted to the mitochondria by means of electrostatic attraction between the lipophilic TPP cation 
and anionic charge of the mitochondrial membrane potential. These targeted nanoparticles 
showed protection of neurons against oxidative stress studied by ROS formation, mitochondrial 
morphology changes and mitigation of neuronal death markers in AD model of mice [305]. 
1.4.7.5 Higher uptake and retention in lung tissue 
Antimicrobial lung concentrations are of crucial importance, as a drug concentration above the 
MIC and MBIC are required to achieve successful eradication of the infecting pathogens. 
Liposome-encapsulated amphotericin B has long been successfully marketed under the name 
AmBisome for intravenous infusion for the treatment of severe systemic and deep mycosis in the 
lungs. Several studies have been performed delivering these liposomes and other lipid-based 
systems via nebulization directly to the pulmonary tract to achieve high local concentrations and 
reduce undesirable systemic effects [306–308]. One such study has highlighted the beneficial 
effects of nebulized amphotericin B encapsulated in liposomes, compared to Fungizone (sodium 
deoxycholate complex) using a SPAG-2 nebulizer. AmBisome showed an eight-time higher 
concentration in the lungs (207 µg/mg lung tissue) than Fungizone (24.4 µg/mg lung tissue) using 
in vivo in murine models infected with Aspergillus fumigatus. Also, with a medium infection load 
of 107 CFU/g of tissue, AmBisome produced nearly completely eradicate from the lungs (mean 
CFU/g of lung tissue=0.54); however, Fungizone showed no improvement in eradication 
compared to the control group (mean CFU/g of lung tissue=3.31 for Fungizone and 5.30 for 
control). This demonstrates the importance of higher lung retention achieved with 
nanotechnology- based vesicles and their consequent beneficial effects on eradication of bacteria. 
Clinical trials are on-going for nebulized AmBisome (AMBINEB) in the prophylaxis of Invasive 
Pulmonary Aspergillosis in patients with Acute Myeloid Leukaemia and Allogeneic 
Haematopoietic Progenitor Cell Transplantation. Further clinical trials are being conducted 
following completion of Phase II studies of prophylactic nebulization of amphotericin B-lipid 
complex (Albecet®) in paediatric patients with acute leukemia [306–308]. 
1.4.8 Disadvantages of nanotechnology for airways delivery 
1.4.8.1 Formulation drawbacks 
Nanoparticles present many challenges, potentially limiting their progress onto the market. Key 
drawbacks include:  
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(1) Scale up and transitional development from the laboratory bench to industrial production is a 
challenge due to differences in the properties of nanoparticles compared to their bulk counterparts. 
Smaller sizes and commensurate large surface area can lead to high chances of aggregation, 
hindering physical handling at an industrial level [309]  
(2) Low drug encapsulation is a major limitation, and is often dependent on aqueous/lipid 
solubility, as exemplified by a drug’s logP 
(3) Stability of nanocarrier drug formulation may be problematic, for instance, leakage of drug 
on storage, changes in size and surface properties and, particle-particle interaction and 
aggregation  
(4) Stability of formulation for aerosolization processes, especially by nebulization of 
nanocarriers dispersed in liquid may result in particle rupture and drug loss and consequently 
unpredictable deposition patterns within the airways 
1.4.8.2 Toxicity of nanoparticles to the airways 
With the advent of nanoparticle drug delivery in pharmaceutical, biomedicine and cosmeceutical 
areas, the field of nanotoxicology has emerged to investigate potential adverse reactions to 
nanoparticles  [38,310]. Nanomaterial structures, due to their very small size and large surface 
area have a potential to be more toxic than conventionally sized bulk samples of the same 
materials. This is due to their deeper airway penetrations, large surface/mass ratios, aggregation 
capabilities and low water solubility. It has been seen that human alveolar macrophages are not 
capable of removing nanoparticles of size 70 nm and less, leading to their deep lung access and 
entrance into the bloodstream through the alveolar epithelium, and causing evident inflammation 
in other organs. The aggregation state is another important determinant. Aggregates of ultrafine 
carbon particles at concentrations of 1 µg/mL and greater impair the phagocytic function of 
human alveolar macrophage [38,310]. The large surface area/mass ratio enables these 
nanoparticles to undergo various reactions which result in toxicity and cause inflammation in 
animal models, whereas their counterpart larger particles have a demonstrable safety. This is due 
to novel surface characteristics which may contribute to reactions like generation of reactive 
oxygen species, i.e. free radical formation as shown for CuO and SiO2 nanoparticles; interlukin-
8 cytokine production evident following exposure to cobalt or TiO2 nanoparticles; increase in 
mRNA levels of inflammatory markers shown for by yttrium and zinc oxide nanoparticles 
[38,310]. 
To study toxicity, regulatory authorities require animal studies; however, in vivo studies are 
conducted using oral, intraperitoneal or dermal routes which do not completely portray inhalation 
effects. In vitro methods have been developed to study toxic effects on airway cells (Calu-3 
human cell line), alveolar epithelium (A549-human pulmonary cell line) or tissues. These are 
quicker, simpler and less expensive than in vivo tests. However, they do not completely take in 
account lung characteristics, such as microenvironments and inhalation effects [310].  
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1.5     Scope and Content of the thesis 
The aim of the thesis is to examine various nanocarriers encapsulating hydrophobic drugs 
engineered with favorable aerosol characteristics to be delivered via the airways. To achieve the 
aim, the objectives of the thesis are: 
• To engineer nanoparticles for the delivery of hydrophobic drugs, modulated to have desirable 
features to improve the efficacy of the drug formulation and to characterize these 
• To develop aerosol formulations and study parameters that dictate aerosolization efficiency 
• To investigate the effect of the formulation parameters on the in vitro biological performance 
of the nanoparticles 
For this purpose, the thesis has been divided into 6 chapters beginning with the introduction as 
chapter 1 which summarizes the literature relevant to the present work, followed by the general 
methods in chapter 2. Chapter 3-5 embodies the experimental sections of the research work 
carried out concluding with chapter 6 comprising of general discussions and future work. Each 
chapter outlines a brief introduction, followed by aims and objectives, materials and methods, 
results and discussion ending with a conclusion.
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2.1 Determination of particle size and zeta potential (surface charge) using Malvern 
Zetasizer 
The hydrodynamic diameter and the polydispersity index (PDI) of the nanosized formulations 
and the re-constituted spray dried powders were measured using dynamic light scattering (DLS) 
on a Malvern Zetasizer Nano ZS (Malvern Instruments Inc., UK) at a backscattering angle of 
173°, calculated using the Mark-Houwinck parameter. The dispersion medium for both the studies 
was deionized water with a viscosity of 0.8872 cP, refractive index of 1.330 and dielectric 
constant 78.5. 
0.5% w/v dispersion of each of the formulations were prepared in deionized water, of which 2 
mL was placed in a clear disposable polystyrene sizing cuvette (DTS0012) and measurements 
were performed immediately after preparation/reconstitution in triplicate at 25°C. The reported 
size was the Z-average size (or cumulative mean) and the PDI was a width parameter calculated 
from the cumulative data of signal intensities.   
The surface charge i.e. zeta potential was also determined using Malvern Zetasizer Nano ZS 
(Malvern Instruments Inc., UK), by calculating from the Smoluchowski's equation with an F(Kα) 
value of 1.50 using the principle of electrophoretic light scattering also known as laser Doppler 
velocimetry. 1 mL of the same 0.5% w/v solution was placed in a clear disposable zeta-cell 
(DTS1060C, Malvern Instruments Inc., UK) and measurements performed at 25°C. The results 
were expressed as the mean of triplicate measurements. 
2.2 Fourier transform infrared (FT-IR) spectroscopy  
FT-IR spectrum of the spray dried, physically mixed and co-ground powders were determined to 
analyze the chemical interactions between the drug and the excipients of the respective 
formulations (Chapter 3). FT-IR was also used to study the success of synthesis of mannosylated 
chitosan by analysis of the change in the fingerprint of the chemical groups on the chitosan 
polymer backbone (Chapter 4). A Spectrum™ 100 spectrophotometer (PerkinElmer, UK) 
operating in the mid-infrared region, equipped with a Universal Attenuated Total Reflectance 
(UATR) device was used. The UATR polarization assembly features a robust diamond crystal to 
study reflectance from the sample and has a 9-bounce diamond top-plate serving as a sample lens. 
Triplicate scans for each sample were run in the spectral region of 4000-6500 cm−1 with 25 scans 
recorded at a 4-cm resolution. Approximately 2 mg of powder was placed on the sample lens and 
pressed against it with the UATR device. Scans were run and the spectrum recorded using a 
PerkinElmer spectrum express software version 1.02.00. Before each scan, a background was run 
to eradicate any peaks arising from impurity on the sample lens. 
2.3 X-ray powder diffraction (XRPD) 
The crystallinity of individual raw materials, physically mixed powders, co-ground powders and 
the spray dried powders was determined at room temperature using wide angle X-ray diffraction 
with a 5th generation Rigaku Miniflex 600 X-ray powder diffractometer equipped with a 600-watt 
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X-ray tube, a copper anode operating in reflectance mode at wavelength kα λ 1.5418 Å, voltage 
of 40 kV and current 15 mA. The instrument uses a NaI scintillator as the detector, Kβ foil filter, 
and a graphite monochromator. Samples to be analyzed for crystallinity were mounted 
perpendicular to the horizontal axis and then rotated to obtain a scanning range of 5-60° 2ϴ at a 
step size of 0.025°/min and step rate of 2 step/min at 25°C, and hence a scanning time of 27.5 
min per sample with a total of 2750 points. The relative long-range order (crystalline) versus non-
order (amorphous) was assessed by comparison of the data obtained by XRPD for each sample 
using the PDXL version 2.7 software (Rigaku, Kent, England) linked to the diffractometer. 
2.4 Morphology analysis using electron microscopy 
Electron microscopy (EM) is a widely-used tool for structural analysis of particles in the 
nanometric and micrometric scale, which provides an insight into the morphology of particles in 
the liquid and solid state. Along with morphology, EM also provides some information about 
crystallinity, particle topography, density, surface roughness and porosity of particles which may 
influence the dispersibility of particles, and their aerodynamics.  
2.4.1 Scanning electron microscopy (SEM) 
The shape and surface morphology of the spray dried powders was examined using a FEI Quanta 
200F Scanning Electron Microscope (FEI, Netherlands). The samples were prepared by placing 
a small amount of freshly prepared spray dried powder, with the help of a brush, onto a 12.5 mm 
aluminium specimen pin stub covered with a double-sided adhesive black carbon tabs (Agor 
Scientific, UK) and then sputter-coated with gold in a Qourum Q150R rotary-pumped sputter 
coater (Qourum Technologies, UK). A coating of approximately 10 nm was established under 
vacuum, and an argon atmosphere purge at 20 mA for 3 min to prepare the non-conducting or 
poorly conducting specimens’ optimum for observation under SEM at 20 kV. 
2.4.2 Transmission electron microscopy (TEM) 
TEM micrographs for morphological examination of nanoparticles after preparation and 
reconstituted spray dried microparticles was carried out using an FEI CM120 BioTwin 
Transmission Electron Microscope (FEI/Philips, USA). 10 µL of nanoparticulate solution was 
placed on a Formvar/carbon coated 300-mesh copper specimen grid (F196/100:3.05 mm, Tab 
Labs, UK) after which excess sample was removed using a Whatman filter paper No.1, then 
negatively stained with 1% uranyl acetate (Sigma-Aldrich, Poole, UK) aqueous solution for 90 s 
and allowed to dry at room temperature. This specimen grid was then loaded onto a CM120 grid-
holder which was inserted into the goniometer compustage wherein the sample was exposed to 
an operating voltage of 120 kV and high-resolution images were captured using a digital camera 
AMT XR80 (AMT Imaging, USA). 
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2.5 Laser diffraction particle size analysis  
The particle size distribution of the co-ground and spray dried powders was determined using 
Sympatec HELOS particle size analyzer (Sympatec GmbH, Clausthal-Zellerfeld, Germany) 
based on the principle of laser diffraction following the Lorenz-Mie theory. An R2 lens was 
selected which measures particle size in the range 0.25 to 87.5 µm, and powders were dispersed 
with a RODOS i.e. ‘Rotating Dosing and Dispersing System’ dry powder disperser (Sympatec) 
at different pressures [311]. The analysis was carried out using a parallel beam from an optical 
system consisting of a helium-neon laser at 623.8 nm and a semicircular 180° multi-element 
photodetector [312]. Particle size distribution data was processed by MIEE, i.e. Mie Extended 
Evaluation, for spherical particles of known refractive index in the range of 0.1-8750 µm. Data 
obtained were expressed as the volume-weighted mean particle size using a WINDOX 5 software 
[313].  
Measurements were performed on a RODOS/M disperser supplying a near constant mass flow of 
sample equipped with a micro-dosing device ASPIROS/L designed to feed small amounts of 
powder. A feed rate of 50 mm/s was applied and analysis performed at different pressures. An 
empty sample glass vial was placed into the ASPIROS and a measurement was run to be read as 
a reference after which approximately 5-10 mg of each sample powder was filled into the glass 
vial and placed back in the ASPIROS. Three replicates were performed on a single sample of 
powder and three batches of each powder analyzed to ensure accuracy and reproducibility of 
measurements. Results recorded on a HELOS system was expressed as volume weighted mean 
particle size namely Dv10, Dv50 and Dv90 (also known as X10, X50, X90). The Span of the 
volume distribution i.e. a dimensionless parameter used for quantification of volume distribution 
relative to the 10th, 50th and 90th percentile of cumulative distribution was derived from equation 
2.1:  
Span= 
-./01-.20-.30  
where, Dv10, Dv50 and Dv90 stand for the particle sizes of a given percentage of particles smaller 
than the specified size. Span is reflective of the uniformity of distribution wherein a high Span 
value is an indication of a wider particle size distribution and size heterogeneity of the powders. 
2.6 In vitro aerosol deposition and aerodynamic behavior studies using the Next Generation 
Impactor (NGI) 
Spray dried microparticles prepared with the intention of being delivered as a dry powder 
inhalation were tested for their aerodynamic behavior using the Next Generation Pharmaceutical 
Impactor (Copley Scientific, Ph. Eur. Apparatus E, NGI) operated in specifications by the 
European Pharmacopoeia (Ph. Eur. 9th edition, monograph 2.9.18).  
In each experiment size 3 transparent gelatin capsules (Dr T & T Health, UK) were filled manually 
with 30 ± 0.2 mg of formulation and used for NGI. As per the European Pharmacopeia, two 
Equation 2.1 
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factors were to be considered before performing and accepting results from the NGI. The first 
important factor to consider is the mass balance phenomenon. To ensure a valid inference, it is 
important to recover 100 ± 25% of the initial average dose of the active drug. Re-entrainment 
being the second factor should be prevented by coating the pans with silicone oil, glycerol or 
other high viscosity liquids through the evaporation of a volatile solvent. Re-entrainment was 
minimized in the present experiment by coating the pans of stages 1-7 of the NGI with 1% silicone 
oil (Sigma- Aldrich, UK) in n-hexane and leaving them aside for 20 min for n-hexane to evaporate 
and the pans to be evenly coated with silicone oil. A 75-mm internal filter (Copley Scientific, 
UK) was placed in stage 8, i.e. the micro-orifice collector (MOC), to prevent very fine particles 
of the formulation to exit into the pump and cause clogging. After the pans were dried, the 
apparatus with the assembly of pans on the bottom frame was closed by the seal body using the 
clamping handle (Figure 2.1).  
 
 
The central cup of the pre-separator insert was filled with 15 mL of solvent used for HPLC 
(DMSO: methanol (1:1) for amphotericin B nanocomplexes and methanol for rifampicin and 
ibuprofen co-encapsulated liposomes). The pre-separator was then closed by clamping the two 
side clutches together and subsequently placed onto the port of the first stage as seen in Figure 
2.1B. This was then connected to a stainless steel 90° induction port which was connected to the 
mouthpiece and inhalation device Cyclohaler®.  
The vacuum pump (Model HCP5, Copley Instruments, UK) that was attached to the outlet of the 
NGI was switched on and was modulated to achieve an air flow of 60 L/min which was well 
within the accepted pharmacopoeial limits of 30-100 L/min. This flow rate was confirmed using 
an efficient flow meter model DFM2000 (Copley Scientific, UK). An actuation time of 4 s 
controlled by a timer on the critical flow controller was chosen to match the pharmacopeial 
standard, to achieve 4 L in a normal adult [314]. After this was set, the induction port was 
connected to a mouthpiece adapter and was attached to a Cyclohaler® (also known as the 
Aerolizer®, Pharmacemie, UK) containing filled capsules. The capsule was pierced, and without 
leaving the pins of the Cyclohaler® it was placed into the mouthpiece adapter. The timer was 
instantly put on when the pins were released and perforations on the capsule allowed discharge 
of the dry powder formulation during actuation. 
 seal body 
MOC 
 bottom frame 
 1  3 
 2 4 
 5 
 6  7 
clamping 
handle 
pre-separator 
induction port 
Figure 2.1: NGI in open view (A) and closed view (B) (adapted from www.copleyscientific.com) 
(A) (B) 
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The stage classifications and dilutions are as given in Table 2.1 below: 
Table 2.1: Table showing NGI stage differentiations and cut-off diameters at 60 L/min 
Stage NGI components 
Cut-off diameter 
(µm) 
Dilutions (mL) 
X Capsules - 10 
A Cyclohaler® + Mouthpiece adapter - 50 
B Induction port - 25 
C Pre-separator - 50 
1 Stage 1 8.06 10 
2 Stage 2 4.46 10 
3 Stage 3 2.82 10 
4 Stage 4 1.66 10 
5 Stage 5 0.94 10 
6 Stage 6 0.55 10 
7 Stage 7 0.34 10 
8 
Micro orifice collector 
+75mm filter 
0.14 10 
 
After the experiment, each stage was rinsed with the HPLC solvent (DMSO: methanol (1:1) for 
amphotericin B nanocomplexes and methanol for rifampicin and ibuprofen co-encapsulated 
liposomes), placed in separate volumetric flasks and appropriate dilutions performed (taking into 
consideration the Beer-Lambert linearity range for each drug, Table 2.1) to detect the 
concentration of drug(s) at each stage of the NGI after experimentation using HPLC. 
 
Calculations were performed to determine the aerosol parameters as follows:  
Emitted dose (ED)- expressed as a percentage; is the total mass of drug that exited the capsule 
and was impacted into the NGI from stage A to stage 8 over the total average mass of drug loaded 
into the capsules. It can be expressed as equation 2.2:  45	 % = 	789:;<	9=	!>:?	>@A9B@>@!	=>98	C<D?@	7	<9	8789:;<	9=	!>:?	>@A9B@>@!	=>98	C<D?@	F	<9	8	×100 
 
 
Fraction recovered (FR)- expressed as a percentage; is the total mass of drug aerosolized and 
recovered from stage X to 8, versus the total average mass of drug that was initially loaded into 
the capsules and aerosolized. It can be expressed as equation 2.3: JK	 % = 	789:;<	9=	!>:?	>@A9B@>@!	=>98	C<D?@		F	<9	8789:;<	9=	!>:?	<ℎ@>9@<MADNNO	D@>9C9NMP@! ×100 
 
 
Fine Particle Fraction (FPF, expressed as a percentage) and fine particle dose (FPD, expressed 
in mg); is the total mass of drug impacted from stage 2 to stage 8 that is having an aerodynamic 
Equation 2.2 
Equation 2.3 
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diameter below 5 µm, versus the total sum of drug recovered from impaction on stage X to stage 
8 of the NGI. Stage 2 had a cut-off diameter of 4.46 µm at an operational flow rate of 60 L/min 
(Table 2.1). FPF can be expressed as equation 2.4:  
 JQJ	(%) = 	789:;<	9=	!>:?	>@A9B@>@!	=>98	C<D?@	2	<9	C<D?@	8789:;<	9=	!>:?	>@A9B@>@!	=>98	C<D?@	F	<9	8 ×100 
 
Each measurement was performed in triplicates and reported as mean ±SD.  
 
Mass median aerodynamic diameter (MMAD)- expressed in µm; is defined as the median 
particle diameter i.e. diameter at which 50% of the particles are smaller and 50% are larger by 
mass, deposited within the NGI. 
 
Geometric standard deviation (GSD)- measures the spread of the mass median aerodynamic 
particle size distribution, calculated as the square root of the aerodynamic diameter at the 84.13th 
percentile (d84.13) over the 15.87th percentile (d15.87) of the aerosol mass. It can be expressed as 
equation 2.5:  
ST5 = 	 !UV.2X!23.UY 
The MMAD and GSD of the formulations were determined using the plot of cumulative mass 
distributions versus the logarithm of aerodynamic diameter, on the MMAD calculator 
(www.mmadcalculator.com), which follows recommendations by the ISO 27427:2013 
Nebulizing Systems and Components. 
2.7 High-performance liquid chromatography (HPLC) 
The drug content of formulations after encapsulation and spray drying, and the amount of drug 
deposited at each stage of the NGI was determined with an HPLC using Agilent 1260 infinity 
series (Agilent Technologies UK Ltd., UK). The specific methods for drug elution and detection 
are outlined in the individual chapters. The analytical method development and validation were 
in accordance with the International Conference on Harmonisation (ICH) guideline Q2(R1): 
Validation of Analytical Procedures: Text and Methodology. 
 
Analytical method validation 
HPLC method developed for the determination of amphotericin B, rifampicin, ibuprofen, 
CNB001 or curcumin, was validated for linearity, accuracy, and precision, to ascertain that the 
method adopted was unbiased and without error. 
Linearity:  Linearity of an analytical method can be defined by the Beer-Lambert law, as a 
mathematical relationship where absorbance is directly proportional to the concentration of 
Equation 2.4 
Equation 2.5 
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analyte in a sample within a definite range of study [315]. Beer-Lambert law of linear regression 
operates over a range of diluted analytes and it should be kept in mind that deviation from linearity 
can be observed when the sample is too concentrated or below the limit of quantification (LOQ). 
Hence, the range of interest for each drug was set in accordance with the Beer-Lambert law of 
linear regression. 
A standard curve (calibration curve) was constructed for each sample analysis in triplicate using 
the same method of HPLC analysis as that intended for the formulations. Peak area as an average 
of 5 replicates was used to derive the standard equation and correlation coefficient (R2) of the best 
fit line, by least square regression method. This standard equation was then considered linear if 
the R2 value was approximately 1 and used for calculation of the concentration of drug in the 
respective nano-formulations and for determination of the fraction of drug retained at each stage 
of the NGI. 
 
Accuracy: Accuracy can be referred to as closeness of agreement of an individual observation or 
an average of a set of observations, i.e. the ‘measured value’ to the conventional ‘true value’ or 
an accepted reference value [316,317]. The ‘true value’ considered in the calculation of accuracy 
is the result that would be expected in an absence of error, i.e. random or systemic errors related 
to the test procedure and result [315]. Accuracy in intraday and inter-day analysis was determined 
by 9 determinations over a minimum of 3 different concentrations covering a specified range with 
low, medium and high concentrations of drug within the range. The accuracy obtained is 
represented as % bias or % relative error (i.e. error from the added theoretical concentration) and 
can be defined as the percentage agreement, calculated from equation 2.6, and a value of <15% 
for all concentrations was considered as acceptable [318,319]: 
                                                                                                                  K@ND<MB@	@>>9>	(%) = Z>:@	BDN:@ − 8@DC:>@!	BDN:@Z>:@	BDN:@ 	×100 
 
Precision: Precision is the extent of variation (percent coefficient of variance) or closeness in 
agreement of a series of measurements obtained by multiple sampling of a single sample under 
similar conditions of analysis [316,320]. It helps to analyze random errors in intra and inter-day 
analysis. It can be subdivided into two aspects namely reproducibility and repeatability by 
determination of the coefficient of variance (CV) or the relative standard deviation (RSD) (from 
the true precision) for the analysis. The RSD or CV expressed as a percentage can be calculated 
using the equation 2.7: 
  KT5	9>	\]	(%) = C<D;!D>!	!@BMD<M9;8@D; 	×100 
 
Equation 2.6 
Equation 2.7 
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2.8 Statistical analysis 
The values were calculated as an average of three separate repeats and presented as mean±SD. 
Comparison of groups was undertaken using One-way Analysis of Variance (ANOVA) Tukey 
post-hoc test using the software OriginPro 8 SR0 v8.0724. Repeated Measures One-way ANOVA 
(rANOVA) Tukey post-hoc was used to compare different groups measured at multiple time 
points to see changes to the response as a whole. This was studied using the software IBM SPSS 
Statistics v24.0. A p value of less than 0.05 was considered significant for both the statistical tests.
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3.1    Introduction 
3.1.1 Pulmonary fungal infections 
Pulmonary fungal infections can be categorized as endemic infections affecting both 
immunocompetent and immunocompromised patients, or opportunistic infections which can 
specifically affect immunocompromised patients. Opportunistic infections have steadily 
increased over the past few decades owing to ever-growing risk factors such as human 
immunodeficiency virus (HIV), solid organ or haematopoietic cell transplant and haematological 
malignancy, leading to immune suppression and increased susceptibility to fungal infections.  
Invasive pulmonary aspergillosis being a highly opportunistic life-threatening infection affects 
immunocompromised patients the most, however, over the previous years an increase rate of 
infection has been seen in immunocompetent patients, patients with COPD on corticosteroid 
therapy and critically ill patients diagnosed with invasive pulmonary aspergillosis. Review of 
literature for the invasive aspergillosis infection in 1941 patients demonstrated that about 70% of 
infections involved the pulmonary tract, wherein, patients with malignancies and HIV were most 
likely to develop invasive pulmonary aspergillosis [55,321]. Pulmonary candidiasis is another 
serious fungal infection, which mostly challenges immunocompromised patients and has seen an 
increase in incidence over the past years. However, the diagnosis of pulmonary candidiasis can 
be difficult as normal human flora has the presence of Candida spp, and hence the mortality rate 
associated with pulmonary candidiasis is alarmingly high, especially in patients with 
malignancies [322–324]. Current pulmonary fungal infections and their treatment strategies have 
been outlined in Table 3.1, which indicates the importance of use of amphotericin B as a broad 
spectrum antifungal agent in clinical practice. 
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Table 3.1: Current treatment strategies for lung fungal infections (amphotericin B formulations in bold) 
[56,57,323,325,326] 
Pulmonary 
Infection First-line treatment Second-line treatment 
Opportunistic infections 
Aspergillosis Voriconazole 
 
4 mg/kg bid IV 
Lipid amphotericin B 
(Abelcet® /Amphocil®/ 
AmBisome®) 
 
5 mg/kg/d IV 
Cryptococcosis Severe or immunocompromised 
patients: 
Lipid amphotericin B 
(Abelcet®/Amphocil®/AmBisome®), 
 
3-5 mg/kg/d IV + flucytosine 25 
mg/kg/qid oral 
 
Amphotericin B deoxycholate 
(Fungizone®) 
 
0.7-1 mg/kg/d IV + flucytosine 
25 mg/kg/qid oral 
Candidiasis Echinocandin caspofungin 
 
70mg/d or Fluconazole (12 
mg/kg/d) IV or oral 
Lipid amphotericin B 
(Abelcet®/Amphocil®/ 
AmBisome®) 
 
3-5 mg/kg/d IV 
Mucormycosis Lipid amphotericin B  
(Abelcet®/Amphocil®/AmBisome®), 
 
5 mg/kg/d or more IV 
Amphotericin B deoxycholate 
(Fungizone®) 
 
1 mg/kg/d IV + Echinocandin 
Endemic infections 
Histoplasmosis Severe or immunocompromised 
patients: 
Lipid amphotericin B 
(Abelcet®/Amphocil®/AmBisome®) 
 
3-5 mg/kg/d IV 
Amphotericin B deoxycholate 
(Fungizone®) 
 
0.7-1 mg/kg/d IV until stable 
then Itraconazole 200 mg bid 
oral 
Blastomycosis Severe or immunocompromised 
patients: 
Lipid amphotericin B 
(Abelcet®/Amphocil®/AmBisome®) 
 
3-5 mg/kg/d IV 
Amphotericin B deoxycholate 
(Fungizone®) 
 
0.7-1 mg/kg/d IV until stable 
then Itraconazole 200 mg bid 
oral 
Coccidioidomycosis Severe or immunocompromised 
patients: 
Lipid amphotericin B 
(Abelcet®/Amphocil®/AmBisome®) 
 
3-5 mg/kg/d IV 
Amphotericin B deoxycholate 
(Fungizone®) 
 
0.7-1 mg/kg/d IV until stable 
then Itraconazole 200 mg bid 
oral 
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3.1.2 Amphotericin B: The ‘gold’ standard treatment and its shortcoming 
Despite the advent of other antifungal drugs, for over 50 years since its first clinical experience 
and approval around 1966 as a deoxycholate complex (Fungizone®), amphotericin B a 
macrocyclic polyene antifungal has been regarded as the ‘gold standard’ for the management and 
treatment of varied fungal infections, due its broad spectrum of activity and low rate of fungal 
resistance [327,328]. Fungal resistance to amphotericin B by Candida albicans has been reported 
only in vitro, however, no such resistance has been noted during clinical use of the drug to any 
fungal species [327]. Hence this polyene antibiotic is still the first choice of treatment for serious 
life-threatening fungal infections  
Amphotericin B (Figure 3.1 and Table 3.2) a zwitterionic amphiphile, is very poorly absorbed 
following oral administration wherein peak serum levels of only 0.04-0.05 µg/mL were observed 
on administration of 1.6-5 g/day [327].  
 
Figure 3.1: Structure of amphotericin B 
Table 3.2: Physicochemical properties of amphotericin B 
 
 
 
 
 
 
 
 
Numerous studies to alter the oral dosage regimen of amphotericin B have been carried out with 
no progress, and hence to date treatment of pulmonary and systemic fungal infections have been 
restricted to the parenteral route. Owing to its poor water and organic solvent solubility, being 
classified as BCS Class IV compound (low solubility and permeability), a more soluble form of 
amphotericin B needs to be parenterally administered, and hence Fungizone® also known as 
‘conventional form of amphotericin B’ has been used over the years [329]. The parenteral route 
of administration, however, has several limitations, the most serious being life-threatening 
hyperkalemia, inducing arrhythmias, which has been observed with rapid amphotericin B infusion 
requiring slow infusion rates [330]. Goodwin et al. reported 71% patients receiving amphotericin 
B (Fungizone®) IV infusion developed at least one infusion-related adverse effect including 
Molecular 
formula 
C47H73NO17 
pKa 5.5 
Molecular 
weight 
924.091 g/mol 
Solubility 
Practically insoluble in water, 
ethanol, toluene and ether 
Soluble in dimethylformamide 
and DMSO 
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nausea, fever, chills, thrombophlebitis and arthralgia [331]. Hence, efforts are being made to 
progressively utilize nanomedicine and develop other soluble forms of amphotericin B which 
might be better tolerated than the conventional form Fungizone®.  
Other than infusion-related adverse effects, administration of amphotericin B as its deoxycholate 
salt has been greatly challenged by the issues of dose-limiting acute or chronic organ toxicity, 
especially nephrotoxicity. Amphotericin B selectively binds to ergosterol in the fungal cell 
membrane, forming pores ultimately leading to fungal death due to rapid leakage of monovalent 
ions like potassium, sodium and chloride. Moreover, amphotericin B also has an affinity to 
cholesterol in human host cell membrane, although less than its affinity to fungal cell membrane 
ergosterol. This non-selective binding to human cell membrane cholesterol leads to the formation 
of pores and hence its lethal effects on human cells [332,333].  
The currently marketed nano-formulations of amphotericin B are outlined in Table 3.3. 
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Table 3.3: Marketed amphotericin B nano-formulations for treatment of fungal infections  [334–336] 
Formulation name, type 
and composition 
Route of 
administe-
ration and 
dose 
Drawback Cost and treatment outcomes(s) 
Surfactant-based nano 
formulation 
 
Fungizone® (colloidal 
system) 
50 mg Amphotericin B: 41 
mg sodium deoxycholate 
Lyophilized powder forms 
micellar dispersion on 
reconstitution, however, on 
infusion in the blood, the 
CMC of deoxycholate is not 
reached and hence forms 
monomeric dissociates of 
amphotericin B 
 
 
 
1-1.5 
mg/kg 
IV infusion 
over 2-6 h 
 
(> 1.5 
mg/kg is 
lethal dose) 
Fever, chills, 
nausea, 
hypotension, 
tachypnea and 
nephrotoxicity 
which is the 
major dose-
limiting factor 
£3.88/ 50 mg vial 
 
Although Fungizone® is the 
cheapest and oldest 
amphotericin B formulation 
approved by FDA in 1966, 
the toxicity profile associated 
with this formulation has 
necessitated the need for 
development of less toxic 
amphotericin B formulations 
Lipid-based nano 
formulation 
 
Abelcet®/ Amphocil® (lipid 
complex) 
Amphotericin B 1:1 lipid 
(DMPC: DMPG 7:3) 
>250 nm ribbon-like 
structure, 1.6–11 µm 
 
Amphotec® (colloidal lipid 
dispersion) 
Amphotericin B 1:1 sodium 
cholesteryl sulphate, 
122 nm x 4 nm colloidal 
disc-shaped particles 
 
 
 
5 mg/kg IV 
infusion 
over 2 h 
(allows fast 
infusion) 
 
 
3-4 mg/kg 
IV infusion 
at a rate of 
1 mg/kg/h 
Fever, chills, 
nausea and 
vomiting 
£77.50/ 20 mL vial Abelcet® 
and £63.58/ 100 mg vial 
Amphotec®, FDA 1995 and 
1996 respectively 
 
Targeting to the mononuclear 
phagocytes helps in selective 
transfer of the amphotericin 
B lipid complex to the fungal 
wall and hence minimal 
uptake in human cells 
Liposomes 
 
AmBisome® (Unilamellar 
liposomes) 
Amphotericin B 50 mg 
encapsulated in 
hydrogenated soy PC: Chol: 
DSPG (2:0.8:1 molar) 
spherical 60-70 nm 
 
 
 
3-5 mg/kg 
IV infusion 
over 1-2 h 
(allows fast 
infusion) 
IV infusion of 
AmBisome® 
leads to fever, 
chills, nausea 
and diarrhoea 
£82.19/ 50 mg vial, FDA 
1997 
The negative charge on the 
liposome helps in uptake into 
the mononuclear phagocytes, 
and hence a direct transfer 
onto the fungal wall leading 
to minimal association and 
toxicity with human cells. 
A comparative double-blind 
study compared to Fungizone 
and Abelcet® showed that 
AmBisome® is significantly 
less nephrotoxic than the 
other formulations 
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Nephrotoxicity is a major concern especially when the treatment group consists of 
immunocompromised patients. A study on severely immunocompromised patients treated with 
conventional amphotericin B for the management of suspected or proven aspergillosis, the kidney 
function declined indicated by the doubling of the creatinine levels for 53% of the patients. 14.5 
% patients underwent dialysis, of which 76% patients died due to nephrotoxicity [337,338]. 
Increased renal failure and fatality due to amphotericin B nephrotoxicity have also been reported 
previously in other clinical studies [339,340]. Harbarth et al. evaluated the outcome of 
conventional amphotericin B treatment in a 9-year study involving 494 hospitalized patients. He 
concluded that nephrotoxicity was involved with a 2.7-fold higher fatality rate (p <0.001) 
[336,341]. Hence, although amphotericin B is considered a mainstay therapy for treatment of 
systemic fungal infections due to its broad spectrum of activity and lack of drug resistance, its 
clinical use is discouraged due to its low tolerability, especially in immunocompromised patients. 
Numerous strategies like dose reduction, alternative amphotericin dosing and intervals, saline 
loading and vigorous patient hydration, have been used to reduce the nephrotoxicity and infusion-
related adverse effects of amphotericin B  [329]. However, these did not reduce the undesirable 
tolerance profiles of the drug [329].  
Replacement of Fungizone® with other amphotericin B formulations as shown in Table 3.3, has 
been found to significantly improve the tolerability of the formulation by reducing adverse effects. 
Comparative studies of lipid-based Abelcet® versus Fungizone® demonstrated a lower circulation 
amphotericin B serum concentration. It was observed that due to the large size (1.6-11 µm) of the 
discs, the complexes were readily uptaken by macrophages, and distributed to the liver, spleen 
and lung. An approximately 6.8 and 13.2-fold higher level of amphotericin B in the lungs as 
compared to AmBisome® and Fungizone® respectively, revealed its prospect in use for treatment 
of pulmonary fungal infections [336]. Moreover, the complexes were more stable in plasma when 
compared to Fungizone® and released amphotericin B from the lipid complexes at sites where 
activated host inflammatory cells or invading fungal cells released phospholipases [342]. Owing 
to this, free amphotericin B was not available in the bloodstream reducing the chances of toxicity 
to human cells. Further pharmacokinetic studies suggesting that Abelcet® acts as a depot for 
amphotericin B release, limiting its exposure to human cells hence improving the toxicity profile 
of amphotericin B [336,343,344]. 
Liposomal amphotericin B AmBisome® owing to the small size (60-70 nm) and high negative 
surface charge has been shown to establish a much higher Cmax of 83 ± 35.2 µg/mL as compared 
to the Cmax of Fungizone® 1.5–2.9 µg/mL or Abelcet® 1.7 µg/mL. This is due to its ability to 
avoid initial substantial recognition and uptake by the macrophages on infusion. Moreover, the 
pharmacokinetic profile of amphotericin B is altered wherein slow release from the liposomes 
and prevention of uncontrollable drug leakage reduces the chances of host cell interactions and 
hence reduces the toxicity of amphotericin B [336]. Clinical trial studies have demonstrated that 
liposomal amphotericin B is at least as or better tolerated than other lipid-based amphotericin B 
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formulations and significantly better tolerated than conventional amphotericin B [330]. 
Furthermore, a significantly better clinical efficacy in HIV patients infected with moderate to 
severe disseminated histoplasmosis owing to its lower clearance and higher Cmax, showed its 
superiority in treatment of systemic fungal infections [330].  
However, clinical use of lipid-based amphotericin B nano-formulations are limited by the high 
cost of these i.e. 24-40 times more than conventional amphotericin B. This along with other 
reasons such as requiring patient hospitalization and still prevalent adverse effects (to a lower 
extend with lipid based amphotericin B formulations) has limited their widespread clinical use 
suggesting progressive development of nano-formulations of amphotericin B is necessary. 
3.1.3 Amphotericin B aerosolization 
Treatment of pulmonary fungal infections may be tackled by using direct inhalation strategies 
instead of IV infusion, as it could help in overcoming the nephrotoxicity and infusion-related 
adverse effects of amphotericin B. Delivering high concentrations at the site of infection reducing 
the dose, increasing residence time of antimicrobial and eventually reducing toxicity along with 
costs, make direct aerosolization more practical. IV administration of the amphotericin B 
formulations at a 5 mg/kg/day dose has been shown to be insufficient for eradication of fungus 
from the lungs [345]. Gavaldà et al. studied the effect of nebulized versus IV infusion of 
Fungizone® and AmBisome® in immunosuppressed female Wistar rats. The study highlighted 
that aerosolized formulations significantly improved or at least prolonged survival rate, 
suggesting its usefulness for treatment of invasive pulmonary Aspergillosis [345]. Numerous pilot 
randomized trials and clinical trials to study the effect of nebulized amphotericin B formulations 
have been carried out and outlined in Table 3.4. 
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Table 3.4: Randomized clinical trials evaluating the use of aerosolized amphotericin B nano-formulations for   
treatment of fungal infections 
Formulation Side effects Conclusion 
Nebulized Fungizone® 
as prophylaxis 
[65] 
Well tolerated with only a 
few mild side effects  
 
Severe bronchospasm 
observed requiring for 
withdrawal of prophylaxis in 
only one patient 
 
Minimal systemic absorption of 
the drug was noticed hence no 
amphotericin B related 
nephrotoxicity recorded  
Treatment with nebulized 
amphotericin B was successful in 
preventing invasive aspergillosis 
Nebulized Fungizone® 
as prophylaxis 
[346] 
Well tolerated with no 
apparent toxicity in a 49-day 
follow-up study 
Nebulization of 0.6 mg/kg/day of 
amphotericin B, there were no 
cases of invasive aspergillosis 
reported  
 
Nebulized Fungizone® 
(25mg) versus nebulized 
Abelcet® (50 mg) 
[347,348] 
Discontinuation of 
prophylactic treatment was 
more evident in patients 
administered Fungizone® as 
compared to Abelcet® due to 
adverse effects 
Clinical efficacy of both the 
formulations was the same 
however, tolerance profile of 
Abelcet® was much better than 
Fungizone®   
 
Nebulized Fungizone® 
(25mg) versus nebulized 
AmBisome® (50 mg) 
[349,350] 
Tolerability data for both 
these formulations were 
similar wherein 2.9% 
patients were withdrawn 
from the treatment with 
nebulized AmBisome® and 
4.1% for Fungizone® both 
due to bronchospasms 
Minimal systemic absorption of 
the drug was noticed hence averts 
the risk of amphotericin B related 
nephrotoxicity  
The rate of aspergillus infection in 
patients receiving the 
formulations remained similar 
(10.2% for Fungizone®, 7.7% for 
AmBisome®) 
 
Nebulized Fungizone® 
as prophylaxis 
[351] 
No discontinuation of 
treatment was recorded 
Significantly lower rate of 
invasive aspergillosis (IA) 
(2.5%=Fungizone®, 
6.6%=placebo) and higher 
mortality in patients diagnosed 
with IA (66.6%=Fungizone®, 
94.1%=placebo) was evident. 
Moreover, a higher overall 
survival rate at the end of a 4.6-
year period (59%=Fungizone®, 
42.4%=placebo)  
 
Amphotericin B 
inhalation powder 
(ABIP) 
DSPC spray dried 
powder 
[206,207] 
No changes in pulmonary 
functional markers was 
observed in contrast to 20% 
reduction in pulmonary 
function on aerosolization of 
other amphotericin B 
formulations  
Minimal systemic amphotericin B 
was observed on inhalation of dry 
powders containing high doses of 
amphotericin B up to 25 mg in 
clinical human studies 
(amphotericin B dose 50% w/w of 
dry powder) 
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3.1.4 Excipients used in study 
Ascorbic acid-2-glucoside 
Ascorbic acid and ascorbic acid-2-glucoside (AA2g, Figure 3.2) have been FDA approved for 
intravenous administration as an anti-scorbutic agent and for intradermal applications like skin 
lightening and UV protection. However, ascorbic acid is unstable to thermal and oxidative 
degradation under normal culture conditions of 37°C and in the presence of aqueous solutions. 
For this reason, a more stable, safe, physiologically active derivative of ascorbic acid i.e. ascorbic 
acid-2-glucoside was used for solubilization of the antifungal drug amphotericin B [352]. 
 
Figure 3.2: Structure of ascorbic acid-2-glucoside 
 
Lactose 
Lactose (Lactohale® LH300) is a common sugar approved by the Food and Drug Administration 
as an excipient to improve the aerosolization of powder as it imparts roughness to the surface of 
the particles when added to the feedstock prior to spray drying, leading to a reduction in adhesive 
forces between particles, consequently increasing aerosolization of powder [353,354]. During the 
process of spray drying, low product yield is a major disadvantage as the particles are sucked by 
the airflow and get trapped in the filter, hence are not collected [355]. This is of chief concern for 
expensive drugs. Moreover, an elevated temperature used during the process tends to be 
detrimental for temperature-sensitive drugs [355]. An attractive approach to overcome these 
shortcomings is to co-spray dry the drug-excipient systems with carriers such as lactose, glucose, 
sucrose etc. to provide protection to the drugs and improve yield [355]. 
 
L-leucine 
L-leucine used as a dispersibility enhancer has been attributed to increase fine particle fraction 
for many drugs like salbutamol sulphate, disodium chromoglycate, dapsone and budesonide 
[356–361]. Incorporation of L-leucine leads to decrease in surface energy of the particles, an 
increase in geometric particle diameter leading to significant decrease in particle surface area and 
density due to the formation of hollow spheres consequently increasing aerosolization [361]. 
Along with dispersibility enhancement, L-leucine can also protect the spray dried powders from 
moisture absorption [362]. This is of advantage for amorphous spray dried microparticles which 
are likely to absorb atmospheric moisture, causing aggregation due to recrystallization and 
capillary forces [362]. 
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3.2    Aims and Objectives 
Amphotericin B is poorly soluble in all aqueous solvents and a few organic solvents because of 
its zwitterionic and amphiphilic nature, and asymmetrical distribution of hydrophobic and 
hydrophilic groups [334]. This leads to aggregation in aqueous solutions, which has been reported 
to be the cause of toxicity and low membrane permeability resulting in limited oral absorption of 
amphotericin B [236].  
 
Hence, the aim of the study was  
• To engineer nanocomplexes for the delivery of hydrophobic drug amphotericin B by co-
grinding with antioxidant ascorbic acid-2-glucoside 
• To design and develop dry powder aerosols and study parameters that dictate aerosolization 
efficiency 
• To investigate the effect of the formulation parameters on the in vitro antifungal activity 
against Candida spp namely Candida albicans and Candida tropicalis  
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3.3    Materials 
Amphotericin B ≥ 95% purity (HPLC grade) was purchased from Cayman chemical (Michigan, 
USA), ascorbic acid-2-glucoside (AA2g) was a gift from Aston chemicals (Aylesbury, UK), L-
leucine ≥ 98.0% purity (TLC grade) and HPLC grade ethylenediaminetetraacetic acid disodium 
salt (EDTA-Na2) were purchased from Sigma-Aldrich (Poole, UK) and lactose (Lactohale® 
LH300) was purchased from Friesland Foods Domo (Zwolle, Netherlands). 
For the NGI, silicon oil (high temperature) was obtained from Sigma-Aldrich (Poole, UK) and 75 
mm internal micro-orifice collector (MOC) filter was purchased from Copley Scientific 
(Nottingham, UK). 
Candida albicans and Candida tropicalis were purchased from ATCC (England, UK) and AM3 
broth was purchased from BioMérieux (Basingstoke, UK) for in vitro antifungal studies. 
HPLC grade acetonitrile, water, n-hexane were purchased from Fisher Scientific (Loughborough, 
UK). Deionized water was used throughout the experiments. All other reagents used were of 
analytical grade. 
3.4    Methods 
3.4.1 Solubilization enhancement and preparation of respirable powders 
3.4.1.1 Solubility enhancement of amphotericin B 
Solubility enhancement of amphotericin B was studied by co-grinding at different molar ratios 
with AA2g in a mortar with a pestle for 10 min at room temperature (Table 3.5). 10 mL of 
deionized water was then added to the ground mixture to make a solution, which was passed 
through a 0.22 µm mixed cellulose esters syringe-driven filter (Millex MP, Ireland) to remove the 
unsolubilized amphotericin B. The solubility of amphotericin B at the different molar ratios to 
solubilization agent AA2g was investigated using the HPLC to determine the optimum 
stoichiometric ratio of drug and AA2g required to obtain maximum drug content of the 
nanocomplexes formed (section 3.4.2.2 and section 3.4.2.3). The stability of these nanocomplexes 
was investigated for their size and zeta potential using the Nano Zetasizer ZS (Malvern 
Instruments, UK) on storage at 25°C and 4-8°C on day 1, 6 and 10. 
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Table 3.5: Different molar ratio of drug (amphotericin B) to solubilizer (AA2g) for optimization studies 
Formulation 
(molar ratio) 
Amphotericin B 
(molecular weight 
924.08) [mg] 
AA2g 
(molecular weight 
338.27) [mg] 
Amphotericin B: AA2g 1:0.5 46.25 8.46 
Amphotericin B: AA2g 1:1 46.31 16.91 
Amphotericin B: AA2g 1:2 46.21 33.83 
Amphotericin B: AA2g 1:3 46.27 50.74 
Amphotericin B: AA2g 1:4 46.39 67.65 
 
The solutions were prepared based on the dosage indications of the marketed amphotericin B 
formulations for pulmonary aspergillosis which ranges from 0.5-0.7 mg/kg/day (35-49 mg/day) 
to 25-50 mg/day/twice a week as a nebulization or 25 mg/day as a dry powder inhalation (ABIP, 
Nektar therapeutics) for treatment of pulmonary aspergillosis, depending on the patients cardio-
renal function and pathogenesis status of fungal infection [306,307,345,363,364].  
3.4.1.2 Preparation of dry powders suitable for inhalation 
Considering the latest application trends in the industry for pharmaceutical formulations and 
nanotechnology, dry powder inhalation wherein particle size in the micrometer range for effective 
peripheral pulmonary delivery was intended.  Dry powders for inhalation were prepared by spray 
drying, carried out on a lab-scale Büchi B-90 Nano spray dryer (Büchi Labortechnik, 
Switzerland). The final optimized process parameters are given in Table 3.6. 
Table 3.6: Process parameters for spray drying on the Buchi B-90 Nano spray dryer 
Parameters Value 
Inlet temperature 120 °C 
Outlet temperature 82-85 °C 
Aspiration 100 % 
Pump flow rate 20 mL/h 
Gas flow rate 133 L/h 
Instrument pressure 47 mbar 
Nozzle mesh size 5.5 µm 
 
The spray dryer was set up for the stated inlet temperature and neat solvent was pumped 
until the desired outlet temperature between 82-85°C was achieved and stabilized, after 
which spraying was commenced. All the solutions were spray dried individually and the 
instrument temperature was allowed to cool below 60°C, after which the powder was 
collected from the electrostatic particle chamber using a collecting brush. The yield of the 
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final product was determined gravimetrically and the powder was immediately transferred to 
a glass vial and stored in a desiccator to prevent powder crystallization due to absorption of 
environmental moisture. 
A parallel spray drying process with different processing parameters was performed using lab-
scale Büchi B-290 Mini spray dryer (Büchi Labortechnik, Switzerland) to compare the difference 
in yield of the microparticles obtained. The final optimized process parameters are given in Table 
3.7. 
Table 3.7: Process parameters for spray drying on the Buchi B-290 Mini spray dryer 
Parameters Value 
Inlet temperature 120 °C 
Outlet temperature 62-65 °C 
Aspiration 80% 
Pump flow rate 20% (6 mL/min) 
Spraying gas flow rate 500 L/h (50 bar) 
Drying gas flow rate 35 m3/h 
Nozzle tip diameter 0.7 mm 
 
3.4.2 Formulation characterization 
3.4.2.1 Determination of particle size and zeta potential (surface charge) using Malvern 
Zetasizer 
The hydrodynamic diameter and the polydispersity index (PDI) of the nanocomplexes were 
measured by DLS and the zeta potential was measured by laser Doppler velocimetry using 
Malvern Zetasizer Nano ZS (Malvern Instruments Inc., UK) as described in chapter 2, section 
2.1. 
3.4.2.2 High-performance liquid chromatography (HPLC) and analytical method 
validation for determination of amphotericin B 
	The drug content of amphotericin B after co-grinding and spray drying, and the amount of 
amphotericin B deposited on each stage of the NGI was determined using HPLC on an Agilent 
1260 infinity series HPLC (Agilent Technologies UK Ltd., UK), equipped with an ultrasensitive 
diode array UV detector, G1329A autosampler and a highly efficient quaternary pump. A number 
of methods for HPLC analysis of amphotericin B have been described previously [365–368]. For 
this experiment, a new, rapid, sensitive, precise and accurate method was developed, which gave 
reproducible results, separation of retention between amphotericin B and AA2g, and 
chromatograms with sharp peaks and a stable baseline.  
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Briefly, 20 µL samples were eluted with a mobile phase flow rate at 1.3 mL/min comprising 0.25 
M disodium EDTA in HPLC grade water: HPLC grade acetonitrile using a gradient elution as 
shown in Table 3.8. 
Table 3.8: Time programming of the gradient elution tested to determine amphotericin B by HPLC 
Time (min) 
0.25 M disodium EDTA 
in water (%v/v) 
Acetonitrile 
(%v/v) 
0 67 33 
3.25 55 45 
4.25 55 45 
5.00 67 33 
6.00 67 33 
 
Elution was performed using an Agilent 15 cm×4.6 mm, 3.5 µm Eclipse Plus C18 column (Agilent 
Technologies, Chesire, UK) with UV detection wavelength of 405 nm and column compartment 
temperature of 40°C. The HPLC method developed for determination of amphotericin B was 
validated for linearity, accuracy and precision; to ascertain that the method adopted was robust 
and without error. The validation method based on ICH recommendations is described in Chapter 
2 for HPLC analytical validation, section 2.7. 
A standard curve (calibration curve) was constructed for amphotericin B before each sample 
analysis in triplicate using the same method of HPLC analysis as that intended for the 
formulations. Concentrations of amphotericin B for the standard were 1-12 µg/mL, and peak area 
as an average of the triplicates was used to derive the standard equation and correlation coefficient 
(R2) of the best fit line by least square regression method. This standard equation was then 
considered linear if the R2 value was approximately 1 and used for calculation of content of 
amphotericin B in the nanocomplexes and for determination of the fraction of amphotericin B 
retained at each stage of the NGI. 
3.4.2.3 Determination of drug content of the nanoparticulate solutions 
Drug content of the formulations after co-grinding was determined using HPLC, to quantify the 
amount of amphotericin B solubilized at the different molar ratios. Dilutions of the formulation 
following removal of unsolubilized drug after syringe filtration (0.22 µm mixed cellulose esters 
syringe-driven filter (Millex MP, Ireland)) was performed by diluting to obtain 12 µg/mL of 
amphotericin B, considering 100% theoretical drug content, by dilution in DMSO: methanol (1:1) 
to obtain a solution concentration appropriate for HPLC measurement as per the Beer-Lambert 
linearity concept. The solutions were filtered into HPLC vials and quantified as described (section 
3.4.2.2). The peak area for amphotericin B was used for calculation of the content of drug using 
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the linear regression equation from calibration curve with correlation coefficient 0.9988. It was 
expressed as a percentage using the following equation (Equation 3.1): 
 5>:?	A9;<@;<	(%) 	= ^_"`ab`"c	"defga#_b`bh	i	`gha#ha	jk	l^mn	"oa#_	`g1&_bhpbh&	qf#g_#ab`"c	"defga#_b`bh	i	`gha#ha	bhbab"cck	r#b&f#p ×100 
 
3.4.2.4 Stability studies 
Stability studies were performed on the co-ground formulations on aqueous re-dispersion to 
ascertain the stability of the nanocomplexes formed, and hence consequently the solubilization of 
amphotericin B at definite time intervals. These were performed on co-ground syringe-filtered 
formulations formed at different molar ratios of amphotericin B to AA2g which were stored at 
room temperature 25°C and at 4-8°C, wrapped in aluminium foil protected from light. The size 
and charge were determined using the Zetasizer Nano ZS (Malvern Instruments Inc., UK) and 
drug content was determined using HPLC (Agilent technologies, Chesire, UK) on day 1, 6 and 
10 by filtering the respective formulation using a 0.22 µm mixed cellulose esters syringe-filter, to 
ensure that any dissociated amphotericin B from the nanocomplex was entrapped in the membrane 
of the filter and removed prior to analysis. This helps to verify the interaction capability and the 
strength of association of amphotericin B with AA2g over the period of study, also serving to 
ascertain the molar ratio of solubilizer to drug necessary to form stable nanocomplexes. 
3.4.3 Powder characterization 
3.4.3.1 Determination of yield following spray drying 
The yield of spray dried microparticles was determined by gravimetry and calculated as a 
percentage by comparing the initial amount of compounds in the feedstock of formulation to the 
spray dried powder obtained after the process. 
3.4.3.2 Determination of drug content of spray dried powders 
The drug content of the spray dried powders was analyzed using HPLC (section 3.4.2.2). A known 
amount of spray dried powder in mg quantities (above 5 mg to achieve consistency in weighing 
and minimizing manual error) was weighed to approximately obtain 12 µg/mL of amphotericin 
B on appropriate dilution considering a 100% theoretical drug content of amphotericin B. The 
powder was weighed and dissolved in 100 mL of DMSO:methanol (1:1) using a vortex mixture 
and was further diluted approximately 40 times to obtain a solution concentration appropriate for 
HPLC measurement as per the Beer-Lambert linearity concept. The solutions were filtered into 
HPLC vials and determination was performed with the same method as that of HPLC calibration 
curve for amphotericin B (section 3.4.2.2). The peak area for amphotericin B was used for 
calculation of the content of drug using linear regression equation from calibration curve with R2 
Equation 3.1 
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of 0.9988. Drug content was expressed as a percentage using the following equation (Equation 
3.2): 5>:?	A9;<@;<	(%) 	= Q>DA<MADN	D8sℎ9<@>MAM;	t	A9;<@;<	uO	vQw\Zℎ@9>@<MADN	D8sℎ9<@>MAM;	t	A9;<@;<	 	×100 
 
3.4.3.3 Laser diffraction particle size analysis 
The particle size distributions of all the spray dried powders were analyzed using laser diffraction 
with a Sympatec HELOS particle size analyzer, on a RODOS/M particle dispenser fitted with a 
micro-dosing device ASPIROS/L (Sympatec GmbH, Clausthal-Zellerfeld, Germany) as outlined 
in chapter 2, section 2.5. 
3.4.3.4 Morphology analysis using electron microscopy  
The method used to explore the morphology of nanocomplexes in solution using the TEM and 
spray dried microparticles using the SEM is outlined in chapter 2, section 2.4. 
3.4.3.5  X-Ray powder diffraction (XRPD) 
The order of the molecules and hence crystallinity of individual raw materials, physically mixed 
powders, co-ground powders and the spray dried powders were determined at room temperature 
using wide angle X-ray diffraction. The method used is as mentioned in chapter 2, section 2.3. 
3.4.3.6 Fourier transform infrared spectroscopy (FT-IR) 
FT-IR of the spray dried, physically mixed and co-ground powders were determined to analyze 
the chemical interactions between the drug and the excipients of the respective formulations.  The 
procedure followed is as mentioned in chapter 2, section 2.2. The spectrum for the co-ground/ 
spray dried powder was compared with drug, excipient, physical mixtures and co-ground powders 
at the same molar ratios to characterize the interactions in the co-ground/spray dried powders 
which consequently affects the solubilisation of amphotericin B. 
3.4.3.7 In vitro aerosol deposition and aerodynamic behavior studies using the Next 
Generation Impactor 
The aerosol parameters and deposition of spray dried microparticles at the different stages of the 
NGI were determined using the method described in chapter 2, section 2.6. In each experiment 
size 3 transparent gelatin capsules (Dr. T & T Health, UK) were filled manually with 30 ± 0.2 mg 
of spray dried microparticles and aerosolized using the Cyclohaler®. As per literature the dose of 
nebulized amphotericin B was 40-50 mg, hence, approximately 45 mg amphotericin B was used 
per analysis of NGI for powders by adjusting the number of capsules aerosolized. 
3.4.3.8 In vitro antifungal assessment of amphotericin B nanocomplexes by MIC studies 
The minimum inhibitory/fungicidal concentration (MIC) of amphotericin B, AA2g and the co-
ground and spray dried formulations were determined by the broth dilution method in 96-well 
Equation 3.2 
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microplates (BD biosciences Falcon™, UK). Two amphotericin B sensitive strains of Candida 
were used for the experiment namely Candida albicans and Candida tropicalis.  
Preparation of inoculum: Candida spp were grown on a recovery media i.e. Sabouraud’s 
dextrose agar at 37°C in ambient environment for 24-36 h until the yeast grew well on the agar 
bed. Fungal suspensions were prepared in phosphate buffer saline (PBS) by picking up a distinct 
colony of about 1 mm diameter from the agar bed and vigorously mixing it in PBS and vortexing 
to form a stable suspension.  The suspension was diluted to obtain an optical density (OD) of 0.8 
at 530 nm which corresponds to 1-5×106 CFU/mL, after which a 100 times dilution with non-
synthetic broth Antibiotic Medium 3 (AM3) was performed to obtain 1-5×104 CFU/mL which 
was the final concentration used in the determination of MIC. 
Preparation of test solution of amphotericin B: A final working concentration of 64 µg/mL of 
amphotericin B was prepared based on the MIC shown from previous studies. However, 
amphotericin B being a hydrophobic drug, the original stock solution was made 100 times more 
concentrated than the required working concentration in absolute DMSO and then diluted 100 
times with AM3 broth to obtain the test solution with minimal acceptable amount of DMSO (less 
than 1% DMSO in the final test sample of amphotericin B). 
Preparation of test solution of amphotericin B particles: Aqueous solutions in single strength 
AM3 broth of spray dried and co-ground powders were prepared as per the drug loading for each 
formulation to obtain a concentration of 64 µg/mL of amphotericin B in each of the test solutions.  
All the solutions were filtered through a 0.22 µm mixed cellulose esters syringe-filter (Millex, 
Ireland) to ensure that they were sterile. 
Microplate preparation: Broth dilutions were performed serially in a 96-well plate to obtain 
concentrations ranging from 64 µg/mL to 0.006 µg/mL in a final volume of 50 µL in each well. 
To these wells 50 µL of the respective Candida spp (Candida albicans or Candida tropicalis) 
suspensions with 1-5×104 CFU/mL in AM3 broth were added into each well reducing the working 
concentration of the test solutions by 50% i.e. from 32 µg/mL to 0.003 µg/mL. A control well 
(column 12) containing 50 µL of drug-free AM3 broth and 50 µL of the same yeast suspension 
was prepared as a sterility control for the media and also to ascertain that the yeast grew 
appropriately in the experimental setup. The plates were then incubated with shaking at 33°C.  
Reading results: The MIC endpoints for all the tested materials were read at 24 h and 48 h by 
visual inspection where no turbidity corresponded to inhibition of growth of the organism and 
hence was the minimum concentration of the test formulation required for inhibition of a 
respective strain of Candida spp. 
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3.5   Results and discussion  
3.5.1 Rationale of study and solubilization of amphotericin B 
In the preliminary study, 47 mg of amphotericin B was dispersed in 10 mL of deionized water. 
This suspension was passed through a 0.22 µm syringe filter. The undissolved amphotericin B 
was trapped in the mixed cellulose esters membrane of the filter and the filtrate obtained was clear 
and colorless as shown in Figure 3.3. The clear colorless filtrate indicates that amphotericin B had 
little or no solubility in deionized water. The filtrate gave no absorbance as evident by the absence 
of amphotericin B peak in the HPLC chromatogram at a retention time of 4.14 min measured at 
405 nm, indicative of aggregation of hydrophobic amphotericin B in deionized water. 
A strategy to enhance the solubility of amphotericin B using solubilizing agent AA2g was 
investigated. Two different approaches were used. In the first approach, 47 mg of amphotericin 
B and 51 mg of AA2g were mixed physically, followed by vortexing the dispersion in 10 mL of 
deionized water. This was passed through a 0.22 µm syringe filter to obtain a clear and colorless 
filtrate, and absence of amphotericin B peak in the HPLC chromatogram was evident. This 
confirmed that physically mixing amphotericin B with solubilizing agent (AA2g) was not 
sufficient to improve aqueous solubility of the antifungal drug. This is as evident in Figure 3.4.  
Figure 3.3: Lack of solubility of amphotericin B in deionized water  
A) Dispersion of amphotericin B in deionized water 
B) Dispersion of amphotericin B passing through 0.22 µm syringe filter 
C) Colourless filtrate the in-solubilization of amphotericin B 
 
 Chapter 3| Inhalable microparticles of amphotericin B nanocomplexes  
 
80	
	
	 	
  
The second strategy involved co-grinding together amphotericin B and AA2g. There was a 
difference in the appearance of the solution when the co-ground powder mixture was dispersed 
in water and filtered through a 0.22 µm syringe filter (Figure 3.5). The solution obtained was 
yellow in color and a peak corresponding to amphotericin B at 4.14 min was observed in the 
HPLC chromatogram. This shows that co-grinding of amphotericin B and AA2g is a crucial step 
to form stable nanocomplexes to achieve solubilization of the hydrophobic drug.  
 	
Figure 3.4: Lack of solubility of amphotericin B in deionized water when physically mixed with AA2g   A) Physical 
mixture of amphotericin B and AA2g dispersed in deionized water 
B) Dispersion of physically mixed amphotericin B and AA2g passing through 0.22 µm syringe filter 
C) Colourless filtrate 
Figure 3.5: Solubilization of amphotericin B in deionized water when co-ground with AA2g  
A) Co-ground mixture of amphotericin B and AA2g dispersed in deionized water 
B) Dispersion of co-ground mixture of amphotericin B and AA2g passing through 0.22 µm syringe filter 
C) Yellow coloured filtrate solution confirming the solubilization of amphotericin B 
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Solubilization of the hydrophobic drug clarithromycin by co-grinding and physically mixing with 
AA2g has been studied previously [369]. Physically mixing AA2g and clarithromycin at a molar 
ratio of 1:1 improved the wettability and solubility of clarithromycin, hence enhancing the drug 
solubilization by 80% [369]. On co-grinding with AA2g complete solubilization of 
clarithromycin was evident [369]. However, for solubilization of amphotericin B, physically 
mixing with AA2g was not sufficient for solubility enhancement and co-grinding was crucial for 
molecular interaction with AA2g to take place. Further studies to evaluate the interactions 
between amphotericin B and AA2g affecting solubilization has been explained in section 3.5.3.7.  
3.5.2 Formulation characterization 
3.5.2.1 Particle size and zeta potential (surface charge) 
DLS was used to determine the mean hydrodynamic diameter (nm) and polydispersity index 
(PDI) of the nanocomplexes formed by co-grinding amphotericin B and AA2g at the different 
molar ratios. Figure 3.6A and Figure 3.6B shows the hydrodynamic diameter of nanocomplexes 
on day 1, 6 and 10 when stored at room temperature 25°C and in the fridge at 4-8°C respectively. 
A unimodal and sharp distribution was seen when measuring the size using DLS, indicative of a 
narrow distribution of nanocomplexes for all the molar ratios studied at each time interval. The 
hydrodynamic diameter of nanocomplexes formed on co-grinding decreases with increasing 
molar ratio of amphotericin B: AA2g. The lowest ratio of amphotericin B: AA2g being 1:0.5 
shows mean diameters of 122±2.02 nm, whereas the highest ratio of amphotericin B: AA2g (1:4) 
shows a mean diameter of 110±1.82 nm on day 1, which implies that increasing the amount of 
AA2g for complexation of a constant amount of amphotericin B leads to formation of smaller 
size nanocomplexes. However, ANOVA/Tukey analysis depicts that the difference between the 
mean diameters of nanocomplexes on day 1 at the molar ratios 1:2, 1:3 and 1:4 is insignificant at 
a level of p is 0.05. Hence, from the molar ratio of 1:2 amphotericin B: AA2g onwards the 
nanocomplexes formed were stable with respect to mean diameter studied on day 1. 
The PDI of the nanocomplexes (data not shown) were seen to increase from 0.24 to 0.33 with an 
increase in amount of AA2g which could be attributed to a higher loading of amphotericin B onto 
the complexes, wherein, the difference was only significant between (p < 0.05) complexes made 
with 1:0.5 amphotericin B: AA2g over 1:3 and 1:4 amphotericin B: AA2g. There was no 
significant difference (p > 0.05) in the PDI of the other formulations relative to each other. 
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Figure 3.6: Hydrodynamic diameter (nm) of nanocomplexes formed at different molar ratios of amphotericin 
B: AA2g; (A) stored at 4-8°C and (B) stored at RT; (n=3, mean ± SD)		
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Nanocomplexes formed at a molar ratio of 1:0.5 amphotericin B: AA2g stored at 25°C and 4-
8°C, and nanocomplexes formed at a molar ratio of 1:1 amphotericin B: AA2g stored at 25°C 
showed a significant difference (p < 0.05) in mean diameters on day 10 as compared to day 1. 
The other molar ratios namely 1:2, 1:3 and 1:4 amphotericin B: AA2g stored at 25°C and 4-8°C 
also showed a significant difference (p < 0.05) in mean diameters between the respective days 
under the duration of study. This suggested that storage conditions had an influence on the 
nanocomplex integrity with respect to mean diameter, hence, the aqueous nanocomplexes of 1:2 
amphotericin B: AA2g were converted into dry powder microparticles by spray drying 
immediately after formulation.  
Study of particle size of nanoparticles by light scattering formed by co-grinding clarithromycin 
and AA2g has been reported in literature. Co-grinding at a molar ratio of 2:1 clarithromycin: 
AA2g, the formation of nanoparticles with a size 280 nm was observed [369]. The process of co-
grinding clarithromycin with AA2g was carried out in a vibration mill, whereas in the present 
study amphotericin B and AA2g were co-grounded manually in a mortar and pestle. Hence, the 
difference in the method of preparation adopted could lead to differences in mean diameter of the 
nanoparticles. 
Zeta potential analysis of the nanocomplexes indicated a high positive surface charge of 20-30 
mV on the nanoparticle surface as seen in Figure 3.7. The different molar ratios in the order of 
increasing AA2g showed a continuous significant (p < 0.05) increase in the positive charge on 
the nanoparticle surface, on day 1. This trend was evident due to an increase in the number of 
positive NH2 groups on the amphotericin B molecule present, as a higher amount of amphotericin 
B was solubilized (Table 3.10) by increasing the amount of AA2g. Co-grinding clarithromycin 
and AA2g, a similar positive zeta potential of 25.2±1.5 mV, attributed to the positive charge on 
the nitrogen of dosamine of clarithromycin was evident in a previous study [369]. The 
electrostatic repulsion due to the high surface positive charge contributed to nanocomplex 
stability, which was evident by the insignificant reduction in amphotericin B drug content (Figure 
3.9) on storage at 4-8°C  
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Figure 3.7: Zeta potential (mv) of nanocomplexes formed at different molar ratios of amphotericin B: AA2g; 
(A) stored at 25°C and (B) stored at 4-8°C; (n=3, mean ± SD) 
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3.5.2.2 High-performance liquid chromatography (HPLC) and analytical method 
validation for determination of amphotericin B 
Linearity: The data for HPLC calibration curve of amphotericin B was fitted into an equation of 
y=43.24x–2.859 (where x=concentration of analyte and y=area under curve), and was observed 
to follow linearity and hence Beer-Lambert law in the concentration range under study i.e.1-12 
µg/mL as shown in Figure 3.8. A regression analysis was performed and correlation coefficient 
R2 of 0.9988 indicated the existence of a linear relationship between peak area and concentration 
of drug analyzed.  
 
Figure 3.8: Calibration curve of amphotericin B analyzed by HPLC (mean±SD, n=5) 
 
Parameters determining linearity from HPLC analysis for amphotericin B are shown in Table 3.9. 
Table 3.9: Linearity parameters for HPLC analysis method of amphotericin B 
Parameters Results 
λmax 405 
Linearity range 1-12 µg/mL 
Regression equation y = 43.24x–2.859 
Correlation coefficient 0.9988 
Retention time 4.14 min 
 
Representative chromatogram of amphotericin B and validation for accuracy and precision of 
HPLC method is as seen in Appendix 1, A1.1. 
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3.5.2.3 Amphotericin B drug solubilization in co-ground nanocomplexes 
 
Figure 3.9: Amphotericin B drug content of co-ground formulations as determined by HPLC analysis (n=3, 
mean ± SD) 
Stable nanocomplexes over a 10-day period of the study analyzed on storage at 4-8°C (Figure 
3.9) depicted minimal loss in amphotericin B observed by HPLC analysis, showing that the 
complexes formed were stable. There was a significant increase (p < 0.05) in amphotericin B 
solubilization with an increasing amount of AA2g when the different molar ratios were compared 
on day 1, as seen in Table 3.10. On increasing the amount of AA2g to make nanocomplexes, there 
was an increase in OH groups of AA2g available for complexation to the NH2 groups of 
amphotericin B, and consequently, a higher amount of amphotericin B was loaded in the 
nanocomplexes.  
The drug content of amphotericin B was maximal for the nanocomplexes with molar ratio 1:2 
amphotericin B: AA2g. This indicates that a molar ratio of 1:2 amphotericin B: AA2g is a perfect 
stoichiometry to form stable nanocomplexes and is the minimum molar ratio of amphotericin B: 
AA2g required to achieve high amphotericin B solubilization and content. Moreover, an increase 
in the stoichiometric molar ratio to 1:3 or 1:4 showed a significant decrease (p < 0.05) in 
amphotericin B content since there was an increase in the solubilization agent AA2g. Hence, a 
ratio of 1:2 amphotericin B: AA2g was chosen for further studies, so as to deliver more drug by 
reducing the amount of excipients in the formulation.  
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Table 3.10: Amphotericin B drug solubilization and drug content in co-ground nanocomplexes 
Formulation 
(molar ratio) 
Amphotericin B 
solubilization on day 1 
(relative to the total amount 
of amphotericin B initially 
added, %) 
Amphotericin B drug 
content on day 1 
(relative to the total 
amount of amphotericin B 
and AA2g, %) 
Amphotericin B: AA2g 1:0.5 11.12 ± 0.20 37.81 ± 0.42 
Amphotericin B: AA2g 1:1 33.58 ± 2.72 47.86 ± 2.02 
Amphotericin B: AA2g 1:2 78.06 ± 2.00 51.60 ± 0.64 
Amphotericin B: AA2g 1:3 84.36 ± 0.89 43.48 ± 0.26 
Amphotericin B: AA2g 1:4 89.27 ± 0.33 37.97 ± 0.09 
 
3.5.3 Powder characterization 
3.5.3.1 Spray dried amphotericin B powder yields 
The use of an electrostatic particle collector on the Büchi B-90 Nano spray dryer gave good yields 
of spray dried microparticles ranging from 69-76%. A similar experiment performed on the Büchi 
B-290 Mini spray dryer showed significantly lower (p < 0.05) yields for each of the powders with 
and without excipients, as shown in Table 3.11. 
Table 3.11: Drug yields of spray dried microparticles (n=3; mean ± SD) 
Spray dried 
powders 
Prep 
weight 
(mg) 
Weight of 
powders obtained 
after spray drying 
(mg) 
Yield (%) 
Büchi 
B-90 
Büchi 
B-290 
Büchi B-
90 
Büchi 
B-290 
Amphotericin B: 
AA2g (1:2) 
300 205.4 
214.7 
200.2 
129.6 
114.7 
133.0 
68.92 
± 
2.45 
41.92 
± 
3.24 
Amphotericin B: 
AA2g (1:2): 
L-Leucine 
375 284.7 
248.3 
280.2 
174.9 
161.3 
157.2 
73.17 
± 
3.76 
43.85 
± 
2.47 
Amphotericin B: 
AA2g (1:2): 
lactose 
600 444.1 
467.0 
453.9 
388.1 
353.8 
397.4 
75.83 
± 
1.91 
53.29 
± 
3.82 
 
The yield obtained on the B-290 for spray dried amphotericin B: AA2g without excipients was 
41.92 ± 3.24%, of which only 10.21% was collected from the particle collector and the rest 
31.71% was scraped from the cyclone walls; while it was 68.92 ± 2.45% for the B-90 collecting 
chamber. This could be attributed to the low density of powder formed which got lost in exhaust 
gases of the cyclone technology of the B-290. In the B-290 collection is dependent on the mass 
of the particles generated on spray drying leading to lower mass particles carried with the gas 
stream, and hence collected in the filter, not depositing in the collection chamber or cyclone. In 
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the B-90 spray drying is carried out using a piezoelectric driven droplet atomizing technology in 
conjunction with an electrostatic particle collector, where particles are deposited directly 
downwards without being dependent on mass or density. Hence, a higher yield was seen when 
Nano spray dryer B-90 was used for spray drying the formulations as compared to Mini spray 
dryer B-290. 
3.5.3.2 Content of amphotericin B in spray dried powders 
 
Table 3.12: Amphotericin B content (%) of the spray dried microparticles 
Spray dried powders Amphotericin B content before spray drying (%) 
Amphotericin B content 
after spray drying (%) 
Amphotericin B: AA2g 45.21 ± 4.13 42.80 ± 2.54 
Amphotericin B: AA2g: 
L-leucine 35.10 ± 4.77 31.45 ± 1.73 
Amphotericin B: AA2g: 
lactose 27.43 ± 3.20 21.04 ± 3.89 
 
There was no significant loss (p > 0.05) of amphotericin B on spray drying as seen in Table 3.12. 
3.5.3.3 Laser diffraction particle size analysis 
Dv50 represents the volume median diameter (VMD) of particles, which corresponds to the 
diameter of particles where 50% distribution is above and below the said value of particle size, 
hence, displays average particle size taking into account the total powder volume selected 
randomly. A bar chart indicative of Dv50 values of all the powders studied at pressures 1, 2 and 
4 bar are represented in Figure 3.10.  
Figure 3.10A indicates that the size of nano spray dried amphotericin B microparticles were in 
the respirable range appropriate for deposition in the peripheral airways i.e. the Dv50 was in a 
range of 2.41-3.06 µm for spray dried microparticles of amphotericin B: AA2g (1:2) with and 
without excipients. Aspergillus fumigatus has been shown to deposit within the peripheral 
airways, and hence targeted delivery to the alveoli and bronchi using amphotericin B inhalation 
powder (ABIP, Nektar therapeutics) in clinical trials has been shown to be advantageous for 
treatment of invasive pulmonary aspergillosis, due to an aerodynamic size in the range of 2-5 µm 
[206].  
The physically mixed powders of the same ratio of constituents as that of the spray dried showed 
significant difference (p < 0.05) in the size analyzed by laser diffraction, wherein the physically 
mixed powders were not in the respirable range of 2-5 µm. This indicates that spray drying is a 
crucial step required to engineer particles appropriate to deliver the drug to the peripheral airways 
where the fungal infection resides.  
 
 Chapter 3| Inhalable microparticles of amphotericin B nanocomplexes  
 
89	
	
	 	
 
Figure 3.10: Effect of pressure on size analysis (Dv50) of spray dried, physically mixed and co-ground 
microparticles (Inset A: effect of pressure on size analysis of spray dried microparticles) (n=3, mean ± SD) 
As seen in Figure 3.11, the particle size distribution of spray dried amphotericin B: AA2g was 
unimodal with particle size distribution well in the respirable range, whereas, the distribution 
profile of co-ground amphotericin B: AA2g was found to multimodal, with a wide size 
distribution of the co-ground microparticles making them sub-optimum to be delivered to the 
peripheral lung to target fungal infections.  
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Figure 3.11: Particle size distribution of A) spray dried amphotericin B: AA2g B) co-ground amphotericin B: 
AA2g 
As seen in Figure 3.12, the particle size distribution of spray dried amphotericin B: AA2g: L-
leucine and spray dried amphotericin B: AA2g: lactose was shown to be unimodal with a particle 
size in the respirable range. 
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Figure 3.12: Particle size distribution of A) spray dried amphotericin B: AA2g: L-leucine B) spray dried 
amphotericin B: AA2g: lactose 
Physically mixed powders, co-ground powders and raw materials showed a high Span value, 
significantly different (p < 0.05) when compared to the Span of spray dried microparticles, 
indicative of heterodisperse powders and multimodal distribution pattern as seen in Table 3.13. 
The data obtained are expressed in the terms of particle diameter at 10, 50 and 90% of volume 
distribution, as Dv10, Dv50 and Dv90 respectively. 
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Table 3.13: Laser particle size distribution data (Dv10, Dv50 and Dv90 are in units of µm) (n=3, mean ± SD) 
Microparticles 
4 bar Span 
Dv10 Dv50 Dv90 at 4 bar 
Amphotericin B 2.32±0.67 12.03±2.07 31.4±4.90 2.42±0.06 
Ascorbic acid-2-glucoside 
(AA2g) 
5.62±2.06 36.97±2.99 79.27±0.43 2.00±0.22 
Co-ground amphotericin B: 
AA2g 
1.58±0.05 8.03±0.27 29.39±2.08 3.46±0.22 
Physically mixed amphotericin 
B: AA2g 
2.9±0.216 16.59±0.89 55.14±1.71 3.16±0.26 
Spray dried amphotericin B: 
AA2g 
0.91±0.01 2.41±0.04 4.87±0.08 1.65±0.02 
Physically mixed amphotericin 
B: AA2g: lactose 
2.35±0.06 10.52±0.43 27.9±1.93 2.43±0.08 
Spray dried amphotericin B: 
AA2g: lactose 
1.17±0.03 3.06±0.10 6.43±0.17 1.72±0.01 
Physically mixed amphotericin 
B: AA2g: L-leucine 
2.86±0.55 18.93±1.00 57.7±0.37 2.90±0.17 
 Spray dried amphotericin B: 
AA2g: L-leucine 
0.93±0.02 2.21±0.04 4.22±0.09 1.49±0.01 
 
Effect of pressure applied during measurement on the particle size distribution of spray 
dried, physically mixed and raw material microparticles 
Choice of an optimum pressure for dispersion of particles is of crucial importance to achieve and 
read diffraction of primary particles from the agglomerated dry powder fed into the Sympatec. 
Very high pressures applied might fracture the primary particles, whereas low pressure applied 
may lead to inadequate segregation of the agglomerated particles, both resulting in erroneous 
results. For this purpose, three different pressures of 1, 2 and 4 bar were used on the Sympatec to 
compare the dependence of particle size analyzed on the pressure applied indicative of ease of 
dispersion from the inhalation device and hence a direct correlation on the patient-to-patient 
variation of dry powder size on inhalation. Patient to patient variation arises from the difference 
in age e.g. the force of inhalation for paediatric patients might be less as compared to adults; there 
might also be variations in the force of inhalation for diseased patients. These parameters would 
lead to dosage variations and hence effect end-point treatment. Hence, engineering particles that 
show a minimal patient-to-patient variation on inhalation and a low difference in the fine particle 
fraction and fine particle dose, dependent on patients’ flow rate is desired. 
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Figure 3.13: Effect of pressure on the volume mean size 
of powders analyzed by Sympatec (CG=co-ground, 
NSD=nano spray dried, PM=physically mixed) (n=3, 
mean ± SD) 
 
As evident in Figure 3.13, the nano spray dried microparticles of amphotericin B: AA2g show no 
significant difference (p < 0.05) in the D10, Dv50 and Dv90 particle size at 1, 2 or 4 bar pressure, 
indicative of a pressure-independent analysis using laser diffraction. On the other hand, co-ground 
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amphotericin B: AA2g and raw materials amphotericin B and AA2g, showed a significant 
difference (p < 0.05) in particle size analyzed by laser diffraction at 1, 2 or 4 bar pressure, 
indicative of pressure-dependent analysis and consequently a potential patient-to-patient 
variation. This highlights the potential of spray dried amphotericin B: AA2g to be used as a 
successful dry powder aerosol to treat peripheral lung fungal infections. 
However, laser diffraction results are based on the volume mean diameter i.e. the geometric 
diameter and not the aerodynamic diameter. It assumes that the particles are spherical when laser 
diffraction is applied, however, micronized co-ground, spray dried and raw material 
microparticles could show deviation from this spherical behavior, hence making it necessary to 
study the aerodynamic diameter (section 3.5.3.8) of the various powders [370].  
3.5.3.4 Morphology analysis of spray dried microparticles by electron microscopy: 
Scanning electron microscope 
SEM was performed on freshly prepared spray dried and co-ground powder samples stored in a 
desiccator at room temperature. The SEM micrographs were captured at different degrees of 
magnification to highlight the specific details of the particles.  
SEM micrographs of raw material amphotericin B and AA2g (Figure 3.14) showed the presence 
of columnar irregular crystals stacked as blocks, with a wide size distribution. The crystallinity 
of the raw materials was confirmed by X-ray powder diffraction (Figure 3.19 and Figure 3.20). 
Particle sizes observed from these micrographs were in accordance to that obtained for the raw 
materials using laser diffraction (Figure 3.10). Due to an elongated flat shape, there is a larger 
contact area between the longitudinal surfaces of these columnar particles due to high surface 
energy, which is responsible for the cohesiveness and poor flowability subsequently leading to a 
poor aerosolization.  
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
  
A B 
Figure 3.14: SEM micrographs of unprocessed raw materials (A) amphotericin B and (B) AA2g
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SEM micrograph of co-ground and spray dried amphotericin B: AA2g- To study the effect 
of spray drying on microparticle morphology 
As indicated in the SEM micrographs, co-ground (Figure 3.15A) and spray dried (Figure 3.15B) 
powders of amphotericin B: AA2g complexes differ not only in the surface morphology but also 
in the bulk morphology and particle size. The co-ground powder without excipients was 
aggregated into small clusters showing an irregular rough surface and shape (Figure 3.15A). The 
sheer and impact stress applied during the co-grinding process transformed the particles, and 
hence a change from complete crystalline columnar form of amphotericin B and AA2g to a less 
crystalline co-ground form confirmed by X-ray powder diffraction (Figure 3.21) was evident. 
Spray drying of the amphotericin B: AA2g complexes lead to the formation of non-agglomerated 
and spherical microparticles (Figure 3.15B), indicative of an amorphous nature as confirmed by 
X-ray powder diffraction (Figure 3.22A). This spherical morphology of the microparticles 
decreases the contact area between the neighboring particles, decreasing interparticulate 
interactions, leading to greater flowability and consequently reduced cohesiveness. The SEM 
micrograph of spray dried amphotericin B: AA2g showed a narrow particle size distribution, with 
a particle size in good agreement with the size measured by laser diffraction analysis i.e. between 
1-3 µm optimum for aerosolization to the peripheral lung (Figure 3.10). 
	
	
	
	
	
	
The slight presence of corrugations (roughness) on the particle surface of spray dried 
amphotericin B: AA2g can be explained examining the spray drying process. The liquid feed 
during the atomization phase, was sprayed through the nozzle of a 5.5 µm mesh in the form of 
fine droplets into the drying chamber, where it encountered hot gas at temperatures of about 90-
120°C. When a co-current method is adopted, the droplets are subjected to the highest temperature 
in a moist state which leads to instant drying of the external surface of droplets. The temperature 
of the drying chamber gradually decreases due to this heat exchange needed to dry the external 
surface of droplet, and further drying takes place by the formation of holes to let go out the trapped 
A B 
Figure 3.15: SEM micrographs of (A) co-ground amphotericin B: AA2g and (B) spray dried amphotericin B: 
AA2g	
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internal solvent. This leaves behind the dried solid with a size similar to the size of the atomized 
droplet. Previous literature has confirmed that a spray drying temperature of 110/74°C is 
responsible for greater degree of shrinkage and hence corrugations as compared to drying at 
higher temperatures [371].	
SEM micrograph of spray dried amphotericin B: AA2g with excipients- To study the effect 
of spray drying with excipients on the particle morphology 
To further increase the aerosolization and hence fine particle fraction of spray dried amphotericin 
B: AA2g, it was spray dried with excipients which would further decrease its cohesiveness. 
Numerous approaches have been implemented to engineer microparticles with improved 
dispersion and respirable powder performance. It was evident in literature that improvement of 
dispersibility and hence respirable fraction can be achieved by decreasing interparticulate 
interactions between the cohesive drug particles by incorporation of excipients in the spray drying 
feedstock [372,373].  
L-leucine- Amphotericin B: AA2g was spray dried with amino acid L-leucine which has been 
shown to improve the aerosolization of powders as evident in previous literature [373–375]. The 
SEM micrographs of spray dried amphotericin B: AA2g with 25% mass fraction of L-leucine in 
Figure 3.16 shows the presence of fractured hollow surfaced spheres with curved plates of 
nanometric thickness. These have spaces which are capable of being filled and hence produce 
open powder structures which can encapsulate cohesive powders like amphotericin B and increase 
dispersibility (confirmed by NGI). This SEM micrograph was similar to that reported by various 
authors previously [372,373,361,376]. Incorporation of L-leucine leads to decrease in surface 
energy of the particles, an increase in geometric particle diameter leading to significant decrease 
in particle surface area and density due to the formation of hollow spheres consequently 
increasing aerosolization [361]. 
The effect of inlet temperature of the spray dryer also plays a major role in the morphology of 
particles containing L-leucine, wherein low temperatures of 100°C showed open structures (as 
evident from the micrograph) obtained by surface diffusion of L-leucine in its condensed phase 
and subsequent deposition on the surface of the powder at the air-water interface during spray 
drying. However at higher temperatures of 180- 200°C, sublimation of L-leucine occurs and 
gaseous L-leucine molecules directly transform into solid crystals and nucleate on the drug 
surface [375,357,356]. Hence, a proper control of temperature during spray drying plays a crucial 
role on the crystallization and consequently the aerosolization of powders containing L-leucine.  
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Lactose- SEM micrographs of spray dried amphotericin B: AA2g with lactose (Figure 3.17) 
showed the formation of non-agglomerated, spherical, rough particles with a particle size in good 
agreement of that obtained by laser diffraction studies on the Sympatec (Figure 3.10). 
	
	
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
A B 
                                                                          
A B 
Figure 3.16: SEM micrographs of spray dried amphotericin B: AA2g with L-Leucine at different magnifications 
(Boxes indicate representatives of particle morphology) 
Figure 3.17: SEM micrographs of spray dried amphotericin B: AA2g with lactose at different magnifications  	
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3.5.3.5 Morphology analysis of spray dried microparticles by electron microscopy: 
Transmission electron microscope 
			
 
 
 
The TEM micrographs for co-ground amphotericin B: AA2g nanocomplexes (Figure 3.18A), and 
re-dispersed spray dried amphotericin B: AA2g microparticles with and without L-leucine/lactose 
(Figure 3.18B, Figure 3.18C, Figure 3.18D), showed the presence of nanometric range of 
spherical particles. These images confirm that nanocomplexes were obtained on redispersion of 
A B 
C D 
Figure 3.18: TEM micrographs of nanocomplexes; (A) co-ground amphotericin B: AA2g (1:2), (B) spray dried 
and re-dispersed amphotericin B: AA2g (1:2), (C) spray dried and re-dispersed amphotericin B: AA2g (1:2): 
L-leucine, (D) spray dried and re-dispersed amphotericin B: AA2g (1:2): lactose 
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microparticles after spray drying, similar to the co-ground nanocomplexes, confirming 
maintenance of complexation and consequently solubilization of amphotericin B. 
The particle size of the nanocomplexes as evident by the TEM micrographs was in the range of 
18-25 nm, showing a unimodal and even distribution pattern. However, the particle size analyzed 
by laser diffraction using the Nano Zetasizer showed that the particle size was 115.86 ± 1.066 nm 
which was significantly (p < 0.05) different from that observed by electron microscopy. When 
nanocomplexes are analyzed by laser diffraction the size read is the hydrodynamic diameter, 
measured indirectly via a principle of photon correlation spectroscopy, and hence there could be 
a deviation between true size and hydrodynamic diameter observed. Previous literature studies 
have portrayed that when the nanoparticle size is very low (<30 nm) the particles have a tendency 
to absorb some of the laser light incident on them, instead of scattering it completely. Hence, the 
principle of dynamic light scattering used by the Zetasizer fails at this point and leads to a 
hydrodynamic diameter significantly larger than the actual size of dispersion [377]. Hence, for 
this reason, a more direct microscopic method like TEM would be of greater benefit to view the 
morphology, size and homogeneity of nanoparticles 
3.5.3.6 Molecular order evaluation using X-ray powder diffraction 
XRPD was performed on the raw materials amphotericin B and AA2g, co-ground amphotericin 
B: AA2g, physically mixed amphotericin B: AA2g and spray dried amphotericin B: AA2g with 
and without excipients. XRPD of crystalline compounds is detected by sharp characteristic peaks 
whereas those of amorphous compounds are indicated by simple halos above the baseline. 
The XRPD diffractogram of marketed amphotericin B (Figure 3.19) exhibits sharp peaks at 2Θ 
values of 9.24, 13.85, 15.08, 17.04, 18.21 and 21.53 characteristic of untreated amphotericin B, 
which confirms the definite crystalline structure and identity of amphotericin B from previous 
literature [378,379]. The XRPD diffractogram of marketed AA2g (Figure 3.20) exhibits sharp 
peaks, characteristic of untreated AA2g which confirms the definite crystalline structure and 
identity of AA2g from previous literature studies [369]. 
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Figure 3.19: X-ray powder diffractogram of marketed amphotericin B	
                            
 
Figure 3.20: X-ray powder diffractogram of marketed AA2g 
 
X-Ray powder diffractogram of physically mixed and co-ground powders- To study the 
effect of co-grinding on crystallinity of powder 
The crystalline raw materials when mixed together forming the physical mixture at the molar ratio 
amphotericin B: AA2g 1:2 exhibited sharp crystalline deflections super-imposed on a slight halo 
indicative of crystalline raw materials mixed together (Figure 3.21). Co-grinding the drug with 
solubilizing agent AA2g at the same molar ratio for 10 min showed no significant change in the 
molecular order of the raw materials since diffractograms exhibited the same sharp crystalline 
deflections as that of the physical mixture superimposed on a halo. However, the peaks were less 
intense as compared to the physical mixture which could be attributed to the shear and impact 
forces applied during co-grinding.  
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Figure 3.21: X-ray powder diffractogram of amphotericin B: AA2g co-ground (CG) and physically mixed 
                      
X-Ray powder diffractogram of physically mixed and spray dried powders with and without 
excipients- To study the effect of spray drying on crystallinity of powder 
Spray drying the co-ground amphotericin B: AA2g formulation with and without excipients 
lactose/L-leucine showed a change in the XRPD diffractogram confirming an arrangement of 
long-range molecular disorder i.e. amorphous state (Figure 3.22). Physically mixing the 
respective excipients or co-grinding them showed the presence of sharp reflections indicative of 
long-range molecular ordered arrangement i.e. crystalline nature. On spray drying these 
formulations, the XRPD diffractogram showed a halo between the 2ϴ of 15-25° indicative of 
their amorphous nature. 
The molecular order of a compound is very important as it dictates dissolution rate and stability 
of a compound. Amorphous particles have better dissolution characteristics as compared to 
crystalline particles; however, they have the capability of re-crystallizing on storage in the 
presence of moisture and hence need to be stored well preferably in low moisture conditions. 
Hence, in the present study spray dried powders were stored in a desiccator at room temperature. 
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Figure 3.22: X-ray powder diffractogram of A) spray dried amphotericin B: AA2g; B) physically mixed 
amphotericin B: AA2g; C) spray dried amphotericin B: AA2g: lactose; D) physically mixed amphotericin B: 
AA2g: lactose; E) spray dried amphotericin B: AA2g: L-leucine and F) physically mixed amphotericin B: 
AA2g: L-leucine 
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3.5.3.7 Molecular interaction studies using attenuated Fourier transform infrared 
spectroscopy  
FT-IR was performed on the spray dried and co-ground amphotericin B: AA2g to study the 
interactions between the functional groups of amphotericin B with AA2g, which resulted in the 
enhancement of amphotericin B solubilization in deionized water. FT-IR of the spray dried and 
co-ground microparticles were compared with that of raw materials and physically mixed 
powders, to observe the interactions on co-grinding. If functional groups underwent chemical or 
hydrogen bonding, there would be a change in FT-IR spectrum due to characteristic absorption 
by the newly formed bond. FT-IR of amphotericin B and AA2g shows characteristic absorption 
peaks as shown in Table 3.14, which are important to study the interactions between the two 
compounds. 
Table 3.14: FT-IR spectrum absorption peaks associated with interaction and functional group representation 
of the raw materials 
Peak absorption (cm-1) Characteristic of functional group 
Amphotericin B: 
3676.2 Symmetric and asymmetric stretching of amine (N-H) 
3364.7 
761.28 Wagging vibration of N-H of amine 
1640.1 Scissoring and bending vibration of N-H of amine 
AA2g: 
1765.4 C=O stretching vibration of lactone 
1700.1 C=C stretching vibration of lactone 
3490 O-H vibration of OH at C2 of lactone 
3281.2 O-H vibration of OH at C3 of lactone 
 
In the frequency range of 1650-1800 cm-1 (as seen in Figure 3.25 and Figure 3.26) of the raw 
material AA2g, a characteristic absorption at 1769 cm-1 (group 1) attributed to the C=O stretching 
of the lactone ring was clearly evident. No such peak was observed in the spectra of amphotericin 
B indicative of the absence of a lactone functional group. A similar lower intensity peak around 
1764 cm-1 was also evident in the FT-IR spectra of physically mixed amphotericin B: AA2g, 
attributed to no change associated with the functional groups of AA2g on physically mixing with 
drug amphotericin B. However, on co-grinding of amphotericin B with AA2g there was a clear 
shift of the peak associated with lactone C=O to a lower frequency at 1742.3 cm-1. This could be 
attributed to an interaction between the drug and the lactone C=O of AA2g.  
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FT-IR of amphotericin B: 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.23: FT-IR spectrum of raw material amphotericin B 
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Figure 3.24: FT-IR spectrum of raw material AA2g 
 
 
 
 
 
 
FT-IR of AA2g: 
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FT-IR of co-ground and physically mixed amphotericin B: AA2G- To study the effect of co-grinding on the interactional changes in the functional 
groups of the drug and solubilization agent (Group 1) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.25: FT-IR spectrum of co-ground and physically mixed amphotericin B: AA2g (split view, group 1) 
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Figure 3.26: FT-IR spectrum of co-ground and physically mixed amphotericin B: AA2g from frequency range 1400-2200 cm-1 (overlay view, group 1) 
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In the frequency range of 1550-1650 cm-1 (Figure 3.27 and Figure 3.28) of raw material 
amphotericin B, a characteristic absorption at 1628.4 cm-1 attributed to the scissoring and bending 
vibration of N-H group on amphotericin B was noticeable. No such peak around the same 
frequency was evident in the FT-IR spectra of AA2g, confirming the absence of primary amine 
group on AA2g. FT-IR spectra of physically mixed amphotericin B: AA2g in this spectral region 
showed similar absorption peaks to amphotericin B around 1631.4 cm-1, indicative of no 
interactions when amphotericin B and AA2g were mixed physically. On grinding together 
amphotericin B and AA2g, the peak attributed to scissoring and bending vibration of the primary 
amine group was seen to shift to a lower frequency with an increase in intensity at 1582.4 cm-1. 
This could be attributed to interactions taking place with the amine group of amphotericin B. 
In the frequency range of 3200-3500 cm-1 (as seen in Figure 3.29) many overlapped peaks were 
evident since in this spectral region there are absorptions associated with many functional groups 
namely amine and alcohol which are found in abundance in the molecular structure of 
amphotericin B and AA2g. However, around this spectral region, there is a noticeable difference 
between the physically mixed amphotericin B: AA2g and co-ground amphotericin B: AA2g at 
around 3489.4 cm-1 (group 3). A clear peak attributed to the O-H stretching vibration of AA2g 
lactone was evident in the spectra of AA2g and physically mixed amphotericin B: AA2g around 
this frequency range. However, this high-intensity peak was not evident in the F-IR spectra of co-
ground amphotericin B: AA2g at molar ratio 1:2. This could be attributed to the interaction of the 
O-H bond of AA2g lactone with amphotericin B on co-grinding. 
This study demonstrated that there is an interaction mostly a hydrogen bond formation which 
takes place between the oxygen groups namely C=O and O-H on the lactone ring of AA2g with 
the amine group on amphotericin B on co-grinding, resulting in increased solubilization of 
hydrophobic amphotericin B in deionized water. These interactions are not evident in the FT-IR 
spectra of physically mixed amphotericin B: AA2g at the same molar ratio, and hence no 
solubilization enhancement of amphotericin B is seen in aqueous solution on simple mixing with 
AA2g. Hence, this study clearly depicts the importance of co-grinding of amphotericin B with 
AA2g for enhancement of aqueous solubility of the hydrophobic antifungal. 
The interactions leading to solubility enhancement of clarithromycin by co-grinding with AA2g 
was studied by Inoue et al. using 13C NMR (carbon-13 NMR), which confirmed that hydrogen 
bond interaction between the ketone groups of the lactone ring of AA2g with the N, N-dimethyl 
amino groups on the desosamine sugar of clarithromycin was responsible for the enhanced 
solubility of the hydrophobic drug [369]. There was similar type of interaction between the amine 
groups of amphotericin B and lactone ketone and hydroxyl groups of AA2g, confirmed by FT-IR 
studies, which was responsible for the solubility of hydrophobic drug amphotericin B in deionized 
water. 
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FT-IR of co-ground and physically mixed amphotericin B: AA2g- To study the effect of co-grinding on the interactional changes in the functional 
groups of the drug and solubilization agent (Group 2) 
 
 
 
                 
 
Figure 3.27: FT-IR spectrum of co-ground and physically mixed amphotericin B: AA2g from 1550-1650 cm-1(split view, group 2) 
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Figure 3.28: FT-IR spectrum of co-ground and physically mixed amphotericin B: AA2g from 1550-1650 cm-1(overlayed view, group 2) 
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Figure 3.29: FT-IR spectrum of co-ground and physically mixed amphotericin B: AA2g from 3200-3500 cm-1(overlayed view, group 3) 
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It is also important to ascertain if these interactions between amphotericin B and AA2g are still 
prevalent after spray drying, to ensure that amphotericin B is also soluble on re-dispersion of 
microparticles. Hence, the FT-IR spectrum of spray dried and physically mixed amphotericin B: 
AA2g on the addition of excipients lactose and L-leucine was studied. The spectrum (as seen in 
Figure 3.30 and Figure 3.32) clearly indicates that the interaction between amphotericin B and 
AA2g still prevails, and spray drying does not have any detrimental effect on the complexation 
and consequently solubilization of amphotericin B. 
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FT-IR of spray dried and physically mixed amphotericin B: AA2g: lactose- To study the effect of spray drying on the interactional changes in 
the functional groups of the drug and solubilization agent  
 
     
      
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.30: FT-IR spectrum of spray dried and physically mixed amphotericin B: AA2g: lactose (overlayed view) 
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Figure 3.31: FT-IR spectrum of spray dried and physically mixed amphotericin B: AA2g: lactose (split view) 
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FT-IR of spray dried and physically mixed amphotericin B: AA2g: L-leucine- To study the effect of spray drying on the interactional changes in 
the functional groups of the drug and solubilization agent  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.32: FT-IR spectrum of spray dried and physically mixed amphotericin B: AA2g: L-leucine (overlayed view) 
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Figure 3.33: FT-IR spectrum of spray dried and physically mixed amphotericin B: AA2g: L-leucine (split view) 
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3.5.3.8 In vitro aerosol deposition and aerodynamic behavior of amphotericin B 
microparticles 
The in vitro aerodynamic behavior and deposition of amphotericin B microparticles illustrated in 
Figure 3.34 and Figure 3.35 was studied using a Next Generation Impactor. In this study, 
aerosolization efficiency parameters (Table 3.15) were analyzed in triplicate for the freshly 
prepared spray dried and co-ground amphotericin B powders and represented as a histogram of 
the mean percentage of amphotericin B impacted on each stage as compared to the initial amount 
of amphotericin B aerosolized, ± SD.  
Table 3.15: Aerosol efficiency parameters studied from the NGI (n=3, mean ± SD) 
Microparticle ED (%) 
FR 
(%) 
FPF 
(%) 
FPD 
(mg) 
MMAD 
(µm) GSD 
Co-ground 
amphotericin B: 
AA2g 
57.19 
± 
4.22 
81.99 
± 
2.31 
13.87 
± 
4.22 
6.24 
± 
1.90 
3.38 
± 
0.21 
2.78 
± 
0.17 
Spray dried 
amphotericin B: 
AA2g 
89.80 
± 
2.86 
82.69 
± 
3.14 
37.85 
± 
2.15 
17.02 
± 
0.97 
2.32 
± 
0.15 
2.02 
± 
0.23 
Spray dried 
amphotericin B: 
AA2g: L-leucine 
99.86 
± 
1.14 
80.11 
± 
1.97 
56.75 
± 
1.46 
25.54 
± 
0.66 
2.55 
± 
0.13 
2.05 
± 
0.15 
Spray dried 
amphotericin B: 
AA2g: lactose 
92.59 
± 
3.62 
76.84 
± 
3.47 
42.23 
± 
3.08 
19.00 
± 
1.39 
3.45 
± 
0.29 
1.45 
± 
0.20 
Physically mixed 
amphotericin B: 
AA2g 
95.34 
± 
2.71 
76.06 
± 
1.21 
8.22 
± 
1.17 
3.70 
± 
0.53 
4.60 
± 
0.67 
5.44 
± 
0.17 
ED- emitted dose, FR- fraction recovered, FPF- fine particle fraction, FPD- fine particle dose, MMAD- mass 
median aerodynamic diameter, GSD- geometric standard deviation 
Fraction recovered: It is very important to have a mass balance throughout the NGI [380]. A 
small percentage of the unrecoverable drug gets entrapped into the seal body and makes it 
necessary to study the mass balance of each experiment individually. A good mass balance was 
encountered for all the experiments with data lying between the pharmacopeial acceptable limits 
i.e. 76.1-82.7%. The difference in the fraction recovered of all the powders (i.e. co-ground, 
physically mixed and spray dried powders) was insignificant (p > 0.05).  
 
Emitted dose: The ED was studied from the amount of drug left in the capsules after 
aerosolization and calculated as per drug content for respective formulations. High dispersibility 
and hence ED was exhibited by the spray dried powders with more than 86.2% contents being 
emitted during aerosolization for each. However, a significantly lower (p < 0.05) ED was evident 
for co-ground amphotericin B: AA2g microparticles of around 57.2%. This could be attributed to 
the dense property of the co-ground powder leading to poor flowability along with greater particle 
size (Dv50) and a significantly higher Span as compared to the spray dried microparticles when 
analyzed by laser diffraction (section 3.5.3.3). The spray dried microparticles containing the 
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dispersibility enhancer L-leucine also showed a significantly greater (p < 0.05) ED as compared 
to the spray dried microparticles without L-leucine and spray dried microparticles with lactose, 
indicative of the fact that incorporation of L-leucine in the feedstock before spray drying could 
enhance the amount of microparticles emitted from the capsules. This was evident due to the 
surface diffusion of L-leucine in its condensed phase and subsequent deposition on the surface of 
the microparticles at the air-water interface during spray drying consequently affecting 
aerosolization parameters [375,357,356]. 
 
MMAD and GSD: Mass median aerodynamic diameter (MMAD) refers to particle diameter as 
half the aerosol mass contained smaller than MMAD and half that is larger. All the spray dried 
powders show an MMAD of below 5 µm, wherein, the largest of 4.60 µm is achieved for 
physically mixed amphotericin B: AA2g and the smallest of 2.32 µm for spray dried amphotericin 
B: AA2g. MMAD for all the microparticles were found to be well in the respirable limits of 2-5 
µm and can indicate potential deep lung deposition patterns of these microparticles. The 
geometric standard deviations are around 1-2 for the spray dried microparticles of amphotericin 
B: AA2g with and without excipients and co-ground amphotericin B: AA2G indicative of 
monodispersed systems and unimodal distribution of microparticles. However, the GSD of 
physically mixed amphotericin B: AA2g was found to be significantly (p < 0.05) larger i.e. 5.44 
µm, indicative of the fact that simply mixing the drug and solubilizing agent together is not 
sufficient to obtain a well dispersible unimodal distribution of microparticles for aerosolization. 
 
Fine particle fraction and dose: FPF and FPD are important determinants of the fraction and 
dosage of aerosolized drug that has potential to be deposited in the peripheral lungs and hence 
show therapeutic efficacy. These are explained in detail with the potential pulmonary deposition 
histograms. 
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Potential pulmonary deposition of amphotericin B microparticles 
Table 3.15 and Figure 3.34, shows the effect of spray drying by comparing spray dried 
amphotericin B: AA2g with the physically mixed and co-ground amphotericin B: AA2g powders 
formulated at the same molar ratio. There was a significant increase (p < 0.05) in FPF and FPD 
of spray dried amphotericin B: AA2g as compared to the co-ground amphotericin B: AA2g and 
physically mixed amphotericin B: AA2g, emphasizing the importance of spray drying to produce 
microparticles suitable for delivery to the peripheral lung as it could offer a proper tuning of the 
particle size distribution, shape and density which are important parameters for a successful 
inhalation.  
Figure 3.34: NGI deposition profile of spray dried, physically mixed and co-ground microparticles (n=3, mean 
± SD) 
As evident in Figure 3.34, physically mixed and co-ground amphotericin B: AA2g showed a very 
high deposition of amphotericin B in the throat and pre-separator stages of the NGI, indicative of 
higher oropharyngeal and throat deposition rather than deeper peripheral deposition in the lungs, 
with only 3.70±0.53 mg and 6.24±1.9 mg amphotericin B respectively reaching the lower stages 
of the NGI. Comparison of FPF and FPD between co-ground and physically mixed powders by 
one-way ANOVA at a level of p=0.05 shows that the these were significantly different. (p < 0.05) 
This depicts that co-grinding can help to improve the FPF of formulations rather than simple 
physical mixing. 
The deposition profile obtained from the NGI indicates that simple mixing of amphotericin B 
with AA2g, or co-grinding amphotericin B with AA2g which helps in solubilization of the drug 
in aqueous solutions, is not sufficient to improve the lung deposition profile of amphotericin B, 
portraying the importance of spray drying. On spray drying amphotericin B: AA2g 
nanocomplexes a significantly (p > 0.05) higher FPD of 17.02 ± 0.97 mg amphotericin B as 
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compared to co-ground or physically mixed amphotericin B: AA2g was seen to deposit in the 
lower stages of the NGI. Spray drying produced spherical particles with a narrow size distribution 
as confirmed by SEM and laser diffraction studies, and particles were found to be amorphous as 
seen by the XRPD diffractograms. On the other hand, physically mixing and co-grinding retained 
the crystalline nature of the drug amphotericin B as seen in the XRPD diffractograms, along with 
wide size distribution resulted in a poor potential peripheral pulmonary deposition. This 
characteristic was as that reported earlier by several authors for drugs like curcumin, theophylline 
and terbutaline sulphate [381–383]. 
Furthermore, there was also a significantly higher (p < 0.05) FPF seen on addition of bulking 
agent lactose and dispersibility enhancer L-leucine which displays the importance of particle 
modification and reduction of interparticulate forces to consequently obtain a higher FPF.  
 
The effect of addition of excipients in the spray drying feedstock on aerosolization and hence 
deposition of microparticles-  
Spray dried microparticles were prepared by incorporating L-leucine in the feedstock solutions 
prior to spray drying. A minimum of ≥25% is required to cause a significant change in powder 
characteristics and subsequently aerosolization, as per published literature [361]. A significant 
increase (p < 0.05) in FPF and FPD was seen on aerosolization of amphotericin B: AA2g with 
dispersibility enhancer L-leucine, where 56.75% of microparticles were deposited in stages 2-8 
accounting for 25.54±0.66 mg amphotericin B, indicative of potential deeper peripheral airways 
leading to higher dosage delivery to the areas of fungal infection and lower oropharyngeal and 
upper airway deposition, consequently leading to lower toxicity issues. This was evident by 
studying its deposition profile (Figure 3.33) which clearly portrays a higher deposition of 
microparticles in stages 2 to 5 as compared to the deposition profile of other microparticles 
formulated. As seen in the SEM micrographs (Figure 3.16), there was a change in morphology of 
the microparticles producing opened powdered structures on the incorporation of L-leucine at 
25% weight concentration of the total constituents of the microparticles. Targeted delivery to the 
alveoli and bronchi using amphotericin B inhalation powder (ABIP, Nektar therapeutics) in 
clinical trials at a starting dose of 25 mg has been shown to be advantageous for treatment of 
invasive pulmonary aspergillosis, due to an aerodynamic size in the range of 2-5 µm [206]. 
Around 25 mg of amphotericin B was deposited in stages 2-8 of the NGI, suggesting potential 
peripheral lung deposition of the formulation spray dried with L-leucine for the treatment of 
invasive pulmonary aspergillosis. 
Lactose was incorporated at a ratio of 50% of the total constituent of spray drying feedstock. 
However, it showed no significant difference (p > 0.05) in FPF and FPD as compared to the 
microparticles spray dried without excipients. Hence, the dose of amphotericin B delivered using 
microparticles spray dried with lactose would be lower as compared to the dose delivered using 
microparticles spray dried without excipients, indicating that incorporation of lactose did not have 
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a beneficial role for amphotericin B: AA2g microparticle aerosolization at a proportion of 50% 
weight. 
 
 
Figure 3.35: NGI deposition profile of spray dried microparticles with and without excipients (n=3, mean ± SD) 
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3.5.3.9 In vitro antifungal assessment of amphotericin B nanocomplexes against Candida spp 
by MIC studies 
Optimized spray dried microparticles of amphotericin B were shown to possess in vitro fungicidal 
activity against Candida spp planktonic cells at varied minimum inhibitory concentration (MIC) 
as shown in Table 3.16. 
Table 3.16: MIC (µg/mL) for various formulations against Candida albicans and Candida tropicalis 
Powder 
Minimum inhibitory concentration 
(µg/mL) 
Candida albicans Candida tropicalis 
 24 h 48 h 24 h 48 h 
Amphotericin B 1.33 ± 
0.58 
5.33± 
2.31 
2 5.33± 
2.31 
AA2g >64 >64 >64 >64 
Co-ground amphotericin B: 
AA2g 
1.67 ± 
0.58 
5.33 ± 
2.31 
2 8 
Spray dried amphotericin B: 
AA2g 
1.67± 
0.58 
5.33 ± 
2.31 
2 8 
Spray dried amphotericin B: 
AA2g: L-leucine 
1.33 ± 
0.58 
4.67± 
3.055 
2 4 
Spray dried amphotericin B: 
AA2g: lactose 
1.33 ± 
0.58 
5.33 ± 
2.31 
2 5.33 ± 
2.31 
 
The study was carried out against two different species of Candida, namely Candida albicans and 
Candida tropicalis. A very similar or 2- fold difference in MIC was evident for the spray dried 
powders as compared to raw material amphotericin B.  However, the decrease was insignificant 
(p > 0.05) as analyzed by one-way ANOVA Tukey post-hoc test. This confirms that on the 
formation of nanocomplexes by interactions between the amine group on amphotericin B and 
lactone carbonyl on AA2g to enhance the solubility of amphotericin B there was no detrimental 
effect on the antifungal activity of the drug. 
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3.6   Conclusion 
The aim of the chapter was to prepare nanocomplexes to solubilize hydrophobic antifungal agent 
amphotericin B for treatment of pulmonary fungal infections.  
Based on the aforementioned results presented in this chapter, it can be concluded that: 
1. Nanocomplexes were successfully formed by co-grinding at different molar ratios antioxidant 
solubilization agent ascorbic acid-2-glucoside (AA2g) with amphotericin B. The 
nanocomplexes formed at the different molar ratios between amphotericin B: AA2g were 
stable at 4-8°C and 25°C for 10 days with respect to hydrodynamic size, surface charge and 
drug content.  
2. Molecular interaction between the drug and AA2g was studied to ascertain the reason for an 
improved amphotericin B solubilization. FT-IR studies revealed hydrogen bond interactions 
between the amine groups on amphotericin B and the lactone ring of AA2g on co-grinding, 
which was not evident on physically mixing the two compounds. This explained the improved 
solubilization of amphotericin B on specifically co-grinding with AA2g.  
3. The most stable complexes keeping in mind the dosage requirements of amphotericin B and 
proper stoichiometry between the two complexing molecules i.e. amphotericin B: AA2g 1:2, 
(molar ratio) were taken forward for the preparation of dry powders intended for inhalation.  
4. Dry powder microparticles were successfully prepared by spray drying with or without 
excipients to aid dispersibility and laser diffraction particle size analysis confirmed that spray 
dried microparticles exhibited a volume mean size lower than 5 µm, which is suitable for 
lower respiratory tract deposition, preferably to the alveolar regions where the infections 
prevail. 
5. The spray dried microparticle morphology observed using SEM, displayed particles with a 
size in good agreement with that obtained from the laser diffraction studies. The particle 
morphology was summarized to be spherical, non-agglomerated and with slight corrugations 
on the surface. 
6. The study of in vitro aerosol properties of amphotericin B microparticles on the NGI exhibited 
that an improved fine particle fraction and dose of amphotericin B on spray drying the co-
ground nanocomplexes was obtained, due to the engineering microparticles with appropriate 
properties for aerosolization. On addition of dispersibility enhancer L-leucine to the spray 
drying feedstock of amphotericin B: AA2g a further improvement in fine particle fraction and 
dose was evident, with up to 25 mg of amphotericin B seen to deposit in the later stages of 
the NGI, indicative of potential peripheral pulmonary deposition.  
7. In vitro antimicrobial assessment against Candida spp namely Candida albicans and Candida 
tropicalis by the MIC assay showed retainment of fungal activity on complexation and spray 
drying of amphotericin B.   
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4.1   Introduction 
Tuberculosis (TB) remains a serious healthcare issue, two decades on from the first time it was 
declared as a global health emergency by the World Health Organization (WHO) due to its 
resurgence fuelled by an increase in multi-drug resistance and coinfection due to the spread of 
HIV. According to the WHO, TB affected about 10.4 million people in 2015, of which 1.4 million 
people died as a result of it [50]. Control of the disease has become increasingly challenging 
because of the alarming rise of resistance in Mycobacterium tuberculosis, the etiological agent of 
TB. Multi-, extensively- and more recently, totally-drug resistant TB (MDR-, XDR-, TDR-TB) 
cases have increased steadily over the last decade. WHO reported 0.48 million new incidences of 
MDR-TB and an additional 0.1 million new cases of rifampicin-resistant TB (RR-TB)  in 2015 
alone [50,51]. Hence MDR-TB accounted for 3.9% of new TB cases and 21% of previously 
treated TB cases, of which 9.5% were XDR-TB [51]. The current portfolio of antibiotics used for 
anti-TB therapy is extensive but not adequate for treatment of the resistant strains of the bacteria, 
and hence TB remained in the top 10 leading causes of death in 2015 [50,51]. HIV and TB co-
infection is presently a serious threat, as TB is the major killer of people living with HIV, 
accounting for about 35% of HIV deaths in 2015 [50,51].  
The present study is based on the fact that TB bacilli are primarily located within alveolar 
macrophages in pulmonary TB hence posing a challenge to its treatment by conventional 
antitubercular chemotherapeutics. Previous studies have highlighted the potential of exploiting 
the innate property of macrophages to engulf foreign particles, hence demonstrating an improved 
uptake of nanocarriers encapsulating chemotherapeutics for delivery into the macrophages where 
the TB bacilli are primarily located (Table 4.1). 
Moreover, it has been reported that receptors expressed on macrophages could be used to actively 
target chemotherapeutics encapsulated in varied types of nanocarriers decorated with targeting 
ligands for further improving the therapeutic efficacy of the drugs and hence treatment (section 
4.1.5). 
4.1.1 Re-purposing drugs for tackling MDR-TB 
Development of new and effective drug treatment with novel and diverse mechanisms of action 
is of paramount importance to outpace the evolving resistance of the TB pathogen. MDR-TB 
occurrence has progressed due to adaption of the pathogen to combat the effects of drugs by 
genetic evolution. Inappropriate drug administration, sub-optimal drug concentration due to 
inadequate diffusion inside the lung tissue on systemic administration and patient non-compliance 
due to the drug regimen being extensively long, expensive, complicated in administration and 
toxic has hastened TB resurgence, especially in low-income countries that struggle due to 
excessive populations, malnutrition, poverty and HIV co-infection [384,385]. Moreover, the 
dormant state of the TB pathogen causes a latent TB infection that is harboured by one-third of 
the global population due to its resilience and coping nature to varied environments. It has the 
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capacity to convert to an active TB infection in 10% cases, hence requiring a lengthy drug regimen 
that is not only capable of  eradicating the active TB, but also eliminates the dormant pathogen 
from the infected host [385]. 
New chemical entities require at least a decade to progress from the laboratory bench to clinical 
use and when finally administered it is not unlikely that resistance to these novel entities will 
develop. Repurposing drugs offer a rapid, safer and effective solution to circumvent the 
investment of time and other resources required for conventional drug discovery and 
development. For instance, sildenafil developed by Pfizer originally for the treatment of 
hypertension and erectile dysfunction is now being considered as a host-directed adjuvant therapy 
to shorten TB treatment times, as it has resulted in faster mycobacterial clearance and improved 
tissue resolution [386]. Forthcoming clinical trials in India are investigating repurposed 
Verapamil, i.e. an approved anti-hypertensive drug for its effective acceleration in clearance of 
mycobacterium in conjunction with other first-line treatment drugs, hence significantly reducing 
the treatment duration [387]. 
Non-steroidal anti-inflammatory drugs (NSAIDs), commonly used for pain relief have been 
reported to exhibit anti-TB properties both in vitro and in vivo [388–391]. Whole cell phenotypic 
screening has revealed the off-patent NSAID oxyphenbutazone to have antitubercular properties 
against actively replicating, non-replicating and drug-resistant isolates of M. tuberculosis 
[388,392]. NSAIDs ibuprofen, carprofen and other 2-aryl propanoic acid derivatives have also 
demonstrated antitubercular activity in whole-cell phenotypic assay [389]. Moreover, ibuprofen 
has demonstrated enhanced elimination of in vivo bacterial loads when used in combination with 
the antitubercular drug pyrazinamide [393]. Furthermore, NSAIDs may also facilitate healing of 
the lung tissue that has been damaged due to prolonged antitubercular drug regimens owing to 
their anti-inflammatory activity [385]. However, development of ibuprofen as an antitubercular 
drug for the lungs is limited by its highly acidic nature. 
4.1.2 Drug delivery systems for treatment of TB 
Development of drug delivery systems capable of direct administration of drugs to the lungs could 
represent a breakthrough in the treatment of TB. This can circumvent the requirement of high oral 
doses to reach optimal sputum levels for the elimination of bacillary load. High doses of anti-TB 
drugs like rifampicin for a protracted period causes considerable systemic toxicity, such as 
nephrotoxicity and hepatotoxicity, along with a serious effect on the gut microflora and a 
substantial contribution in developing antibiotic resistance and its transmission. Aerosolization 
would help target specific regions in the lungs with the aid of nanoscale drug delivery systems to 
administer higher doses of drug and reduce systemic toxicity. Other potential advantages would 
be improving the stability of the drug, the feasibility of incorporation of both hydrophilic and 
hydrophobic substances and controlled (sustained) drug release from the lipid/polymer matrix. 
Nanoparticles delivered via the pulmonary route have demonstrated potential to enable 
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improvement of drug bioavailability and reduce the dosing frequency, which could resolve the 
problem of non-adherence, one of the major roadblocks in TB control [394]. 
Liposomal formulations of clofazimine were much more effective in being taken up naturally by 
the macrophages where the infection prevails, hence improving treatment outcome [270]. Stoops 
et al. have reported that aerosolization of lipids/surfactants along with antitubercular drugs have 
the tendency to strip off the waxy trehalose dimycolate armor of mycobacterium, acting as cell 
permeabilizing agents, hence increasing the effectiveness of the co-administered antibiotics for 
the treatment of pulmonary TB [395].  
Ever-mounting evidence has demonstrated that Mycobacterium tuberculosis and several other 
mycobacterial species have a strong propensity to grow matrix encapsulating structures ‘biofilms’ 
which induce antibiotic drug tolerance as a survival strategy in chronic infection [68,396,397]. 
Various studies on nano-liposomal antibiotic formulations have demonstrated successful 
penetration through bacterial biofilms and effective eradication of bacteria. A study of cationic 
liposomes encapsulating rifampin has been shown to effectively eradicate Staphylococcus 
epidermidis from biofilms, reducing the bacterial load much efficiently compared to rifampin 
alone [398,399]. 
4.1.3 TB etiology and pathogenesis: Rationale for macrophage targeting 
TB is an airborne disease and infection starts with the host inhaling viable tubercle bacilli 
contained in droplets [208,400,401]. Tubercle bacilli are aerobic, acid-fast, gram-positive, slender 
rod-shaped and non-motile bacteria [401]. They have a capacity to adapt to changes in the 
environment including host defense mechanisms viz. nutrient deprivation, hypoxia, 
intraphagosomal acidification and exogenous stress from the environment, staying viable in the 
air for a long time [208,401]. Mycobacterium tuberculosis has a unique cell wall which is 
composed of mycolyl arabinogalactan–peptidoglycan (mAGP) complex, i.e. a complex composed 
of mycolic acids and peptidoglycans, along with other glycolipids, cell-wall proteins and cord 
factors [208,402]. This constitutes a strong diffusion barrier making mycobacteria around 100-
1000 times less permeable than E.coli to the passage of hydrophilic molecules, resistant to 
digestion by phagolysosomal enzymes and pH, and the killing effects of pulmonary macrophages 
[208,402]. Hence the hydrophobic cell wall of the tubercle bacilli is a major determinant of its 
virulence due to the resistance it possesses to the entry of antibiotics. 
Tuberculosis is most commonly caused by reactivation of the latent tubercle bacilli which the host 
carries for many years rather than by primary infection [208,400]. During the latency period of 
the bacilli, they are hosted in macrophages, wherein surviving bacilli remain alive and consume 
host lipids but do not multiply [208,400]. Alveolar macrophages act as a double-edged sword as 
they primarily serve to limit the growth and dissemination of bacilli into the extrapulmonary areas. 
This helps the bacilli to stay within the granuloma and produce large numbers of lipid-free 
vacuoles and lipid-containing bodies known as foamy macrophages, formed due to oxygenation 
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of the mycolic acids. Alveolar macrophages serve as a reservoir for preserving bacilli for a long 
time, hence altering their function and phenotype as immune defense cells [208,400]. These 
macrophages then gets surrounded by a fibrous capsule which leads to exclusion of immune 
lymphocytes from the bacilli, leading to active infection [208,400,403]. The bacterial foci within 
the macrophages break down when the host defense is weak and re-grow particularly in alveolar 
spaces and disseminate the infection [208,400,403]. After 3 months of active infection, numerous 
small foci develop in highly irrigated organs like CNS, spine, lymph nodes, liver, kidney and 
genitalia leading to exaggerated extrapulmonary manifestation known as miliary TB [208,400]. 
4.1.4 Passive macrophage targeting by liposomes on IV/pulmonary delivery 
The adapted macrophages act as a formidable barrier to delivery of small molecule drugs, 
vaccines and diagnostic agents for the eradication of the intracellular TB bacilli. It is hence of 
extreme importance to understand the structure of the macrophages and generate strategies to 
increase the uptake of antimycobacterial agents by targeting the macrophages where the TB bacilli 
are protected from the host immune surveillance. Macrophages have an innate propensity to 
engulf foreign particles as a mean of defense, which is a highly size-dependent [208,404]. 
Particles 1-3 µm in size are most likely to be passively taken up by alveolar macrophages, 
whereas, particles <0.2 µm and >10 µm may escape phagocytic endocytosis [404]. Particles <0.2 
µm undergo cytosis via pinocytosis that includes micropinocytosis (100 nm-0.2 µm), clathrin-
medicated pinocytosis (~100 nm), caveolin-mediated pinocytosis (~80 nm) or clathrin and 
caveolin-independent pinocytosis (~50 nm) [404,405].   
Moreover, the surface chemistry of particles also plays an important role in macrophage uptake. 
Internalization of liposomes into cells has been reported to occur by means of surface adsorption, 
membrane fluidization and membrane-bilayer fusion leading to diffusion and endocytosis [404]. 
Fluorescence microscopy of FITC-Bovine serum albumin (BSA) encapsulated liposomes and 
radioactivity studies of I131-BSA along with liposomal membrane marker studies have suggested 
that liposomes are taken up intact into macrophages by phagocytosis.  Exploiting this natural 
tendency, passive drug delivery using liposomes would seem like an attractive approach to treat 
intracellular pathogens like mycobacterium. Passively targeted liposomes for IV/pulmonary 
delivery of antitubercular drugs in literature and their treatment outcomes are outlined in Table 
4.1. 
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Table 4.1: Passively targeted liposomes encapsulating tubercular drugs (IV/nebulization) 
MLVs-multilamellar vesicles, PC- phosphatidylcholine, Chol- cholesterol, DSPG- distearyl 
phosphatidylglycerol, DMPG- dimyristoyl phosphatidylglycerol, DPPC- dipalmitoyl phosphatidylcholine, IV- 
intravenous 
Antimicrobial 
drug 
Liposomal 
composition Therapeutic effect Treatment outcome(s) 
Rifabutin 
IV 
(mice) 
 
[208,406] 
 
Liposome 
MLVs  
 
DPPC: 
DSPG 
(7:3 molar) 
Significant accumulation of the 
liposomes in the spleen and liver, 
and hence a significant reduction in 
bacterial load as compared to the 
free drug treated group. 
No significant difference in bacilli 
load resident in the lungs between 
the two groups 
Good to tackle 
extrapulmonary 
disseminated TB 
infection 
For pulmonary TB 
treatment, aerosol 
administration would be 
an interesting approach 
Amikacin 
IV  
(mice) 
 
[208,407] 
 
Liposome 
MLVs 
 
Soya PC: 
DSPG: Chol 
(2:0.1:1 
molar) 
Liposomal amikacin showed 2.4-5 
fold superior activity against 
mycobacterium as compared to free 
amikacin in an acute murine TB 
model 
Liposomes showed a low clearance 
rate and hence prolonged residence 
time of the drug 
An attractive approach 
for reducing the 
administration 
frequency and hence 
enhancing patient 
compliance  
Clofazimine  
IV  
(mice) 
 
[270] 
Liposome 
MLVs  
 
DMPC: 
DMPG  
(7:3 molar) 
Liposomal clofazimine showed a 
reduction in toxic effects of the 
drug clofazimine in vitro and in 
vivo 
 
Excellent approach for 
treatment of 
extrapulmonary TB and 
to some extent 
pulmonary TB 
Adams et al. advised 
that direct aerosol 
inhalation of the 
liposomal clofazimine 
would be attractive for 
treatment of pulmonary 
TB  
Rifampicin 
and Isoniazid 
co-
encapsulation 
 
Inhalation by 
nebulization 
(guinea pigs) 
 
[209] 
Liposome 
MLVs  
 
PC: Chol 
(2:1.5 molar) 
Sustained release of drugs from the 
liposomal formulations was evident 
and consequently a longer duration 
of alveolar drug stay up to 120 h 
with nebulized liposomal 
rifampicin and isoniazid as opposed 
to 48 h for free drugs nebulized or 
given IV was seen with a single 
dose 
 
Reduction in the dosing 
frequency could be 
achieved with the 
liposomal drugs and 
hence better patient 
compliance 
Rifampicin 
 
Intratracheal 
instillation of 
re-suspended 
freeze-dried 
liposomes 
(Wister rats) 
 
[408] 
Liposome 
 
Soya 
lecithin: Chol 
(varied 
ratios) 
 
Enhanced drug permeation through 
alveolar epithelium was evident for 
liposomal rifampicin in alveolar 
macrophages 
Pulmonary residence time of 
liposomal rifampicin was superior 
to the free drug 
Sustained release of 
drug from the liposomes 
would be an attractive 
approach to reduce 
dosing frequency  
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4.1.5 Active macrophage targeting by liposomes on IV/pulmonary delivery 
Binding to receptors on macrophages has shown promise in the targeting of delivery systems to 
internalize chemotherapeutics via receptor-mediated endocytosis for several diseases viz. 
rheumatoid arthritis, AIDS, leishmaniasis, TB and Gaucher disease [176]. Active targeting of 
antitubercular delivery systems involves modification of the carrier surface with ligands, 
antibodies or peptides for inducing selective affinity and interaction with the macrophages and 
hence uptake [409].  
Carbohydrate receptors bind specifically to polysaccharides like mannose, galactose, pectin and 
sialic acid and have been extensively researched in previous years. Mannose receptors i.e. a trans-
membrane protein receptor expresses three extracellular regions, specifically, a C-type lectin 
receptor with the carbohydrate-recognition domain, an amino-terminal cysteine-rich domain and 
a fibronectin domain [176,409]. These are highly expressed on alveolar macrophages and hence 
can be exploited for the treatment of intracellular tuberculosis which is primarily hosted inside 
alveolar macrophages [176,409].  
Moreover, active targeting of delivery systems can also be achieved by exploiting the scavenger 
receptors present on the surface of macrophages, specifically the SR-B1 and CD36 classes of 
scavenger macrophage receptors which bind tightly to polyanionic molecules like. anionic 
phospholipids [410]. Tuftsin a naturally occurring tetrapeptide produced by enzymatic cleavage 
of the heavy chains of immunoglobulin G has a natural tendency to target the macrophages and 
lead to upregulation of macrophage-mediated phagocytosis, and hence can enhance the innate 
bactericidal and tumouricidal activity of macrophages [411]. This makes tuftsin an attractive 
ligand for attachment to the surface of nanocarriers for binding specifically to macrophages 
carrying intracellular pathogens. Moreover, its natural killer potentiation activity by upregulation 
of phagocytosis can help to improve the therapeutic efficacy of antitubercular drugs [411]. 
Actively targeted liposomes for IV/pulmonary delivery of antitubercular drugs in literature for 
macrophage targeting and their treatment outcomes are outlined in Table 4.2. 
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Table 4.2: Actively targeted liposomes encapsulating tubercular drugs to macrophages (Targeting moiety in bold) 
Antimicrobial 
drug/ targeting 
Liposomal 
composition Therapeutic effect 
Treatment 
outcome(s) 
None 
 
Mannose receptor 
 
Inhalation with 
liquid Micro 
Sprayers 
(Rats) 
 
[412] 
Liposome MLVs 
 
Soybean PC: Chol: 
DCP: 
4-aminophenyl-a-D-
mannopyranoside 
2.2-fold enhanced drug 
uptake by 
alveolar/peritoneal 
macrophages was seen 
both in vitro (NR8383 
cells) and in vivo (rats) for 
the mannosylated 
liposomes as compared to 
non-mannosylated 
liposomes 
 
Good approach for 
delivery of 
antitubercular drugs to 
the alveolar 
macrophages for 
treatment of 
pulmonary TB 
None 
 
Mannose receptor 
 
Intratracheal 
instillation 
(Rats) 
 
[212] 
Liposome 
 
DSPC, Chol, 
Fluorescein-DHPE: 
Mannosylated 
cholesterol  
Alveolar macrophage 
uptake of mannosylated 
liposomes increased with 
an increase in surface 
functionalization with 
mannosylated cholesterol 
derivative 
Increasing mannose 
residues on the surface 
appeared to be a good 
approach for delivery 
of antitubercular drugs 
to the alveolar 
macrophages for 
treatment of 
pulmonary TB 
 
None 
 
Mannose 
Receptor 
 
Intratracheal spray 
(Male SD rats) 
 
[213] 
 
Liposome 
 
Egg PC Chol: DCP: 
4-aminophenyl-a-D-
mannopyranoside 
An enhanced uptake of 
mannosylated liposomes 
was evident both in vitro 
(NR8383) and in vivo 
(rats) alveolar 
macrophages 
Good approach for 
delivery of 
antitubercular drugs to 
the alveolar 
macrophages for 
treatment of 
pulmonary TB 
Rifampicin 
 
Class B1 scavenger 
receptor 
 
Inhalation aerosol 
using the nose-only 
exposure model 
(Wistar Albino 
rats)  
 
[211,413] 
Liposome 
MLVs 
 
PC: Chol (7:3 molar) 
Coated with DPPE-
MBSA (maleyated 
bovine serum 
albumin) 
 
 
 
 
 
PC: Chol: DCP 
(7:3:0.1) 
MBSA targeted anionic 
liposomes resulted in 
39.6±3.3% lung 
accumulation in 
macrophages after 6 h of 
aerosolization, whereas 
on aerosolization of 
neutral liposomes there 
was an initial high lung 
accumulation which 
dropped to nil over 6 h, 
similar to the free drug. 
 
With the DCP anionic 
liposomes the lung 
accumulation was 
29.7±2.9% after 6 h of 
aerosolization 
 
Aerosolization of 
antitubercular drug 
encapsulated 
liposomes surface 
modified to attain an 
anionic charge could 
be useful to target to 
the scavenger 
receptors and hence 
deliver more payload 
to the lung 
macrophages to treat 
pulmonary TB  
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Table 4.2: Actively targeted liposomes encapsulating tubercular drugs to macrophages (Targeting moiety in bold) 
(continued) 
Antimicrobial 
drug/ targeting 
Liposomal 
composition Therapeutic effect 
Treatment 
outcome(s) 
None 
 
Class B1 scavenger 
receptor 
 
[410] 
Liposome 
ULVs 
 
Egg PC: Chol: 
phosphatidyl serine 
(1:1:1) 
 
Egg PC: Chol: 
phosphatidyl inositol 
(1:1:1) 
In vitro uptake and 
receptor-binding studies 
showed an enhanced 
uptake of anionic 
liposomes with 
phosphatidyl serine or 
phosphatidyl inositol as 
compared to neutral or 
cationic liposomes 
Passive targeting to the 
scavenger receptors on 
the macrophages could 
serve to enhance 
delivery to the 
macrophages in the 
lung for treatment of 
pulmonary 
tuberculosis 
Rifampicin and 
Isoniazid 
 
Carbohydrate 
receptor using 
polysaccharide 
pectin 
 
IV (mice) 
 
[210] 
 
 
Liposome 
MLVs 
 
Egg PC: Chol, O-
SAP (O-stearyl 
amylopectin) (2:3 
molar, coated with 
O-SAP) 
 
Egg PC: Chol: DCP, 
O-SAP (2:3:2 molar, 
coated with O-SAP) 
1h post IV injection in 
tuberculosis mice lung 
accumulation of the O-
SAP targeted liposomes 
was 19.0 ±2.0% as 
opposed to 4.70±1.06% 
for non-targeted 
liposomes due to higher 
recognition by the RES. 
Moreover, addition of 
DCP further enhanced 
drug accumulation to 23.0 
±2.0% due to targeting of 
the anionic liposomes by 
dual specificity to 
scavenger and 
carbohydrate receptors 
The study suggested 
the possibility of 
enhancing lung 
accumulation by 
delivery of 
antitubercular drugs in 
liposomes with surface 
modified to have 
greater recognition by 
the RES and hence an 
attractive approach for 
treatment of 
pulmonary TB 
administered 
systemically 
Rifampicin 
 
Tuftsin tetrapeptide 
for targeting to 
peptide receptors  
 
IV 
(Swiss Albino 
Mice) 
 
[208,411] 
Liposome 
SUVs 
 
Egg PC: Tuftsin (7-
8% of by weight of 
egg PC) 
The efficiency of the 
liposomes with tuftsin 
was found to be better 
than non-targeted 
liposomes for a two week 
twice weekly 
administration, wherein, 
there was a 2000-fold 
reduction in 
Mycobacterium 
tuberculosis load and 
mice lung weight as 
compared to free drug 
More effective 
formulation for 
macrophage targeting 
and hence treatment of 
pulmonary TB on 
administration of drug 
systemically 
MLVs-multilamellar vesicles, SUVs- small unilamellar vesicles, ULVs- unilamellar vesicles, PC- 
phosphatidylcholine, DCP- dicetylphosphate, Chol- cholesterol, DSPC- distearyl phosphatidylcholine, DHPE- 
dihexadecanoyl phosphoethanolamine, IV-intravenous 
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4.1.6 Drugs and excipients used in study 
In the present study, development of dry powder microparticles of liposomes co-encapsulating 
antitubercular drugs rifampicin and ibuprofen was aimed. 
Rifampicin 
Rifampicin (Figure 4.1), a first-line antitubercular drug, is one of the most potent and broad-
spectrum antibiotic for the treatment of pulmonary tuberculosis.  
 
Figure 4.1: Structure of rifampicin 
 
Table 4.3: Physicochemical properties of rifampicin 
 
 
 
 
 
  
 
 
Due to its optimum physiochemical properties (Table 4.3), it diffuses freely into intracellular 
compartments of living cells, tissues and bacteria and hence is useful for treatment of 
Mycobacterium tuberculosis [414]. Rifampicin binds to and inhibits DNA-dependent RNA 
polymerase with high affinity, hence the bacterial cells can no longer produce RNA more than 2-
3 nucleotide long, ultimately failing protein transcription. Resistance against rifampicin arises 
from mutation in the β subunit of the RNA polymerase site required by the drug to show activity 
[80]. 
Ibuprofen 
Re-purposing of NSAID ibuprofen (Figure 4.2, section 4.1.1), a 2-aryl propanoic acid derivative 
previously demonstrated antitubercular activity was intended.  
Molecular 
formula 
C43H58N4O12 
pKa 2.7 
Molecular 
weight 
822.953 g/mol 
Solubility 
Slightly soluble in water at pH 
7.3 
Soluble in dimethylformamide, 
methanol, chloroform, acetone 
and DMSO 
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Figure 4.2: Structure of ibuprofen 
Table 4.4: Physicochemical properties of ibuprofen 
 
 
 
 
 
 
 
Trehalose 
Dehydrating liposomes in the absence of additives may lead to reduction of head group spacing, 
aggregation, fusion of liposomes and leakage of the encapsulated material during rehydration of 
liposomes. Phosphate groups on dry DPPC liposomes exhibit an FT-IR wavenumber of 1254    
cm-1, whereas, phosphate groups in the hydrated form interacts with the surrounding water 
molecules by means of hydrogen bonding and hence exhibit a wavenumber of 1230 cm-1. 
Phosphate groups on DPPC liposomes spray dried in the presence of trehalose or glucose have 
shown to exhibit a wavenumber similar to hydrated liposomes, indicating formation of hydrogen 
bonds between hydroxyl groups on stabilizers and phosphate groups on DPPC. Moreover, 
hydrogen bond formation helps to alter the packing density and increases lipid head group 
spacing, decreasing intermolecular Van der Waals interaction [415]. Trehalose a non-reducing 
sugar with a Tg of 117°C has been used as a bulking powder and stabilizer to produce powders 
for aerosol applications for spray dried liposomes, due to its lyoprotection action.  
L-leucine 
L-leucine was added as a dispersibility enhancer in the formulation before spray drying. Its role 
is clarified in section 3.1.4. 
  
Molecular 
formula 
C13H18O2 
pKa 3.97 
Molecular 
weight 
206.285 g/mol 
Solubility 
Insoluble in water 
Soluble in ethanol, methanol, 
chloroform and acetone 
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4.2 Aims and Objectives 
The present investigation was aimed towards the development of dry powder microparticles of 
liposomes co-encapsulating antitubercular drugs rifampicin and ibuprofen, actively targeted to 
the scavenger or the mannose receptor of macrophages to enhance uptake of the formulation.  
Hence, the aim of the study was  
• To engineer liposomes for the co-delivery of hydrophobic drugs rifampicin and ibuprofen, 
prepared by thin film hydration 
• To design and develop dry powder aerosols and study parameters that dictate aerosolization 
efficiency 
• To investigate the effect of charge (neutral, anionic or cationic) and/or targeting moiety 
mannose on the qualitative and quantitative in vitro cellular uptake kinetics in RAW 264.7 
murine macrophage cell line 
 
Figure 4.3: Various liposomal nanocarrier formulations designed to study macrophage uptake 
The various liposomal formulations investigated in the present chapter are shown in Figure 4.3. 
Liposomes co-encapsulating rifampicin and ibuprofen with a neutral, positive and negative 
liposomal charge were formulated, to study the effect of surface charge on the uptake of liposomes 
by macrophages (Figure 4.3B). Negative liposomes were further mannosylated either by coating 
them with synthesized mannosylated chitosan imparting a final positive charge (Figure 4.3C) or 
by embedding mannose moieties viz. mannosamine and PAM (p-amino phenyl 
mannopyranoside) by interaction of the positive amine groups with the negative charge of the 
liposomal bilayer (Figure 4.3C). 
A 
B 
C 
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4.3    Materials 
Rifampicin ≥ 98.0% purity (HPLC grade) with molecular weight of 822.94 g/mol and 2-(4-
isobutylphenyl) propanoic acid (ibuprofen) ≥ 98.0% purity (HPLC grade) with molecular weight 
of 206.29 g/mol were purchased from Tokyo Chemical Industry UK (Oxford, UK). Lipids 1,2-
dipalmitoyl-sn-glycero-3-phosphatidylcholine (DPPC) and 1,2-dioctadecanoyl-sn-glycero-3-
phospho-(1'-rac-glycerol) (sodium salt) (DSPG) were purchased from Lipoid GmbH 
(Ludwigshafen, Germany) and used without further purification. L-leucine ≥ 98.0% purity (TLC 
grade), HPLC grade di-potassium hydrogen orthophosphate, mannopyranosyl phenyl 
isothiocyanate, 4-aminophenyl α-D-mannopyranoside and D-mannosamine hydrochloride were 
purchased from Sigma-Aldrich (Poole, UK) and lactose (Lactohale® LH300) was purchased from 
Friesland Foods Domo (Zwolle, Netherlands). Chitosan <3K was purchased from Carbosynth 
Ltd. (Berkshire, UK).  
For the NGI, silicon oil was obtained from Sigma-Aldrich (Poole, UK) and 75 mm internal micro-
orifice filter was purchased from Copley Scientific (Nottingham, UK). For in vitro cell culture 
studies fetal bovine serum (FBS), Dulbecco's Modified Eagle Medium (DMEM), penicillin-
streptomycin and PBS pH 7.4 used to evaluate qualitative and quantitative cellular uptake were 
purchased from ThermoFisher Scientific (Loughborough, UK). Coumarin-6 fluorescent dye was 
obtained from Sigma-Aldrich (Poole, UK). 
HPLC grade tetrahydrofuran, water, n-hexane and isopropanol were purchased from Fisher 
Scientific (Loughborough, UK).  Deionized water was used throughout the experiments unless 
specifically mentioned. All other reagents used were of analytical grade.  
4.4    Methods  
4.4.1 Preparation of rifampicin and ibuprofen co-encapsulated liposomes 
Liposomes were prepared using the thin film hydration method as previously described [416–
420].  Multilamellar vesicles (MLVs) were prepared by dissolving constitutive lipids as per the 
formulations in 20 mL of 1:2 v/v methanol: chloroform. A known amount of drug rifampicin and 
ibuprofen was then added to the lipid solution and the organic solvent was removed under vacuum 
using a rotary evaporator KNF RC 900 (KNF Neuberger UK, Oxfordshire, UK) at 55 °C and 200 
rpm for 20 min. A dried thin and homogeneous lipid film was obtained and further dried under a 
stream of nitrogen gas for 20 min to ensure complete removal of residual solvent. The lipid film 
was then hydrated using 15 mL deionised water adjusted to pH 7.0 (3.5 mg lipid/mL) at 55 °C 
i.e. a temperature above the phase transition temperature of the lipids at 250 rpm for 20 min and 
was then left to anneal at room temperature for 1 h. The liposomes obtained were negatively-
charged or had a neutral charge depending on their composition.  
Macrophage-targeted liposomes were prepared by either coating liposomes with mannosylated 
chitosan, or by incorporating mannose moieties within the liposomal bilayers (section 4.4.3.2). 
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To obtain a positively-charged liposomal surface, chitosan <3K was added to the negatively-
charged liposomal suspension after hydration to induce coating by electrostatic attraction. Briefly, 
the liposomal suspension was allowed to anneal for 1 h after hydration and then varied volumes 
and concentrations of chitosan (Table 4.10) was added to the suspension which was magnetically 
stirred at 600 rpm for 30 min at room temperature to allow interaction between the negatively-
charged liposomal surface and positively-charged chitosan. Mannosylated positively-charged 
liposomes were prepared by coating liposomes with chitosan-mannose (section 4.4.3.1) in the 
same manner as described for chitosan coating. 
Unentrapped amphiphilic rifampicin and uncoated chitosan <3K/ chitosan-mannose <3K (in the 
case of positively-charged liposomes) was removed from liposomal preparations by exhaustive 
dialysis using a Spectra/Por® dialysis membrane (3500 Da MW cut-off, <2 nm pore size; 
Spectrum Laboratories, UK) against deionized water at room temperature for 2 h (replacing water 
every 15 min). This allowed ‘sink conditions’ for the dissolution and consequent removal of the 
unentrapped amphiphilic rifampicin and/or uncoated chitosan <3K, and avoided the 
destabilization and breakage of the liposomes by osmotic swelling and vesicle fusion. The 
resultant liposomal dispersion was then size reduced to obtain small unilamellar vesicles (SUVs) 
using a probe sonicator (Soniprep 150 ultrasonic disintegrator, MSE Crowley, London, UK), 
using 5 cycles of 2 min each (with 1 min between the cycles, in an ice bath) for size reduction. 
The clear red opalescent dispersion obtained was filtered using a 0.22 µm syringe filter (Millex 
MP, Ireland) to remove the unentrapped hydrophobic ibuprofen and amphiphilic rifampicin. The 
resultant liposomal dispersion was then characterized for size and charge using the Nano Zetasizer 
ZS (Malvern instruments, Malvern, UK) and the encapsulation efficiency of the co-encapsulated 
drugs developed using HPLC (section 4.4.4.2). 
4.4.2 Design of experiments (DoE) for developing optimal liposomal formulation 
4.4.2.1 DoE 1- Choice of lipids 
DPPC (transition temperature, Tm 41°C) was used as the major constituent of the liposome 
bilayer as it is the most abundant component of lung surfactant, constituting up to one-third of the 
total phospholipids present [421].  
The traditional approach of one factor at a time experimentation commonly known as the OFAT 
i.e. changing one factor at a time whilst keeping the other conditions constant can suffer various 
limitations including more resources, time and costly experimentation, and it is not a suitable 
method to study the interactions between the different experimental factors. For this reason, a 
matrix-based multifactorial method of experimentation involving Design of Experiments (DoE) 
has been recognized as an important tool for understanding and rapid development of 
pharmaceutical processes and products. The validation of the experiments was studied using DoE 
and the choice of factors and responses to be investigated was largely based on a study of the 
literature and experience. 
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A randomized full factorial design was initiated using Design-Expert® 10 trial version (Stat-Ease, 
USA) for generation and evaluation of a statistical experimental design to study the effect of two 
independent factors (X) DSPG and cholesterol content on the response (Y) of the liposomal size 
(Y1), zeta potential (Y2), polydispersity index (Y3) as well as the encapsulation of rifampicin (Y4) 
and ibuprofen (Y5).  
Chitosan/chitosan-mannose coating was intended for the surface of the liposomes so as to achieve 
targeting to the macrophages, where tubercular infection prevails. This could be achieved by 
imparting a negative charge to the liposomal surface which could electrostatically bond the 
positive targeting ligand or the positive mannose moieties mannosamine and p-amino phenyl 
mannopyranoside. For this reason, the first independent variable (X1) negative lipid DSPG was 
studied at 5 different levels.  
The second independent variable (X2) cholesterol was also studied at 5 different levels as 
cholesterol has been long known to alter the lipid bilayers membrane fluidity and ordering, and 
hence imparts better stability to the system. Therefore, a full factorial design of experimental trials 
(shown in Table 4.5) generated 25 possible experiments, each of which was repeated in triplicate.  
Table 4.5: DoE factors and responses for choice of lipid 
Factors (Independent variables) Levels Factor levels used 
Amount of DSPG (µM) 5 
0 
10 
20 
30 
40 
Amount of cholesterol (µM) 5 
0 
5 
10 
20 
30 
Responses (Dependent variables) Method 
Size (nm)- Y1 Section 2.1 
Zeta potential (mV)- Y2 Section 2.1 
Polydispersity index- Y3 Section 2.1 
Encapsulation efficiency of rifampicin (%)- Y4 Section 4.4.4.3 
Encapsulation efficiency of ibuprofen (%)- Y5 Section 4.4.4.3 
	
4.4.2.2 DoE 2- Ratio of drugs 
Once a stable liposomal formulation was determined, the optimum ratio of the two drugs that 
could be loaded within the chosen liposomal constitution and their interactions was to be studied. 
A full factorial design (shown in Table 4.6) incorporating two independent factors (X) namely 
rifampicin (X1) and ibuprofen (X2) at 3 levels each was developed using Design-Expert® 10. This 
matrix generated 9 possible experiments each of which was repeated in triplicate.  
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Table 4.6: DoE factors and responses for ratio of rifampicin and ibuprofen 
Factors (Independent variables) Levels Factor levels used 
Amount of rifampicin (µM) 3 
12.5 
25 
50 
Amount of ibuprofen (µM) 3 
50 
75 
100 
Responses (Dependent variables) Method 
Size (nm)- Y1 Section 2.1 
Zeta potential (mV)- Y2 Section 2.1 
Polydispersity index- Y3 Section 2.1 
Encapsulation efficiency of rifampicin (%)- Y4 Section 4.4.4.3 
Encapsulation efficiency of ibuprofen (%)- Y5 Section 4.4.4.3 
 
4.4.2.3 DoE 3- Preparation of dry powders suitable for inhalation 
Critical process parameters during spray drying can affect the final product and hence the 
aerodynamic behaviour of the microparticles intended to be delivered using a dry powder 
inhalation. A two-level factorial design (shown in Table 4.7) was developed with three 
independent variables (X) namely amount of lyoprotectant trehalose (X1), addition of 
dispersibility enhancer L-leucine (X2) and temperature of spray drying (X3), using Design-
Expert® 6. This matrix generated 8 possible experiments each of which was repeated in triplicate. 
 
Table 4.7: DoE factors and responses for preparation of dry powders suitable for inhalation 
Factors (Independent 
variables) 
Levels Factor levels used Factor codes 
Amount of trehalose (with 
respect to total formulation) 
2 
0.5  
(33.33% of final powder) 
1.0  
(50% of final powder) 
A- 
A+ 
20% (w/w) L- leucine (with 
respect to total formulation) 
2 
- 
+ 
C- 
C+ 
Temperature of spray 
drying (°C) 
2 
80 
120 
B- 
B+ 
Responses (Dependent variables) Method 
Mean particle size at 50th percentile of cumulative distribution Dv50 Section 2.5 
Mean particle size at 90th percentile of cumulative distribution Dv90 Section 2.5 
Span- Sympatec Section 2.5 
Moisture content (%)- Thermogravimetric analysis Section 4.4.2.3.3 
 
An open-loop mode was used to spray dry the formulations on the Büchi B-290 Mini spray dryer 
(Büchi Labortechnik, Switzerland) using compressed air as drying gas. Other process parameters 
during spray drying, shown in Table 4.8, were kept constant for all the experiments. The spray 
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dryer was set up for the stated inlet temperature and neat solvent was pumped until the desired 
outlet temperature was achieved and stabilized, after which spraying was commenced. All the 
solutions were spray dried individually after which the instrument temperature was allowed to 
cool below 25°C. The powder was then collected from the cyclone and collector using a particle 
collecting brush. The powder was immediately transferred to a glass vial and stored in a desiccator 
to prevent powder uptake of environmental moisture. 
Table 4.8: Process parameters for spray drying using the Büchi B-290 Mini spray dryer 
Parameters Value 
Aspiration 100 % 
Pump flow rate 20% (6 mL/min) 
Spraying gas flow rate 500 L/h  
Drying gas flow rate 35 m3/h 
Nozzle tip diameter 0.7 mm 
 
The typical matrix of experiments to be investigated, developed by the software in all the above 
cases, was performed and results were analyzed using ANOVA statistical model to determine the 
significance of the model developed and the significance of each of the factors and their 
interactions on the responses under study, wherein a probability value p < 0.05 was considered 
significant. A 3-Dimensional plot was generated which revealed the influence of each of the 
independent factors and their interactions on the outcome of the responses under study. 
4.4.2.3.1 Surface morphology analysis using Scanning electron microscopy (SEM) 
Method used to explore the morphology of liposomes spray dried as microparticles using the SEM 
is outlined in chapter 2, section 2.4.1. 
4.4.2.3.2 Laser diffraction particle size analysis  
The particle size distributions of all the spray dried powders were analyzed using laser diffraction 
with a Sympatec HELOS particle size analyzer, on a RODOS/M particle dispenser fitted with a 
micro-dosing device ASPIROS/L (Sympatec GmbH, Clausthal-Zellerfeld, Germany) as outlined 
in chapter 2, section 2.5. 
4.4.2.3.3 Moisture content using thermogravimetric analysis (TGA) 
The determination of the residual water content of the spray dried microparticles was performed 
using TGA, wherein the change in mass of the powder depending on its thermal stability and 
solvent content is measured as a function of temperature and time, in a controlled temperature 
atmosphere. This was performed using Pyris 6 TGA (Perkin Elmer, UK). 7 to 9 mg samples filled 
in re-usable open ceramic pans were placed on the balance and heated from 20°C to 300°C at a 
rate of 10°C/min. Details of the method is as given in Table 4.9. The moisture content of the 
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formulations was determined by the percentage weight change recorded by the thermobalance 
between 20°C to 130 °C. 
Table 4.9: TGA experimental conditions 
Sample mass (mg) 7-9 
Sample container Open ceramic pans 
Purge gas nitrogen 
Purge gas flow rate (mL/min) 20 
Heating rate (°C/min) 10 
Temperature range (°C/min) 20-300 
 
4.4.3 Coating/incorporation of targeting polymer 
Mannose, the targeting moiety chosen to actively target liposomes encapsulating antitubercular 
drugs to macrophages was coated onto the liposomes or incorporated into the bilayers.  The effect 
of the position of the targeting moiety on the uptake of the liposomes was then studied using flow 
cytometry to ascertain whether the appearance of the mannose to the mannose receptors on the 
macrophages would cause differential uptake kinetics.  
4.4.3.1 Coating liposomes with mannosylated chitosan 
To obtain positively-charged liposomes, chitosan/chitosan-mannose which has a high positive 
charge (0.05% in 0.2% acetic acid +52±1.24 mV and 0.03% in 0.2% acetic acid +40±1.24 mV) 
was added to the negatively-charged liposomes to coat the surface via electrostatic attraction. 
Uncoated chitosan < 3K/chitosan-mannose < 3K was removed via exhausted dialysis using a 3500 
Da MW cut-off dialysis membrane, as described in section 4.4.1.  
4.4.3.1.1 Synthesis of mannosylated chitosan for coating liposomes 
Mannosylation of chitosan was carried out using the method previously reported (Figure 4.4) 
[422]. Briefly, 500 mg chitosan <3K (Carbosynth Ltd., Berkshire, UK) was dissolved in 8 mL of 
water, and 25 mg of α-D-Mannopyranosyl phenyl isothiocyanate (Carbosynth Ltd., Berkshire, 
UK) in 2 mL DMSO was added. The reaction mixture was magnetically stirred (multi-position 
magnetic stirring, RO 10 power IKA WERKE, Germany) for 24 h at room temperature, after 
which mannosylated chitosan was precipitated out using excess isopropanol. The precipitate was 
then collected by centrifugation at 13,000 rpm for 10 min after which the synthesized polymer 
was washed with isopropanol 5 times and finally collected using centrifugation at 13,000 rpm for 
10 min. 
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Figure 4.4: Reaction scheme for synthesis of mannosylated chitosan <3K 
4.4.3.1.2 1H-NMR proton nuclear magnetic resonance 
High resolution 1H-NMR was conducted using a Bruker AVANCE 500 spectrometer (Bruker 
Corporation, Massachusetts, USA) to confirm the macromolecular structure of chitosan and 
mannosylated chitosan and ascertain the success of derivatization. The spectra were obtained at 
298 K using 64 scans per sample at a resonance frequency of 500.13MHz for 1H. The polymer 
solution was prepared at a concentration of 10 mg/mL in D2O. The NMR solvent was used as an 
internal standard to assign chemical shifts to the particular protons in the macromolecular 
structures of chitosan and synthesized chitosan derivative. 
4.4.3.1.3 Fourier transform infrared spectroscopy 
FT-IR spectrum of chitosan and mannosylated chitosan were determined to analyze the success 
of mannosylation. A Spectrum™ 100 spectrophotometer (PerkinElmer, UK) operating in the mid-
infrared region equipped with a UATR device was used. The procedure followed was as described 
in chapter 2, section 2.2. 
 
An appropriate ratio of cationic and anionic charges is necessary to achieve an interaction leading 
to formation of a homogeneous dispersion. After a certain range of electroneutrality between the 
positive and negative charges, complexes formed might aggregate and precipitate in solution. 
Preliminary experiments were performed and then different volume and concentration of chitosan 
solutions were investigated to obtain homogeneous chitosan-coated liposomal dispersions (shown 
in Table 4.10) in triplicate. 
O
N=C=S
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Table 4.10: Conditions for coating liposomal dispersions with targeting polymer 
Type of polymer 2 
Chitosan <3K 
Chitosan-mannose <3K 
Concentration of chitosan (%) in 
0.2% acidified water 
2 
0.03 
0.05 
Volume of chitosan solution (per 
15 mL formulation) (mL) 
3 
2.5 
5 
7.5 
4.4.3.2 Incorporation of mannose within liposomal bilayers 
20 mg of D-mannosamine hydrochloride (36.75% mole) or 10 mg p-aminophenyl 
mannopyranoside (18.78% mole) were added to the organic phase in the preparation of liposomes 
before solvent evaporation, as seen in section 4.4.1. This helped in incorporating these mannose 
moieties within the bilayer since hydration at pH 7.0 (i.e. HPLC grade water was adjusted to pH 
7) the NH2 group of these mannosylated derivatives are protonated to a positive charge and would 
electrostatically embed in the negatively-charged headgroup region of the liposomes. 
4.4.4 Formulation/powder characterization 
4.4.4.1 Determination of particle size and zeta potential (surface charge) using Malvern 
Zetasizer 
The hydrodynamic diameter and the polydispersity index (PDI) of the liposomal formulations 
were measured by DLS and the zeta potential was measured by laser Doppler velocimetry using 
Malvern Zetasizer Nano ZS (Malvern Instruments Inc., UK) as described in chapter 2, section 
2.1. 
4.4.4.2 High-performance liquid chromatography (HPLC) and analytical method 
validation for simultaneous determination of rifampicin and ibuprofen 
The encapsulation efficiency of rifampicin and ibuprofen in liposomes and the amount of these 
drugs deposited in each stage of the NGI (section 4.4.4.6)  was determined using HPLC using an 
Agilent 1260 infinity series HPLC (Agilent Technologies UK Ltd., UK), equipped with an 
ultrasensitive diode array UV detector, G1329A auto sampler and a highly efficient quaternary 
pump. A number of methods for HPLC analysis of both rifampicin and ibuprofen have been 
described [423–427]. However, for this study a new, rapid, sensitive, precise and accurate method 
was developed, which gave reproducible results, separation of the retentions between the two 
drugs, and chromatograms with sharp peaks and a stable baseline.  
Briefly, 10 µL samples were eluted with the mobile phase comprising of a ratio of 60:40 50 µM 
phosphate buffer at pH 7.4 in HPLC grade water: HPLC grade tetrahydrofuran at a flow rate of 1 
mL/min using an isocratic elution method. Separation was performed using an Agilent 15 cm×4.6 
mm, 3.5 µm Eclipse Plus C8 column (Agilent Technologies, Cheshire, UK) with a bimodal UV 
detection wavelength of 335 nm for the first 5 min i.e. at the λmax of rifampicin and 220 nm for 
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the following 10 min of elution i.e. at the λmax of ibuprofen, using a column compartment 
temperature of 40°C. The HPLC method developed for simultaneous determination of rifampicin 
and ibuprofen was validated for linearity, accuracy and precision; to ascertain that the method 
adapted was robust and without error. The validation method based on ICH recommendations is 
described in Chapter 2 for HPLC analytical validation, section 2.7. 
A standard curve (calibration curve) was constructed individually for ibuprofen and rifampicin 
before each sample analysis in triplicate using the same method of HPLC analysis as that intended 
for the formulations. Concentrations of rifampicin and ibuprofen for the standard were 2.5, 5, 10, 
20, 30, 40, 50, 60, 70, 80, 90 and 100 µg/mL and peak area as an average of the triplicates was 
used to derive the standard equation and correlation coefficient (R2) of the best fit line, by least 
square regression method. This standard equation was then considered linear if the R2 value was 
approximately 1 and used for calculation of concentration of rifampicin and ibuprofen 
encapsulated in the liposomes and for determination of the fraction of rifampicin and ibuprofen 
retained at each stage of the NGI. 
4.4.4.3 Determination of drug encapsulation efficiency of the liposomal preparations 
Encapsulation efficiency of the formulations after preparation was determined using HPLC to 
quantify rifampicin and ibuprofen solubilized in the liposomal formulations.  Dilutions of the 
formulation following removal of unsolubilized drugs by dialysis (Spectra/Por® dialysis 
membrane, 3500 Da MW cut-off, <2 nm pore size; Spectrum Laboratories, UK) and filtration 
(0.22 µm mixed cellulose esters syringe-driven filter (Millex MP, Ireland)) was performed by 
diluting approximately 50 times in methanol to obtain a solution concentration appropriate for 
HPLC measurement as per the Beer-Lambert law. The solutions were filtered into HPLC vials 
and quantified as described (section 4.4.4.2). The peak areas for rifampicin and ibuprofen from 
the formulations were used for calculation of the encapsulation efficiency of drug, using linear 
regression equation from calibration curve with correlation coefficients of 0.9997 and 0.9999 for 
rifampicin and ibuprofen respectively. Encapsulation efficiency was expressed as a percentage 
using the equation 4.1: !"#$%&'($)*+"	-..*#*-"#/(%) = 45$#)*#$((/	6-)-57*"-6	$7+'")	+.	65'8		*"	.+57'($)*+"97+'")	+.	65'8	*"*)*$((/	:-*8ℎ-6	 ×100 
 
4.4.4.4 Determination of particle size and zeta potential (surface charge) on rehydration of 
spray dried liposomes in deionized water using Malvern Zetasizer 
5 mg of spray dried powder was dispersed in 2 mL of deionized water previously heated to 37°C 
(to mimic body temperature) and bath sonicated for 2 min. The hydrodynamic diameter and the 
polydispersity index (PDI) of the resulting re-dispersed spray dried liposomes were measured by 
DLS and the zeta potential was measured by laser Doppler velocimetry using Malvern Zetasizer 
Nano ZS (Malvern Instruments Inc., UK) at 37°C.  
Equation 4.1 
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4.4.4.5 Morphology analysis of liposomes using Transmission electron microscopy 
TEM micrographs for morphological examination of liposomal preparations was carried out using 
the method outlined in chapter 2, section 2.4.2. 
4.4.4.6 In vitro aerosol deposition and aerodynamic behaviour studies using the Next 
Generation Pharmaceutical Impactor 
The aerosol parameters and deposition of spray dried microparticles at the different stages of the 
NGI were determined using the method described in chapter 2, section 2.6. In each experiment 
five size 3 transparent gelatin capsules were filled manually with 30±0.2 mg of spray dried 
microparticles and aerosolized using the Cyclohaler® (Pharmacemie, UK). 
4.4.4.7 Quantitative assessment of cellular uptake kinetics using flow cytometry and 
qualitative assessment using fluorescent microscopy 
Flow cytometry was used to examine the cellular uptake kinetics of various liposomal 
formulations, encapsulating fluorescent dye coumarin-6 to study the effect of the liposomal 
charge and the targeting moiety on the interaction and uptake in the murine macrophage cell line 
RAW 264.7, at different time points. Specifically, 2x105 RAW 264.7 cells/well (cells were 
routinely passaged at 80-85% confluency using cell scrapers, passage no. 9-15 used for 
experiment) were seeded in 12-well plates in Dulbecco’s Modified Eagle medium (DMEM) 
supplemented with 10% fetal bovine serum and 1% penicillin-streptomycin (complete media) and 
grown at 37°C and 5% carbon dioxide for 36 h. The medium was then carefully aspirated and the 
cells were washed with PBS pH 7.4, to remove any dead/suspension cells. The cells were then 
treated with liposomes diluted in complete media at a final concentration of coumarin-6 of 1 
µg/well and incubated for 0.25, 0.5, 2, 4 or 8 h. At the specific time points, the cells were washed 
3 times with ice-cold PBS pH 7.4 to remove any liposomes adhered to the cells and to stop uptake. 
The cells were then suspended in warm PBS pH 7.4 using cell scrapers and transferred into 
Falcon™ round bottom polystyrene tubes (Fischer Scientific, UK). The fluorescence intensity of 
coumarin-6 at each time point for each liposomal formulation was analyzed using MACSQuant® 
Analyzer 10 (Miltenyi Biotech, Surrey, UK) Flow Cytometer in the FL B-2 channel excitation 
emission. Prior to the experiment, blank RAW 264.7 cells were used to set up the voltage of the 
forward scatter (FSC), side scatter (SSC) and FL B-2 channel to ensure that all the cells under 
study were accommodated into the window of analysis. The region ‘P1’ then selected was such 
so as to exclude dead cells, cell debris and clumped cells and to study specifically living cells, 
which accounted for around 83-86% for all the samples analyzed. 
For visualizing the coumarin-6 uptake at the different time points for the various liposomal 
formulations, 1x105 cells were seeded in 12-well plates in complete media and grown at 37 °C 
and 5% carbon dioxide for 36 h. The medium was then carefully aspirated and the cells were 
washed with PBS pH 7.4, to remove any dead/suspension cells. The cells were then treated with 
liposomes diluted in complete media at a final concentration of coumarin-6 of 0.2 µg/well and 
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incubated for 0.25, 0.5, 2, 4 or 8 hours. At the specific time points, the cells were washed 3 times 
with ice-cold PBS pH 7.4, to remove any liposomes adhered to the cells and stop uptake and then 
imaged under EVOS™ Fluorescence Cell Imaging System using the GFP filter (470 nm 
excitation, 525 nm emission) under 20X magnification and phase contrast annuli 4/10 condenser.  
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4.5    Results and Discussion 
4.5.1 High-performance liquid chromatography (HPLC) and analytical method validation 
of simultaneous determination of rifampicin and ibuprofen 
Linearity: The data for HPLC calibration curve of rifampicin and ibuprofen was fitted into a 
linear equation of y=17.947x–6.8517 and y=26.385x+1.4183 respectively (where 
x=concentration of analyte and y=area under curve), and was observed to follow linearity and 
hence Beer-Lambert law in the concentration range under study i.e.2.5-100 µg/mL, as shown in 
Figure 4.5 and Figure 4.6. A regression analysis was performed and correlation coefficient R2 of 
0.9997 and 0.9999 (for rifampicin and ibuprofen respectively) indicated the existence of a linear 
relationship between peak area and concentration of drug analyzed. Parameters determining 
linearity from HPLC analysis for rifampicin and ibuprofen are shown in Table 4.11. 
 
Figure 4.5: Calibration curve of rifampicin analyzed by HPLC (mean±SD, n=5) 
 
Figure 4.6: Calibration curve of ibuprofen analyzed by HPLC (mean±SD, n=5) 
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Table 4.11: Linearity parameters for HPLC analysis method of simultaneous determination on rifampicin and 
ibuprofen 
Parameters Results (Rifampicin) Results (Ibuprofen) 
λmax 335 220 
Linearity range 2.5-100 µg/mL 2.5-100 µg/mL 
Regression equation y=17.947x–6.8517 y=26.385x+1.4183 
Correlation coefficient 0.9997 0.9999 
Retention time 2.78 min 9.10 min 
Limit of detection (LOD)  0.89 µg/mL 0.44 µg/mL 
Limit of quantification (LOQ) 2.47 µg/mL 1.48 µg/mL 
 
Representative chromatogram of rifampicin and ibuprofen and validation for accuracy and 
precision of HPLC method is as seen in Appendix 1, A1.2. 
4.5.2 Design of Experiment (DoE) 
4.5.2.1 DoE 1- Choice of lipids 
ANOVA studies for effect of factors DSPG (X1) and cholesterol (X2) on all the responses (Y) 
(Table 4.5) generated a statistically significant (p < 0.0001) factorial model, which could be used 
to determine the best choice of lipids to formulate a stable liposomal dispersion. Lack of fit test 
(F-test) and diagnostic plot of normal percentage probability of studentized residuals (Appendix 
2) were used to validate the model statistics, which was in good correlation with the ANOVA 
studies performed for the factorial model. In the normal percentage probability plot the spread of 
data points was approximately along a straight line depictive of a good correlation between the 
model predicted and model fitted, confirming that the model fitted was normal and could be used 
to study the effect of the different factors on the various responses [428]. 
The response of zeta potential (Y2) (Figure 4.7A) demonstrates a significant decrease in the value 
of zeta potential with an increase in content of negative lipid DSPG (X1, p < 0.0001). Cholesterol 
also showed a significant (X2, p = 0.0015) effect on the value of zeta potential. Point-based 
ANOVA (OriginPro v8.0724) studies demonstrated that the addition of cholesterol produced a 
statistically significant reduction (p < 0.05) in the value of zeta potential when added to neutral 
DPPC liposomes. This was in good correlation to previously reported studies, where addition of 
cholesterol decreased the zeta potential of neutral DPPC and DSPC liposomes to negative values 
[429,430]. Strong hydrogen bond interactions between the choline methyl groups of PC lipids and 
the hydroxyl groups of cholesterol which increases the state of order by lipid chain conformational 
changes to prevent rapid release of the drugs from the liposomes, which is responsible for the 
reduction in the zeta potential values [430–432].   However, the effect of cholesterol on the value 
of zeta potential in the highly negatively-charged liposome bilayer containing DPPC: DSPG (all 
ratios) was probably shielded and hence showed no significant difference (p > 0.05) of addition 
of cholesterol on zeta potential for negative liposomes. 
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ANOVA studies of the developed factorial model showed a significant influence of the factors 
DSPG (X1, p < 0.0001) and cholesterol (X1, p < 0.0001) on the mean size (hydrodynamic 
diameter) of the liposomes (Figure 4.7B). Moreover, a significant interaction was seen between 
the two factors X1X2, p < 0.0001, wherein a decrease in size was seen with increasing DSPG with 
a more gradual effect in DPPC liposomes with a high percentage of cholesterol. An increase in 
liposomal size was evident with increasing cholesterol, wherein the effect was more evident in 
DPPC liposomes with a lower percentage of negative lipid DSPG. 
Study of polydispersity index of the liposomes demonstrated a significant effect of DSPG (X1, p 
< 0.0001, Figure 4.7C) was seen on the PDI of the liposomes. Cholesterol however did not have 
a significant (X1, p = 0.1192) effect on the PDI; a higher PDI was evident for neutral DPPC 
liposomes (DPPC liposomes without DSPG) (0.30-0.50). Addition of negative lipid DSPG 
reduced the PDI to around 0.21-0.25 for most of the formulations.  
The model developed to study the effect of factors X1 (DSPG) and X2 (Cholesterol) on the 
response of co-encapsulation efficiency of the drug rifampicin (Y4) demonstrated a significant (p 
< 0.0001, Figure 4.8A) effect of addition of DSPG and cholesterol. Addition of 10-20 micromolar 
DSPG caused a reduction in rifampicin encapsulation for the formulations with higher cholesterol 
content (20-30 micromolar), which may be due to the improper bilayer formation leading to an 
increased leakage of drug at the particular ratio of components. With an increase in DSPG (30-40 
micromolar) this effect was nullified. Maximum loading of rifampicin was observed for DPPC: 
DSPG: Chol 100:40:0, 100:40:20 and 100:40:30.  
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Figure 4.7: DoE 1- Choice of lipids, the effect of factors DSPG and cholesterol on responses zeta potential (A), 
mean size (B) and PDI (C) (mean±SD, n=3, 3D surface plot Design-Expert® 10 (Stat-Ease, Inc.)) 
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Moreover, the model developed to study the effect of factors X1 (DSPG) and X2 (Cholesterol) on 
the co-encapsulation efficiency of drug ibuprofen (Y5) depicted a significant (p < 0.0001, Figure 
4.8B) effect of addition of DSPG on the encapsulation of ibuprofen, however, addition of 
cholesterol did not significantly affect its encapsulation. A pattern similar to encapsulation of 
rifampicin was observed, wherein, addition of 10-20 micromolar DSPG caused a reduction in 
ibuprofen encapsulation with a gradual increase in encapsulation of ibuprofen with greater 
amounts of DSPG (30-40 micromolar), indicating that for proper bilayer formation approximately 
23% mole of DSPG to total lipids is required to co-encapsulate rifampicin and ibuprofen.  
 
 
 
 
  
Figure 4.8: DoE 1- Choice of lipids, the effect of factors DSPG and cholesterol on responses encapsulation 
efficiency of rifampicin (A) and encapsulation efficiency of ibuprofen (B) (mean±SD, n=3, 3D surface plot 
Design-Expert® 10 (Stat-Ease, Inc.)) 
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Previous literature using 28% and 35% mole of DSPG to phosphatidylcholine has been shown to 
successfully encapsulate hydrophobic drug cisplatin and hydrophilic drug sodium selenite 
[433,434]. There was a more drastic effect of lipid composition evident on the encapsulation 
efficiency of rifampicin (Figure 4.8B) which ranged from 57.51-92.91%, as compared to the 
encapsulation efficiency of ibuprofen (Figure 4.8B) which ranged from 80.82-105.19%. This was 
due to the bulky size of rifampicin which required optimal packing of the bilayer for improved 
rifampicin incorporation, in good correlation with previous studies [191].   
 On analyzing the responses observed in the above factorial model a maximum co-loading of 
drugs was desired with small size and high negative zeta potential for an optimum and stable 
formulation. Keeping in mind the encapsulation profile of rifampicin and ibuprofen, 40 
micromolar negative lipid DSPG (28.57% mole of total lipids) was chosen. Moreover, there was 
no significant difference (p > 0.05) in all the responses for DPPC: DSPG (100:40) formulations 
at 20 micromolar (14.29% mole cholesterol to lipids) and 30 micromolar (21.43% mole of 
cholesterol to lipids) cholesterol, hence DPPC: DSPG: Chol 100:40:20 was chosen as the 
optimum composition of lipids. 
4.5.2.2 DoE 2- Ratio of drugs 
Maximum loading of antitubercular drugs is desirable to reduce the amount of formulation to be 
administered to the patient. Moreover, earlier studies have reported the importance of 
hydrophobicity of drug on the stability of DPPC liposomes, wherein destabilization of liposomes 
and hence a greater dye leakage was evident on storage when hydrophobic rhodamine was 
encapsulated as compared to hydrophilic fluorescein [435]. This was due to an increased 
expulsion of the hydrophobic dye from the liposomal bilayer on movement of the phospholipid 
tail on storage, as opposed to the cargo of hydrophilic dye inside the liposomal core [435]. 
Furthermore, complexity of the liposomal system increases when different drugs are co-
encapsulated making it important to study the interaction of one drug on the encapsulation of the 
other and vice versa, to be able to determine an optimum ratio for maximum encapsulation of 
both the drugs.  The matrix developed using DoE® 10.1 was evaluated with experimentation and 
the responses obtained have been highlighted in Figure 4.9 and Figure 4.10.		
It was evident that a statistically significant model explaining the effect of amount of rifampicin 
(X1) and amount of ibuprofen (X2) was developed for responses zeta potential (Y2) and 
encapsulation efficiencies of rifampicin (Y4) and ibuprofen (Y5). Mean size (hydrodynamic 
diameter, Y1) and PDI (Y3) of the liposomes did not change on alteration of the amount of drugs 
encapsulated and hence the model developed was insignificant and could not be used to study the 
significance of the individual terms and their interactions with respect to these responses. Point-
based ANOVA Tukey post-hoc analysis using OriginPro v8.0724 was hence performed, which 
confirmed that there was no significant difference in mean size and PDI (p > 0.05, p > 0.005) for 
the different formulations under experimentation.   
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Lack of fit test (F-test) and diagnostic plot of normal percentage probability of studentized 
residual (Appendix 2) were used to validate the model statistics, which were in good correlation 
with the ANOVA studies performed indicating that the factorial model was well fitted to study 
the effect of factors (amount of rifampicin and ibuprofen) on the statistically significant responses 
(Y2, Y4 and Y5). 
ANOVA study of the response of zeta potential (Y2, Figure 4.9C) indicated that there was a 
significant effect of amount of rifampicin (X1, p < 0.0001) and ibuprofen (X2, p = 0.0039) on the 
value of zeta potential of the liposomes. However, the interaction between the two factors 
rifampicin and ibuprofen (X1X2, p = 0.0761) was not significant on the change of zeta potential. 
The results explaining the response of encapsulation of rifampicin (Figure 4.10A) and ibuprofen 
(Figure 4.10B) demonstrated that the individual factors X1 and X2 had a significant effect (p < 
0.0001) on the encapsulation efficiency of rifampicin as well as ibuprofen.  
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Figure 4.9: DoE 2- Ratio of antitubercular drugs, the effect of factors amount of rifampicin and amount of 
ibuprofen on responses mean size (A), PDI (B) and zeta potential (C) (mean±SD, n=3, 3D surface plot Design-
Expert® 10 (Stat-Ease, Inc.)) 
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Moreover, there was an interaction between the two factors X1X2, wherein, an increase in 
ibuprofen caused a significant reduction (p < 0.0001) in amount of rifampicin encapsulated. 
An increase in the amount of rifampicin similarly caused a reduction in amount of ibuprofen, 
indicating a significant (p = 0.0458) interaction between X1 and X2. Rifampicin and ibuprofen 
are incorporated within liposomal bilayers due to their hydrophobic nature [191,436]. 
Moreover, due to the bulky size of rifampicin molecules, displacement of cholesterol from 
bilayers of DPPC liposomes have been previously reported [191,437]. Hence, it was evident 
that increase in the amount of one drug reduced the encapsulation of the other, due to a 
competition between these to be incorporated within the liposomal bilayer. 
 
	
 
Figure 4.10: DoE 2- Ratio of antitubercular drugs, the effect of factors amount of rifampicin and amount of 
ibuprofen on responses encapsulation efficiency of rifampicin (A) and encapsulation efficiency of ibuprofen 
(B) (mean±SD, n=3, 3D surface plot Design-Expert® 10 (Stat-Ease, Inc.)) 
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encapsulated within the liposomes. Formulations with 75 micromolar versus 50 micromolar of 
ibuprofen did not show any significant difference (p > 0.05) on encapsulation of rifampicin, in 
point-based ANOVA studies, when compared keeping the amount of rifampicin constant in the 
formulation. However, there was a significant difference (p < 0.05) in encapsulation of rifampicin 
in formulations with 75 micromolar versus 100 micromolar ibuprofen. Moreover, there was a 
significant (p < 0.05) difference in the encapsulation efficiency of ibuprofen in formulations with 
25 micromolar versus 50 micromolar rifampicin, when ibuprofen was kept constant, and no 
significant difference (p > 0.05) in encapsulation of ibuprofen in formulations with 25 micromolar 
versus 12.5 micromolar rifampicin. Hence 25 micromolar rifampicin and 75 micromolar 
ibuprofen was chosen for the preparation of liposomes to be converted into dry powder aerosols. 
4.5.2.3 DoE 3- Preparation of dry powders suitable for inhalation 
Effects of spray drying inlet and outlet temperature, amount of lyoprotectant trehalose and 
dispersibility enhancer L-leucine on the powder properties like crystallinity, morphology, 
roughness, density and stickiness are evident, making these a critical process parameters to study. 
These powder properties directly affect its aerosolization and hence the fine particle dose reaching 
the site of infection. Rifampicin is stable in a solid form at temperatures up to 70°C and hence the 
inlet temperature for spray drying was chosen so as to achieve an outlet temperature of lower than 
70°C [438].  
Trehalose a non-reducing sugar with a Tg of 117°C has been used as a bulking powder and 
stabilizer to produce powders for aerosol applications for spray dried liposomes, due to its 
lyoprotection action. Previous studies have shown that high concentration of trehalose i.e. >50% 
w/w may result in particle agglomeration due to the adhesive nature of the non-reducing sugar 
[439]. Hence, in the present study 33.33% (factor level 0.5 i.e. 0.5 times trehalose to final 
formulation) and 50% (factor level 1.0 i.e. 1.0 time trehalose to final formulation) was studied to 
ascertain the effect of stabilizer addition on the aerosolization of the dry powder. 20% w/w L-
leucine has been shown to produce hollow-surfaced spheres and hence an open powder structure 
with good dispersion in previous literature [373]. This concentration of L-leucine in the feedstock 
spray dried at 100°C has been shown to improve aerosolization by means of surface diffusion of 
L-leucine in its condensed phase and subsequent deposition on the surface of the microparticles 
during spray drying [375,357,356]. 
A statistically significant model explaining the effect of factors amount of trehalose (X1), addition 
of 20% (w/w) L-leucine (X2) and temperature of spray drying (°C) (X3), on the responses, volume 
mean particle size at 90th percentile of cumulative distribution DV90 (Y2, p = 0.0165), Span (Y3, 
p = 0.0058) and moisture content (%) (Y4, p = 0.0255) was developed. Volume mean particle size 
at 50th percentile of cumulative distribution VMD (DV50, Y1, p = 0.3528) of the spray dried 
liposomal microparticles did not undergo change on alteration of the factors and hence the model 
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developed was insignificant and could not be used to study the significance of the individual 
factors and their interactions.  
Lack of fit test (F-test) were used to validate the model statistics which was in good correlation 
with the ANOVA studies performed for the factorial model indicating that the model was well 
fitted to study the effect of factors on the statistically significant responses (Y2, Y3 and Y4). This 
study generated 3D cubic graphs for each response, where the vertices of the cube represents a 
point which reflects the value of the particular response (DV50, DV90, Span or moisture content) 
based on the three factors under study along the X, Y and Z-axis. For factor codes refer to Table 
4.7. 
ANOVA study of the response of mean particle size at 90th percentile of cumulative distribution 
DV90 (Y2, Figure 4.11B) with the various experimental trials developed a significant factorial 
model which indicated that there was a significant effect of amount of trehalose (X1, p =0.0267), 
addition of 20% (w/w) L-leucine (X2, p =0.0105) and inlet temperature of spray drying (X3, p = 
0.0086) on the DV90 of the spray dried microparticles. Moreover, there was a significant 
interaction between the amount of trehalose and addition of 20% w/w L-leucine (X1X3, p = 
0.0350), and amount of trehalose and temperature of spray drying (X2X3, p = 0.0116) on the DV90 
of the spray dried microparticles. 
Study of Span (Y3) of the spray dried microparticles as depicted in Figure 4.11C, demonstrated a 
significant effect of amount of trehalose (X1, p = 0.0110), addition of 20% (w/w) L-leucine (X2, 
p = 0.0041) and temperature of spray drying (X3, p = 0.0030) on the Span of the spray dried 
microparticles. Similar interaction as that of DV90 i.e. X1X2, p = 0.0110 and X1X3, p = 0.0039 
was seen for the Span of microparticles. 
These studies are explained in more detail with respect to the microparticle morphology and 
volume particle size distribution in section 4.5.2.3.1. 
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Figure 4.11: DoE 3- Preparation of dry powders suitable for inhalation, the effect of factors on responses 
DV50 (or X50) (A). DV90 (or X90) (B) and Span (C) (mean±SD, n=3, 3D cube plot Design-Expert® 6 (Stat-
Ease, Inc.)) (For factor codes refer to Table 4.7) 
A 
B 
C 
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4.5.2.3.1 Scanning electron microscopy and laser diffraction analysis 
Dehydrating liposomes using spray drying involves the use of high temperature and shear stress 
of atomization, which could lead to a detrimental impact on the liposomes structure, like 
disruption of the liposomal bilayer structure and degradation of the lipid components during the 
process [415]. Hence it was important to carefully adjust the additives used for spray drying, their 
concentration versus the concentration of the lipid and the spay drying process parameters. SEM 
micrographs served as a visual means to screen various microparticulate formulations to be spray 
dried using the matrix of DoE experiments. RODOS/M was used to disperse the particles to 
analyze the volume mean particle size (DV50, VMD), and particle size distribution of the spray 
dried powders using the HELOS laser diffraction technique on the Sympatec. 
SEM micrographs of spay dried microparticles with low amount of lyoprotectant trehalose (0.5 
times trehalose with respect to liposomal formulation) sprayed at 80 °C as seen in Figure 4.12A, 
showed partially fused and agglomerated particles with no proper particle formation. These 
micrographs were supported by the particle size distribution histograms obtained from laser 
diffraction (Sympatec) studies, wherein an DV90 of 72.47 µm and VMD of 6.54 µm (Span 19.53) 
were observed. On addition of 20% w/w L-leucine (Figure 4.12B), SEM micrographs of spray 
dried microparticles with low amount of lyoprotectant trehalose, sprayed at 80 °C showed 
agglomerated spherical particles with better separation as compared to powders without L-leucine 
(Figure 4.12A). Moreover, an improved laser diffraction particle size distribution was also evident 
with an DV90 of 20.91	µm and VMD of 4.67 µm (Span 5.83). To obtain aerosolization and an 
improved dispersion of respirable microparticles the particle size of the spray dried dry powder 
should be less than 5 µm with a unimodal distribution depicted by a Span value close to 1. 
Spray drying at 80 °C with a higher amount of lyoprotectant trehalose (1.0 times trehalose with 
respect to liposomal formulation) without L-leucine (Figure 4.13A) showed the presence of 
spherical particles clumped together and dry powder laser diffraction particle size DV90 of 52.91 
µm and VMD of 3.54 µm (Span 14.53). However, addition of 20% w/w L-leucine to the above 
formulation (Figure 4.13B) improved the dry powder microparticle morphology, wherein, 
particles with wrinkled surface spheres, with an DV90 value of 4.24 and VMD of 2.50 µm (Span 
1.07) were evident. 
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80ºC: 0.5X trehalose 
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Figure 4.12: SEM micrographs and Sympatec histograms of co-spray dried rifampicin and ibuprofen DPPC: 
DSPG: Chol 100:40:20 liposomes at 80ºC (inlet temperature) and low lyoprotectant trehalose concentration (0.5 
times trehalose with respect to liposomal formulation) 
A: without 20% w/w L-leucine, B: with 20% w/w l-leucine 
 
80ºC: 0.5X trehalose: 20% w/w L-leucine 
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80ºC: 1.0X trehalose 
80ºC: 1.0X trehalose: 20% w/w L-leucine 
 
Figure 4.13: SEM micrographs and Sympatec histograms of co-spray dried rifampicin and ibuprofen DPPC: 
DSPG: Chol 100:40:20 liposomes at 80ºC (inlet temperature) and high lyoprotectant trehalose concentration 
(1.0 time trehalose with respect to liposomal formulation) 
A: without 20% w/w L-leucine, B: with 20% w/w l-leucine 
 
A 
B 
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Spray drying to form dry powder microparticles at 120°C with low amount of lyoprotectant 
trehalose (0.5 times trehalose with respect to liposomal formulation) without L-leucine is as 
shown in Figure 4.14A. SEM micrographs of spray dried microparticles at the above conditions 
showed the presence of partially formed spherical particles with a wide range of size distribution, 
having a laser diffraction size DV90 of 8.76	µm and VMD of 3.34 µm (Span 2.47). Spray drying 
with L-leucine (Figure 4.14B) improved the particle morphology resulting in formation of 
wrinkled hollow sphere structures formed as curved plates with an DV90 of 4.29 µm and VMD 
of 2.73 µm (Span 1.39). This morphology has been reported in earlier literature to be responsible 
for producing an open powder structure and hence reduce particle density subsequently improving 
dispersion of aerosols [373].  
Moreover, microparticles produced by spray drying at a higher temperature i.e. 120ºC showed 
slight corrugations (roughness) on the particle surface. The liquid feed during the atomization 
phase was sprayed through a nozzle with a tip diameter of 0.7 mm, in the form of fine droplets 
into the drying chamber, where it encountered hot gas at temperatures of about 90-120°C. The 
droplets are subjected to the highest temperature in a moist state which leads to instant drying of 
the external surface of droplets. The temperature of the drying chamber gradually decreases due 
to this heat exchange needed to dry the external surface of droplet, and further drying takes place 
by the formation of holes to let go out the trapped internal solvent. This leaves behind the dried 
solid with a size similar to the size of the atomized droplet. Previous literature has confirmed that 
a spray drying temperature of 110/74°C is responsible for shrinkage and hence corrugations [371]. 
SEM micrographs and laser diffraction studies of dry powder microparticles spray dried at 120°C 
in the presence of high amount of lyoprotectant trehalose (1.0 time trehalose with respect to 
liposomal formulation) without L-leucine (Figure 4.15A) showed the presence of wrinkled 
surfaced spherical microparticles, with an DV90 of 3.7 and VMD of 2.40 µm (Span 0.98). 
Addition of L-leucine (Figure 4.15B) to the above formulation resulted in change of morphology 
to form hollower wrinkled spherical microparticles with an DV90 of 3.87 and VMD of 2.63 µm 
(Span 1.38), however, a more prominent curved plate hollow microparticle structure was evident 
in formulations spray dried at 120°C (Figure 4.14B) containing lower lyoprotectant concentration 
(0.5 times trehalose). This is attributed to the difference in the weight ratios of trehalose: L-leucine 
in both the formulations and hence a more prominent role of L-leucine where the trehalose 
concentration was less. 
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120ºC: 0.5X trehalose: 20% w/w L-leucine 
120ºC: 0.5X trehalose 
A 
 
 
B 
Figure 4.14: SEM micrographs and Sympatec histograms of co-spray dried rifampicin and ibuprofen DPPC: 
DSPG: Chol 100: 40: 20 liposomes at 120ºC (inlet temperature) and low lyoprotectant trehalose concentration 
(0.5 times trehalose with respect to liposomal formulation) 
A: without 20% w/w L-leucine, B: with 20% w/w l-leucine 
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Figure 4.15: SEM micrographs and Sympatec histograms of co-spray dried rifampicin and ibuprofen DPPC: 
DSPG: Chol 100:40:20 liposomes at 120ºC (inlet temperature) and high lyoprotectant trehalose concentration 
(1.0 times trehalose with respect to liposomal formulation) A: without 20% w/w L-leucine, B: with 20% w/w l-
leucine 
 
120ºC: 1.0X trehalose 
120ºC: 1.0X trehalose: 20% w/w L-leucine 
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Laser diffraction studies at different pressures on the Sympatec for the spray dried microparticles 
(Figure 4.16) gave a further insight into the dependence of pressure applied on the measured 
volume mean particle size, indicative of ease of dispersion. This is of importance when 
considering patient-to-patient variation in the force of inhalation due to age and disease condition 
and the ease of dispersion of powders from devices during aerosolization.  
Effect of pressure applied during measurement on the size of spray dried, physically mixed 
and raw material microparticles: 
Microparticles showing minimal differences in the size at different pressures would be attractive 
as the fine particle fraction and dose would be independent of the patient’s inspiratory flow rate. 
Spray drying liposomes at 80°C with or without 20% w/w leucine at a low trehalose concentration 
(0.5 times trehalose) showed significant differences (p < 0.05) in the volume mean particle size 
i.e. DV50 mean particle size at the different pressures of dispersion (Figure 4.16). Spray drying 
these at the same temperature with a higher trehalose concentration (1.0 times trehalose) was seen 
to improve the particle size profile between the different pressures.  
On the other hand, spray drying liposomes at 120°C with 20% leucine at low and high trehalose 
concentration and spray drying liposomes at 120°C without 20% leucine at high trehalose 
concentration showed no significant difference (p > 0.05) in volume mean particle size analyzed 
by laser diffraction at 1, 2, 3, 4 or 5 bar pressure, indicative of pressure-independent analysis and 
consequently no potential patient-to-patient variation. 
 
 
Figure 4.16: Effect of pressure on size analysis (Dv50) of spray dried microparticles of co-encapsulated DPPC: 
DSPG: Chol 100: 40: 20 liposomes (mean±SD, n=3) 
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4.5.2.3.2 Moisture content analysis by TGA 
Spray drying often leads to formation of amorphous microparticles due to the process adopted, 
wherein, the initial feedstock solution/dispersion droplet formed encounters hot drying gas in the 
drying chamber, which dehydrates the droplet from the outer surface to the inner droplet core, 
leaving behind a stable, homogenous amorphous powder with a size similar to the size of the 
initial droplet formed [371]. However, this increases the tendency of water sorption and 
recrystallization of microparticles on storage. Hence, it was important to study the content of 
moisture that is sorbed to the microparticle.  
The response of moisture content (%) (Y4) (Figure 4.17) clearly demonstrates than a significant 
increase in moisture of microparticles was seen with an increase in the amount of trehalose (X1, 
p = 0.0088). The other factors i.e. temperature of spray drying and addition of 20% w/w L-leucine 
had no significant effect on the moisture content of the microparticles. 
 
Figure 4.17: DoE 3- Preparation of dry powders suitable for inhalation, the effect of factors on response moisture 
content (%) (mean±SD, n=3, 3D cube plot Design-Expert® 6 (Stat-Ease, Inc.)) (For factor codes refer to Table 
4.7) 
 
On analyzing the responses observed in the above factorial model DoE 3 for preparation of dry 
powders suitable for inhalation, it was evident that temperature of spray drying had a significant 
effect on the DV90 and Span, hence, the potential aerosol properties of the microparticles 
especially when low amount of trehalose was used. SEM morphology and laser diffraction 
volume size distribution were useful to select 4 formulations (1 formulation with 0.5 times 
trehalose and 3 formulations of 1.0 time trehalose relative to final formulation) out of the matrix 
of 8 initially designed for spray drying that. These powders had DV50 and DV90 below 5 µm and 
a Span close to 1, necessary for a good dispersion to enhance delivery to the lungs. A decrease in 
drug content of the dry powder and an increase in moisture content were evident with an increase 
in trehalose from 33.33% (0.5 times trehalose) to 50% (1.0 time trehalose), and hence dry powders 
for further analysis were selected with lower amount of trehalose (0.5 times) and 20% w/w L-
leucine spray dried at an inlet temperature of 120°C (outlet temperature of 62°C). 
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4.5.3 Polymer coating  
4.5.3.1 1H-NMR proton nuclear magnetic resonance 
The 1H-NMR of commercial chitosan is shown in Figure 4.18. The internal standard used for 
assigning the chemical shifts of protons was D2O. The chemical shifts of internal standard 
appeared at 4.75 ppm.  
 
Figure 4.18: 1H-NMR spectrum of commercial chitosan < 3K 
The chemical shift at 2.0-2.1 ppm represents three protons (-NH-CO-CH3) of N-acetyl 
glucosamine (GlcNAc). The chemical shifts of the non-anomeric protons connected to ring 
skeleton of glucosyl residue having similar electron densities show a partially overlapping 
behaviour to produce a broad signal around 3.5-4.0 ppm. The –CH-OH, HOHC-CH-CH2 and –
CH2-OH protons appear at around 3.73 ppm, whereas, the chemical shifts of –CH-CH2 and 
CH2*OH appears at 3.64 ppm. The anomeric proton due to their neighbouring glycosidic and ring 
oxygen appear at higher chemical shifts as compared to non-anomeric protons i.e. at 3.09 ppm. 
The –CH-NH2 proton appears at a chemical shift of 3.11 ppm [373]. The 1H-NMR of 
mannosylated chitosan shown in Figure 4.19 contains similar peaks to commercial chitosan 
confirming the backbone of chitosan. However, a new peak at 7.19-7.22 ppm assigned to phenyl 
group with four hydrogen atoms from the phenyl isothiocyanate attached to mannopyranoside 
confirmed the successful reaction of mannosylated chitosan as seen in previous literature [422].  
 
 
Figure 4.19: 1H-NMR spectrum of mannosylated chitosan < 3K 
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4.5.3.2 Fourier transform infrared spectroscopy (FT-IR) 
 
Figure 4.20: Overlay of FT-IR spectra of chitosan<3K and mannosylated chitosan <3K 
 
FT-IR spectra of chitosan is as that reported previously by various authors. Spectrum (Figure 
4.20) shows characteristic absorption peaks at 3239 cm-1 indicative of amino N-H bend 
absorption of -NH2 functional group overlapping with N-H stretch of amide at 3100 cm-1 hence 
giving a broad peak. Absorption peak at 2877 cm-1 corresponds to aliphatic –CH and –CH2 
stretching, whereas, double peaks of absorption occurring at 1622 cm-1 and 1514 cm-1 
corresponding to C=O absorption and N-H group bending vibration respectively of N-acetamido 
group are evident. C=O absorption normally takes place roughly at a frequency of 1700 cm-1 or 
greater, however, due to resonance stabilization there is a ‘back-donating’ effect leading to 
transfer of unpaired electrons of nitrogen resulting in increased single bond C-O absorption and 
lowering of double bond C=O absorption. The bands appearing at frequencies 1061 cm-1 and 
1029 cm-1 corresponds to stretching of C-O group, whereas, band at 1375 cm-1 corresponds to 
stretching of C-O-N group. Lastly, the absorption bands occurring at a frequency of 899 cm-1 and 
1150 cm-1 can be attributed to glycosidic bonding i.e. β (1à4) stretching of chitosan sugar 
backbone. These characteristic absorption bands confirm the presence of chitosan [373].  
FT-IR spectrum of mannosylated chitosan exhibited characteristic band of mannose at 899 cm-1 
and 948 cm-1. Moreover, there was a shift and increase in intensity at 1510 cm-1 which is 
attributed to the contribution by the phenyl group of mannopyranoside isothiocyanate and reaction 
at the amine of chitosan leading to changes in the N-H bending also confirmed by shift in the peak 
at 1622 cm-1 to 1633 cm-1 affecting the N-H bending of chitosan amine [422]. Previous literature 
has also shown that disappearance of peak of isothiocyanate group from mannopyranoside phenyl 
isothiocyanate at 2125 cm-1 is indicative of reaction of these groups with polymer backbone [440]. 
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4.5.4 Final formulations selected for spray drying 
Based on the DoE experiments, different formulations (Table 4.12) were selected as final 
formulations to be spray dried. These formulations were also used to study the in vitro cellular 
uptake by encapsulation of 0.25 mg fluorescent dye coumarin-6 instead of the drugs rifampicin 
and ibuprofen. The concentration of coumarin-6 used for the study was to obtain a 100% 
encapsulation for all the formulations and a similar hydrodynamic size so as to prevent difference 
in uptake kinetics due to these parameters. The difference in zeta potential between the different 
formulations was however necessary to study the effect of charge on the surface of the liposomes 
and incorporation of targeting moieties on the uptake in macrophage RAW 264.7 cells. 
Table 4.12: Characterization of the final formulations selected for aerosolization and uptake studies 
Formulation (lipid 
concentration in 
molar) 
Drug/ 
Fluorescent 
dye 
Hydrodynamic 
diameter (nm) 
Zeta-potential 
(mV) 
Encapsulation 
efficiency (%) 
Negative liposomes 
(DPPC: DSPG: Chol 
100:40:20) 
Rifampicin 
and Ibuprofen 
84.09 ± 
3.89 
-43.5 ± 
1.50 
RIF-89.75 ± 2.40 
IBU-99.0 ± 2.20 
Coumarin-6 103.18 ± 5.41 
-45.00 ± 
0.75 104.31 ± 2.12 
Negative liposomes 
PAM (DPPC: DSPG: 
Chol 100:40:20) 
Rifampicin 
and Ibuprofen 
93.12 ± 
3.11 
-41.21 ± 
2.15 
RIF- 87.14 ± 1.28 
IBU-91.21 ± 2.07 
Coumarin-6 129.73 ± 1.62 
-42.77 ± 
3.07 104.67 ± 3.87 
Negative liposomes 
MAN (DPPC: DSPG: 
Chol 100:40:20) 
Rifampicin 
and Ibuprofen 
85.94 ± 
2.63 
-43.67 
1.84 
RIF-93.59 ± 3.14 
IBU-97.84 ± 2.74 
Coumarin-6 103.13 ± 4.26 
-43.10 ± 
2.62 94.68 ± 0.23 
Positive liposomes 
chitosan-coated 
(DPPC: DSPG: Chol 
100:20:20) 
Rifampicin 
and Ibuprofen 
145.34 ± 
2.12 
37.21 
1.89 
RIF-63.12 ± 1.06 
IBU-92.51 ± 2.0 
Coumarin-6 130.43 ± 3.37 
37.73 ± 
1.79 95.56 ± 1.63 
Positive liposomes 
chitosan-mannose 
coated 
(DPPC: DSPG: Chol 
100:20:20) 
Rifampicin 
and Ibuprofen 
141.67 ± 
3.68 
35.33 
2.70 
RIF-62.22 ± 1.79 
IBU-89.33 ± 1.69 
Coumarin-6 122.33 ± 1.05 
35.63 ± 
1.03 97.67 ± 0.98 
Neutral liposomes 
(DPPC: Chol 100:20) 
Rifampicin 
and Ibuprofen 
135.91 ± 
2.52 
0.23 ± 
0.36 
RIF-69.14 ± 5.21 
IBU-92.04 ± 4.33 
Coumarin-6 130.8 ± 4.08 
4.03 ± 
0.33 100.93 ± 3.12 
DPPC- dipalmitoyl phosphatidylcholine, DSPG- distearyl phosphatidylglycerol, Chol- cholesterol, MAN- 
mannosamine hydrochloride, PAM- p-aminophenyl α-D-mannopyranoside 
4.5.4.1 Re-hydration of spray dried liposomes 
Critical process parameters were carefully considered for dehydration of liposomes to ensure that 
they would re-disperse on aerosolization in the airway fluid, without considerable loss of 
formulation integrity and retention of particle size post-aerosolization. It is important to study the 
size of liposomes following spray drying on re-hydration in water or buffer, as the liposomes can 
suffer from disruption or aggregation and hence drug leakage during dehydration.  
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There was no significant difference (p > 0.05) in the hydrodynamic diameter and zeta-potential 
of liposomes studied post dehydration, when the spray dried powders were redispersed in 
deionized water, indicative of optimal spray drying conditions for the liposomal formulation 
under study (Table 4.13). 
Table 4.13: Characterization of the formulations on rehydration of spray dried liposomes in deionized water 
Formulation 
(lipid 
concentration in 
molar) 
Hydrodynamic 
diameter (nm) 
before spray 
drying 
Zeta-potential 
(mV) before 
spray drying 
Hydrodynamic 
diameter (nm) 
on rehydration 
in deionized 
water 
Zeta-potential 
(mV) on 
rehydration in 
deionized 
water 
Negative liposomes 
(DPPC: DSPG: 
Chol 100:40:20) 
84.09 ± 3.89 -43.5 ± 1.50 77.25 ± 4.83 -42.7 ± 1.18 
Negative liposomes 
PAM (DPPC: 
DSPG: Chol 
100:40:20) 
93.12 ± 3.11 -41.21 ± 2.15 96.30 ± 2.17 -39.3 ± 1.34 
Negative liposomes 
MAN (DPPC: 
DSPG: Chol 
100:40:20) 
85.94 ± 2.63 -43.67 ± 1.84 89.11 ± 2.96 -46.2 ± 2.63 
Positive liposomes 
chitosan-coated 
(DPPC: DSPG: 
Chol 100:20:20) 
145.34 ± 2.12 37.21 ± 1.89 149.7 ± 3.04 39.92 ± 0.98 
Positive liposomes 
chitosan-mannose 
coated 
(DPPC: DSPG: 
Chol 100:20:20) 
141.67 ± 3.68 35.33 ± 2.70 147.9 ± 2.11 37.11 ± 0.52 
Neutral liposomes 
(DPPC: Chol 
100:20) 
135.91 ± 2.52 0.23 ± 0.36 140.12 ± 5.21 -0.11 ± 1.01 
DPPC- dipalmitoyl phosphatidylcholine, DSPG- distearyl phosphatidylglycerol, Chol- cholesterol, MAN- 
mannosamine hydrochloride, PAM- p-aminophenyl α-D-mannopyranoside 
4.5.4.2 Transmission electron microscopy 
Charge of the liposomal surface has an effect on the negative staining process since it affects the 
binding of the contrasting agent uranyl, the electron scattering pattern and eventually the TEM 
micrograph. Moreover, negative stain EM for liposomes suffers from various drawbacks of 
sample preparation which might cause liposomal fusion, aggregation or rouleau formation 
[441,442]. For this reason an optimized staining protocol as previously published was followed 
for improving the contrast of the micrographs [442].  
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 Negative liposomes  
(DPPC: DSPG: Chol 100:40:20) 
Neutral liposomes  
(DPPC: Chol 100:20) 
 
Negative liposomes PAM 
(DPPC: DSPG: Chol 100:40:20)  
 
Positive liposomes chitosan-coated 
(DPPC: DSPG: Chol 100:20:20)  
Negative liposomes MAN  
(DPPC: DSPG: Chol 100:40:20) 
 
Positive liposomes chitosan-mannose coated 
(DPPC: DSPG: Chol 100:20:20)
 
Figure 4.21: TEM micrographs of liposomes co-encapsulating rifampicin and ibuprofen, (A) DPPC:DSPG:Chol 
100:40:20 liposomes, (B) DPPC:Chol 100:20 liposomes, (C) DPPC:DSPG:Chol 100:40:20-PAM liposomes, (D) 
chitosan-coated DPPC: DSPG: Chol 100:20:10 liposomes, (E) DPPC:DSPG:Chol 100:40:20 MAN liposomes, (F) 
mannosylated chitosan-coated DPPC: DSPG: Chol 100:20:10 liposomes 
A B 
C D 
E F 
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The TEM micrographs for liposomes as captured in Figure 4.21 showed the presence of 
nanometric range of spherical particles with a smooth surface. Particle size was in good 
correlation with that obtained from the DLS analysis using the Zetasizer ZS (Table 4.12). 
4.5.4.3 Scanning electron microscopy and laser diffraction analysis 
SEM was performed on freshly prepared spray dried samples (chosen from the final formulations) 
stored under a desiccator at room temperature. It was performed to analyze the morphological and 
surface behaviour associated with the different compositional powders and to study their particle 
size. The SEM micrographs were captured at different degrees of magnification to highlight the 
details of the particles. 
Spray drying to form dry powder microparticles of negatively-charged non-targeted and targeted 
liposomes at 120°C with lower lyoprotectant trehalose concentration (0.5 times) and L-leucine is 
as depicted in Figure 4.22. SEM micrographs of spray dried microparticles of negatively-charged 
liposomes (Figure 4.22A) at the above conditions with L-leucine resulted in formation of wrinkled 
hollow sphere structures formed as curved plates with an DV90 of 4.29 µm and VMD of 2.73 µm 
(Span 1.39). This morphology has been reported in earlier literature to be responsible for 
producing an open powder structure and hence reduce particle density subsequently improving 
dispersion [373].  
Moreover, negatively-charged liposomes containing p-amino phenyl mannopyranoside (PAM, 
Figure 4.22B) and mannosamine hydrochloride (MAN, Figure 4.22C) embedded in the bilayer 
spray dried at the same conditions also showed the presence of wrinkled hollow sphere structures 
formed as curved plates with an DV90 of 4.71	µm (VMD 2.24 µm, Span 1.73) and DV90 4.75 
µm (VMD 1.91	µm, Span 1.55) respectively. 
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DPPC: DSPG: Chol (100:40:20) liposomes  
A 
DPPC: DSPG: Chol (100:40:20) PAM liposomes 
B 
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DPPC: DSPG: Chol (100:40:20) MAN liposomes 
C 
Figure 4.22: SEM micrographs and Sympatec histograms of co-spray dried rifampicin and ibuprofen DPPC: 
DSPG: Chol 100:40:20 negative liposomes at 120ºC (inlet temperature), low lyoprotectant concentration (0.5 
times trehalose with respect to liposomal formulation) and 20% w/w L-leucine 
A: Negative liposomes, B: Negative PAM liposomes, C: Negative MAN liposomes 
Spray drying to form dry powder microparticles of positively-charged chitosan-coated and 
mannosylated chitosan-coated liposomes at 120°C with lower lyoprotectant trehalose 
concentration (0.5 times) and L-leucine is as depicted in Figure 4.23. SEM micrographs of 
positively-charged chitosan-coated liposomes spray dried as microparticles (Figure 4.23A) at 
the above conditions with L-leucine resulted in formation of spherical microparticles with an 
DV90 of 4.44	 µm (VMD 2.55	 µm, Span 1.20). Moreover, positively-charged mannosylated 
chitosan-coated liposomes (Figure 4.23B) showed the presence of similar spherical structures 
with an DV90 of 4.54	µm (VMD 2.70 µm, Span 1.17).  
All the above microparticles were spray dried under the same conditions with 33.33% trehalose 
and 20% w/w L-leucine showed desirable DV50, DV90, Span and morphology to obtain an 
aerosol for potential peripheral pulmonary deposition to the site of infection. These spray dried 
microparticles were evaluated for their in vitro aerosol efficiency parameters and pulmonary 
deposition pattern using the NGI. 
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Chitosan-coated DPPC: DSPG: Chol (100:20:20) liposomes 
 
Mannosylated chitosan-coated DPPC: DSPG: Chol (100:20:20) liposomes 
 
B 
 
Figure 4.23: SEM micrographs and Sympatec histograms of co-spray dried rifampicin and ibuprofen chitosan-
coated DPPC: DSPG: Chol 100:20:20 negative liposomes at 120ºC (inlet temperature), low lyoprotectant 
concentration (0.5 times trehalose with respect to liposomal formulation) and 20% w/w L-leucine 
A: Positive chitosan-coated liposomes, B: Positive mannosylated chitosan-coated liposomes 
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4.5.5 In vitro aerosol deposition and aerodynamic behaviour studies of rifampicin and 
ibuprofen liposomal microparticles 
The in vitro aerodynamic behaviour and deposition of the liposomal rifampicin and ibuprofen 
microparticles illustrated in Figure 4.24 and Figure 4.25 was studied using a Next Generation 
Impactor. In this study, aerosolization efficiency parameters (Table 4.14) were analyzed in 
triplicate for the freshly prepared spray dried powders and represented as a histogram of the mean 
percentage of rifampicin or ibuprofen impacted on each stage as compared to the initial amount 
of drugs aerosolized, ±SD. 
Table 4.14: Aerosol parameters studied using the NGI 
Microparticle Drug ED (%) FR (%) 
FPF 
(%) 
FPD 
(mg) 
MMAD 
(µm) 
GSD 
Negative liposomes 
(DPPC: DSPG: 
Chol 100:40:20) 
Rifampicin 
91.15 ± 
3.59 
88.23 ± 
5.45 
62.83 ± 
4.06 
6.33 ± 
0.41 
2.95 ± 
0.20 
1.70 ± 
0.04 
Ibuprofen 
91.47 ± 
3.02 
90.04 ± 
4.72 
63.28 ± 
4.05 
5.32 ± 
0.34 
2.87 ± 
0.17 
1.72 ± 
0.06 
Negative liposomes 
PAM (DPPC: 
DSPG: Chol 
100:40:20) 
Rifampicin 
93.80 ± 
0.82 
93.03 ± 
2.29 
61.68 ± 
2.02 
6.22± 
0.20 
2.85 ± 
0.13 
1.67 ± 
0.09 
Ibuprofen 
93.59 ± 
1.09 
93.02 ± 
2.12 
58.99± 
2.09 
4.51 ± 
0.16 
2.82 ± 
0.26 
1.7 ± 
0.11 
Negative liposomes 
MAN (DPPC: 
DSPG: Chol 
100:40:20) 
Rifampicin 
94.69 ± 
1.23 
91.30 ± 
3.2 
61.69 ± 
2.25 
6.42 ± 
0.20 
2.47 ± 
0.15 
1.82 ± 
0.07 
Ibuprofen 
93.92 ± 
0.88 
83.42 ± 
3.93 
61.46 ± 
1.03 
5.16 ± 
0.09 
2.47 ± 
0.09 
1.84 ± 
0.05 
Positive liposomes 
chitosan-coated 
(DPPC: DSPG: 
Chol 100:20:20) 
Rifampicin 
96.99 ± 
2.64 
81.08 ± 
1.78 
62.82 ± 
1.12 
4.51 ± 
0.08 
3.16 ± 
0.33 
1.55 ± 
0.21 
Ibuprofen 
96.87 ± 
3.92 
82.88 ± 
0.94 
64.79 ± 
3.34 
5.03 ± 
0.26 
3.03 ± 
0.35 
1.58 ± 
0.19 
Positive liposomes 
chitosan-mannose 
coated 
(DPPC: DSPG: 
Chol 100:20:20) 
Rifampicin 
96.54 ± 
1.37 
83.21 ± 
2.41 
60.50 ± 
2.01 
4.22 ± 
0.14 
3.14 ± 
0.41 
1.54 ± 
0.24 
Ibuprofen 
96.22 ± 
2.47 
82.64 ± 
1.44 
62.09 ± 
1.39 
4.76 ± 
0.10 
3.09 ± 
0.32 
1.61 ± 
0.26 
Neutral liposomes 
(DPPC: Chol 
100:20) 
Rifampicin 
92.11 ± 
1.14 
89.32± 
1.07 
61.96 ± 
0.97 
4.79 ± 
0.08 
3.27 ± 
0.24 
1.79 ± 
0.14 
Ibuprofen 
93.24 ± 
1.07 
88.14± 
0.91 
62.41 ± 
0.84 
4.83 ± 
0.07 
3.15 ± 
0.31 
1.84 ± 
0.18 
PAM- p-aminophenyl α-D-mannopyranoside, MAN- mannosamine hydrochloride, ED- emitted dose, FR- 
fraction recovered, FPF- fine particle fraction, FPD- fine particle dose, MMAD- mass median aerodynamic 
diameter, GSD- geometric standard deviation 
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Fraction recovered: It is very important to have a mass balance throughout the NGI, wherein, a 
total mass balance of active substance recovered should not be less than 75% nor more than 125% 
of average delivered dose as per the European Pharmacopeia [380]. A small percentage of 
unrecoverable drug gets entrapped into the seal body and makes it necessary to study the mass 
balance of each experiment individually. A good mass balance was encountered for all the spray 
dried with data lying between the limits of 81.08-93.03%. 
 
Emitted dose: The ED was studied from the amount of drug left in the capsules after 
aerosolization and calculated as per drug loading for respective formulations. High dispersibility 
and hence ED was evident for the spray dried powders with more than 91.15% contents being 
emitted during aerosolization for each, indicative of low adhesion to the inhaler. The study of 
dependence of pressure on the volume mean particle size and hence dispersion of spray dried 
microparticles (section 4.5.2.3.1) studied by laser diffraction, was well correlated with the high 
dispersion seen in the in vitro aerosolization studies.  
It was evident that the emitted dose for all the powders of the different liposomal formulations 
compared for the individual drugs was insignificant (p > 0.05). The spray drying conditions 
derived from Design of Experiment (DoE 3, section 4.5.2.3) i.e. inlet temperature, amount of 
lyoprotectant trehalose and addition of 20% w/w/ L-leucine, were used for spray drying these 
liposomal formulations, and hence there was no difference in aerosolization of the different 
microparticles. 
 
MMAD and GSD: Mass median aerodynamic diameter (MMAD) refers to particle diameter as 
half the aerosol mass contained smaller than MMAD and half that is larger. All the spray dried 
powders show an MMAD of below 5µm, wherein, the largest of 3.27 µm was achieved for the 
spray dried neutral DPPC: Chol liposomes and the smallest of 2.47 µm for spray dried negative 
DPPC: DSPG: Chol liposomes incorporating targeting agent mannosamine hydrochloride. 
MMAD for all the microparticles were found to be well in the respirable limits of 2-5 µm and 
indicates potential deep lung deposition patterns of these microparticles. The geometric standard 
deviation for the spray dried microparticles was around 1-2 indicative of monodispersed systems 
and unimodal distribution of microparticles.  
 
Fine particle fraction and dose: FPF and FPD are important determinants of the fraction and 
dosage of aerosolized drug that has potential to be deposited in the peripheral airways and hence 
show therapeutic efficacy. Fine particle fraction of the different liposomal microparticles for both 
rifampicin and ibuprofen was not significantly different (p > 0.05). Moreover, the FPF of 
rifampicin and ibuprofen obtained for each spray dried microparticle formulation was similar 
indicating that the microparticles constituted and dispersed both the drugs homogenously on 
aerosolization. Chougule et al. reported a similar, high FPF of 62.8 ± 2.8% on aerosolization of 
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spray-dried DPPC: Chol liposomes encapsulating dapsone, formulated with lactose, and delivered 
from a DPI Brev I. S. F. device into an Andersen Cascade Impactor [360]. 
The FPD of rifampicin and ibuprofen co-encapsulated in negative DPPC: DSPG: Chol liposomes 
non-targeted and targeted with mannose moieties was significantly greater (p < 0.05) than the 
neutral DPPC: Chol and positively-charged chitosan-coated DPPC: DSPG: Chol liposomes, 
owing to differences in the encapsulation efficiency of the drugs within the different liposomal 
formulations (Table 4.12). 
 
Potential pulmonary deposition of rifampicin and ibuprofen microparticles 
Figure 4.24 and Figure 4.25 demonstrates the potential pulmonary deposition profile for all the 
microparticles spray dried from the different liposomal feedstocks, indicating that the conditions 
used for spray drying were optimum to produce microparticles suitable for delivery to the 
peripheral lung. Spray drying offers a proper tuning of the particle size, shape and density which 
are important parameters for successful inhalation of DPIs.  
All the spray dried microparticles showed low deposition in the throat and pre-separator stages of 
the NGI (<20%), indicative of low oropharyngeal and throat deposition and hence a deeper 
peripheral deposition in the lungs as depicted by increased deposition (>60%) in the stages 2-7 
and MOC (stage 8) of the NGI. Negatively-charged DPPC: DSPG: Chol liposomal microparticles 
non-targeted and targeted (Figure 4.24), displayed predominant deposition in stages 2-5 of the 
NGI, especially in stage 3 and stage 4 having cut-off dimeter 2.82 µm and 1.66 µm respectively. 
 
 
Figure 4.24: NGI deposition profile of spray dried negatively-charged DPPC: DSPG: Chol liposomal 
microparticles (mean±SD, n=3) 
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Positively-charged chitosan-coated DPPC: DSPG: Chol liposomal microparticles non-targeted 
and targeted and neutral-charged DPPC: Chol liposomal microparticles (Figure 4.25), displayed 
predominant deposition in stages 2-5 of the NGI, especially in stage 2 and stage 3 having cut-off 
dimeter 4.46 µm and 2.82 µm respectively. Therefore, the overall MMAD of the positively-
charged liposomal microparticles was greater than the negatively-charged liposomal 
microparticles.  
 
Figure 4.25: NGI deposition profile of spray dried positively-charged chitosan-coated DPPC: DSPG: Chol and 
neutrally-charged DPPC: Chol liposomal microparticles (mean±SD, n=3) 
 
4.5.6 Cellular uptake studies 
The cellular uptake kinetics of the various formulations encapsulating fluorescent dye coumarin-
6 using flow cytometry and fluorescence microscopy was assessed on the macrophage RAW 
264.7 cells at numerous time points until saturation of uptake into the cells was observed. Uptake 
kinetics is dependent on the liposomal charge, particle size, surface chemistry and shape [443]. 
In the present study, the mean size of all the formulations was around 110-130 nm (Table 4.12) 
for coumarin-6 encapsulated liposomes, hence, the difference in uptake would be specifically due 
to the differences in surface charge and chemistry of the liposomes. The comparison of mean 
fluorescence intensity of the different liposomal formulations at varied time points is as shown in 
Figure 4.26.  
The uptake of all the liposomes was linear at 37 °C for about 4 hours after which it levelled off 
due to saturation of the capacity of RAW 264.7 cells. Repeated Measures One-way ANOVA 
(rANOVA) using Tukey post-hoc analysis was performed to compare the different groups 
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considering ‘time’ as an independent variable, wherein p at a level of 0.05 i.e. p < 0.05 was a 
significant difference. When the model was analyzed a p value of 0.275 was obtained, confirming 
that the model was valid to be studied using Ranova, as it did not violate Mauchly’s Test of 
Sphericity and that the variances of difference between the different subject groups (formulations) 
at all levels were equal. 
Comparison of the uptake of neutral-charged DPPC: Chol liposomes with the negatively-charged 
DPPC: DSPG: Chol liposomes and the positively-charged chitosan-coated DPPC: DSPG: Chol 
showed a significantly slower uptake (rANOVA, p < 0.05), reaching saturation between 4-8 hrs. 
 
Figure 4.26: Mean fluorescence intensity (arbitrary units) showing quantitative cellular uptake kinetics as 
measured by the flow cytometer (mean±SD, n=3) 
Figure 4.27 shows the uptake kinetics of neutral liposomes qualitatively and quantitatively over 
a period of 8 h. An increase in fluorescence intensity was evident with increasing time (Figure 
4.27A-E) depicting increased uptake of neutral-charged DPPC: Chol liposomes. The flow 
cytometry histogram (Figure 4.27F) for the region selected for study ‘P1’, shows the x-axis as the 
fluorescence intensity and y-axis as cell count. The results support the qualitative fluorescence 
microscopy images that the uptake of neutral-charged DPPC: Chol liposomes increased up to 4 
h, after which an overlap of histograms for 4 h and 8 h was evident (light blue and black 
histograms) suggesting saturation of uptake after 4 h, also confirmed by the mean fluorescence 
intensity shown in Figure 4.26. 
Negatively-charged DPPC: DSPG: Chol liposomes showed a significantly higher (rANOVA, p = 
0) uptake as compared to neutral-charged DPPC: Chol liposomes and positively-charged 
chitosan-coated DPPC: DSPG: Chol liposomes (rANOVA, p = 0.019), as evident by the mean 
fluorescence intensity kinetics in Figure 4.26. An increase in the fluorescence intensity was seen 
with increasing time (Figure 4.28A-E), wherein, at the 2 h time-point more fluorescence was 
evident for the negatively-charged liposome treated cells as compared to the neutral-charged 
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liposome treated cells. This was supported by the mean fluorescence intensity value and shift in 
histogram at 2 h (dark blue), wherein, an overlap between the histograms at 2 h (dark blue), 4 h 
(light blue) and 8 h (black) was seen. These results proposed that negatively-charged DPPC: 
DSPG: Chol (Figure 4.28F) liposomes were taken up more quickly as compared to neutral 
liposomes, suggesting an active scavenger receptor mediated endocytosis of the anionic 
liposomes as seen earlier by Rigotti et al. [410].  
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Figure 4.27: Time-dependent qualitative uptake of neutrally-charged DPPC: Chol liposomes monitored using 
fluorescence microscopy at (A) 0.25 h, (B) 0.5 h, (C) 2 h, (D) 4 h and (E) 8 h 
(F) Time-dependent quantitative uptake of neutrally-charged DPPC: Chol liposomes studied using flow 
cytometry (P1 is the region chosen for the study) 
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Figure 4.28: Time-dependent qualitative uptake of negatively-charged DPPC: DSPG: Chol liposomes monitored 
using fluorescence microscopy at (A) 0.25 h, (B) 0.5 h, (C) 2 h, (D) 4 h and (E) 8 h 
(F) Time-dependent quantitative uptake of negatively-charged DPPC: DSPG: Chol liposomes studied using flow 
cytometry (P1 is the region chosen for the study) 
To further improve uptake of negatively-charged DPPC: DSPG: Chol liposomes targeting moiety 
mannosamine was incorporated into the bilayer by interaction of the positive amino groups of 
mannosamine with the negatively-charged liposomal bilayer induced by phosphatidylglycerol at 
pH 7. Negatively-charged mannosylated liposomes incorporating mannosamine or p-
aminophenyl mannopyranoside have previously been shown to improve uptake in vivo and in 
vitro in epithelial cells and alveolar macrophages [213,444,445].  
Negatively-charged mannosamine incorporated DPPC: DSPG: Chol liposomes showed an 
improved uptake kinetics as compared to both neutral-charged DPPC: Chol liposomes (rANOVA, 
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p = 0) and negatively-charged DPPC: DSPG: Chol liposomes (rANOVA, p = 0.009) as seen in 
Figure 4.29. An increase in uptake of negatively-charged DPPC: DSPG: Chol mannosamine 
liposomes was seen in the fluorescence microscopy images (Figure 4.29A-E) with increasing 
time. The flow cytometry histograms (Figure 4.29F) for the selected region also showed a quicker 
uptake, wherein, an overlap of histograms for the initial 0.25 h (green) and 0.5 h (brown) time 
point was seen indicating a quicker uptake, due to an increased initial interaction obtained by 
active targeting to both the scavenger and mannose receptors on the macrophage cell membrane. 
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Figure 4.29: Time-dependent qualitative uptake of negatively-charged DPPC: DSPG: Chol mannosamine 
liposomes monitored using fluorescence microscopy at (A) 0.25 h, (B) 0.5 h, (C) 2 h, (D) 4 h and (E) 8 h 
(F) Time-dependent quantitative uptake of negatively-charged DPPC: DSPG: Chol mannosamine liposomes 
studied using flow cytometry (P1 is the region chosen for the study) 
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Maximal uptake was seen within 2 h apparent by the overlap of the fluorescence intensity 
histograms for uptake at 2 h (dark blue), 4 h (light blue) and 8 h (black). Chono et al. reported a 
similar enhanced drug uptake by alveolar/peritoneal macrophages in vitro (NR8383 cells) and in 
vivo (rats) when inhaled from a liquid Micro Sprayer device, for the mannosylated negatively-
charged PC: Chol liposomes as compared to non-mannosylated negatively-charged liposomes 
[412]. Youngren et al. also reported an enhanced uptake of mannosamine targeted DPPC: DSPG: 
Chol liposomes in vitro in MH-S mouse alveolar cells [433]. 
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Figure 4.30: Time-dependent qualitative uptake of negatively-charged DPPC: DSPG: Chol p-aminophenyl 
mannopyranoside liposomes monitored using fluorescence microscopy at (A) 0.25 h, (B) 0.5 h, (C) 2 h, (D) 4 h 
and (E) 8 h 
(F) Time-dependent quantitative uptake of negatively-charged DPPC: DSPG: Chol p-aminophenyl 
mannopyranoside liposomes studied using flow cytometry (P1 is the region chosen for the study) 
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Another strategy to improve the uptake of negatively-charged DPPC: DSPG: Chol liposomes into 
macrophages was by incorporation of p-aminophenyl mannopyranoside (PAM) by means of 
attraction of the amino group on PAM with the negatively-charged liposomal bilayer. There was 
a significantly improved (rANOVA, p = 0) uptake of negatively-charged DPPC: DSPG: Chol 
PAM liposomes as compared to the neutral-charged DPPC: Chol liposomes, however, uptake was 
not significantly improved (rANOVA, p = 1) as compared to the negatively-charged DPPC: 
DSPG: Chol liposomes. This is due to insufficient PAM incorporated within the liposomal 
bilayers used in the study. 
There was a time-dependent increase in fluorescence intensity of thes negatively-charged DPPC: 
DSPG: Chol PAM liposomes (Figure 4.30A-E), levelling off at around 2 h evident by the overlay 
in fluorescence intensity histograms (Figure 4.30F) at 2 h (dark blue), 4 h (light blue) and 8 h 
(black), similar to the negatively-charged DPPC: DSPG: Chol liposomes. 
Positively-charged chitosan-coated DPPC: DSPG: Chol liposomes showed a significantly higher 
uptake (rANOVA, p = 0.008, Figure 4.26) as compared to the neutral-charged DPPC: Chol 
liposomes, which is attributed to a higher extent of interaction between the positively-charged 
liposomal surface and negatively-charged cell membrane, hence, bringing the liposomes closer to 
the cells consequently improving uptake by endocytosis. However, uptake was significantly lower 
than actively targeted negatively-charged DPPC: DSPG: Chol liposomes (rANOVA, p = 0.019) 
and mannosylated negatively-charged DPPC: DSPG: Chol liposomes (rANOVA, p = 0 
negatively-charged mannosamine liposomes, p = 0.016 negatively-charged PAM liposomes). The 
fluorescence intensity was seen to increase with time (Figure 4.31A-E). The flow cytometry 
histograms (Figure 4.31F) for the selected region ‘P1’ also showed an increased uptake levelling 
off at 4 h depicted by the overlay between the florescence intensity histogram at 4 h (light blue) 
and 8 h (black). 
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Figure 4.31: Time-dependent qualitative uptake of positively-charged chitosan-coated DPPC: DSPG: Chol 
liposomes monitored using fluorescence microscopy at (A) 0.25 h, (B) 0.5 h, (C) 2 h, (D) 4 h and (E) 8 h 
(F) Time-dependent quantitative uptake of positively-charged chitosan-coated DPPC: DSPG: Chol liposomes 
studied using flow cytometry (P1 is the region chosen for the study) 
To further improve the uptake of positively-charged DPPC: DSPG: Chol liposomes into 
macrophages they were coated with mannosylated chitosan to achieve active targeting using 
mannose receptors on the macrophage cell membrane. A significantly higher uptake (rANOVA, 
p = 0, Figure 4.26) was seen for the mannosylated chitosan-coated DPPC: DSPG: Chol liposomes 
as compared to the neutral-charged DPPC: Chol liposomes. Moreover, mannosylated chitosan-
coated liposomes also showed a higher uptake when compared to positively-charged chitosan-
coated liposomes (rANOVA, p = 0), negatively-charged liposomes targeted to scavenger 
receptors (rANOVA, p = 0.009) and negatively-charged PAM liposomes (rANOVA, p = 0.011). 
However, the uptake kinetics of mannosylated chitosan-coated liposomes studied using mean 
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fluorescence intensity at the various time points was not significantly different (rANOVA, p = 1, 
Figure 4.26) when compared to the negatively-charged mannosamine liposomes, depicting that 
both the formulations had an improved uptake due to efficient targeting to the mannose receptors. 
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Figure 4.32: Time-dependent qualitative uptake of positively-charged mannosylated chitosan-coated DPPC: 
DSPG: Chol liposomes monitored using fluorescence microscopy at (A) 0.25 h, (B) 0.5 h, (C) 2 h, (D) 4 h and (E) 
8 h 
(F) Time-dependent quantitative uptake of positively-charged mannosylated chitosan-coated DPPC: DSPG: 
Chol liposomes studied using flow cytometry (P1 is the region chosen for the study) 
 
0.25 h 
0.5 h 
2 h 
4 h 
8 h 
Control 
  
  
 
A B 
C D 
E 
F 
E 
Chapter 4| Inhalable microparticles of rifampicin and ibuprofen in mannosylated liposomes
  
188	
	
There was a time-dependent increase in the fluorescence intensity of mannosylated chitosan-
coated positively-charged liposomes as confirmed by the fluorescence microscopy images and 
flow cytometry histograms as seen in Figure 4.32. The fluorescence intensity histograms (Figure 
4.32F) showed levelling off uptake in 2 h indicated by the overlay of the histograms for uptake at 
2 h (dark blue), 4 h (light blue) and 8 h (black) and the mean fluorescence intensities in Figure 
4.26. 
In conclusion, changing the surface charge of liposomes from neutral to negative or positive 
showed a significant improvement (rANOVA, p < 0.05) in uptake by means of endocytosis by 
targeting the scavenger receptors (negative liposomes) or by simple attraction of the positively-
liposomes to the negatively-charged cell membrane. Moreover, mannosylation of the negatively 
or positively-charged liposomes showed a significantly higher uptake (rANOVA, p < 0.05) as 
compared to their charged counterparts or neutral-charged liposomes. Hence, macrophage cellular 
uptake of liposomes may be improved by not only passive targeting of formulations directly to 
the lung by means of DPIs, but also improving uptake into the macrophages where the 
intracellular TB infection resides by means of actively targeting the scavenger or mannose 
receptors once the liposomes are dispersed in the lung fluid.  
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4.6    Conclusion  
The aim of this chapter was to not only utilize the art of preparation of liposomes to aid in 
solubilization of hydrophobic drugs to be delivered to the lungs, but also alter the surface 
chemistry of the liposomes to obtain active targeting when infections are intracellularly-located 
within deep compartments of the lungs.  
Based on the aforementioned results presented in this chapter, it can be concluded that: 
1. Liposomes co-encapsulating antitubercular drugs rifampicin and ibuprofen were successfully 
formulated with the help of Design of Experiment, by developing a factorial design for 
studying the effect of choice of lipids DPPC: DSPG: Chol and their constitution on the mean 
size, zeta potential, PDI of the liposomes and encapsulation efficiencies of rifampicin and 
ibuprofen. The lipid constitution of 100: 40: 20 DPPC: DSPG: Chol was selected to form 
stable liposomes with encapsulation efficiency of 89.75±2.40% and 99.00±2.20% for 
rifampicin (25 micromolar) and ibuprofen (50 micromolar) respectively, with a mean size of 
84.09±3.89 nm and surface zeta potential of -43.5±1.5 mV.  
2. Co-encapsulation of antitubercular drugs into one liposomal system can be complex due to 
interaction between the drugs. A second factorial design was successfully developed to study 
the interaction of rifampicin and ibuprofen in the liposomal system chosen from the first 
study. 
3. To further enhance uptake by targeting actively to the scavenger and the mannose receptors, 
negatively-charged DPPC: DSPG: Chol liposomes were further successfully modified with 
mannose moieties mannosamine hydrochloride and p-aminophenyl mannopyranoside, by 
means of embedding these within the negatively-charged liposomal bilayer by electrostatic 
attraction with the positively-charged amino groups on these mannose moieties at pH 7.  
4. Positively-charged liposomes were prepared by coating the negative surface of DPPC: DSPG: 
Chol (100: 20: 20) liposomes with chitosan by means of electrostatic attraction. The 
liposomes so formed showed an encapsulation efficiency of 63.12±1.06% and 92.50±2.00% 
for rifampicin and ibuprofen respectively, with a mean size of 145.34±2.12 nm and surface 
charge of +37.21±1.89 mV.  
5. To further enhance cellular uptake by targeting the positively-charged liposomes to the 
mannose receptors, coating with mannosylated chitosan was carried out in a similar way to 
that of chitosan. Mannosylated chitosan was successfully synthesized and its structure was 
confirmed using 1H-NMR and FT-IR.  
6. A full factorial design was set up to gain an insight and understanding on the formulation of 
inhalable microparticles of the above liposomal formulations, by studying the effects of 
amount of lyoprotectant trehalose, dispersibility enhancer L-leucine and inlet temperature of 
spray drying on dry powder particle size distribution, Span and moisture content. 
Microparticles obtained by spray drying at 120°C in the presence of 33.33% of lyoprotectant 
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trehalose and 20% dispersibility enhancer L-leucine had dry powder particle size in respirable 
range of 2-5 µm, along with low moisture content. These process parameters were also used 
to spray dry the targeted negative liposomes, non-targeted and targeted positive liposomes. 
7. In vitro potential pulmonary deposition studies for the microparticles sprayed from the 
different liposomal constitutions co-encapsulating rifampicin and ibuprofen showed a low 
deposition in the throat and pre-separator stages of the NGI (<20%), and an increased 
deposition (>60%) in the stages 2-7 and MOC of the NGI, wherein a fine particle fraction of 
58.99-64.79% was evident for all the microparticles, indicative of potential peripheral 
pulmonary deposition. 
8. In vitro cellular uptake was performed qualitatively using the fluorescence microscope and 
quantitatively using the flow cytometer on murine macrophage RAW 264.7 cells by replacing 
the drugs with fluorescent dye coumarin-6. Neutral DPPC: Chol liposomes showed the 
slowest uptake kinetics. Changing the surface charge of liposomes to negative i.e. DPPC: 
DSPG: Chol liposomes or positive chitosan-coated DPPC: DSPG: Chol liposomes 
significantly improved uptake (rANOVA, p < 0.05) when compared to neutral DPPC: Chol 
liposomes. Moreover, embedding mannosamine in the negatively-charged DPPC: DSPG: 
Chol bilayer or coating with mannosylated chitosan to confer a final positive charge to 
liposomal surface) facilitated uptake as compared to both neutral liposomes and negatively-
charged non-targeted liposomes. Hence, cellular uptake studies validated the hypothesis of 
using actively targeted nanocarrier systems for delivering tubercular drugs directly to the 
alveolar macrophages, where the TB bacilli infects and resides. 
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5.1    Introduction 
5.1.1 Neurological effects of curcumin  
Curcumin (Figure 5.1) is a naturally occurring polyphenol extracted from the dried ground 
rhizome of Curcuma longa commonly known as turmeric.  
 
Figure 5.1: Structure of curcumin 
Table 5.1: Physicochemical properties of curcumin 
 
 
 
 
 
 
 
Pharmacological and therapeutic benefits of curcumin are restricted due to its pharmacokinetic 
properties (Table 5.1) especially its hydrophobic nature, leading to delivery issues of low oral 
absorption and poor bioavailability, extensive metabolism and rapid elimination [446]. Hence, to 
overcome these and increase its bioavailability its entrapment within nanocarriers such as 
liposomes, cyclodextrins and polymeric nanoparticles has been researched extensively [446]. 
Moreover, encapsulation of curcumin can protect the drug from degradation and metabolism 
along with improving drug efficacy, specificity, tolerability and therapeutic index [446]. 
Furthermore, drug targeting to the site of interest can be achieved by passive targeting of curcumin 
encapsulated nanocarriers e.g. enhanced permeability and retention (EPR) effect in cancer or 
active targeting to the upregulated receptors by means of ligands e.g. folic acid/CD44 receptor 
targeting in cancer and mannose receptors on macrophages for tuberculosis and rheumatoid 
arthritis.  
Curcumin and brain cancer 
Curcumin has diverse pharmacological effects such as anti-inflammatory, antimicrobial, 
neuroprotection, antioxidant and anticancer, hence, has diverse therapeutic application for 
diseases like diabetes, Alzheimer’s disease, Parkinson’s disease, stroke, inflammatory bowel 
conditions, arthritis, glioblastoma and lung cancer. The underlying mechanisms of these effects 
are dependent on the regulation of multiple targets. Curcumin has the ability to intervene in 
molecular and biochemical cascades by directly binding and modulating receptor activity by 
means of upregulation or downregulation, or indirectly regulating receptor function [446–448].  
Molecular 
formula 
C21H20O6 
pKa 8.54 
Molecular 
weight 
368.385 g/mol 
Solubility 
Insoluble in water and ether 
Soluble in ethanol, acetone and 
chloroform 
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Its cancer growth prevention and tumor growth suppression properties has been attributed to its 
strong free radical scavenging and anti-inflammatory effects. Specifically, curcumin supresses 
nuclear factor kappa B (NF-κB) and activates extracellular-signal-regulated kinase pathways 
ultimately leading to suppression of cancer [449]. It has the ability to completely block the 
activation of NF-κB by blocking the IκK-mediated phosphorylation and degradation of IκBα in 
the cytoplasm. As a consequence, binding between NF-κB and IκBα is altered and thus NF-κB is 
not able to enter the nucleus to activate RNA transcription [449]. 
The numerous molecular targets of curcumin conferring its anticancer properties in brain cancer 
has been outlined in Figure 5.2. 
 
Figure 5.2: Molecular targets of curcumin (turmeric) in brain cancer [450] 
5.1.2 Neurological effects of CNB001 
CNB001 (Figure 5.3) i.e. 4-((1E)-2-(5-(4-hydroxy-3-methoxystyryl-)-1-phenyl-1H-pyrazoyl-3-
yl) vinyl)-2-methoxy-phenol, a novel pyrazole derivative of curcumin was synthesized by Salk 
Institute for Biological Sciences (California, USA). This molecule is a hybrid of two 
neuroprotective drugs namely, curcumin and cyclohexyl bisphenol A, and has improved CNS 
bioavailability, demonstrating neuroprotection superior to curcumin in vivo in diseased models of 
Alzheimer’s and Parkinson’s disease [451,452].  
 
Figure 5.3: Structure of CNB001 
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Table 5.2: Physicochemical properties of CNB001 
 
 
 
 
 
 
Curcumin has shown to exhibit excellent neuroprotection of dopaminergic neurons in vitro due 
to its potential effects on ROS formation, ATP production and mitochondrial membrane potential  
[451,452]. However, due to low bioavailability in the CNS on parenteral administration, owing 
to reduced passage through the BBB, it fails to inhibit excitation of neurons and consequently 
apoptosis [451,452]. CNB001 shows superior neuroprotection to parent molecules in vitro and in 
vivo, due to superior inflammatory properties of CNB001 by suppression of interlukin-6, 
interlukin-13, TNF-α and serine peptidase inhibitor clade E (SERPINE1) studied on normal 
human bronchial epithelial cells [453]. In vitro CNB001 has lower EC50 for tropic factor 
withdrawal, glucose starvation, oxidative stress, excitotoxicity, intracellular and extracellular 
amyloid inhibition and hence superior neuroprotective effect [454].  
Since, bioavailability of curcumin and CNB001 would largely be dictated by the transport of 
molecules across the nasal olfactory epithelium in the present study and not by the passage 
through the BBB on parenteral administration, both curcumin and CNB001 were used as 
neuroprotective molecules. 
5.1.3 Nanotechnology and curcumin 
CNB001 has not been previously delivered in a nanocarrier-based system in vitro or in vivo, 
however, nanocarrier-based curcumin has been extensively researched. Nanocarrier encapsulated 
curcumin for treatment of neurological disorders like brain cancer and neuroprotection are outline 
in Table 5.3. 
  
Molecular 
formula 
C27H24N2O4 
pKa Not reported (hydrophobic) 
Molecular 
weight 
440.49 g/mol 
Solubility Insoluble in water Soluble in DMSO  
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Table 5.3: Nanocarrier therapies under investigation for delivery of curcumin for treatment of neurological 
disorders 
Formulation Effective against Treatment outcome(s) 
Solid lipid nanoparticles 
Precirol, Capmul MCM, Tween 80, 
soya lecithin 
 
Curcumin 
[235] 
Astrocytoma-
glioblastoma 
Significantly higher drug 
concentration of curcumin 
encapsulated in NLCs in the brain 
after intranasal administration as 
compared to plain drug suspension 
was reported  
Dendrosomes 
 
Curcumin 
[455] 
 
Glioblastoma Significantly inhibits glioblastoma 
proliferation 
Synergistic delivery of 
dendrisome curcumin with p53 
overexpression enhanced 
apoptotic cells by 90% as opposed 
to 38% for dendrisome curcumin 
alone 
Lactoferrin nanoparticles  
 
Curcumin 
[456] 
Neuroprotection Greater intracellular uptake, 
sustained retention and superior 
neuroprotection in vitro as 
compared to curcumin alone 
Polymeric nanoparticles 
NanoCurcTM 
N-isopropylacrylamide, 
vinylpyrrolidone and acrylic acid  
Curcumin 
[457] 
Neuroprotection-  
Alzheimer’s 
disease 
NanoCurcTM protects and rescues 
SK-N-SH cells from reactive 
oxygen species- hydrogen 
peroxide insult 
PLGA nanoparticles 
 
Curcumin 
[458] 
Neuroprotection- 
Alzheimer’s 
disease 
Inhibits amyloid aggregates and 
reactive oxygen species, 
responsible for neuroprotection in 
vitro in glioma cells 
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5.2     Aims and Objectives 
The present investigation was aimed towards the development of non-ionic surfactant micelles 
for incorporation of drugs curcumin and CNB001 to be targeted to the brain via the nose, to 
enhance therapeutic efficacy of the drugs by by-passing the blood brain barrier (BBB). 
Hence, the aim of the study was  
• To engineer Kolliphor® micelles for the delivery of hydrophobic drugs curcumin or CNB001, 
prepared by thin film hydration 
• To design and develop aerosol formulations and study parameters that dictate aerosolization 
efficiency 
• To investigate the effect of formulation development of Kolliphor® TPGS micelles 
incorporating curcumin targeted to the mitochondria, on the quantitative in vitro cellular 
cancer growth inhibition in the neuroblastoma SH-SY5Y and lung adenocarcinoma A549 cell 
lines 
• To investigate the effect of formulation development of Solutol® HS 15 (Kolliphor® HS 15) 
micelles incorporating CNB001 or curcumin, on the quantitative and qualitative in vitro 
cellular Parkinson’s disease model insulted with neurotoxin 6-hydroxydopamine, developed 
on the neuroblastoma SH-SY5Y cell line 
The various nanocarrier formulations investigated in the present chapter are shown below: 
(A) Solutol® HS 15 (Kolliphor® HS 15) micelles incorporating hydrophobic neuroprotective 
agent’s curcumin or CNB001 
 
 
 
 
 
 
Solutol® HS 15 (Polyethylene glycol (15)-hydroxystearate, Kolliphor® HS 15) has been shown to 
be neuroprotective in rat models of cerebral ischemia, and hence its use in preparation of micelles 
incorporating hydrophobic potentially neuroprotective molecules was investigated [459].  
 
(B) Kolliphor® TPGS micelles incorporating hydrophobic cancer chemotherapeutic 
curcumin targeted to the mitochondria 
Kolliphor® TPGS (D-α-tocopherol polyethylene glycol 1000 succinate) has been shown to induce 
apoptosis in cancer cell lines as well as to reverse multi-drug resistance in lung cancer,  and hence 
was chosen as the surfactant of choice for preparation of micelles incorporating cancer drugs 
[460,461]. Targeting of the formulations to the mitochondria was intended to further improve the 
Solutol® HS 15 micelles 
encapsulating CNB001/curcumin
CNB001/ 
Curcumin
Hydrophilic residues
Hydrophobic residues
Solutol® HS 15
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delivery of the curcumin to the cancer cell mitochondria by incorporating dequalinium, a cationic 
mitochondrial targeting agent [462]. 
Hydrophobic residues
TPGS Dequalinium micelles 
encapsulating Curcumin
 
. 
  
Hydrophilic	residues	
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5.3    Materials 
Curcumin ≥ 95.0% curcuminoid content (from Tumeric rhizome) with molecular weight of 
368.39 g/mol was purchased from Alfa Aesar UK (Lancashire, UK). CNB001 with molecular 
weight of 440.49 g/mol was purchased from Salk Institute for Biological Sciences (California, 
USA). Non-ionic surfactants Kolliphor® HS 15 (also known as Solutol® HS 15, Polyethylene 
glycol (15)-hydroxystearate) and Kolliphor® TPGS (D-α-tocopherol polyethylene glycol 1000 
succinate) were purchased from BASF (Cheshire, UK) and used without further purification. 
Cholesterol, sodium dodecyl sulphate (SDS), acetic acid, sodium chloride, potassium chloride, 
calcium chloride dihydrate were purchased from Sigma-Aldrich (Poole, UK). 
For in vitro cell culture studies fetal bovine serum (FBS), Roswell Park Memorial Institute 
(RPMI) 1640, Minimum Essential Medium Eagle (MEM), Ham's F12 Nutrient Mixture, 
penicillin-streptomycin, L-glutamine, non-essential amino acids and PBS pH 7.4 were purchased 
from ThermoFisher Scientific (Loughborough, UK). 6-hydroxydopamine, 2′,7′-
dichlorofluorescin diacetate, bisBenzimide H 33258 (Hoechst) ≥98%, (3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide (MTT reagent), sulforhodamine B sodium salt, Trizma® 
(TRIS base) and trichloroacetic acid were purchased from Sigma-Aldrich (Poole, UK). 
HPLC grade water, acetonitrile and dimethyl sulfoxide (DMSO) were purchased from Fisher 
Scientific (Loughborough, UK).  Deionized water was used throughout the experiments unless 
specifically mentioned. All other reagents used were of analytical grade.   
5.4    Methods 
5.4.1 Preparation of CNB001 or curcumin incorporated Kolliphor® micelles 
The surfactant/polymer was selected for each study to achieve a good encapsulation of the 
hydrophobic drug along and based on the end-use of the formulation i.e. Kolliphor® TPGS for 
cancer formulations and Solutol® HS 15 for neuroprotection formulations. 
50 mg of non-ionic surfactant (Kolliphor® TPGS or Solutol® HS 15) and 5 mg of drug (CNB001 
or curcumin) were dissolved in 20 mL methanol:chloroform 1:1. For preparation of stable 
Solutol® HS 15 micelles, cholesterol at different molar ratios was added at this stage. Moreover, 
for Kolliphor® TPGS micelles intended for delivery of cancer chemotherapeutics, the 
mitochondrial targeting moiety dequalinium chloride was added at different molar ratios in 
organic solvent. The organic solvent was removed under vacuum using a rotary evaporator KNF 
RC 900 (KNF Neuberger UK, Oxfordshire, UK) at 60 °C and 200 rpm for 20 min. A dried thin 
and homogeneous film was obtained and was further dried under a stream of nitrogen gas for 20 
min to ensure complete removal of residual solvent. The film was then hydrated using 20 mL of 
acidified deionised water (0.2% glacial acetic acid, pH 3.14) at 60 °C and 250 rpm for 20 min, 
and was finally bath sonicated (Clifton M-14 ultrasonic bath sonicator, Progen Scientific, 
London) for 15 min. 
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5.4.2 Formulation characterization 
5.4.2.1 Determination of particle size and zeta potential (surface charge) using Malvern 
Zetasizer 
The hydrodynamic diameter and the polydispersity index (PDI) of the micellar formulations were 
measured by DLS and the zeta potential was measured by laser Doppler velocimetry using 
Malvern Zetasizer Nano ZS (Malvern Instruments Inc., UK) as described in chapter 2, section 
2.1. 
5.4.2.2 High-performance liquid chromatography (HPLC) and analytical method 
validation for determination of CNB001 and curcumin 
The encapsulation efficiency of CNB001 or curcumin in Solutol® HS 15 micelles and 
encapsulation efficiency of curcumin in Kolliphor® TPGS, was determined with HPLC using an 
Agilent 1260 infinity series HPLC (Agilent Technologies UK Ltd., UK), equipped with an 
ultrasensitive diode array UV detector, G1329A auto sampler and a highly efficient quaternary 
pump. For this study a new, rapid, sensitive, precise and accurate method was developed, which 
gave reproducible results and chromatograms with sharp peaks and a stable baseline.  
10 µL curcumin samples were eluted with the mobile phase comprising of 50:50 0.1% 
trifluoroacetic acid in HPLC grade water: HPLC grade acetonitrile at a flow rate of 1 mL/min 
using an isocratic elution method. Separation was performed using a Phenomenex 250 mm×4.6 
mm, 4 µm Synergi Polar-RP C18 column (Phenomenex Inc., Cheshire, UK) with a UV detection 
wavelength of 420 nm, using a column compartment temperature of 40°C.  
For CNB001, 10 µL samples were eluted with the mobile phase comprising of 40:60 0.1% 
trifluoroacetic acid in HPLC grade water: HPLC grade acetonitrile at a flow rate of 1 mL/min 
using an isocratic elution method. Separation was performed using a Phenomenex 250 mm×4.6 
mm, 4 µm Synergi Polar-RP C18 column (Phenomenex Inc., Cheshire, UK) with a UV detection 
wavelength of 326 nm, using a column compartment temperature of 40°C.  
The HPLC method developed for curcumin and CNB001 was validated for linearity, accuracy 
and precision; to ascertain that the method adapted was robust and without error. The validation 
method based on ICH recommendations is described in Chapter 2 for HPLC analytical validation, 
section 2.7. 
A standard curve (calibration curve) was constructed individually for curcumin and CNB001 
before each sample analysis in triplicate using the same method of HPLC analysis as that intended 
for the formulations. Concentrations of the standard tested were 1.0-50 µg/mL for curcumin and 
1.25-30 µg/mL for CNB001, and peak area as an average of the triplicates was used to derive the 
standard equation and correlation coefficient (R2) of the line of best fit by least square regression 
method. The equation was then considered linear if the R2 value was approximately 1 and used 
for calculation of concentration of curcumin or CNB001 encapsulated in the micelles. 
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5.4.2.3 Determination of drug encapsulation efficiency of the micellar formulations 
Encapsulation efficiency of the formulations after preparation was determined using HPLC to 
quantify curcumin or CNB001 solubilized in the micellar formulations. Dilutions of the 
formulation following removal of unsolubilized drugs by filtration (0.22 µm mixed cellulose 
esters syringe-driven filter (Millex MP, Ireland)) was performed by diluting approximately 50 
times in methanol to obtain a solution concentration appropriate for HPLC measurement as per 
the Beer-Lambert law. The solutions were filtered into HPLC vials and quantified as described 
(section 5.4.2.2). The peak areas for curcumin or CNB001 from the formulations were used for 
calculation of the encapsulation efficiency of drug using linear regression equations from 
calibration curve with correlation coefficients of 0.9999 and 1.0000 for curcumin and CNB001 
respectively. Encapsulation efficiency was expressed as a percentage using equation 5.1: !"#$%&'($)*+"	-..*#*-"#/(%) = 45$#)*#$((/	6-)-57*"-6	$7+'")	+.	65'8		*"	.+57'($)*+"97+'")	+.	65'8	*"*)*$((/	:-*8ℎ-6	 ×100 
 
5.4.2.4 Laser diffraction aerosol droplet size analysis 
Nasal spray droplet measurement size was performed by laser diffraction studies using a Malvern 
Spraytec® (Malvern Instruments Inc., UK) with RT Sizer software in an open bench 
configuration. The Nasal™ Mucosal Atomization Device (Nasal™ MAD) was used as it has the 
capability to aerosolize medicament to the posterior mucosal surfaces of the nose and hence target 
the brain. The method employed was modified from earlier studies to suit the Spratyec®, device 
and nano-formulations under study, as this combination has not been studied before [463,464]. 
Prior to measurement initiation, the device was primed by firing 3 actuations to waste. 0.4 mL of 
nano-formulations were withdrawn into a 1 mL syringe and leur-locked onto the atomization 
spray plug of the device (Figure 1.7). This was then mounted at a 3 cm distance from the laser 
beam (He-Ne Laser, 632.8nm) at an angle of 45° to allow firing in an upward self-administration 
fashion. Droplet size distribution was studied at 25°C by laser diffracted using 6 actuations per 
formulation and plotted as a volume weighted average distribution from which Dv10, Dv50 and 
Dv90 (10%, 50% and 90% of the cumulative volume undersize) were calculated. Span was 
calculated using equation 5.2:  Span=	CDEFGCDHFCDIF 	
To ascertain the effect of aerosolization on the size of micelles incorporating drug, change in 
particle size using laser diffraction studies on the Malvern Zetasizer was studied before and after 
the formulation was aerosolized using the Nasal™ MAD in to glass vials. 
5.4.2.5 In vitro drug release from micelles 
The release of curcumin from the Solutol® HS 15 or Kolliphor® TPGS micelles and CNB001 
from the Solutol® HS 15 micelles was determined using Franz diffusion cells (PermeGear, PA, 
Equation 5.1 
Equation 5.2 
Chapter 5| Kolliphor® micelles for nose-to-brain delivery  
 
201	
	
USA) with a surface area of 0.64 cm2 and a receptor chamber volume of 5 mL mounted with 
mixed cellulose acetate/cellulose nitrate membrane (Merck Millipore, England, UK). The 
receptor compartment was filled with simulated nasal electrolyte fluid at pH 6.5 containing 
potassium, calcium and sodium at biological human nasal fluid concentrations [465]. 2% SDS 
was added to obtain ‘sink conditions’ to enhance the solubility of the hydrophobic curcumin or 
CNB001 released from the micelles into dissolution medium. 250 µL of micelles were placed in 
the donor compartment and drug release was studied at 37 °C under magnetic stirring at 300 rpm. 
At predetermined time points (0, 1, 2, 4, 6, 8, 10, 12, 24, 30, 36 h), 200 µL aliquots was taken 
from the receptor arm and replaced with an equivalent amount of fresh release medium. The 
aliquots were assayed for the drug using HPLC and studies were replicated four times to obtain 
the drug release plots of cumulative release with respect to time as a mean ± SD. 
The kinetics of drug release from the polymeric micelles was studied by fitting the data to the 
following mathematical models. 
 
Zero-order model: This model assumes that drug release from the nano-formulations is 
independent of concentration or time, and hence follows a steady state kinetics [466–468], 
described by equation 5.3: Qt=ko×t  
where Qt is the cumulative amount of drug released (%) at time t and K0 is the zero-order rate 
constant of drug release expressed in units of concentration/time. A plot of cumulative drug 
release (%) versus time was plotted and the regression coefficient was calculated. 
 
First-order model: This model assumes that drug release from the nano-formulations is 
dependent on the initial concentration of drug present and time, and hence follows an exponential 
reduction within the system [466–468], described by equation 5.4:  N" 100 − P)100 = QH	×	) 
where K1 is the first-order rate constant at time t. A plot of log cumulative drug remaining (%) 
versus time was plotted and the regression coefficient was calculated. 
5.4.2.6 In vitro cytotoxicity studies for neuroprotective and cancer formulations 
Cytotoxicity of CNB001 and curcumin when encapsulated within Solutol® HS 15 micelles was 
determined to ascertain the maximum non-toxic concentration (MNTC) of the respective 
formulations after 24 and 48 h incubation, using the sulforhodamine B (SRB) assay [469]. The 
MNTC or the maximum tolerable dose i.e. the Ec80 is the maximum dose at which the 
encapsulated neuroprotective molecules would show neuroprotection without false negative 
outcomes of toxicity (since the cell line used is a neuroblastoma cell line SH-SY5Y and curcumin 
or CNB001 also possess cancer activity).  
Equation 5.3 
Equation 5.4 
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Further, cytotoxicity of curcumin encapsulated within Kolliphor® TPGS micelles was determined 
to ascertain the Ic50 i.e. drug concentration at which 50% cell death was evident using the 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. Since the Kolliphor® TPGS 
formulations incorporating curcumin were intended to be targeted to the mitochondria, MTT 
assay would be appropriate as it directly reads the mitochondrial dehydrogenase activity. 
 
SH-SY5Y cells: Complete media composition for SH-SY5Y cells was basal medium 1:1 MEM: 
Ham’s F-12 supplemented with 10% FBS, 1% penicillin-streptomycin, 1% non-essential amino 
acids and 1% L-glutamine. For both the SRB and MTT assay, dopaminergic like human 
neuroblastoma SH-SY5Y cells were seeded at a density of 1x105 cells in 96-well plates and 
cultured till 80 % confluency for 48 h at 37°C, 5% CO2. The media was then replaced with the 
different serially diluted treatments in complete media (curcumin and CNB001 dissolved in 0.1% 
DMSO in complete media) with 0.1% DMSO in complete media as a blank, and further incubated 
for 24 and 48 h.  
 
A549 cells: For studying the anticancer activity of the formulations, the human lung 
adenocarcinoma cell line A549 was used (to validate the anticancer activity and hence 
effectiveness of the formulations on more than one cell line). Complete media composition for 
A549 cells was basal medium RPMI-1640 supplemented with 10% FBS, 1% penicillin-
streptomycin and 1% L-glutamine. A549 cells were seeded at a density of 1.25x105 cells in 96-
well plates and cultured till 80% confluency for 24 h. The media was then replaced with the 
different serially diluted treatments in complete media (curcumin dissolved in 0.1% DMSO in 
complete media) with 0.1% DMSO in complete media as a blank, and further incubated for 48 h.  
 
For the SRB assay (neuroprotection), at the end of the incubated period, cell fixation was carried 
out by addition of 50 µL of 40% trichloroacetic acid to each well supernatant for 1 h at 4°C. The 
plates were then washed with deionized water four times and were allowed to air-dry at 25 °C 
overnight. Cell staining was carried out by addition of 100 µL of 0.057% of SRB solution and 
left at room temperature for 1 h. The plates were washed with 1% acetic acid solution to remove 
the unstained SRB reagent four times and allowed to air-dry. 200 µL of 10 mM Tris base (pH 
10.5) was added to solubilize the protein bound SRB dye and optical density (OD) was measured 
by spectroscopy (SpectraMAX Plus 384, Molecular Devices, Berkshire, UK) at 510 nm after 
shaking the plates mechanically for 5 min.  
For the MTT assay (cancer), at the end of the incubation period the treatments from all the wells 
were removed carefully and 50 µg/mL MTT solution (stock of 5 mg/mL MTT salt in PBS, pH 
7.4) diluted in complete media was added to each well. After further incubation of 2 h in a 
humidified atmosphere (37°C, 5% CO2), the medium was carefully removed and any formazan 
crystals generated were solubilized with 100 µL of DMSO. Thereafter, the OD was measured 
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using spectroscopy (SpectraMAX Plus 384, Molecular Devices, Berkshire, UK) at 570 nm after 
shaking the plates mechanically for 2 min.  
The relative cell viability (%) was calculated using equation 5.5 as follows:  R-((	S*$T*(*)/	 % = 	 UV	+.	)-&)	:-((UV	+.	5-.-5-"#-	:-(( 	×100 
The cell viability was presented as percentage of control cells and a dose-response curve of cell 
viability vs log (concentration) was plotted for accurate determination of Ec80/Ic50 for each 
treatment. 
5.4.2.7 In vitro Parkinson’s disease model development 
Neurotoxin 6-hydroxydopamine-insulted dopaminergic-like human neuroblastoma SH-SY5Y 
cells have been shown to be a suitable experimental model to study in vitro Parkinson’s disease 
(PD) in previous studies [470,471]. To determine the neuroprotection potential of CNB001 or 
curcumin encapsulated Solutol® HS 15 micelles, a PD model was developed.  
SH-SY5Y cells were seeded at a density of 1x105 cells in 96-well plates and cultured till 80% 
confluency for 48 h. Thereafter media was carefully removed and serially diluted neurotoxin 6-
hydroxydopamine (stock prepared in PBS pH 7.4, 2 mg/mL, 11822 µM) in complete media was 
added to insult the neuroblastoma cells. After 24 h, cell viability at the different concentrations 
was determined using the SRB assay as in section 5.4.2.6 and the Ic50 of 6-hydroxydopamine 
insult, i.e. the concentration that reduced viability of cells to about 50% was determined by 
plotting a dose-response curve of cell viability versus log (concentration of neurotoxin). This 
concentration of neurotoxin 6-hydroxydopamine was used further for the neuroprotection assays. 
5.4.2.8 Protective effects of Solutol® HS 15 micelles incorporating curcumin and CNB001 
on in vitro PD model: Neuroprotection assay 
SH-SY5Y cells were seeded at a density of 1x105 cells in 96-well plates and cultured till 80% 
confluency for 48 h. Thereafter media was carefully removed and 100 µL of serially diluted 
micellar formulations below the maximum non-toxic concentration of the drugs, i.e. 18 µM of 
curcumin or CNB001, were added to the cells, taking into consideration the critical micellar 
concentration of the formulations. The cells were incubated at 37°C, 5% CO2 for 2 h, after which 
the cells were insulted with 100 µL of 30 µM neurotoxin 6-hydroxydopamine (added on top of 
the formulations already present) for 24 h. Negative controls comprised cells only treated with 
formulations and not insulted with neurotoxin thereafter. The concentration of the formulations 
and neurotoxin was adjusted taking into consideration the final volume of the well on addition of 
all reagents. After 24 h, the SRB assay (section 5.4.2.6) was performed to determine the cell 
viability to ascertain the effect of formulations on protection of insulted neuroblastoma cells. Cell 
viability of cells insulted and/or treated was calculated as a percentage of the viability of control 
cells in the reference well. 
Equation 5.5 
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5.4.2.9 Protective effects of Solutol® HS 15 micelles incorporating curcumin and CNB001 
on in vitro PD model: ROS formation assay 
For determination of cellular reactive oxygen species (ROS), a fluorescent-based assay was 
carried out in black plates and under dark conditions throughout. SH-SY5Y cells were seeded at 
a density of 1x105 cells in 96-well plates and cultured till 80% confluency for 48 h. Thereafter 
media was carefully removed and 100 µL of serially diluted micellar formulations below the 
MNTC of the drugs, were added. The cells were incubated at 37°C, 5% CO2 for 2 h, after which 
the cells were insulted with 100 µL of 30 µM neurotoxin 6-hydroxydopamine (added on top of 
the formulations already present) for 1 h. Thereafter, 50 µL of probe 10 µM 2,7-
dichlorofluorescein diacetate (DCFH-DA) was added and the cells were further incubated. In the 
presence of an oxidant like ROS, DCFH-DA is taken up by the cells and is converted to a highly 
fluorescent molecule dichlorofluorescein which can be measured quantitatively on the 
fluorescence plate reader. A kinetic experiment was performed wherein ROS production was read 
at intervals of 4, 6, 8, 12, 16, 20 and 24 h, incubating the plates in the dark in between. At each 
time-point, fluorescence was measured spectrometrically on a fluorescence microplate reader 
(SpectraMAX Plus 384, Molecular Devices, Berkshire, UK) at excitation and emission 
wavelengths of 485 nm and 520 nm respectively. Each experiment was performed five 
independent times and results for the ROS production on treatments were expressed as: 
 ROS	production %= FD	of	treated	&	insulted	cells − FD	of	treated	cells + FD	of	CM − FD	of	reference	wellFD	of	reference	well 		×100 
 
where CM is complete media and FD is fluorescence density.  
 
The FD of treated cells without insult was taken into consideration as curcumin is a naturally 
fluorescent molecule and hence would result in false negative results due to the higher intensity 
contributed by the innate fluorescence of curcumin. FD of complete media was considered so as 
to eliminate any interaction in fluorescence intensity from the media. 
The FD of insulted cells without treatment was expressed as:  
 ROS	production	 % = 	 FD	of	insulted	cells − FD	of	CM − [FD	of	reference	well]FD	of	reference	well 	×100 
 
5.4.2.10 Nuclear staining for assessment of apoptosis: Hoechst staining 
The nuclear morphology of the apoptotic cells was investigated by staining with chromatin-
specific dye; Hoechst 33258.The SH-SY5Y cells were seeded on Nunc™ Lab-Tek™ II Chamber 
Slides™ (ThermoFisher Scientific, Paisley, UK) and cultured till 80% confluency for 24 h at 
Equation 5.6 
Equation 5.7 
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37°C, 5% CO2. The media was then replaced with 18 µM of the neuroprotective drugs or drugs 
encapsulated in Solutol® HS 15 micelles and incubated for 2 h. These treated cells were then 
insulted by addition of 30 µM of neurotoxin 6-hydroxydopamine (added on top of the 
formulations already present) for 24 h. The media was removed after 24 h and the cells were fixed 
for 10 min with 4% paraformaldehyde in PBS at room temperature. The cells where then rinsed 
with PBS, pH 7.4 three times and subsequently stained with 10 µg/mL Hoechst 33258 in PBS, 
pH 7.4 for 10 min at 37°C. The stain was rinsed off with PBS three times and the mounted slides 
were visualized under EVOS™ Fluorescence Cell Imaging System using the DAPI filter (360 nm 
excitation, 447 nm emission) under 20X magnification and phase contrast annuli 4/10 condenser. 
To semi-quantify the fluorescence intensity of cells to distinguish between apoptotic cells and 
non-apoptotic cells, image processing program ImageJ v1.48 (National Institute of Health, USA) 
was used. 
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5.5    Results and Discussion 
5.5.1 Formulation characterization 
5.5.1.1 High-performance liquid chromatography (HPLC) and analytical method 
validation for determination of CNB001 and curcumin 
Linearity: The data for HPLC calibration curves of curcumin and CNB001 fitted into the linear 
equations y=60.117x–4.3765 and y=73.653x-10.2370 respectively (where x=concentration of 
analyte and y=area under curve) and being in the concentration range under study i.e. 1.0-50 
µg/mL and 1.25-30 µg/mL for curcumin and CNB001 respectively, as shown in Figure 5.4 and 
Figure 5.5. A regression analysis was performed and correlation coefficient R2 of 0.9999 and 1.00 
(for curcumin and CNB001 respectively) indicated linear relationship between peak area and 
concentration of drug analyzed.  
	
 
Figure 5.4: Calibration curve of curcumin analyzed by HPLC (n=5, mean ± SD) 
  
Figure 5.5: Calibration curve of CNB001 analyzed by HPLC (n=5, mean ± SD) 
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Parameters determining linearity from HPLC analysis are shown in Table 5.4. 
Table 5.4: Linearity parameters for HPLC analysis method of curcumin and CNB001 
Parameters Results (Curcumin) Results (CNB001) 
λmax 420 326 
Linearity range 1.0-50 µg/mL 1.25-30 µg/mL 
Regression equation y=60.117x–4.3765 y=73.653x-10.2370 
Correlation coefficient 0.9999 1.00 
Retention time 10.49 min 7.25 min 
Limit of detection (LOD)  0.27 µg/mL 0.11 µg/mL 
Limit of quantification (LOQ) 0.89 µg/mL 0.38 µg/mL 
 
Representative chromatograms of curcumin and CNB001, and validation for accuracy and 
precision of HPLC method is as seen in Appendix 1, A1.3 
5.5.1.2 Solutol® HS 15 micelles incorporating curcumin or CNB001  
5.5.1.2.1 Morphology investigation and particle size analysis 
Solutol® HS 15 micelles, with and without cholesterol, incorporating curcumin/CNB001 were 
formed within the size range of 15-100 nm (Figure 5.6). The size of CNB001 or curcumin 
encapsulated Solutol® HS 15 micelles without cholesterol were in good correlation with the size 
of Solutol® HS 15 micelles developed in previous studies [472,473].  
With an increase in cholesterol content in the Solutol® HS 15 micelles there was an increase in 
mean size as evident by the intensity size distribution Z-average seen in Figure 5.6. 
 
Figure 5.6: Size and encapsulation efficiency for the Solutol® HS 15 micelles with varying concentrations of 
cholesterol prepared by thin-film hydration, at a concentration of 2.5 mg/mL polymer. (n=3, mean ± SD) 
The structure and physical properties of a non-ionic surfactant vesicles has been shown to be 
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opposed to micelles [474]. It modulates their fluidity, rigidity, mechanical strength and cohesion, 
consequently their permeability to water [474]. At a particular molar ratio of cholesterol: non-
ionic surfactant micelles start to convert into niosomes However, preparation of niosomes 
requires higher amount of cholesterol relative to non-ionic surfactant as previously reported to be 
1:1-1:2 molar ratio surfactant: cholesterol [475–477]. 
Addition of cholesterol in general, has resulted in an increased encapsulation efficiency of 
primaquine phosphate and pregabalin in Span 60 vesicles due to hydrogen bond interactions as 
seen in Figure 5.7 [474,478]. Similarities in structure of Span 60 with Solutol® HS 15 suggests 
that cholesterol could stabilize the micelles and improve the encapsulation of neuroprotective 
molecules by forming hydrogen bond interactions with the oxoethylene bridge of Solutol® HS 15. 
  
Figure 5.7: Structural interaction between cholesterol and oxoethylene bridge of (A) Span 60, (B) Solutol® HS 
15 
As HLB of surfactant increases above 10, cholesterol is required to stabilize the micelles by 
interactions with the larger head groups [474,479]. Brij et al. studied the effect of presence of 
cholesterol on the stability of non-ionic surfactants incorporating insulin with varied HLB 4.9-
16.9 [479]. Vesicles with higher HLB values 15.7 and 16.9 could not spontaneously form without 
cholesterol due to a mismatch between the volume of hydrophilic and hydrophobic chains [479]. 
Addition of cholesterol to higher HLB vesicles prepared by thin film hydration method showed a 
better encapsulation of insulin and stability. Moreover, there was no significant increase in 
entrapment of drug with increasing cholesterol prepared with lower HLB (4.9 and 5.3) non-ionic 
surfactants. Since, the HLB of Solutol® HS 15 is 15.2, cholesterol was added to improve the 
stability of the micelles and study the effect of increasing molar concentration of cholesterol on 
encapsulation of hydrophobic drugs curcumin and CNB001. 
TEM images were studied to evaluate the morphology of the micelles, and to gain a better 
understanding into the vesicle system generated on addition of cholesterol. For the Solutol® HS 
15 micelles without cholesterol incorporating curcumin or CNB001, the micelles were spherical, 
well dispersed and size was in good correlation to the peak of hydrodynamic diameter obtained 
using the DLS of around 16-18 nm as seen in Figure 5.8 and Figure 5.9. 
 
 
 
A B 
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Figure 5.8: TEM images of curcumin encapsulated Solutol® HS 15 micelles cholesterol (A) and CNB001 
encapsulated Solutol® HS 15 micelles without cholesterol (B) 
 
  
 
 
Figure 5.9: Size distribution by intensity (1) and volume (2), of Solutol® HS 15 micelles without cholesterol 
incorporating (A) curcumin and (B) CNB001  
For the Solutol® HS 15 micelles with 15% mole cholesterol incorporating neuroprotective drugs 
curcumin and CNB001, the micelles were spherical and well dispersed (Figure 5.10). Size 
distribution by intensity as analyzed by the DLS shows the presence of 2 peaks at around 110-
140 and 15-23 nm (Figure 5.11A-1 and Figure 5.11B-1). Two-sized vesicles with a similar size 
can also be seen in the TEM images (Figure 5.10). Addition of cholesterol to non-ionic surfactants 
has been proposed to prepare niosomes, i.e. bilayered vesicles that have greater particle size and 
stability like liposomes, but are low cost and easy to prepare [476]. Niosomes incorporating 
curcumin were prepared by addition of cholesterol at a 50% molar concentration to Tween 20 
(HLB=16.7) [476]. The size of the niosomes were around 100 nm as measured by DLS and 
A-1 
B-1 
A-2 
A B 
B-2 
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showed improved stability to temperature due to hydrogen bond interactions between the 
oxoethylene units on the Tween-20 headgroup and the curcumin hydroxyl groups [476].  
Intensity distribution measurement by DLS is naturally weighted as per the scattering of each 
particle and hence larger particle species can dominate the distribution profile in the presence of 
smaller particle species. Thus, conversion of intensity distribution that describes the scattering 
capability of the species to volume distribution describing the volume of each species was 
undertaken. Size distribution by volume (Figure 5.11A-2 and Figure 5.11B-2) shows that smaller 
particles around 14-20 nm dominated (85%) the volume distribution histogram which was in good 
correlation with the sizes observed on the TEM. The larger particles around 100 nm were likely 
bilayered vesicles niosomes that were present in lower amount (volume) compared to the 
micelles, since the maximum amount of cholesterol relative to the non-ionic surfactant was 30% 
mole. As previously mentioned, preparation of niosomes requires higher amount of cholesterol 
relative to non-ionic surfactant as previously reported to be 1:1-1:2 molar ratio surfactant: 
cholesterol [475–477]. 
 
  
Figure 5.10: TEM images Solutol® HS 15 micelles with 15% mole cholesterol incorporating curcumin (A) and 
CNB001 (B) 
 
 
 
 
A B 
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Figure 5.11: Size distribution by intensity (1) and volume (2), of Solutol® HS 15 micelles with 15% mole 
cholesterol incorporating (A) curcumin and (B) CNB001 
For the Solutol® HS 15 micelles with 30% mole cholesterol incorporating CNB001, the micelles 
were spherical and well dispersed as seen in Figure 5.12. Size distribution by intensity as analyzed 
by the DLS shows the presence of 2 peaks at around 140-170 and 19-25 nm (Figure 5.13A-1 and 
Figure 5.13B-1). Two-sized vesicles with a similar size can also be seen in the TEM images. Size 
distribution by volume (Figure 5.13A-2 and Figure 5.13B-2) exhibited that smaller particles 
around 16-22 nm dominated (90%) the volume distribution histogram which was in good 
correlation with the sizes observed on the TEM.  
Hence, Solutol® HS 15 incorporating curcumin or CNB001, in the presence of cholesterol 
produced two-sized vesicular systems dominated by micelles, as evident from the volume size 
distribution and TEM images, hence, the system will be referred to as micelles hereafter. 
  
Figure 5.12: TEM images Solutol® HS 15 micelles with 30% mole cholesterol incorporating curcumin (A) and 
CNB001 (B) 
A-1 A-2 
B-1 B-2 
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5.5.1.2.2 Curcumin or CNB001 encapsulation efficiency in Solutol® HS 15 micelles 
An increase in encapsulation efficiency of CNB001 or curcumin was evident with increasing 
cholesterol, with maximum encapsulation for the Solutol® HS 15 micelles with 15% mole 
cholesterol, as seen in Figure 5.6. An encapsulation efficiency of around 80% was obtained for 
both curcumin and CNB001 in Solutol® HS 15 micelles without cholesterol. The addition of 15% 
mole cholesterol, improved the encapsulation to approximately 100% for curcumin and CNB001. 
This is likely due to the hydrogen bond interaction between the oxyethylene of Solutol® HS 15 
and hydroxyl group of cholesterol. As previously demonstrated, non-ionic surfactants with higher 
HLB cannot spontaneously form stable vesicles, due to a mismatch between the hydrophilic and 
hydrophobic chains [479]. Incorporating cholesterol would improve the stability of the vesicles, 
however, stability studies would be helpful to give a better insight to this. 
5.5.1.3 Kolliphor® TPGS micelles incorporating curcumin 
5.5.1.3.1 Particle size analysis and zeta potential (surface charge) 
Kolliphor® TPGS micelles, with and without dequalinium, incorporating curcumin were formed 
within the size range of 12.51-14.44 nm with no significant difference (p > 0.05) between the 
various formulations (Figure 5.14). This was in good correlation with the size of Kolliphor® TPGS 
micelles described in previous studies [480–482]. It was important to ensure that the targeting 
moiety dequalinium was incorporated into the Kolliphor® TPGS micellar layer rather than 
forming DQAsomes incorporating curcumin separately. The size distributions by intensity for 
curcumin encapsulated in Kolliphor® TPGS:30% mole dequalinium and Kolliphor® TPGS:0% 
mole dequalinium are seen in Figure 5.15A-1 and Figure 5.15B-1. Size distribution by volume 
A-2 
B-2 
Figure 5.13: Size distribution by intensity (1) and volume (2), of Solutol® HS 15 micelles with 30% mole 
cholesterol encapsulating (A) curcumin and (B) CNB001 
A-1 
B-1 
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(Figure 5.15A-2 and Figure 5.15B-2) confirmed that 100% micelles were of size 8.91±0.57 nm 
for curcumin encapsulated in Kolliphor® TPGS:30% mole dequalinium. Curcumin encapsulated 
DQAsomes prepared by thin-film hydration have been studied in literature to have size ranging 
from 170-225 nm depending on the ratio of dequalinium and curcumin [462]. Since there was no 
peak evident in the size distribution data in this range, it is apparent that a mixed micellar structure 
contributed majorly by Kolliphor® TPGS, incorporating dequalinium was achieved. 
 
Figure 5.14: Mean hydrodynamic diameter and zeta potential for the non-targeted and targeted Kolliphor® 
TPGS micelles prepared by thin-film hydration, at a concentration of 2.5 mg/mL polymer. Data are mean ± SD 
(n=3) 
 
   
 
 
 
Cationic peptide nanoparticles stable on intravenous administration reported in literature had a 
CMC value of 0.031 mg/mL (10.1 µM) [483]. Since, the CMC value of Kolliphor® TPGS has 
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been previously reported to be around 0.2 mg/mL (132.2 µM), it is unstable for intravenous 
injection, as the micelles can easily dissociate on excessive dilution in plasma [484]. There are 
several published reports on preparation of mixed micelles of Kolliphor® TPGS with lipids and 
polymers such as DSPE-PEG 2000, Pluronic® P105, Pluronic® P123 and Soluplus®, intended for 
intravenous administration [484–487]. However, administration of the curcumin encapsulated 
Kolliphor® TPGS micelles prepared in this study is proposed for nose-to-brain delivery for the 
treatment of glioma/neuroblastoma, hence these micelles should be relatively stable and not 
dissociate in the low volume nasal fluid. 
The zeta potential is as reported in Figure 5.14. The surface charge was neutral for curcumin 
encapsulated Kolliphor® TPGS micelles without dequalinium. On addition of targeting moiety 
dequalinium there was a significant increase (p < 0.05) in positive charge up to 30% mole of 
dequalinium to Kolliphor® TPGS, after which addition of dequalinium did not result in any 
significant increase (p > 0.05) in zeta potential. This suggests that at a 30% mole dequalinium, 
the Kolliphor® TPGS micelles could no longer incorporate dequalinium into the structure and 
have reached a saturation point; hence any increase would have no more dequalinium 
incorporated and hence no further effect on the charge. The increase in positive charge was due 
to the presence of amine groups in the structure of dequalinium which was now incorporated 
within the neutral Kolliphor® TPGS micellar layer. Therefore, the formulation of curcumin 
encapsulated Kolliphor® TPGS:30% mole dequalinium was taken forward for further studies. 
There was no significant difference evident (p > 0.05) in the mean polydispersity index of the 
various Kolliphor® TPGS micellar formulations, with and without dequalinium, which ranged 
from 0.24-0.28. 
5.5.1.3.2 Curcumin encapsulation efficiency in Kolliphor® TPGS micelles 
Kolliphor® TPGS micelles with and without dequalinium had a high encapsulation efficiency of 
around 100% (Figure 5.16). Compared with Kolliphor® TPGS micelles in previous studies, levels 
of 75-85% have been reported, depending on the drug encapsulated [480,481]. Nonetheless, the 
high encapsulation suggests a strong interaction between curcumin and the hydrophobic core of 
vitamin E within the Kolliphor® TPGS micelles. Furthermore, incorporation of targeting moiety 
dequalinium in the micellar structure did not significantly influence (p > 0.05) the drug loading. 
There was no change in mean size of the micelles, as seen in Figure 5.14, due to a similar amount 
of curcumin encapsulated within the micelles for each formulation. 
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Figure 5.16: Encapsulation efficiency of curcumin in Kolliphor® TPGS micelles with increasing molar ratio of 
dequalinium. Data are mean±SD (n=3) 
5.5.1.3.3 Transmission electron microscopy 
     
Figure 5.17: TEM images of curcumin encapsulated Kolliphor® TPGS micelles without dequalinium (A) and 
with 30% mole dequalinium (B) 
TEM images for curcumin encapsulated Kolliphor® TPGS micelles is shown in Figure 5.17. Both 
formulations showed Kolliphor® TPGS micelles that were spherical, well dispersed and the sizes 
were in good correlation to the DLS results. 
5.5.1.4 Laser diffraction aerosol droplet size analysis  
The FDA requires the use of laser diffraction or cascade impactors for determination of droplet 
size distribution of nasal aerosols [128,464]. Formulation properties such as viscosity and surface 
tension, device design and actuation properties greatly affect the measured aerosol droplet size 
distribution [464]. Average weighted scatter graphs of time-history transmission (%) against time 
(h:m:s) was obtained by the software wherein 3 regions were allocated as shown in Figure 5.18. 
The time-history plots were studied from aerosol droplet formation to final aerosol dissipation 
where drastic fluctuations for laser transmission, Dv10 and Dv50 were evident in region 1 and 3 
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with a prominently stable region 2. Post-actuation of aerosol from the device, there was a fall in 
transmission evident due to rapidly rising aerosol droplet concentration known as the ‘formation 
phase’. The ‘fully developed phase’ which followed had a stable droplet flow value and hence 
transmission, indicating stable aerosol particle size and concentration. Thus region 2 was chosen 
to study the droplet size distribution for comparative analysis, as recommended by the FDA. As 
the dose was delivered and the device was emptied droplet concentration and flow rate dropped 
to zero and laser transmission increased giving rise to the ‘dissipation phase’. 
  
 
Figure 5.18: Time-history plots showing changes in transmission (%) and droplet size distribution i.e. Dv10, 
Dv50 and Dv90 (µm) on actuation with respect to time (h:m:s, ranging from 0-1.1278 min) 
Aerosol droplet particle size distribution and volume particle diameter measured as Dv10, Dv50 
and Dv90 by laser diffraction, measured in region 2, of the time-history plots of the Solutol® HS 
15 and Kolliphor® TPGS micellar formulations, is shown in Figure 5.19.  
  
   Formation                        Fully developed phase                         Dissipation 
Region 1                              Region 2                             Region 3 
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Curcumin: Solutol® HS 15 formulations: 
 
 
CNB001: Solutol® HS 15 formulations: 
  
Curcumin: Kolliphor® TPGS formulations: 
 
For efficient delivery to the posterior nasal tract a median particle size of 30-120 µm is considered 
appropriate [128]. Particle size greater than 120 µm have the tendency to deposit in the anterior 
nose. The Nasal™ MAD produces a broad aerosol spray of 30-100 µm droplet size which covers 
a wide mucosal area on delivery (http://www.lmaco.com/products/lma-mad-nasal). Formulation 
factors can affect the final spray parameters consequently affecting the deposition site and 
medicament efficiency, hence it was important to study the aerosol droplet size of the micelles 
especially since this device has not been investigated previously for delivery of nanocarrier 
formulations.  
All the micellar formulations of Solutol® HS 15 and Kolliphor ® TPGS showed mean Dv50 
between 42.75-54.86 µm. There was a significant increase (p < 0.05) in the Dv50 of formulations 
with increasing cholesterol content for curcumin encapsulated Solutol® HS 15 micelles from 
44.86±1.27 µm (0% mole cholesterol) to 49.55±1.62 µm (15% mole cholesterol) and 54.86±2.46 
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Figure 5.19: (A) Aerosol frequency particle size distribution (%) and (B) Particle diameter (µm) at 10, 50 and                   
90th percentile for the various micellar formulations as measured by laser diffraction on the Spraytec®, n=3, mean± 
SD 
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µm (30% mole cholesterol). A similar significant increase (p < 0.05) was observed for CNB001 
encapsulated Solutol® HS 15 micelles from 42.75±1.60 µm (0% mole cholesterol) to 46.82±0.83 
µM (15% mole cholesterol) and 49.67±1.20 µm (30% mole cholesterol). With increased 
cholesterol content the distribution curve was skewed towards the larger particle size and hence 
a more prominent effect of addition of cholesterol on the 90th percentile particle size was seen 
(Figure 5.19). 
FDA requires the measurement of Span as a measure of the quality of the aerosol generated, with 
smaller Span values representing narrow droplet size distribution [464]. Studies have shown that 
aerosols with the same droplet size but different Span have different deposition profiles [464]. 
With increasing concentration of cholesterol, there was an increase in the Span for Solutol® HS 
15 micelles incorporating curcumin and CNB001. Curcumin encapsulated Solutol® HS 15 
micelles showed Span values of 1.52±0.13 (0% mole cholesterol), 1.62±0.05 (15% mole 
cholesterol) and 1.75±0.18 (30% mole cholesterol). A similar trend was evident for CNB001 
encapsulated Solutol® HS 15 micelles with Span values of 1.50±0.17 (0% mole cholesterol), 
1.68±0.01 (15% mole cholesterol) and 1.70±0.08 (30% mole cholesterol). However, the 
difference was not significant at a level of 0.05 as analyzed by One-way ANOVA. The Span 
values for Kolliphor ® TPGS incorporating curcumin micelles with and without dequalinium were 
1.70±0.11 and 1.63±0.16 respectively, however the difference was not significant (p > 0.05). 
There was no significant difference (p > 0.05) in the size of the micelles before and after 
aerosolization (Figure 5.20), indicating that aerosolization using this device does not cause 
micellar rupture. Hence, due to favourable aerosol droplet size, Span and micellar stability; the 
Nasal™ Mucosal Atomization Device could be used to effectively deliver nanocarrier-based 
formulations to the posterior nasal tract for brain targeting. 
 
Figure 5.20: Mean hydrodynamic diameter for the micelles incorporating CNB001 or curcumin before and after 
spraying through the Nasal™ MAD, at a concentration of 2.5 mg/mL polymer, n=3, mean±SD 
5.5.1.5 In vitro drug release 
CNB001 and curcumin release from Solutol® HS 15 micelles is as shown in Figure 5.21. CNB001 
exhibited release in a sustained manner over 36 h, whereas, curcumin was released in a burst 
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manner in the first 10 h and then a slower release for the remainder of the study up to 36 h. The 
log P values reported in literature for CNB001 and curcumin is 5.7 and 3.29 respectively; CNB001 
being more hydrophobic than curcumin. Differences in the hydrophobicity of the drugs may affect 
their interactions with the hydrophobic micellar core and hence contribute to in vitro release 
profile differences. Increased hydrophobicity would result in increased interaction of the drug 
with the hydrophobic hydroxystearate chains of the Solutol® HS 15 micelles and hence a slower 
release profile as seen for CNB001 in comparison to curcumin. 
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Figure 5.21: In vitro cumulative drug release profiles of (A) CNB001 and (B) Curcumin from Solutol® HS 15 
micelles into simulated nasal fluid (SNF), 2% SDS and 0.05% sodium azide from the various formulations. Data 
are mean ± SD (n=4) 
There was a significant increase (p < 0.05) in cumulative release of CNB001 with increase in 
mole % of cholesterol from 0% to 15% mole and 30% mole as analyzed by repeated measures 
ANOVA (rANOVA). Moreover, release profiles of curcumin from Solutol® HS 15 micelles 
showed a significant (p < 0.05, rANOVA) increase in cumulative release on addition of 
cholesterol up to 15% mole. However, there was no significant (p > 0.05, rANOVA) difference 
in release of curcumin when 30% mole cholesterol was added. Addition of cholesterol to non-
ionic surfactant micelles/niosomes of different HLB values has been shown to alter micellar 
mechanical strength, permeability to water and hence drug release [474,488]. Hence, results 
suggest that with an increase in mole % of cholesterol in Solutol® HS 15 micelles there was an 
increase in drug release rate as compared to Solutol® HS 15 micelles without cholesterol due to 
alterations in drug-surfactant interactions on cholesterol incorporation. Increased hydrogen 
bonding between cholesterol hydroxyl groups and the Solutol® HS 15 oxoethylene bridge, may 
lead to possible reductions in available oxoethylene molecules to form hydrogen bonds with 
curcumin or CNB001, resulting in an increased cumulative drug release with respect to Solutol® 
HS 15 micelles without cholesterol. 
Curcumin release from Kolliphor® TPGS micelles into simulated nasal fluid is shown in Figure 
5.22. There was no significant difference (p > 0.05, rANOVA) between the release profile of 
curcumin from Kolliphor® TPGS micelles with or without dequalinium, wherein, a sustained 
release was evident for 48 h with approximately 40% curcumin being released. Drug release 
A B 
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profiles from Kolliphor® TPGS micelles are dependent on the log p and drug content due to 
differences in interaction with polymer core. Docetaxel (log p=2.83) has been shown to 
demonstrate significantly different release profiles on variation of the surfactant: drug content, 
with a slower drug release kinetics from 87% to 40% with reducing drug content due to stronger 
interaction of the drug with TPGS [480,481].   
Moreover, release profiles of curcumin from Solutol® HS 15 (Figure 5.21B) and Kolliphor® TPGS 
(Figure 5.22) micelles were significantly different (p < 0.05, rANOVA). This may be attributed 
to the differences in the HLB values of the two polymers; 15.2 and 13 for Solutol® HS 15 and 
Kolliphor® TPGS respectively. With a decrease in HLB value of surfactants an increase in 
hydrophobicity is evident. Kolliphor® TPGS having a more hydrophobic core would seem to 
interact more strongly with hydrophobic drug curcumin and hence impedes its release. 
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Figure 5.22: In vitro cumulative drug release profiles of curcumin from Kolliphor® TPGS micelles into simulated 
nasal fluid (SNF), 2% SDS and 0.05% sodium azide from the formulations with and without dequalinium. Data 
are mean ± SD (n=4) 
Release kinetics of the drugs from the different surfactants were fitted into various kinetic models 
and the regression coefficient R2 used to ascertain the best fit model. These kinetic models are 
shown in Appendix 3 and the calculated R2 are shown in Table 5.5. 
For CNB001 release from Solutol® HS 15 micelles with 0% mole cholesterol and 15% mole 
cholesterol, a regression coefficient for first-order kinetics was lower than that of zero-order 
kinetics indicating that CNB001 release was independent of CNB001 concentration. However, 
with increase in cholesterol to 30% mole of Solutol® HS 15 first-order release kinetics of CNB001 
was evident wherein release was dependent on the concentration of CNB001. These differences 
were likely to be due to the varied interactions of the drug with the surfactant on addition of 
cholesterol.  
For curcumin release from Solutol® HS 15 micelles with 0% mole cholesterol, a regression 
coefficient for first order kinetics was lower than that of zero order kinetics indicating that 
Curcumin release from Solutol® HS 15 micelles without cholesterol was independent of drug 
concentration, following a zero-order kinetics. However, with an increase in cholesterol to 15 and 
30% mole of Solutol® HS 15 first-order release kinetics of curcumin was evident wherein release 
was dependent on the concentration of the drug. A similar drug release kinetics was evident for 
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Kolliphor® TPGS micelles with and without dequalinium incorporating curcumin, wherein 
release followed a first-order kinetics and hence was dependent on concentration of curcumin. 
This was in good correlation to the release of docetaxel from TPGS micelles, which followed a 
drug concentration-dependent first-order kinetics. 
Table 5.5: Release kinetics of in vitro drug release from various polymers in simulated nasal fluid  
Formulations Zero order R2 First order R2 
CNB001: Solutol® HS 15: 
0% mole cholesterol: 0.9911 0.9738 
CNB001: Solutol® HS 15: 
15% mole cholesterol: 0.9843 0.9625 
CNB001: Solutol® HS 15: 
30% mole cholesterol: 0.9917 0.9937 
Curcumin: Solutol® HS 15: 
0% mole cholesterol: 0.9619 0.9478 
Curcumin: Solutol® HS 15: 
15% mole cholesterol: 0.9690 0.9708 
Curcumin:  Solutol® HS 15: 
30% mole cholesterol: 0.9205 0.9631 
Curcumin: Kolliphor® TPGS: 
0% mole dequalinium 0.9915 0.9974 
Curcumin: Kolliphor® TPGS: 
30% mole dequalinium 0.9965 0.9989 
 
5.5.2 In vitro cellular assays for anticancer activity 
5.5.2.1 Assessment of cellular viability by MTT assay 
MTT assay ((3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) tetrazolium 
reduction assay) was used to study the Ic50, i.e. maximal concentration of drug/formulations 
required to cause 50% inhibition in the biological activity of cancer cells. Dequalinium was used 
to mitochondrially target the micelles incorporating curcumin and hence the MTT assay that 
involves measurement of the mitochondrial activity of the cancer cells was used to study and 
compare the activity of the formulations as potential cancer chemotherapeutics. The Ic50 values 
(µM, concentration of drug incorporated) of the various formulations are shown in Table 5.6 and 
their respective dose-response curves on the A549 and SH-SY5Y cancer cell lines are shown in 
Figure 5.23, Figure 5.24, Figure 5.25 and Figure 5.26. 
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Table 5.6: Ic50 (µM, concentration of drug incorporated) values derived from the dose-response curve of the 
various formulations on the SH-SY5Y and A549 cancer cell lines using the MTT assay (* p < 0.05 as 
compared to blank micelles and # p < 0.05 as compared to curcumin alone) 
  
There was a significant difference (# p < 0.05) between the Ic50 values of curcumin incorporated 
Kolliphor® TPGS micelles with or without dequalinium when compared to curcumin alone in 
both the SH-SY5Y and A549 cells. This was due to the anticancer activity of Kolliphor® TPGS 
as confirmed by the Ic50 of the blank Kolliphor® TPGS micelles (Table 5.6).  
The blank Kolliphor® TPGS micelles with and without dequalinium did not show a significant 
difference (p > 0.05) in the Ic50 values on the A549 cell line, probably since 30% mole of 
dequalinium was not sufficient to exhibit anticancer activity. However, there was a significant 
difference (p < 0.05) in the Ic50 values of curcumin encapsulated Kolliphor® TPGS micelles with 
and without dequalinium. This could be due to an enhanced delivery of curcumin to the 
mitochondria of the A549 cells and hence an increased anticancer activity of the drug. There was 
a significant difference (* p < 0.05, Table 5.6) between similar formulations of micelles 
incorporating and not incorporating curcumin. The transform of dose-response curves (change in 
x-axis to logarithmic concentration to obtain a sigmoid-shaped curve) for the blank and curcumin 
encapsulated formulations on the A549 cell line are shown in Figure 5.23 and Figure 5.24. 
Formulations 
Ic50 best-
fit value 
SH-SY5Y 
Ic50 95% 
confidence 
SH-SY5Y 
R2 
SH-SY5Y 
Ic50 best-
fit value 
A549 
Ic50 95% 
confidence 
A549 
R2 
A549 
Curcumin 29.99 26.63 to 33.76 0.9770 70.59 62.76-96.5 0.9899 
Blank: 
Kolliphor® 
TPGS 
4.514# 4.10-4.63 0.9941 8.765# 8.20-9.37 0.9929 
Curcumin:  
Kolliphor® 
TPGS 
4.355# 4.34-4.69 0.9976 6.526* # 6.09-7.00 0.9895 
Blank:  
Kolliphor® 
TPGS: 30% 
mole 
dequalinium 
2.364# 1.74-1.99 0.9960 7.966# 7.31-8.69 0.9875 
Curcumin:  
Kolliphor® 
TPGS: 30% 
mole 
dequalinium 
1.862# 2.23-2.50 0.9969 4.283* # 3.98-4.61 0.9907 
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Figure 5.23: Dose-response curves with mean values ± SD (n=3) indicating the cell viability at the different 
micellar concentrations of Kolliphor® TPGS formulations as analyzed by the MTT assay on A549 cells 
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Figure 5.24: Dose-response curves with mean values ± SD (n=3) indicating the cell viability at the different 
micellar concentrations of Kolliphor® TPGS: dequalinium formulations as analyzed by the MTT assay on A549 
cells 
Blank and curcumin encapsulated Kolliphor® TPGS micelles with and without dequalinium, 
showed a significant difference (p < 0.05) in the Ic50 values on the SH-SY5Y cell line. The 
transform of dose-response curves (change in x-axis to logarithmic concentration to obtain a 
sigmoid-shaped curve) for the blank and curcumin encapsulated formulations on the SH-SY5Y 
cell line are shown in Figure 5.25 and Figure 5.26 respectively. 
Chapter 5| Kolliphor® micelles for nose-to-brain delivery  
 
224	
	
log(concentration) (µM)
C
el
l v
ia
bi
lit
y 
(%
)
-0.5 0.0 0.5 1.0 1.5 2.0 2.5
0
50
100
Curcumin
Curcumin:TPGS:0% mole dequalinium
Blank: TPGS:0% mole dequalinium
 
Figure 5.25: Dose-response curves with mean values ± SD (n=3) indicating the cell viability at the different 
micellar concentrations of Kolliphor® TPGS formulations as analyzed by the MTT assay on SH-SY5Y cells 
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Figure 5.26: Dose response curves with mean values ± SD (n=3) indicating the cell viability at the different 
micellar concentrations of Kolliphor® TPGS: dequalinium formulations as analyzed by the MTT assay on SH-
SY5Y cells 
Kolliphor® TPGS cisplatin prodrug micelles have shown to have an enhanced uptake efficiency 
and anticancer activity in SH-SY5Y cells as compared to cisplatin-PEG prodrug micelles and 
cisplatin alone [489]. Moreover, enhanced uptake of Kolliphor® TPGS cancer therapeutic 
micelles has been validated on other cells lines such as MCF-7 breast cancer and C-6 brain glioma 
cells wherein a greater intracellular uptake and distribution was evident for the Kolliphor® TPGS 
micelles, which showed a lower Ic50 compared to drug alone (doxorubicin) and hence enhanced 
anticancer activity [490,491]. Mixed micelles of phosphatidylethanolamine-PEG/ Kolliphor® 
TPGS incorporating camptothecin has also shown a remarkably enhanced anticancer activity 
against lung, rectal, melanoma and breast/mammary cancer cells [492,493]. These results of 
enhanced anticancer activity are in correlation with the results obtained for Kolliphor® TPGS 
micelles incorporating anticancer drug previously. Hence, Kolliphor® TPGS micelles targeted to 
the mitochondria with dequalinium could help in enhancement of delivery of cancer 
chemotherapeutics. Curcumin being used as a model hydrophobic anticancer drug in the present 
study could be replaced with more effective anticancer drug like paclitaxel, avastin amd 
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vincristine, currently used for the treatment of malignant brain tumours. Cellular uptake studies 
would give a better insight into the targeting efficacy of the Kolliphor® TPGS formulations with 
dequalinium. 
5.5.3 In vitro cellular assays for neuroprotective activity 
5.5.3.1 Assessment of cellular viability and MNTC by Sulphorhodamine-B (SRB) assay 
The SRB assay was used to determine the MNTC, i.e. EC80 of the formulations by determining 
the protein content and hence the cell density of the cells on treatment with the various 
formulations of potentially neuroprotective molecules. A drug concentration range of 100 µM to 
3.125 µM for CNB001 and curcumin incorporating micelles (serially diluted micelles, 
concentration in µM of active CNB001 or curcumin considering encapsulation efficiency) and a 
similar concentration of blank Solutol® HS 15 micelles were analyzed. The Ec80 results are 
shown in Table 5.7 and transform of dose-response curves (change in x-axis to logarithmic 
concentration to obtain a sigmoid-shaped curve) are shown in Figure 5.27. 
Table 5.7: Maximum non-toxic concentration (Ec80, µM) of active curcumin or CNB001 incorporated in 
micelles as studied by SRB assay  
Formulation 
Ec80 (µM of active 
curcumin or CNB001) 
24 h 
Ec80 (µM of active 
curcumin or CNB001) 
48 h 
Curcumin: Sol:0% mole Chol 29.63 ± 6.35 21.52 ± 1.05 
Curcumin: Sol:15% mole Chol 27.97 ± 2.02 20.42 ± 0.079 
Curcumin: Sol:30% mole Chol 24.14 ± 1.347 21.54 ± 3.27 
Curcumin (drug alone) 23.34 ± 2.38 22.02 ± 1.05 
CNB001: Sol:0% mole Chol 37.98 ± 5.49 21.73 ± 2.33 
CNB001: Sol:15% mole Chol 29.59 ± 6.22 27.91 ± 2.94 
CNB001: Sol:30% mole Chol 24.74 ± 0.75 20.76 ± 5.77 
CNB001 (drug alone) 23.89 ± 0.51 18.17 ± 1.61 
Empty Sol:0% mole Chol 95.26 ± 5.50 62.06 ± 4.52 
Empty Sol:15% mole Chol 77.04 ± 6.85 46.75 ± 3.18 
Empty Sol:30% mole Chol 57.83 ± 6.01 22.99 ± 5.48 
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Figure 5.27: Dose-response curves with mean values ± SD (n=3) indicating the cell viability of the different 
micellar formulations (concentrations of active curcumin or CNB001) (A) empty Solutol® HS 15 micelles after 
24 h, (B) empty Solutol® HS 15 micelles after 48 h, (C) curcumin incorporated Solutol® HS 15 micelles after 24 
h, (D) curcumin incorporated Solutol® HS 15 micelles after 48 h, (E) CNB001 incorporated Solutol® HS 15 
micelles after 24 h and (F) CNB001 incorporated Solutol® HS 15 micelles after 48 h, as analyzed by the SRB 
assay 
Cytotoxicity analysis of curcumin and its formulations showed no significant difference (p > 0.05) 
in Ec80 of the drug alone compared to curcumin incorporated in Solutol® HS 15 micelles with 
varying amounts of cholesterol over 24 and 48 h. However, cytotoxicity studies of CNB001 
encapsulated in micelles showed a significantly higher Ec80 (p < 0.05) (and hence less toxicity) 
when encapsulated in Solutol® HS 15 micelles (without cholesterol) as compared to drug alone at 
24 h. This could be attributed to the release of CNB001 from the micelles which was slower as 
compared to the other formulations (Figure 5.21), hence, the drug not being immediately available 
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leading to lower toxicity and higher non-toxic concentration of this formulation. Moreover, the 
other formulations of CNB001 with varying concentration of cholesterol at 24 and 48 h and 
CNB001 encapsulated in Solutol® HS 15 micelles (without cholesterol) showed no significant 
difference (p > 0.05) in Ec80 as compared to drug alone, since the release rate of these was 
relatively faster (Figure 5.21). Empty micelles of Solutol® HS 15 showed a significantly higher 
(p < 0.05) cytotoxicity with increasing amount of cholesterol incorporated in the micelles.  
To compare similar concentration of formulations for neuroprotection assays, a maximum non-
toxic concentration of 18 µM downwards, of active curcumin or CNB001 incorporated within 
micelles (based on the encapsulation efficiency of each formulation) was chosen. Previous studies 
have reported a MNTC of 20 µM for curcumin on the SH-SY5Y cells, which was in good 
agreement with our studies, however, the MNTC of CNB001 has not been studied previously on 
this cell line [494]. 
5.5.3.2 In vitro Parkinson’s disease (PD) model development: 6 hydroxydopamine-insulted 
SH-SY5Y cells 
It was important to access the effect of the concentration of neurotoxin 6-hydroxydopamine insult 
on the viability of SH-SY5Y cells in vitro. With increasing concentration of the neurotoxin there 
was a dose-dependent reduction in cell viability in both the 24 h and 48 h studies (Figure 5.28). 
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Figure 5.28: Effect of various concentrations of neurotoxin 6-hydroxydopamine for (A) 24 h and (B) 48 h on 
viability of SH-SY5Y cells (* p < 0.05 as compared with control, n=3, mean±SD) 
6-hydroxydopamine at a concentration of 29.73 µM and 33.47 µM for 24 and 48 h respectively 
decreased the cell viability to approximately 50% of control (Ic50), hence a concentration of 30 
µM was selected for further neuroprotection experiments. The results obtained were in good 
agreement with studies which have previously reported that a concentration of 25-30 µM 6-
hydroxydopamine decreases SH-SY5Y cell viability by approximately 50% [494,495]. Moreover, 
there was no significant difference seen in the Ic50 values of neurotoxin dose-response for 24 h 
and 48 h studies when 95% confidence intervals were considered. Hence, further in vitro 
neuroprotection studies were performed over a 24 h time-period. 
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6OHDA													+																				+																						+																			+																					+																					- 
(30	µM) 
5.5.3.3 Protective effects of Solutol® HS 15 micelles incorporating curcumin and CNB001 
on in vitro PD model: Neuroprotection assay 
Pre-treatment with curcumin and CNB001 and the Solutol® HS 15 formulations incorporating 
curcumin or CNB001, at 18, 14, 9 and 7 µM (concentrations of active curcumin or CNB001, 
below the MNTC of the drugs) prior to insulting with neurotoxin 6-OHDA (30 µM) showed 
significant protection (p < 0.05, denoted by *) of the neuroblastoma cells, as seen by an increase 
in the cellular viability (Figure 5.29 and Figure 5.30). A cellular viability of 56.46±3.59% was 
evident for the 6-OHDA (30 µM) insulted SH-SY5Y cells that were not treated with curcumin or 
CNB001, representing significant toxicity (p < 0.05, denoted by #) as compared to control cells 
(not insulted, not treated). 
At 18 and 14 µM pre-treatment, cell viability was not significantly different (p > 0.05) from the 
control cells with a viability of 97.83±4.55% and 93.66±2.50% respectively seen on pre-treatment 
with curcumin. Solutol® HS 15 formulations incorporating curcumin (concentration of active drug 
curcumin 18 and 14 µM) with different concentrations of cholesterol (0%, 15% and 30% mole), 
showed a similar trend to curcumin alone, hence encapsulation of curcumin within micelles did 
not reduce its neuroprotection capability. 
 
 
 
Figure 5.29: Neuroprotective effects of curcumin incorporating Solutol® HS 15 formulations on cell viability of 
SH-SY5Y cells insulted with 6-hydroxydopamine (6-OHDA). Cells were treated with the various formulations 2 
h prior to insulting with neurotoxin 6-OHDA. * p < 0.05 as compared to not treated insulted cells and # p < 0.05 
as compared to control cells (not insulted, not treated), n=3, mean±SD 
Previous reports have demonstrated the neuroprotective effects of curcumin on 6-OHDA induced 
neuronal death at a concentration of 20 µM and 10 µM with a viability of 96.6 ± 4.6% and 86.2 
± 2.6% reported, which was similar to that obtained in the present investigation [494]. 
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The different concentrations, i.e. 18, 14, 9 and 7 µM of CNB001 and the Solutol® HS 15 
formulations incorporating CNB001 showed a significant increase (p < 0.05, denoted by *) in 
cellular viability of 6-OHDA insulted neuroblastoma cells (Figure 5.30). At 18 µM pre-treatment 
with CNB001, cell viability was not significantly different (p > 0.05) from the control cells with 
a viability of 103.5±5.12 % seen on pre-treatment with CNB001, hence, CNB001 can protect the 
cells from neurotoxin 6-OHDA insult. Solutol® HS 15 formulations incorporating CNB001 
(concentration of active drug CNB001 18 µM) with different concentrations of cholesterol (0%, 
15% and 30% mole) showed a similar trend to CNB001 alone, hence encapsulation of CNB001 
within micelles did not reduce its neuroprotection capability. Neuroprotection of CNB001 has not 
been studied previously in vitro on 6-OHDA insulted neuronal cells, however, earlier reports of 
rotenone insulted neuron-like SK-N-SH cells representing Parkinson’s disease model have 
demonstrated an increase in cellular viability on pre-treatment with 2 µM CNB001 [451]. 
 
 
Figure 5.30: Neuroprotective effects of CNB001 incorporating Solutol® HS 15 formulations on cell viability of 
SH-SY5Y cells insulted with 6-hydroxydopamine (6-OHDA). Cells were treated with the various formulations 2 
h prior to insulting with neurotoxin 6-OHDA. * p < 0.05 as compared to not treated insulted cells and # p < 0.05 
as compared to control cells (not insulted, not treated), n=3, mean±SD 
5.5.3.4 Protective effects of Solutol® HS 15 micelles incorporating curcumin and CNB001 
on in vitro PD model: ROS formation assay 
Elevation of ROS and hence oxidative stress is evident when cells are not treated before insulting 
with 6-hydroxydopamine, in the in vitro Parkinson’s disease model. A time-based study was 
performed to compare the various formulations and to understand the ROS formation of the cells 
on neurotoxin insult in vitro. Solutol® HS 15 micelles incorporating curcumin or CNB001, at 
different cholesterol contents (0%, 15% and 30% mole) did not show any significant difference 
(p > 0.05) in neuroprotection, hence, Solutol® HS 15 micelles without cholesterol was chosen for 
further studies.  
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Elevation of ROS was around 45-50% (0% for control cells without treatment and insult) after 24 
h of neurotoxin insult, as seen in Figure 5.31. This was in agreement with previous studies, 
wherein, neurotoxin 6-hydroxydopamine on SH-SY5Y cells caused an elevation of ROS from 1 
(for control cells) to 1.5-fold of control for insulted non-treated cells i.e. elevation by 50% of 
control [494].  
Time-dependent studies revealed that initially there was an elevated amount of ROS generated on 
insult (no treatment), which was then shown to stabilize and level off at around 12 h, up to 24 h, 
since there was no significant difference (p > 0.05) in ROS production after 12 h (Figure 5.31A 
rightmost bar cluster). A similar pattern of levelling off ROS production at 12 h was evident for 
the curcumin alone/curcumin incorporated Solutol® HS 15 micelles at various concentrations as 
evident from Figure 5.31. This reduction in ROS formation in the initial hours of the experiment 
would be due to an increased consumption of the oxidative species to cause cellular apoptosis and 
hence an imbalance between ROS production and consumption which was seen to stabilize after 
12 h. Hence comparison of the different formulations was made at a 24 h time-point after the level 
of ROS was stable for the particular treatment/no treatment after insult. 
Pre-treatment with curcumin drug alone (dissolved in complete media with 0.1% DMSO) (Figure 
5.31A) at 7, 9, 14 and 18 µM for 2 h before exposure to 6-hydroxydopamine for 24 h, significantly 
reduced (p < 0.05) the levels of ROS produced in a concentration-dependent manner to 32.63± 
3.51%, 26.32±4.24%, 8.90±5.74% and -13.43±0.16% from 52.12±2.61% (non-treated insulted 
cells) ROS respectively. This was in good correlation with results obtained in previous studies, 
wherein, curcumin at a level of 5 µM and 10 µM reduced production of ROS relative to control 
to 30% ± 4% and 20%±3% from 50±7% ROS for non-treated insulted cells [494]. 
Solutol® HS 15 incorporated curcumin micelles showed a similar trend of increased ROS initially 
which levelled off after around 12 h, as seen in Figure 5.31B. Pre-treatment with curcumin 
incorporated Solutol® HS 15 micelles at 7, 9, 14 and 18 µM curcumin for 2 h before exposure to 
6-hydroxydopamine for 24 h, significantly reduced (p < 0.05) the levels of ROS produced in a 
concentration-dependent manner to 28.22±1.70%, 18.60±1.24%, -4.92±4.76% and -24.73± 
2.62% respectively from 50.00±2.32% ROS (for non-treated insulted cells), confirming that 
curcumin incorporated in the micelles caused a reduction in oxidative stress to a basal level in the 
in vitro Parkinson’s disease model. There was no significant difference (p > 0.05) in the 
production of ROS between the treatments of curcumin alone and incorporated within Solutol® 
HS 15 micelles, hence, encapsulation of curcumin had no effect on the antioxidant activity of 
curcumin, which is majorly responsible for its neuroprotection effect. 
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Figure 5.31: Neuroprotective effects of curcumin formulations on ROS formation by SH-SY5Y cells insulted 
with 6-hydroxydopamine (6-OHDA). Cells were treated with the (A) Curcumin and (B) Solutol® HS 15: 
Curcumin, 2 h prior to insulting with neurotoxin 6-OHDA, n=5, mean±SD 
Pre-treatment with CNB001 drug alone (Figure 5.32A) at 7, 9, 14 and 18 µM for 2 h before 
exposure to 6-hydroxydopamine for 24 h, significantly reduced (p < 0.05) the levels of ROS 
produced in a concentration-dependent manner to 33.76±1.79%, 28.69±2.40%, 25.49±1.95% and 
20.33±2.12% respectively from 50.90±2.62% ROS (non-treated insulted cells). Previous studies 
have shown that CNB001 can protect dopaminergic SK-N-SH cells against rotenone induced 
oxidative stress, that represents Parkinson’s disease [451,452]. Moreover, CNB001 has been 
shown to protect HT-22 cells against glutamate oxidative stress representative of Alzheimer’s 
disease [454].  
Solutol® HS 15 incorporated CNB001 micelles showed a similar trend of increased ROS initially 
which levelled off after around 12 h, as seen in Figure 5.32B. Pre-treatment with CNB001 
encapsulated in Solutol® HS 15 micelles at 7, 9, 14 and 18 µM of CNB001 for 2 h before exposure 
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to 6-hydroxydopamine for 24 h, significantly reduced (p < 0.05) the levels of ROS produced in a 
concentration-dependent manner to 32.03±1.92%, 29.25±0.72%, 24.84±1.18% and 18.14± 0.94% 
respectively from 49.76±0.34% ROS (non-treated insulted cells), confirming that CNB001 
caused a 60% reduction in oxidative stress in the in vitro Parkinson’s disease model. There was 
no significant difference (p > 0.05) in the production of ROS between the treatments of CNB001 
alone and incorporated within Solutol® HS 15 micelles, hence, encapsulation of CNB001 had no 
effect on the antioxidant activity of CNB001, which is responsible for its neuroprotection effect. 
 
 
 
Figure 5.32: Neuroprotective effects of CNB001 formulations on ROS formation by SH-SY5Y cells insulted 
with 6-hydroxydopamine (6-OHDA). Cells were treated with (A) CNB001 and (B) Solutol® HS 15: CNB001, 
2 h prior to insulting with neurotoxin 6-OHDA, n=5, mean±SD 
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5.5.3.5 Protective effect of the Solutol® HS 15 micelles incorporating curcumin or CNB001 
on 6-OHDA induced cellular apoptosis: Hoechst staining 
Neuronal apoptosis, evident by changes in nuclear morphology of SH-SY5Y cells on insulting 
with 6-OHDA, was studied on staining with DNA-binding Hoechst 33258 dye. Nuclear 
condensation and fragmentation, evident by brightly fluorescent rounded nuclei, and cell density 
reduced significantly when neuronal cells were insulted for 24 h with 30 µM 6-OHDA as seen in 
Figure 5.33B. On the other hand, control cells (non-treated, non-insulted) showed pallid blue 
nuclei as seen in Figure 5.33A.  
   
Control 6-OHDA insulted CNB001 treated 
   
CNB001: Solutol® HS 15 Curcumin treated Curcumin: Solutol® HS 15 
Figure 5.33: Fluorescence microscopic analysis to study the effect of curcumin and CNB001 and their Solutol® 
HS 15 formulations on 6-OHDA-induced neuronal SH-SY5Y cell apoptosis, as studied by nuclei observation on 
staining with DNA-binding fluorochrome Hoechst 33258. Yellow arrows denote apoptotic cells representing 
condensed or fragmented nuclei with bright stain. (A) Control cells (not insulted and not treated), (B) 6-OHDA 
insulted cells (not treated), (C) 18 µM CNB001 treated 6-OHDA insulted cells, (D) 18 µM CNB001: Solutol® HS 
15 treated 6-OHDA insulted cells, (E) 18 µM curcumin treated 6-OHDA insulted cells, (F) 18 µM curcumin: 
Solutol® HS 15 treated 6-OHDA insulted cells 
Pre-treatment with 18 µM CNB001 and curcumin and their Solutol® HS 15 formulations showed 
an improvement in the nuclear morphology of insulted cells, wherein, the number of apoptotic 
nuclei was lower than that observed with untreated insulted cells. Morphological changes studied 
using Hoechst staining due to 6-OHDA neurotoxin insult in SH-SY5Y cells has been previously 
reported [496–498].  
ImageJ was used to semi-quantify the fluorescence intensity of the cells, so as to be able to 
compare different formulations. Mean fluorescence intensity was measured at the centre of the 
cell nucleus and an example of processed 6-OHDA-insult rescued CNB001 SH-SY5Y cells is as 
shown in Figure 5.34. 
A B C 
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Figure 5.34: Measurement of mean fluorescence intensity of SH-SY5Y cells after staining with Hoeschst using 
ImageJ 
There was a significant neuroprotective (p < 0.05) effect of curcumin and CNB001, and their 
Solutol® HS 15 formulations as seen by a decrease in cellular Hoechst fluorescence, on 6-OHDA 
insulted neuronal cells that represent the in vitro Parkinson’s model (Figure 5.35). This 
demonstrates the ability of the Solutol® HS 15 micelles incorporating neuroprotective molecules 
to protect cells from dopamine toxicity. 
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Figure 5.35: Mean fluorescence intensity as measured using ImageJ on 10 images per group. For the treatment 
groups, cells were treated with the various curcumin or CNB001 formulations 2 h prior to insulting with neurotoxin 
6-OHDA. * p < 0.05 as compared to not treated insulted cells and # p < 0.05 as compared to control cells (not insulted, 
not treated) 
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5.6     Conclusion 
The aim of the chapter was to prepare Kolliphor® TPGS and Kolliphor® HS 15 (Solutol® HS 15) 
micelles incorporating hydrophobic drugs CNB001 or curcumin, intended for brain targeting on 
delivery via the nasal airways. 
Based on the aforementioned results presented in this chapter, it can be concluded that: 
1. Kolliphor® TPGS micelles incorporating anticancer curcumin were successfully prepared 
with varying amount of mitochondrial targeting agent dequalinium, by the thin-film 
hydration technique. Kolliphor® TPGS has previously demonstrated apoptosis in cancer 
cell lines due to the active vitamin E (tocopherol) chain of the non-ionic surfactant [461]. 
2. Solutol® HS 15 micelles incorporating neuroprotective molecules CNB001 or curcumin 
were successfully prepared by the thin-film hydration technique, with varying amount of 
cholesterol to confer stability to the micelles. The FDA approved non-ionic surfactant 
Solutol® HS 15 currently used as an injectable, has been shown to possess 
neuroprotection in rat models of cerebral ischemia/stroke [459]. 
3. Aerosolization of the micellar solutions (Kolliphor® TPGS or Solutol® HS 15) was 
studied using the Nasal™ Mucosal Atomization Device that has previously shown 
promise for brain targeting via the nasal airways, as it directs medication to the posterior 
epithelium i.e. the site for nose-to-brain delivery. All the micellar formulations displayed 
a volume mean aerosol droplet size Dv50 between 42.75-54.86 µM, that was in good 
agreement with the manufacturers specifications for delivery of medicament to the 
posterior nasal mucosal surface. 
4. Kolliphor® TPGS encapsulating curcumin with and without dequalinium, showed a 
superior in vitro anticancer activity as compared to curcumin alone, in the neuroblastoma 
SH-SY5Y and lung adenocarcinoma A549 cell lines. This was due to the anticancer 
potential of Kolliphor® TPGS and mitochondrial targeting by dequalinium, however, 
further cellular uptake studies using flow cytometry would be necessary to confirm this. 
5. Solutol® HS 15 encapsulated CNB001 or curcumin, showed neuroprotection on the in 
vitro Parkinson’s disease model i.e. 6-hydroxydopamine-insulted neuroblastoma SH-
SY5Y cells at 18 and 14 µM (concentration of active in the micelles) pre-treatment. 
Moreover, pre-treatment confirmed reduction in the reactive oxygen species formation 
by the Parkinson’s disease model and reduction in apoptotic nuclei evident by DNA-
binding fluorochrome Hoechst 33258 staining, demonstrating the neuroprotective 
activity of the formulations. However, there was no significant difference (p > 0.05) in 
the neuroprotection activity of the micellar formulations as compared to the drugs alone, 
indicating that Solutol® HS 15 is not neuroprotective in Parkinson’s disease models, at 
the concentration and time of study. 
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General discussion and future perspectives 
Systemic delivery of hydrophobic therapeutics presents substantial formulation challenges, which may 
impede optimal benefits due to side effects and sub-therapeutic drug levels at the target site. The 
majority of failures in the development of new drug candidates have been attributed to poor water 
solubility, leading to low bioavailability and suboptimal drug concentrations [499]. Advances in 
combinatorial chemistry have led to an increase in the development of hydrophobic drug 
candidates, accounting for 90% of the discovery pipeline [499]. Moreover, hydrophobic drugs 
belonging to BCS Class IV, such as amphotericin B and paclitaxel, exhibit low water solubility 
and low or variable gastric permeability, hence requiring delivery via the invasive IV route [500]. 
Hydrophobic drugs delivered directly to the airways get trapped within the overall hydrophilic 
mucus, particularly the thick viscoelastic mucus of diseased patients; this is the rate limiting factor 
of diffusion to the site of action [501]. These interactions are governed by hydrophobic bonds 
between the drug and hydrophobic naked protein core of mucin, impeding diffusion to the site of 
action, leading to clearance via the mucociliary escalator [502]. Formulation development of 
hydrophobic drugs can be achieved by [500]: 
1)  particle size reduction using mechanical micronization by milling or homogenization,  
2) particle engineering by crystallization or spray drying/ spray freeze drying, 
3) nanocarriers encapsulating hydrophobic drugs, e.g. liposomes, nanoparticles, 
nanocomplexes, polymeric micelles and self-emulsifying systems. 
Aerosol delivery aimed at enhancing the therapeutic efficacy of hydrophobic drugs by delivering 
a high drug payload at the target site with reduced systemic toxicity would be an attractive 
approach for combating local diseases. This thesis described three distinct novel nanotechnology-
based formulation approached yielding carriers with desirable aerosolization characteristics to be 
delivered to and via the airways for combating pulmonary and neurological disorders. 
6.1 Dry powder microparticles of amphotericin B nanocomplexes 
The studies in chapter 3 describe the development of nanocomplexes of antifungal amphotericin 
B with antioxidant ascorbic acid-2-glucoside (AA2g) for improved drug solubilization.  
Ascorbic acid readily photodecomposes in aqueous media, hence the glucoside derivative of 
ascorbic acid, AA2g, was selected as it has previously shown improved stability to thermal and 
oxidative degradation [503]. An increased solubilization of amphotericin B was evident on 
increasing solubilizing agent AA2g from 1:0.5 molar amphotericin B: AA2g until 1:2 molar 
amphotericin B: AA2g, when the two molecules were co-ground. Further increasing the 
stoichiometric molar ratio to 1:3 or 1:4 molar amphotericin B: AA2g gave no significant increase 
(p > 0.05) in relative amphotericin B content. Hence, a molar ratio of 1:2 amphotericin B: AA2g 
was chosen for further studies, for delivery of a high dose of amphotericin B with minimal 
excipient. Approximately 80% of the initially added amphotericin B was solubilized in the 1:2 
molar co-ground formulation.  
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Nanocomplexes formed by co-grinding amphotericin B and AA2g (before spray drying) showed 
minimal loss of amphotericin B from the complex, studied over a 10-day period when stored at 
4-8°C.  
Synthesized amphiphilic derivatives of antioxidant ascorbic acid, such as ascorbyl–decanoate and 
octanoyl-6-O-ascorbic acid, have previously been reported to form self-assembled micellar 
solutions enhancing the solubility of hydrophobic drugs such as phenacetin, danthron, retinoic 
acid, griseofulvin and dithranol [504,505]. Inoue et al. reported solubilization of clarithromycin 
on physically mixing and co-grinding with hydrophilic AA2g at a 1:1 molar ratio, due to 
molecular interactions between N, N-dimethyl group on clarithromycin with the hydroxyl group 
of AA2g, which was stable over a 7-day period [369]. 100% solubilization was evident on co-
grinding clarithromycin with AA2g; with up to 80% solubilization on physically mixing 
clarithromycin with AA2g [369]. Physically mixing amphotericin B with AA2g did not show 
solubility enhancement and co-grinding seems essential for inducing molecular interactions 
between the drug and excipient. FT-IR studies confirmed molecular interactions via hydrogen 
bond formation between the amine groups on amphotericin B and the lactone ring carboxyl and 
hydroxyl of AA2g on co-grinding. These interactions were not evident on physically mixing the 
two molecules. Zeta potential analysis of the nanocomplexes showed a high positive charge on 
the nanoparticle surface of around +27.7 mV for a 1:2 molar ratio, contributing to good 
nanoparticle stability on storage. This was in good agreement with the zeta potential of around 
+25.2 mV for co-ground clarithromycin: AA2g 1:1 molar ratio [369]. The mean hydrodynamic 
diameter of the nanocomplexes was around 100-120 nm, and increasing the amount of AA2g for 
complexation of a constant amount of amphotericin B, led to the formation of smaller size 
nanocomplexes.  
Dry powder microparticles for aerosol delivery as a dry powder were prepared by spray drying 
the co-ground amphotericin B: AA2g nanocomplexes using the Büchi Nano spray dryer B-90, 
with or without excipients lactose and L-leucine to aid dispersibility. Laser diffraction particle 
size analysis of spray dried microparticles, with and without excipients, showed a mean geometric 
size at 4 bar pressure of 2.21-3.06 µm, which is suitable for lower respiratory tract deposition, 
including the alveolar regions where pulmonary fungal infections prevail. However, the mean 
size of co-ground microparticles was 8.03 µm. This showed the importance of spray drying for 
engineering dry powders suitable for potential peripheral pulmonary deposition. This was further 
highlighted in the study of in vitro aerosolization efficiency using the Next Generation Impactor 
(NGI), whereby, a significantly lower (p < 0.05) fine particle fraction of 16.95± 4.22% (fine 
particle dose of 6.24±1.9 mg amphotericin B) was achieved for the co-ground amphotericin B: 
AA2g microparticles, as opposed to 37.85±2.15% (fine particle dose of 17.02±0.97 mg 
amphotericin B) for the spray dried amphotericin B: AA2g particles. µmization using techniques 
like mechanical jet milling and grinding often lead to highly cohesive compacted powders which 
have a high surface energy and consequently poor flowability and aerosolization [506]. On the 
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other hand, spray drying can improve aerosol performance due to the production of spherical, 
porous/wrinkled microparticles with more uniform surface energy distributions and significantly 
lower dispersive, specific and total surface energy as compared to jet-milled particles [506]. Bulk 
compacted morphology was evident under the SEM for the co-ground microparticles, whereas, 
spherical, non-agglomerated particle morphology with slight corrugations was evident for spray 
dried microparticles.  
The addition of L-leucine has been shown to reduce the surface energy of microparticles due to 
its surfactant-like properties on migration to particle surfaces during spray drying [373,507]. This 
effect was seen in the present studies, wherein addition of L-leucine significantly increased (p < 
0.05) the fine particle fraction of spray dried microparticles to 56.75±1.46 % (fine particle dose 
of 25.54±0.66 mg amphotericin B), even though the MMAD of microparticles was similar i.e. 
2.05 ± 0.15 µm to spray dried microparticles without L-leucine i.e. 2.02 ± 0.23 µm. SEM 
micrographs showed an open powder structure with wrinkled hollow spheres formed as curved 
plates, in good agreement with previous SEM micrographs of spray dried microparticles with L-
leucine [373]. Changes in pressure used to disperse the spray dried microparticles gave no 
significant differences (p > 0.05) in the mean sizes at pressures of 1, 2 and 4 bar for the Sympatec; 
indicative of ease of dispersion and consequently a potentially reduced inter-patient variability in 
deposition on inhalation. 
In vitro antimicrobial assessment of preparations against Candida spp namely Candida albicans 
and Candida tropicalis by the MIC assay showed retainment of the fungal activity of the drug on 
complexation and spray drying, hence signifying the feasibility of using amphotericin B: AA2g 
nanocomplexes, engineered into microparticles suitable for dry powder inhalation, for effective 
therapy of pulmonary fungal infections.  
Amphotericin B inhalation powder (NKTR-024, Nektar Therapeutics, CA, USA) has been 
developed and studied as a spray dried microparticle system with distearoylphosphatidylcholine 
and amphotericin B at 1:1 weight ratio (25 mg amphotericin B) [206]. The aerosol following 
delivery from a DPI device has a mean particle size of 2-5 µm, considered favourable to achieve 
deep lung penetration to target Aspergillus fumigatus that has a similar size of 2-5 µm and has 
been shown to deposit deep in the airways, making its eradication challenging  [206]. In human 
studies, a dose of 25 mg amphotericin B has been shown to be safe, with minimal systemic 
amphotericin B absorption and no change in pulmonary functional markers. In the present study, 
around 25 mg of amphotericin B was deposited in stages 2-8 of the NGI, suggesting potential 
peripheral lung deposition of amphotericin B: AA2g: L-leucine microparticles for the treatment 
of invasive pulmonary aspergillosis. Spray dried microparticles of amphotericin B 
nanocomplexes with antioxidant AA2g would be an extremely valuable and cost-effective option 
(compared to phospholipid-based systems) for the prophylactic therapy of pulmonary fungal 
infections in immunocompromised patients. 
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Future work: Ascorbic acid is an FDA-approved injectable as an antiscorbutic. It helps in 
improved collagen synthesis, resistance to infections and tissue repair due to its involvement in 
tyrosine metabolism, carbohydrate metabolism, iron metabolism, conversion of folic acid to 
active form folinic acid and improved cellular respiration [508]. Moreover, it has also been 
studied as a topical cosmeceutical agent for treatment of UV-induced photodamage and wound 
healing [509,510]. However, the toxicity of ascorbic acid to the lungs delivered as an aerosol 
needs to be considered.  
Several studies have highlighted the major shortcoming of amphotericin B following IV 
administration, being associated with serious side-effects particularly nephrotoxicity. In contrast, 
Alsaadi et al. have shown that nebulization of amphotericin B for treatment of pulmonary 
aspergillosis showed low apparent toxicity in mice [511]. Other studies have yielded similar 
results, with little or no amphotericin B found in organs other than the lungs, including the 
kidneys, following pulmonary administration, suggesting benefit in this approach for combating 
nephrotoxicity-related mortality in patients treated with conventional amphotericin B 
formulations [511–515].  
Amphotericin B has cellular toxicity by means of its interaction with mammalian cell wall 
cholesterol. Strong oxidative bursting of the fungus leads to an increase in reactive oxidative 
species (ROS), subsequently leading to toxicity in the surrounding cells as previously reported 
[516].  
Ascorbic acid is a powerful oxidative scavenger that reacts directly with aqueous ROS by 
inhibition of lipid peroxidation-associated cellular toxicity [517,518]. Therefore, it is important 
to determine the toxicity profile of the amphotericin B formulations under study using a 
pulmonary cell line, such as A549 or Calu-3, to ensure that minimal toxicity is observed to host 
lung cells on airways’ deposition, and to compare the efficacy and toxicity of formulations 
containing ascorbic acid or with the drug alone. This study would also be useful to determine the 
maximum dosage of amphotericin B/amphotericin B formulations associated with minimal 
toxicity to the pulmonary cell line. 
6.2 Dry powder microparticles of co-encapsulated rifampicin and ibuprofen liposomes 
targeted to the macrophages 
Pulmonary infections are difficult to eradicate particularly when the pathogen lifestyle includes 
intracellular infection. In Chapter 4, the liposomes co-encapsulating rifampicin and ibuprofen as 
antitubercular agents targeted to the macrophages where pulmonary tubercle bacilli reside were 
studied. Rifampicin, a common first-line antitubercular drug was chosen. However, multi-drug 
resistant TB is increasing, with WHO reporting 0.48 million new incidences of MDR-TB and an 
additional 0.1 million new cases of rifampicin-resistant TB (RR-TB) in 2015 [50,51]. Re-
purposing of the non-steroidal anti-inflammatory ibuprofen has been proposed as it has 
demonstrated antitubercular activity in whole-cell phenotypic assay [389].  Moreover, ibuprofen 
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has demonstrated enhanced elimination of in vivo bacterial loads when used in combination with 
the antitubercular drug pyrazinamide. Co-delivery of ibuprofen may also facilitate healing of the 
lung tissue that has been damaged due to prolonged antitubercular drug regimens owing to its 
anti-inflammatory activity [385,393]. Current TB therapy consists of systemic delivery of 
multiple drugs for long periods. However, macrophage-resident TB bacilli do not respond entirely 
due to insufficient drug diffusion into the pulmonary tissue and hence to the alveolar 
macrophages. Increasing the dosage leads to systemic toxicity and bacteria persistent during the 
treatment develop resistance. Hence, delivery of multiple drugs encapsulated within a nanocarrier 
system aerosolized directly to the pulmonary tract, ideally targeted to the macrophages would be 
a potentially valuable approach for eradication of intracellular TB. 
Design of Experiments (DoE) was used to generate a factorial design of possible experiments to 
study the amount of negative lipid distearoyl phosphatidylglycerol (DSPG) and cholesterol for 
the formulation of stable negatively-charged liposomes encapsulating rifampicin and ibuprofen. 
Bilayer formation was evident at concentrations of approximately 30% mole and more of DSPG 
to dipalmitoyl phosphatidylcholine (DPPC) required to co-encapsulate maximal rifampicin and 
ibuprofen. This was in correlation to previous literature where 28% and 35% mole of DSPG to 
phosphatidylcholine has been shown to successfully encapsulate the hydrophobic drug cisplatin 
and the hydrophilic drug sodium selenite respectively [433,434]. Based on requirements of 
maximum co-loading of drugs with small size and high negative zeta potential, the formulation 
DPPC: DSPG: Chol 100:40:20 was chosen. This formulation had mean size and mean zeta 
potential of 84.09±3.89 nm 43.5±1.5 mV respectively and an encapsulation efficiency of 
89.75±2.40% and 99.00±2.20% for rifampicin and ibuprofen respectively. Previous studies on 
the addition of DSPG to PC has been reported for encapsulation of drugs such as sodium selenite, 
amphotericin B (marketed formulation AmBisome®) and  cisplatin [433,434,519]. The zeta 
potential of these liposomal formulations ranged from -23.4±1.58 mV to −54.5±1.1 mV, 
depending on the content of DSPG to PC (range 26 to 40  mole%) and the buffer used for 
hydration [433,434,519]. AmBisome® has shown minimal association and hence toxicity with 
human cells, due to an improved uptake into mononuclear phagocytes owing to its negative 
surface charge [308,520]. Liposomal particle sizes ranging from 120.3±1.5 nm to 154.8±23.0 nm 
was seen for the different PC: DSPG: Chol systems, being highly dependent on the method chosen 
for size reduction of the initially prepared multilamellar vesicles [433,519]. Imparting negative 
surface charge to the liposomes was intended to achieve active targeting to the scavenger 
receptors on the macrophage cell membrane and hence facilitate endocytosis as seen in previous 
studies [410].  
Co-encapsulation of antitubercular drugs into one liposomal system can be complex due to the 
interaction between the drugs which may affect their encapsulation and stability within the 
nanocarrier. DoE was used to determine an optimum ratio wherein maximum co-loading of both 
the drugs in the above liposomal system can be achieved. There was an interaction evident 
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between the two drugs due to their hydrophobic nature and hence competition for accommodation 
into the lipid bilayer, whereby an increase in ibuprofen caused a significant reduction (p < 0.05) 
in the amount of rifampicin incorporated, and similarly an increase in rifampicin caused a 
significant reduction (p < 0.05) in the amount of ibuprofen incorporated. Hence, based on results, 
25 micromolar rifampicin and 75 micromolar ibuprofen were chosen for the preparation of 
liposomes to be converted into dry powders for aerosolization. In vitro cellular uptake was 
performed qualitatively using the fluorescence microscope and quantitatively using the flow 
cytometer for murine macrophage RAW 264.7 cells by replacing the drugs with fluorescent dye 
coumarin-6. Negative non-mannosylated liposomes showed a significantly higher (p < 0.05) 
uptake when compared to neutral liposomes. 
Negatively-charged mannosylated liposomes incorporating mannosamine or p-aminophenyl 
mannopyranoside have previously been shown to improve uptake in vivo and in vitro in epithelial 
cells and alveolar macrophages [213,444,445]. In this study, mannose moieties mannosamine 
hydrochloride (36.75% mole) or p-amino phenyl mannopyranoside (18.78% mole) were 
embedded within the negatively-charged liposomal bilayer by electrostatic attraction with the 
positive charge of the amine on the mannose moieties at pH 7. As seen in the in vitro cellular 
uptake studies, association of mannosamine with the negatively-charged bilayer facilitated uptake 
compared to both neutral liposomes (p < 0.05) and negatively-charged liposomes (p < 0.05).  
Positively-charged non-targeted and targeted liposomes were prepared by coating the negative 
surface of liposomes with positive chitosan or mannosylated chitosan. Chitosan coating the 
liposomes formulated with 100:40:20 molar DPPC: DSPG: Chol encapsulating rifampicin and 
ibuprofen resulted in immediate precipitation. Consequently, liposomes with a lower amount of 
DSPG and hence lower surface charge of -25.1±2.31 mV (DPPC: DSPG: Chol; 100:20:20) were 
coated with 0.05% chitosan solution (1 mL of liposomal suspension: 0.5 mL chitosan solution). 
The liposomes so formed showed an encapsulation efficiency of 63.12±1.06% and 92.50±2.00% 
for rifampicin and ibuprofen respectively, with a mean size of 145.34±2.12 nm and surface charge 
of +37.21±1.89 mV. The positive charge on the liposomal surface would be expected to interact 
with the macrophage cells by means of attraction to the negatively-charged cell membrane, hence 
facilitating uptake. To further enhance cellular uptake by targeting the positive liposomes to the 
mannose receptors, coating with mannosylated chitosan was carried out in a similar way to that 
of chitosan. Mannosylated chitosan was synthesized and its structure confirmed using 1H-NMR 
and FT-IR. Positively-charged chitosan-coated liposomes showed improved uptake as compared 
to neutral liposomes (p < 0.05) due to an attraction of the positively-charged liposomes to the 
negatively-charged cell membrane, hence improving the endocytosis kinetics as studied by the in 
vitro qualitative and quantitative cellular uptake. Moreover, mannosylation of the surface of 
positive liposomes by means of coating with mannosylated chitosan facilitated uptake (p < 0.05) 
due to active mannose receptor-mediated endocytosis. Hence, cellular uptake studies validated 
the hypothesis of using actively targeted nanocarrier systems for delivering tubercular drugs 
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directly into the alveolar macrophages where the TB bacilli reside. Mannosylated chitosan-coated 
liposomes have not been studied previously for their potential for macrophage targeting, however, 
nanoparticles made of mannosylated chitosan encapsulating curcumin or rifampicin prepared by 
ionic gelation have been studied [298]. Approximately 2.31-fold higher uptake was evident for 
mannosylated chitosan nanoparticles encapsulating rifampicin in ex vivo macrophage uptake 
studies [298]. In vitro uptake of curcumin-loaded mannosylated chitosan nanoparticles showed a 
significant qualitative and quantitative uptake in infected macrophage J774A.1 cells, and hence a 
significantly lower effective dose i.e. 0.430 ± 0.03 mg/L compared to free curcumin 2.1 ± 0.02 
mg/L was required for treatment of intracellular visceral leishmaniasis [521]. Ciprofloxacin-
loaded mannosylated liposomes showed improved uptake in vitro in the NR8383 macrophage cell 
line, and an improved uptake in vivo in rat alveolar macrophages and epithelial lining fluid when 
aerosolized using a liquid MicroSprayer™, as compared to ciprofloxacin-loaded non-
mannosylated liposomes and ciprofloxacin solution [445]. Moreover, the time and concentration 
above MIC were studied following pulmonary administration in animal models of various 
intracellular organisms. Mannosylated ciprofloxacin liposomes showed a significantly improved 
antibacterial profile particularly against M. tuberculosis, C. pneumoniae, L. pneumophilia and L. 
monoytogenes, at 1/50th of oral clinical dose, highlighting the possibility of dose reduction and 
effective eradication of pulmonary intracellular pathogens [445]. Furthermore, the risk of mutant 
appearance on administration of liposomal ciprofloxacin (mannosylated and non-mannosylated) 
against M. tuberculosis and M. avium was ideal, with a 0% chance of mutant selection as contrast 
to 17% and 34% for ciprofloxacin solution against M. tuberculosis and M. avium respectively 
[445]. 
Spray drying liposomes to produce a powder suitable for inhalation is a critical step: process 
parameters during spay-drying can affect the properties of the final product and hence the 
aerodynamic behavior of the microparticles intended to be delivered to the lung using a dry 
powder inhalation device. Hence, DoE was employed varying the independent factors: trehalose 
content, L-leucine content and temperature of spray drying. The dependent variables studied, i.e. 
particle size distribution (by laser diffraction) and moisture content (by thermogravimetric 
analysis) informed the selection of the optimal spray drying parameters. Drying liposomal 
dispersions could lead to disruption of the bilayer structure and degradation of lipids, due to 
stresses of high temperature and force applied during the process [415]. Previous studies have 
shown that hydrogen bond interactions between the hydroxyl group of lyoprotectant trehalose and 
phosphate groups of DPPC liposomes have conferred stability to the liposomal bilayers on drying 
[522,523]. Microparticles obtained by spray drying at 120 °C (inlet temperature) in the presence 
of 33.33% w/w trehalose and 20% w/w L-leucine yielded product with particle size in respirable 
range with a mean size of 2.73 µm and 90 percentile particle size of 4.21 µm, and a Span of 1.39 
with low moisture content compared to other spray dried formulations. Moreover, the SEM 
micrographs showed an open powder structure with wrinkled hollow spheres formed as curved 
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plates, which was in good agreement with the SEM micrographs of spray dried microparticles 
with L-leucine from previous literature [373]. The study of the dependence of pressure used in 
the Sympatec to disperse the microparticles showed no significant difference (p > 0.05) in mean 
size at pressures in the range of 1-5 bar, indicating ready dispersibility. These drying process 
parameters were used to spray dry the mannosylated (mannosamine or p-aminophenyl 
mannopyranoside incorporated) DPPC: DSPG: Chol liposomes, chitosan-coated DPPC: DSPG: 
Chol liposomes and mannosylated chitosan-coated DPPC: DSPG: Chol liposomes to study the in 
vitro aerosol parameters using the NGI, aerosolized from the commercial DPI Cyclohaler®. 
In vitro studies for the microparticles sprayed from the different liposomal constitutions co-
encapsulating rifampicin and ibuprofen showed a low deposition in the throat and pre-separator 
stages of the NGI (<20%), indicative of low oropharyngeal and throat deposition, and hence a 
deeper peripheral deposition in the lungs as depicted by increased deposition (>60%) in the stages 
2-7 and MOC of the NGI, with fine particle fractions of 58.99-64.79% for all the microparticles. 
Spray dried negatively-charged DPPC: DSPG: Chol liposomes with and without mannose 
moieties, showed predominant deposition in stage 3 and 4 of the NGI, with stage cut-off diameters 
of 2.82 µm and 1.66 µm respectively, whereas, spray dried positively-charged chitosan or 
mannosylated chitosan-coated DPPC: DSPG: Chol liposomes, showed predominant deposition in 
stages 2 and 3 of the NGI, with stage cut-off diameters of 4.46 µm and 2.82 µm respectively 
 
Future work: Previous studies have demonstrated the efficacy of mannosylated nanocarriers 
against mycobacterial strains in vitro and in vivo [298,300,433,445,521]. Delivery of 
mannosylated nanocarriers encapsulating antibiotics has shown a significantly improved 
intracellular bacterial eradication from infected macrophages as compared to free drug/non-
mannosylated nanocarriers.  
Present qualitative in vitro uptake studies using flow cytometry have confirmed the improved 
uptake of charged (positive and negative) and mannosylated liposomal formulations 
encapsulating fluorescent dye coumarin-6. Consequently, it would be valuable to elucidate the 
efficacy of the various co-encapsulated rifampicin and ibuprofen liposomes against 
mycobacterial-infected macrophages along with the drug residence time within the macrophage 
compartments. This would help to ascertain the time of drug concentration above the MIC of the 
organism, and consequently the appropriate dosing concentration and regimen.  
In the present study, the ratio of rifampicin: ibuprofen chosen was based on the liposomal 
formulation design, however, it would also be useful to study the drug combination dose ratio of 
free drugs and their efficacy against mycobacterium in vitro, since the combination of rifampicin 
and ibuprofen for tuberculosis has not been studied previously. The most effective combination 
ratio could be co-encapsulated within targeted liposomes and studied for macrophage uptake and 
tubercular eradication. 
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6.3 Aerosols of Kolliphor® and Solutol® micelles for nose-to-brain delivery  
Kolliphor® TPGS and Solutol® HS 15 (Kolliphor® HS 15) micelles incorporating the hydrophobic 
drugs CNB001 or curcumin were successfully prepared by the thin-film hydration method.  
Kolliphor® TPGS was used as the non-ionic surfactant to prepare micelles incorporating 
curcumin, as this surfactant has shown promise in reversal of multi-drug resistance lung and breast 
cancer, and can induce apoptosis due to the presence of vitamin E (tocopherol), the hydrophobic 
head group of the amphiphilic polymer chain [460,524]. These micelles were adapted for potential 
targeting to the mitochondria for better efficacy of the anticancer system, by inclusion of cationic 
dequalinium chloride as described in previous studies [462]. Kolliphor® TPGS micelles 
incorporating curcumin, with and without dequalinium, were in the size range 13-16 nm, with an 
encapsulation efficiency of ~100%. The zeta potential of the non-targeted micelles was 
approximately neutral. A significant increase (p < 0.05) in the zeta potential to approximately +10 
mV was evident on incorporation of cationic dequalinium. TEM images showed spherical, well 
dispersed micelles with size correlating to that obtained from intensity and volume distribution 
by DLS. 
Solutol® HS 15 was used as the non-ionic surfactant to prepare micelles incorporating the 
neuroprotective drugs CNB001 or curcumin, as this FDA-approved surfactant, currently used in 
injectable products has shown neuroprotection in rat models of cerebral ischemia. To improve the 
stability of Solutol® HS 15 micelles, cholesterol was added in increasing molar ratios from 7.5% 
to 30%. There was a cholesterol concentration-dependent increase in mean size from ~20 nm to 
~95 nm, based on the intensity size distribution profile. However, the volume size distribution 
profile suggested that the predominant vesicles in the formulations incorporating hydrophobic 
neuroprotective drugs were micelles with mean volume size ~20 nm. Increasing the amount of 
cholesterol led to an increase (5-15% by volume distribution) in the presence of larger vesicles, 
known as niosomes, with mean size around 100 nm. Non-ionic surfactant based microemulsions 
of nimodipine with an average size of 25-35 nm administered intranasally, showed a significantly 
increased concentration of nimodipine in the brain as compared to IV administration of the 
formulation or the intranasal administration of nimodipine solution, highlighting the importance 
of formulation propertied for brain targeting via the nasal tract [525]. Moreover, the choice of 
surfactant and percentage of components impacts nasal ciliotoxicity, such that emulsions of 
Labrafil M 1944 showed no evident toxicity as compared to emulsions of Maisine 35-1 and 
isopropyl myristate which exhibited moderate ciliotoxicity. Furthermore, risperidone 
nanoemulsions with globule size 14-17 nm, showed increased direct nose-to-brain transport and 
drug targeting efficiency compared to intranasal risperidone alone, as studied by gamma 
scintigraphy and quantitatively measured by radiochemical biodistribution studies in vivo [526]. 
Moreover, on the administration of nanoemulsion formulations an improved locomotor count and 
hindlimb retraction time were evident, indicating superior activity of risperidone due to greater 
transport to the brain on nasal administration [526]. Taki et al. delivered the anticancer drug 
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camptothecin in mPEG/PCL-Tat micelles with a mean size of 26-50 nm; Tat a cell penetrating 
peptide promotes brain delivery on intranasal administration [238,239]. An improved median 
survival of rats bearing intracranial C6 tumours was achieved, believed to be due to improved 
uptake of the formulation from the nasal tract to the brain as compared to intranasal camptothecin 
alone [238,239]. 
Aerosolization of the micellar solutions was achieved in this study using the Nasal™ Mucosal 
Atomization Device that has previously shown promise for brain targeting via the nasal airways. 
For posterior nasal tract delivery, a droplet size of 30-120 µm using this device is considered 
appropriate [128]. All the micellar formulations of Solutol® HS 15 and Kolliphor® TPGS 
produced aerosols with a volume mean aerosol droplet size Dv50 between 42.75 and 54.86 µm, 
which is in good agreement with the manufacturer's specifications for delivery of medicament to 
the posterior nasal mucosal surface. There was no effect (p > 0.05) of aerosolization using the 
atomization device on the particle size distribution of the micelles, hence indicating that this 
device could be used to effectively deliver these nanocarrier based formulations to the posterior 
nasal tract for brain targeting. 
In vitro cellular viability assays on SH-SY5Y and A549 cancer cells to study the effect of 
Kolliphor® TPGS formulations incorporating curcumin, containing and not containing 
dequalinium, demonstrated improved efficacy (p < 0.05) of the micellar system. This was 
probably due to the anticancer potential of Kolliphor® TPGS and mitochondrial targeting by 
dequalinium, however, further cellular uptake studies using flow cytometry would be a useful 
study to confirm this. 
The neuroprotection assay for the in vitro Parkinson’s disease model, i.e. 6-hydroxydopamine 
insulted neuroblastoma SH-SY5Y cells, confirmed the neuroprotection profile of Solutol® HS 15 
encapsulated CNB001 or curcumin. A cellular viability of 56.46 ± 3.59% was evident for the 6-
OHDA (30 µM) insulted SH-SY5Y cells that were not treated with curcumin or CNB001, 
representing significant toxicity (p < 0.05) compared to control cells. At 18 and 14 µM pre-
treatment before insult with curcumin or curcumin encapsulated Solutol® HS 15 micelles, cell 
viability was not different (p > 0.05) from the control cells, with viabilities of ~97% and 94% 
respectively. Moreover, at 18 µM pre-treatment with CNB001 or CNB001 encapsulated Solutol® 
HS 15 micelles, cell viability was not significantly different (p > 0.05) from the control cells, with 
a viability of ~100 % seen on pre-treatment. Solutol® HS 15 incorporating drugs did not show 
any significant difference (p > 0.05) from the drug alone, hence the surfactant on its own did not 
have a neuroprotection effect at the concentration, model and time tested. Encapsulation of 
CNB001 or curcumin within surfactant micelles did not reduce its neuroprotection capability. 
The ROS formation assay in the in vitro Parkinson’s disease model, confirmed the antioxidant 
profile of Solutol® HS 15 encapsulated CNB001 or curcumin. Elevation of ROS was around 45-
50% (considering 0% ROS for control SH-SY5Y cells without insult) after 24 h of neurotoxin 
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insult. Pre-treatment with curcumin or curcumin encapsulated Solutol® HS 15 micelles at 7, 9, 14 
and 18 µM significantly reduced (p < 0.05) the levels of ROS produced in a concentration-
dependent manner to ~30 %, 20 %, ~0% and -15% from ~51 % ROS of control for non-treated 
insulted cells. Moreover, pre-treatment with CNB001 or CNB001 encapsulated Solutol® HS 15 
micelles at 7, 9, 14 and 18 µM significantly reduced (p < 0.05) the levels of ROS produced in a 
concentration-dependent manner to ~32 %, 28 %, 24 % and 19% from ~50 % ROS of control for 
non-treated insulted cells.  
There was a significant neuroprotective effect (p < 0.05) of curcumin or CNB001 and their 
Solutol® HS 15 formulations, demonstrated by a decrease in cellular fluorescence and 
morphology, using nuclei observation on staining with DNA-binding fluorochrome Hoechst 
33258, on 6-OHDA insulted neuronal cells, clearly demonstrating the ability of the CNB001 or 
curcumin Solutol® HS 15 micelles to protect the neuronal cells in Parkinson’s disease. 
Hence, Kolliphor® TPGS micelles incorporating hydrophobic anticancer agent curcumin, non-
targeted or mitochondrially targeted with dequalinium, is an attractive nanocarrier formulation 
for nasal aerosol delivery as a potential treatment of neuroblastoma, as confirmed by the in vitro 
cellular studies. In addition, this study has demonstrated that Solutol® HS 15 micelles would be a 
valuable delivery system for neuroprotective agents’ curcumin or CNB001 intended for potential 
nose-to-brain targeting in the treatment of neurodegeneration, as confirmed in vitro in the 
Parkinson’s cellular model.  
 
Future work: Mixed micelles of DSPE-PEG 2K/ Kolliphor® TPGS incorporating paclitaxel 
and/or parthenolide has been shown to enhance the anticancer activity on A549 and taxol resistant 
A549-T24 cell lines [461]. Kolliphor® TPGS is known to overcome drug resistance by inhibiting 
P-glycoprotein efflux pumps and hence sensitize multi-drug resistant tumours to cancer 
chemotherapeutics like paclitaxel, doxorubicin and vinblastine [461]. Hence, study of the 
anticancer activity of Kolliphor® TPGS micelles incorporating curcumin with and without 
targeting moiety dequalinium in resistant cell lines would be of great interest. Moreover, 
qualitative and quantitative in vitro cellular uptake studies using fluorescence microscopy and 
flow cytometry respectively, would give a better outlook of the potential mitochondrial targeting 
capacity of these formulations on the SH-SY5Y cell line. 
The neuroprotective efficacy of CNB001 drug has not been studied previously on the 6-
hydroxydopamine insulted SH-SY5Y neuroblastoma cells that represents an in vitro Parkinson’s 
disease model. In the present thesis, neuroprotection with respect to ROS formation and apoptotic 
nuclei has been studied. It would be valuable to study the effect of the drug and its formulations 
on other pathways of neuroprotection, namely, mitochondrial membrane potential and DNA 
fragmentation.  
Solutol® HS 15 has been shown to neuroprotective in focal and cerebral ischemia rat models due 
to structural similarity to stearic acid methyl ester which has previously shown to be 
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neuroprotective in similar models [459]. CNB001 has shown potential as a neuroprotective agent 
to treat stroke previously [527]. It would be interesting to study the efficacy and neuroprotection 
activity of the Solutol® HS 15 micelles incorporating CNB001 in oxygen-glucose depleted in vitro 
models of SH-SY5Y cells that represent ischemia/stroke.  
Passage of nanocarriers from the nasal tract via the olfactory epithelium to the brain and toxicity 
to the nasal mucosa are dependent on the size and surface characteristics of the nanocarrier 
systems, along with its residence time in the nasal tract, as studied previously [238,266,525,526]. 
It would be informative to study the in vitro permeation and toxicity of the Kolliphor® micelles 
using three-dimensional human-derived tracheal/bronchial epithelial cell cultures (EpiAirway™, 
MatTek Corporation, USA) that have been previously validated as a reliable in vitro model to 
screen compounds intended for delivery via the nasal mucosa for brain targeting [528,529]. 
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Appendix 1 | HPLC validation for the analytical methods developed 
A1.1 Amphotericin B 
Accuracy: The accuracy of analytical method is expressed as % bias or the % relative error. 
Tolerance limits obtained from the accuracy determination of each concentration under study is 
as tabulated in Table A1.1 and Table A1.2 for both intraday and inter-day analysis.  No significant 
difference (p > 0.05) was found between the amount of amphotericin B added (true/actual) and 
concentration observed at all the concentrations tested under the linearity range for amphotericin 
B, indicative of the accuracy of the developed HPLC method.  
Precision: Precision of the analytical method was analyzed by determination of amphotericin B 
at different concentrations of 2, 7 and 12 µg/mL that was within the linearity range of the method 
for the drug as per Beer-Lambert law. Three replicate readings of each of the concentrations were 
analyzed and results expressed as relative standard deviation (RSD) was assessed for both inter-
day and intraday evaluation. These are as tabulated in Table A1.1 and Table A1.2. A low % RSD 
(or %CV) is indicative of the precision of the method for analysis of amphotericin B. 
Table A1.1: Intraday precision and accuracy observed for the HPLC analysis method of amphotericin B 
Standard concentration (µg/mL) 
Accuracya (%) Precisionb (%) 
Actual Observed 
2 2.15±0.038 107.55 1.76	
7 7.00±0.180 100.03 2.57	
12 12.1±0.012 101.275 0.10	
a Accuracy expressed as % i.e. (mean observed concentration/actual concentration) x100 
b Precision expressed as RSD (relative standard deviation) = (standard deviation/mean) x100 
Table A1.2: Interday precision and accuracy observed for the HPLC analysis method of amphotericin B 
Standard concentration (µg/mL) 
Accuracya (%) Precisionb (%) 
Actual Observed 
2 1.91±0.064 95.25 3.34	
7 7.03±0.180 100.53 2.57	
12 12.06±0.019 100.52 0.16	
a Accuracy expressed as % i.e. (mean observed concentration/actual concentration) x100 
b Precision expressed as RSD (relative standard deviation) = (standard deviation/mean) x100 
 
Representative HPLC chromatogram of amphotericin B is as shown in Figure A1.1 
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Figure A1.1: Representative HPLC chromatogram of amphotericin B 
A1.2 Rifampicin and ibuprofen 
Accuracy: The accuracy of analytical method is expressed as % bias or the % relative error. 
Tolerance limits obtained from the accuracy determination of each concentration under study is 
as tabulated in Table A1.3, Table A1.4, Table A1.5 and Table A1.6 for both intraday and inter-
day analysis.  No significant difference (p > 0.05) was found between the amount of rifampicin 
and ibuprofen added (true/actual) and concentration observed at all the concentrations tested 
under the linearity range for these drugs, indicative of the accuracy of the developed HPLC 
method. 	
Precision: Precision of the analytical method was analyzed by determination of rifampicin and 
ibuprofen at different concentrations of 10, 50 and 100 µg/mL. These are as tabulated in Table 
A1.3, Table A1.4, Table A1.5 and Table A1.6. A low % RSD (or %CV) is indicative of the 
precision of the HPLC method for analysis of the antitubercular drugs. 
Table A1.3: Intraday precision and accuracy observed for the HPLC analysis method of ibuprofen 
Standard concentration (µg/mL) 
Accuracy a (%) Precision b (%) 
Actual Observed 
10 10.1945 ± 1.212 101.94 1.8930 
50 50.9386 ± 1.762 101.88 3.4583 
100 102.3630 ± 0.543 102.36 5.3054 
a Accuracy expressed as % i.e. (mean observed concentration/actual concentration) x100	
b Precision expressed as RSD (relative standard deviation) = (standard deviation/mean) x100 
Table A1.4: Intraday precision and accuracy observed for the HPLC analysis method of rifampicin 
Standard concentration (µg/mL) 
Accuracy a (%) Precision b (%) 
Actual Observed 
10 10.4306 ± 0.190 104.31 1.8219 
50 50.7646 ± 2.276 101.53 4.4834 
100 101.2127 ± 2.485 101.21 2.4554 
a Accuracy expressed as % i.e. (mean observed concentration/actual concentration) x100	
b Precision expressed as RSD (relative standard deviation) = (standard deviation/mean) x100 
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Table A1.5: Interday precision and accuracy observed for the HPLC analysis method of ibuprofen 
Standard concentration (µg/mL) 
Accuracy a (%) Precision b (%) 
Actual Observed 
10 11.0573 ± 0.611 110.57 5.5258 
50 52.2795 ± 0.349 104.56 6.5449 
100 104.3380 ± 0.413 104.34 3.8516 
a Accuracy expressed as % i.e. (mean observed concentration/actual concentration) x100	
b Precision expressed as RSD (relative standard deviation) = (standard deviation/mean) x100 
Table A1.6: Interday precision and accuracy observed for the HPLC analysis method of rifampicin 
Standard concentration (µg/mL) 
Accuracy a (%) Precision b (%) 
Actual Observed 
10 9.9487 ± 0.924 99.49 9.2916 
50 48.9868 ± 3.056 97.97 6.2382 
100 98.9743 ± 2.743 98.97 2.8282 
a Accuracy expressed as % i.e. (mean observed concentration/actual concentration) x100	
b Precision expressed as RSD (relative standard deviation) = (standard deviation/mean) x100 
 
Representative HPLC chromatogram of simultaneous determination of rifampicin and ibuprofen 
is as shown in Figure A1.2. 
 
Figure A1.2: Representative HPLC chromatogram of rifampicin and ibuprofen simultaneously eluted 
A1.3 CNB001 and curcumin 
Accuracy: The accuracy of analytical method is expressed as % bias or the % relative error. 
Tolerance limits obtained from the accuracy determination of each concentration under study is 
as tabulated in Table A1.7, Table A1.8, Table A1.9 and Table A1.10 and for both intraday and 
inter-day analysis. No significant difference (p > 0.05) was found between the amount of 
curcumin and CNB001 added (true/actual) and concentration observed at all the concentrations 
tested under the linearity range for these drugs, indicative of the accuracy of the developed HPLC 
method. 	
Rifampicin 
Ibuprofen 
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Precision: Precision of the analytical method was analyzed by determination of curcumin and 
CNB001 at different concentrations (as indicated in the tables for each drug). These are as 
tabulated in Table A1.7, Table A1.8, Table A1.9 and Table A1.10. A low % RSD (or %CV) is 
indicative of the precision of the HPLC method for analysis of the drugs. 
Table A1.7: Intraday precision and accuracy observed for the HPLC analysis method of curcumin 
Standard concentration (µg/mL) 
Accuracy a (%) Precision b (%) 
Actual Observed 
2 2.1224 ± 0.22 106.12 1.0251 
20 20.9096 ± 0.835 104.55 2.9941 
50 51.5808 ± 0.861 103.16 1.6695 
a Accuracy expressed as % i.e. (mean observed concentration/actual concentration) x100	
b Precision expressed as RSD (relative standard deviation) = (standard deviation/mean) x100 
Table A1.8: Intraday precision and accuracy observed for the HPLC analysis method of CNB001 
Standard concentration (µg/mL) 
Accuracy a (%) Precision b (%) 
Actual Observed 
5 4.9343 ± 0.044 98.69 0.8957 
20 20.1382 ± 0.526 100.69 2.6142 
50 48.8942 ± 0.5214 97.78 1.0665 
a Accuracy expressed as % i.e. (mean observed concentration/actual concentration) x100	
b Precision expressed as RSD (relative standard deviation) = (standard deviation/mean) x100 
Table A1.9: Interday precision and accuracy observed for the HPLC analysis method of curcumin 
Standard concentration (µg/mL) 
Accuracy a (%) Precision b (%) 
Actual Observed 
2 2.0214 ± 0.0741 101.07 3.6657 
20 20.7320 ± 0.112 103.66 0.5402 
50 49.9564 ± 0.415 99.92 0.8307 
a Accuracy expressed as % i.e. (mean observed concentration/actual concentration) x100	
b Precision expressed as RSD (relative standard deviation) = (standard deviation/mean) x100 
Table A1.10: Interday precision and accuracy observed for the HPLC analysis method of CNB001 
Standard concentration (µg/mL) 
Accuracy a (%) Precision b (%) 
Actual Observed 
5 4.9541 ± 0.124 99.08 2.5029 
20 21.0041 ± 0.457 105.02 2.1758 
50 49.1156 ± 0.874 98.23 1.7795 
a Accuracy expressed as % i.e. (mean observed concentration/actual concentration) x100	
b Precision expressed as RSD (relative standard deviation) = (standard deviation/mean) x100 
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Representative HPLC chromatogram of CNB001 and curcumin is as shown in Figure A1.3 and 
Figure A1.4 respectively. 
 
Figure A1.3: Representative HPLC chromatogram of CNB001 
 
Figure A1.4: Representative HPLC chromatogram of curcumin 
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Appendix 2 | Design of Experiment (DoE) model validation 
Diagnostic plot of normal percentage probability of studentized residuals were used to validate 
the Design of Experiment model statistics. In the normal percentage probability plot the spread 
of data points was approximately along a straight line depictive of a good correlation between the 
model predicted and model fitted, confirming that the model fitted was normal and could be used 
to study the effect of the different factors on the various responses [428]. The normal percentage 
probability plots for DoE1 (choice of lipids) and DoE 2 (ratio of drugs) is as shown in Figure 
A2.1 and Figure A2.2 respectively. 
 
 
 
 
Figure A2.1: DoE 1- Choice of lipids, normal percentage probability plot for zeta potential (A), mean size (B), 
PDI (C), encapsulation efficiency of rifampicin (D) and encapsulation efficiency of ibuprofen (E) (mean±SD, 
n=3, Design-Expert® 10 (Stat-Ease, Inc.)) 
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Figure A2.2: DoE 2- Ratio of drugs, normal percentage probability plot for zeta potential (A), mean size (B), 
PDI (C), encapsulation efficiency of rifampicin (D) and encapsulation efficiency of ibuprofen (E) (mean±SD, 
n=3, Design-Expert® 10 (Stat-Ease, Inc.)) 
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Appendix 3 | In vitro drug release kinetics 
Release kinetics of the drugs CNB001 or curcumin from the different surfactants namely 
Kolliphor® TPGS or Solutol® HS 15, were fitted into various kinetic models and the regression 
coefficient R2 used to ascertain the best fit model. 
 
  
Figure A3.1: Drug release of CNB001: Solutol® HS 15:0% mole cholesterol fitted into zero-order (left) and 
first-order (right) kinetic models 
 
  
Figure A3.2: Drug release of CNB001: Solutol® HS 15:15% mole cholesterol fitted into zero-order (left) and 
first-order (right) kinetic models 
 
  
Figure A3.3: Drug release of CNB001: Solutol® HS 15:30% mole cholesterol fitted into zero-order (left) and 
first-order (right) kinetic models 
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Figure A3.4: Drug release of curcumin: Solutol® HS 15:0% mole cholesterol fitted into zero-order (left) and 
first-order (right) kinetic models 
 
  
Figure A3.5: Drug release of curcumin: Solutol® HS 15:15% mole cholesterol fitted into zero-order (left) and 
first-order (right) kinetic models 
 
  
Figure A3.6: Drug release of curcumin: Solutol® HS 15:30% mole cholesterol fitted into zero-order (left) and 
first-order (right) kinetic models 
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Figure A3.7: Drug release of curcumin: Kolliphor® TPGS:0% mole dequalinium fitted into zero-order (left) 
and first-order (right) kinetic models 
 
  
Figure A3.8: Drug release of curcumin: Kolliphor® TPGS:30% mole dequalinium fitted into zero-order (left) 
and first-order (right) kinetic models 
